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Abstract
Bromodeoxyuridme (BrdU) is a thymidine analogue capable o f inducing 
epitheloid morphology and altering the expression of neuroendocrine markers in 
SCLC cell lines The ability o f BrdU to alter differentiation in neuronal, muscle 
and haematopoietic lineages has been well documented in the literature 
Evidence suggests that this incorporation into the DNA alters the DNA’s 
conformation, which in turn may affect mteractions with specific transcription 
factors, leading to either inhibition or induction of differentiation Following on 
from work previously performed in our laboratory, several pyrimidine analogues 
were studied to investigate if they possessed similar differentiating properties to 
BrdU
The DLKP cell line was established at the NICB from a tumour histologically 
diagnosed as a poorly differentiated lung carcinoma DLKP cells have properties 
which suggest they could be classified as either SLCL-V or non-small-cell-lung 
carcinoma with neuroendocrine differentiation (NSCLC-NE) In this study it 
demonstrate that the DLKP cell line, and the more differentiated adenocarcinoma 
line, A549, upon treatment with the BrdU and a panel of other pyrimidine 
analogues, showed increased expression of cytokeratms 8, 18 and 19 proteins 
Increased protein expression levels of mtegnn subunits ct2 and Pi, as well as the 
cellular adhesion molecule Ep-CAM, was demonstrated in both cell lines 
following exposure to drug
DNA microarray experiments were also performed on DLKP cells exposed to 
BrdU, IdU and 5,2 -FdU Following gene expression analysis on these 
microarray experiments, lists o f differentially expressed genes were generated 
From earlier work performed in this thesis, we demonstrate that all three 
pyrimidine analogues induce a similar pattern of differentiation in DLKP cells 
Therefore, the three microarray experiments were compared to each other in 
order to identify a common differentiation pathway We reveal that a total of 93 
up-regulated genes were common to all three microarray expenments EASE 
analysis was performed on these 93 genes and identified 20 genes from this list 
of 93, which are thought to be involved in cellular development From this list of  
20 development genes, we identify in particular, two families o f transcription 
factors that potentially are involved in the regulation of differentiation in our 
system These transcription factor families are the Id and KLF proteins We 
propose that the Id family of proteins in play an important part in the regulation 
of differentiation in pynmidine-treated DLKP cells We also suggest a role for 
KLF4 in the regulation of cytokeratin expression, mediated through IFNy and 
STAT-1 proteins
The transcription factor YY1 is a 65kDa protein that is ubiquitously expressed 
and is highly conserved among human, mouse and Xenopus YY1 possesses the 
unusual property o f regulating transcription in three ways, depending on the 
cellular context YY1 has been shown to activate, repress or initiate transcription
of a number of cellular genes and has previously been shown to associate with c- 
myc, resulting in its activation and up-regulation
We have also shown that BrdU-treated cells show increased levels of c-Myc and 
eIF-4E protein In order to investigate the role c-Myc and eIF-4E play in the 
differentiation of the DLKP lung cell line, a clonal variant of DLKP, DLKP-SQ, 
was transiently and stably transfected with a human YY1 cDNA expression 
vector It was observed that in stable clones over-expression of YY1 up- 
regulated c-Myc protein levels The over-expression of YY1 appears to have 
further effects on other cellular genes such as increased levels o f eIF-4E, eIF-2a 
and Ornithine Decarboxylase proteins We also demonstrate that the transient 
over-expression of YY1 is capable o f inducing genes identified as differentially 
expressed, namely Id2, Id3, HMOX1 and FHL1, in the DLKP, IdU and 5,2 -FdU 
microarray experiments
Section 1.0 Introduction
l
1.1 Cellular differentiation
Cellular differentiation can be defined as the process leading to the expression of 
phenotype characteristic of the functionally mature cell in vivo As the differentiation 
process progresses there is an associated reduction in cell division and cell 
proliferation activities are eventually lost (Davila, et a l , 1990) The principal cells 
that differentiate are referred to as stem cells, which are capable o f rapid cell growth 
and division These cells are multipotent and have the potential to differentiate into 
several different cell types In general, stems cells possess unlimited proliferative 
potential but they can remain quiescent under certain microenvironment conditions 
(Davila, et a l , 1990) Differentiated cells are thought to be produced, not directly 
from stem cells, but rather via a committed progenitor or transit amplifying 
population (Watt, 1991)
The density of a cell during embryogenesis and development is regulated by gene 
expression which restricts the number of lineages that stem cells have the potential to 
form Previous studies (Ham and Veomott, 1980) have proposed that ‘determination’ 
is a process whereby a cell becomes committed to differentiate into a specific lineage 
A determined or committed cell initially may not appear phenotypically different, this 
only occurs after the genetic blueprint has been implemented (Maclean and Hall, 
1987) A cell can differentiate in a manner which results in either the irreversible loss 
of its proliferative properties, terminally differentiated, or in the retention of some of 
its proliferative capacity while the cell itself is fully differentiated, non-termmally 
differentiated A number of differentiation states are also well documented 
dedifferentiation is the process by which a cell loses its differentiated phenotype and 
transdifferentiation occurs when a cell dedifferentiates and redifferentiates into a new 
and distinct phenotype (Davila, et a l , 1990) It is apparent from this that as a cell 
undergoes differentiation, its gene expression profile will likewise change
The process o f cellular differentiation is often meditated by the tissue type the cell is 
present in A progemtor stem cell represents the progeny of stem cells which possess 
more limited proliferation and differentiation potential This cell is usually involved 
m a single lineage Although stem cells in adult organs are plunpotent, the 
differentiated daughter cells are not usually expressed beyond the relevant organ in
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which the stem cell originates from, 1 e , the cells are tissue determined stem cells 
(TDS) and are thus considered separate from embryonic stem cells (ES cells) (Sell,
1994)
Tissue determined stem cells are believed to undergo a slow cell cycle in order to 
reduce the risk o f errors during DNA replication As TDS cells are present 
throughout the life of an organism, such errors could become amplified in the 
organism (Lajtha„ 1982) and had been proposed that many tumours contain TDS cell 
populations (Khan, et a l , 1991) and that the overlapping expression of differentiation 
markers (Gazdar, et a l , 1988) within cancer cells is indicative o f a stem cell ongm for 
most lung epithelial carcinomas During the differentiation process o f TDS cells it is 
necessary that they maintain a constant cell number One popular model for this is 
asymmetrical cell division According to this model, when the stem cell divides one 
daughter cell remains as a stem cell while the other becomes a transit cell and enters 
the differentiation process
Although proliferation and differentiation appear to be interlinked processes during 
stem cell maturation, they are quite often separate events that occur concomitantly 
This suggests the whole differentiation process may be understood in terms of spiral 
model (Potten and Loffler, 1990) Some TDS cells appear to be highly plunpotent 
giving rise to several different cell lineages, e g the haematopoietic system Given its 
pluripontency, it can be envisaged that depending on the signal, a stem cell will adopt 
one direction of maturation over another
1.2 Lung Development
The development of the lung requires cell proliferation, branching morphogenesis, 
alveolar saccule formation and cell differentiation These processes require well co­
ordinated events, which are achieved by epithelial-mesenchymal interactions, 
activation and repression of transcriptional factors and signalling
The existence o f principle of stem cells and the in vitro cultivation and manipulation 
has now been well established and demonstrated for tissues such as mammary glands 
(Rudland and Barraclough, 1998), Liver (Sell, 1994), haematopoietic tissue (Fraser, et
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a l , 1995) and skin (Jones, et a l , 1995) However, the existence of a similar stem cell 
model has no yet been identified in lung tissue, though is strongly suspected given the 
ability o f the lung to regenerate when exposed to local damage by atmospheric 
components Identification of such lung stem cells is hampered by the complexity of 
the respiratory system and the variety o f cell types present (Plopper and Hyde, 1992, 
Paine and Simon, 1996)
The most predominant hypothesis for stem cells in vivo is that different set of 
progenitor cells exist each destined to give nse to a discrete differentiated cell type 
(Plopper et al 1992) In the case o f type II lung cells, these cell proliferate and then 
differentiate into type I cells (Adamson and Bowden, 1979) and Clara cells can 
differentiate into ciliated cells (Jutten, 1991) However, other thinking on the 
existence of lung stem cells suggests the existence of a monotypic stem cell, which 
gives rise to a transit cell described as a small mucous granule cell (SMGC) This cell 
is defined as being of a secretory yet premature type containing a few small granules 
which are periodic acid Schiff reaction positive, and also possess a well developed 
endoplasmic reticulum, prominent Golgi complex and tonofilmament bundles It is 
believed that SMGCs are able to give nse through dedifferentiation to any 
differentiated secretory cell type
To date, very little scientific evidence exists relating to stem cells of the lung, the 
pathways they follow, their distribution and mechanism of action No markers yet 
exist for lung stem cells and the idea of dedifferentiation is in contrast to the stem cell 
models developed in other tissues suck as the skin, liver and intestine, where stem 
cells pre-exist in the epithelium (Emura, 1997) The lung is susceptible to local 
damage from a number of different sources including ozone, carbon black particles, 
lipophilic chemicals absorbed into the blood stream from the gut, or damage induced 
from bacterial or viral infection Therefore, the lung must posses some form of self 
regeneration, even if  limited to overcome such damage In attempting to identify if a 
cell is a stem cell, its native state is often altered during the investigation This may 
result in loss o f the stem cell or only a limited spectrum of responses being observed 
Thus, due to the variety of cell types present and the complexity o f the respiratory 
system, indemnification of a lung stem cell may prove to be a difficult task
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All o f this has interesting implications with the isolation of a poorly-differentiated 
lung cell line, DLKP, at the NICB (Law, et a l , 1992) Clones derived from this cell 
line exhibit the amazing capacity to regenerate the mixed parental population over 
time The DLKP novel cell line has been categorised as extremely poorly 
differentiated and consists o f at least three subpopulations, termed SQ (Squamous), I 
(Intermediate) and M (Mesenchymal) (McBride, et a l , 1998) These populations 
have demonstrated the ability to mterconvert and eventually, when cultured alone, 
replenish the parental phenotype This, combined with the lack of expression of a 
number of differentiation-specific markers, has lead to the speculation that DLKP 
may represent a stem cell-like population This has afforded a unique opportunity to 
study the process o f lung cancer differentiation in vitro, particularly the early stages 
of this process Such studies will provide insights in the mechanisms of early lung 
development
1 4 Synthetic agents capable of inducing epithelial lung cell differentiation 
1 4 1  Halogenated thymidine analogues - BrdU, IdU and CdU
Bromodeoxyundine (BrdU) is a halogenated thymidine analogue that is known to 
influence the differentiation of cells It is best referred to as a differentiation 
modulating agent since it has been shown to be a potent inducer o f differentiation in 
some cell lines (Yen et a l , 1987, Sugimoto et a l , 1988, Valyi-Nagy et a l , 1993), 
while it can inhibit the differentiation of others (Seecoff and Dewhurst, 1976, 
Tapscott et a l , 1989, Lee et a l , 1992) BrdU competes with naturally occurring 
Thymidine for incorporation into DNA during replication and as such it, and other 
similar compounds, should be ideal candidates for anti-tumour agents, since they 
require cell division and DNA synthesis to exert their effects (Bick and Devine, 1977) 
While few clinical trials are based on the differentiation-modulating properties o f this 
drug (Freeman, 1969, Ameye et a l , 1989), BrdU has been used widely as a 
radiosensitiser in an attempt to improve radiological treatments (Lawrence et a l , 
1992, McGinn and Kinsella, 1993) Radiosensitisation trials to date include the 
treatment of malignant glioma (Vander et a l , 1990), ulcerative herpetic keratitis (van
1 3 Identification of a stem-like lung cell line, DLKP
5
Bijsterveld et a t, 1989), malignant astrocytomas (Greenberg et a l ,  1988) and 
malignant brain tumours (Matsutani et a t, 1988). More recently, Brdll has entered 
clinical trials as a radiosensitiser in the treatment o f pancreatic cancer (Robertson et 
a l. 1997), colorectal liver metastases (Robertson et at., 1997) and cervical cancer 
(Eisbruch et al., 1999), while studies in relation to malignant gliomas continue 
(Prados et al., 1998). Administration of Brdll is normally by controlled perfusion 
(Doirion et a t, 1999), and has been used in combination with radiolabclled 
monoclonal antibodies (Buchsbaum et al., 1994). While radiolabelled antibody 
approaches offer the potential o f targeted chemotherapy, they are limited by low 
dose-relate deliverable. As such, the trials o f Buchsbaum et al (1994) may offer a 
means of enhancing the efficacy o f  low dose radiolabelled monoclonal antibody 
approaches.
BrdU incorporates into DNA in a non-random fashion at sequences termed “fragile 
sites” (Hecht et al., 1988: Sutherland, 1988; Sutherland, 1991). This explains the 
reproducibility o f the effects observed with BrdU-induced differentiation. O’Neill and 
Stockdale (1973) developed a model for BrdU-induced modulation of differentiation 
that assumes that BrdU “sensitivity” resides on a single pair o f chromosomes, 
suggesting the presence o f a “master gene” or target through which BrdU exerts its 
effects. In this model, inhibition of differentiation occurs in a dominant fashion if  
approximately 30% or more of naturally occurring thymidine is replaced by BrdU in 
the readout strand of either chromosome. This sort o f model agrees with the predicted 
mechanisms o f action o f  a number of DNA-intercalating agents. BrdU substitution 
into DNA and intercalation of such agents may have similar effects, thought to be 
through direct DNA bending at either major or minor grooves, thereby altering 
promoter structure and availability to transcription factors. Intercalation of the 
antibiotics, elsamicin A or actinomycin D in the promoter o f the c-myc gene induced 
a decrease in the level o f transcription from this promoter (Vaquero and Portugal, 
1998). However, relatively low levels o f elsamicin incorporation actually induced an 
increase in c-myc transcription through the PI promoter. Bromodeoxyuridine (BrdU) 
has been demonstrated to decrease c-myc expression at the transcriptional level in the 
leukaemie cell line, HL60 (Yen and Forbes, 1990) and in human melanoma lines 
(Valyi-Nagyi et al.. 1993). These results would appear to suggest that the c-myc 
promoter regions are particularly susceptible to modulation by agents that disrupt
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promoter structure either through Thymidine substitution (BrdU) or intercalation 
(Elsamicin). Alternatively, BrdU may directly influence the ability o f proteins to 
associate with DNA. In the lac operon, BrdU-substitution has been shown to result in 
increased binding of the lac repressor protein (Lin and Riggs, 1972), suggesting that 
BrdU may be capable o f altering the binding o f regulatory factors.
The mechanism by which BrdU exerts its differentiation-modulating effects remains 
unclear, but it appears that incorporation into DNA is essential. This involves BrdU 
being converted to Bromodeoxyuridine monophosphate, which competes with 
thymidine for incorporation into DNA (O'Neill and Stockdale, 1974). Experimental 
evidence for this hypothesis comes from a study by Keoffler el al. (1983) which 
showed that a thymidine kinase-deficient human myeloid cell line, HL60, was unable 
to incorporate BrdU into its DNA and subsequently failed to respond to the ability o f  
BrdU to modulate its differentiation status.
A number o f models exist to explain the ability o f BrdU to modulate differentiation: 
Model 1:
This model envisages that BrdU induces chromosomal breakages. These breakages 
and the associated chromosomal aberrations can be associated with stepwise changes 
in the differentiation status o f a cell. These breakages are specific points called 
‘fragile’ sites. 32 o f which have been identified in murine chromosomes. It is 
proposed that BrdU associates with these fragile sites which are known to be 
recombinogenic (Alexander, et al., 1992).
Mode12:
BrdU alters the affinity o f DNA sequences for regulatory proteins. Studies on the lac 
operon with BrdU incorporation demonstrate that the lac suppressor was bound with 
greater affinity (Lin and Riggs, 1972).
Model 3:
In this model BrdU has been found to exert its effects on differentiation by alteration 
of a key regulatory gene(s) that alters transcription of genes involved in 
differentiation (Arnold, et al.% 1988; Rauth and Davidson, 1993). In BrdU inhibition
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of myoblast differentiation, such alterations occurs with the down-regulation or 
complete inhibition of the key regulatory gene, MyoDl (Topscott, et a l , 1989, 
Nanthakumar and Henning, 1993)
Model 4.
This model envisages that BrdU incorporation causes an alteration in the reading 
frame of the DNA template resulting in the formation of abnormal mRNA, which is 
incapable o f synthesising the correct differentiation products (Hill, et a l , 1974)
BrdU is considered by some scientists to be an inducer o f pre-commitment to 
differentiation rather than an actual differentiation inducing agent This was 
highlighted by the findings that BrdU treatment o f HL60s for 24 hours, followed by 
treatment with Retmoic Acid resulted in a faster response to Retinoic Acid (RA) than 
the single addition of RA alone (Yen et a l , 1990) It would appear that BrdU can 
initiate some of the early changes induced by RA in HL60 differentiation, including 
early c-myc down-regulation However, the same author reported previously (Yen et 
a l , 1987) that pre-commitment to differentiation involves an early increase in c-myc 
levels in the same Leukaemic line, as induced by RA This suggests that pre­
commitment to differentiation in these cells involves increased expression of c-myc 
It therefore appears that the true mechanisms of induction and commitment to 
differentiation remain unclear, even in individual cell types
14 2 Mode of Action of Thymidine Analogues
The exact mechamsm(s), by which BrdU and the various thymidine analogues 
investigated in these this study, exert their differentiation-modulating effects remains 
poorly understood In the case of BrdU, it is thought that incorporation into DNA is 
critical in the process (O’Neill and Stockdale, 1974) Low levels o f BrdU have been 
shown to alter the differentiation status of many different cell types in both inhibitory 
e g myoblast cells (O’Neill and Stockdale, 1974) and stimulatory e g neuroblastoma 
cells (Ross A H , et a l , 1995) Incorporation into DNA involves the conversion o f  
BrdU to Bromodeoxyuridine monophosphate, which competes with thymidine for 
incorporation into DNA (O’Neill and Stockdale, 1974) A study by Keoffler et al 
(1983) showed that a thymidine kinase-deficient human myeloid cell line, HL-60, was
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unable to incorporate BrdU into its DNA and subsequently failed to respond to the 
ability o f BrdU to modulate the differentiation status o f HL-60 cells.
Incorporation of BrdU into DNA occurs in a non-random fashion, with incorporation 
occurring into repeated nucleotide sequences; know as ‘fragile sites' (Schwartz and 
Snead. 1982; Hecht et al., 1988). It is as a result o f this consistency o f incorporation 
that may explain the reproducibility o f BrdU-induced differentiation. It is thought 
that breakages in DNA may occur at these fragile sites and these breakages and 
chromosomal aberrations may be associated with changes in the differentiation status 
o f the cell. It was been also reported that BrdU associates with these fragile sites. 
(Alexander e/ al., 1992).
It is also thought BrdU substitution into DNA may also induce effects similar to 
DNA-intercalating agents, by altering DNA bending at either the major or minor 
groves, and thus alter the structure o f promoter regions and the affinity o f DNA 
binding proteins (Lin and Riggs, 1972). Thus, BrdU is likely to exert is effects at 
least in part, on differentiation by altering of expression o f set o f regulatory genes that 
are involved in the control o f another set o f differentiation-related genes (Arnold et a l., 
Rauth and Davidson, 1993).
The biological action o f CdU and IdU is also thought to be similar to that o f BrdU. 
CdU is converted to chlorodeoxyuridine monophosphate by thymidine kinase, and 
has been shown to compete with thymidine for incorporate into DNA (Cortes et al., 
1987).
1.4.3 M ode o f  Action o f F luro-pyrim idines
In contrast to BrdU, IdU and CdU, the 5,5'-Fdu, 5-FU and 5,2'-FdU analogues modes 
of action are slightly different. 5,5*-FdU is cleaved by nucleoside phophorylase 
enzyme to yield 5-flurouracil (5-FU) (Armstrong and Diasio, 1980). The 5-FU 
generated is subsequently metabolised via several steps to yield flurodeoxyuridine 
monophosphate (FdUMP) (Pratt et al.. 1994). FdUMP binds to thymidylatc synthase, 
forming an irreversible covalent ternary complex in which enzyme, folate cofactor, 
and FdUMP are bound, thus inhibiting thymidine monophosphate production and
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hence DNA synthesis (Pratt el al.. 1994). The inhibition of DNA synthesis causes 
cells to delay in the S-phase o f cell cycle and this stall has previously been shown to 
induce differentiation of embryonal carcinoma cells, PC 13, to cndoderm-like cells, 
following exposure of the cells to Retinoic Acid (Nishimure et al. 1983; Mummery et 
a l 1984).
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15 Keratins as markers of epithelial differentiation
A  large proportion o f the cytoplasm o f vertebrate cells, normal and transformed, is 
occupied by components o f the cytoskeleton, including actin, tubulin and the 
intermediate filaments (Moll et a l , 1982) They are formed in different cell types 
from different proteins o f a multigene family or from different subunit polypeptides 
o f a class o f related proteins By far the most striking differentiation specificity o f 
composition has been observed in the intermediate-sized filaments This class o f 
filaments includes the desmin filaments typical o f myogenic cells, the neurofilaments 
typical o f neuronal cells, vimentins occur in mesenchymally derived cells and 
vascular smooth muscle cells, and the keratins occur in epithelial cells (Moll et a l, 
1982, Hatzfeld and Franke, 1985, Daly et a l , 1998) Keratm Intermediate Filament 
(IF) proteins have three domains a central alpha-helical rod domain o f constant size 
that derives from common ancestors, and two end-domains o f variable structure 
thought to be involved in tissue-specific functions (Blumenberg, 1988) The 
specificity o f keratm expression patterns in epithelial cells has been used m 
prognostic and diagnostic situations as markers o f both epithelial ongin and state o f 
differentiation in patients with small cell lung cancer (Bepler et a l , 1987, Broers et 
a l , 1988), and other tumour pathologies (Virtanen et a l , 1984, Trask et a l , 1990) to 
distinguish normal and tumour-denved epithelial cells Keratins are thought to serve a 
structural function to protect the cell against environmental stresses and strains as for 
other filaments (Daly et a l , 1998), but their expression in human ovarian 
adenocarcinoma lines has been associated with altered sensitivity to various 
chemotherapeutic drugs (Parekh and Simpkins, 1995) Interestingly, in studies using a 
number o f chemical differentiating agents the levels o f mdr-l/Pgp (^-glycoprotein) 
increased and expression appears to correlate with the degree o f differentiation 
(Mickley et a l , 1989) However, induction o f these pumps is not always accompanied 
by expression o f the multidrug-resistance phenotype, which may possibly be 
explained by changes in keratin expression during the differentiation o f these cells 
The human K8 mRNA encodes a nucleic acid-binding domain, suggesting that keratm 
filaments may bind to nucleic acid sequences and play a role in regulating DNA 
replication and gene transcription (Yamamoto e t a l , 1990) It is also possible that 
they play a role in the regulation o f translation o f particular mRNAs through their 
localisation to regions withm the cell, in a similar manner to the way in which polar
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expression o f developmental proteins nos and bico id  are regulated (Gavis et al., 1992). 
Genetic disease states associated with loss o f keratin regulation include the blistering 
phenotype o f Epidermolysis Bullosa Simplex (EBS) (Oshima, 1992; Fuchs and Byrne,
1994) and development o f dwarf phenotypes and diabetes in transgenic mice 
expressing the K8 gene (Casanova et al., 1995).
The keratins (K) arc divided into two categories; the acidic type I keratins are K9-20, 
while the more basic type II keratins are K l-8. Keratin filament formation is 
dependent on the pairing o f  partners from both groups to produce a proteolytically 
stable hetero-polymer filament (Kulesch el al., 1989). Despite the fact that their 
function is relatively unknown, the pattern o f expression o f keratin filaments is 
specific to both epithelial origin and degree o f differentiation (Tseng et al., 1982). As 
described in “ The Catalogue o f Human Cytokeratins”  (Moll et al.. 1982), while K9- 
K I 1  is predominant in the epidermis, K 12  has only been observed in the cornea. 
Cytokeratin 8 represents simple epithelia, and its normal partner, K 18 , shows the 
same tissue distribution (Trask et al., 1990). K8 and K 18  are the first keratins to 
appear during mouse development (Casanova et al., 1995) and are thought to be the 
evolutionary ancestors o f many o f the present keratin forms (Blumenberg, 1988). 
Cytokeratin 19 is found in a broad range o f epithelial tissues and is a major 
component o f simple epithelia. K 14  and K 19  are known to be “ promiscuous”  in that 
they can partner Type II Keratins in the absence o f their “ usual”  Type I partner to 
form stable filaments (Hatzfeld and Franke, 1985; Darmon. 1985; Lersch et al., 1989). 
K 19  lacks a variable terminal domain. This, combined with its promiscuity, means 
that K 19  is thought to play a critical regulatory role by pairing with any one o f the 
basic keratins without contributing a potentially harmful variable terminal domain, 
the region in which tissue-specific function o f keratins resides (Blumenberg, 1988). It 
therefore acts to redress keratin imbalances. Keratins 7/8/18/19/20 have been 
associated with simple epithelia, while K4/5/17 are associated with stratified epithelia 
(Mobus et al., 1994). Both classic and variant small cell lung cancers express K8 and 
K 18/19, detectable by western blotting when immunocytochemical staining is weak 
(Elias et al., 1988). Stem cell populations o f the lung have been speculated to exist as 
piuripotent populations residing in tumours and ccll lines (Trask ct al., 1990; Pfeifer 
et al., 1991). The almost complete absence o f  keratin expression in DLKP, a novel
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poorly differentiated NSCLC-NE/SCLC-variant cell line isolated at the NCTCC, has 
led to speculation that this cell line may represent a stem cell-like population
1 5 1  Regulation of Keratin Expression
The regulation o f keratin filament formation is complex and is controlled at multiple 
levels Regulation o f keratin expression has been reported at the transcriptional level 
(Roop et a l , 1988), involving AP-1 activation o f transcription (Neznanov and Oshima, 
1993) which is mediated by the ras signalling pathway (Pankov et a l , 1994) 
Relatively short sequences in the 5 ’ upstream region o f keratin genes can confer 
tissue-specific transcription (Blessing et a l } 1989, Neznanov and Oshima, 1993) In 
addition, histone and chromosomal insulation o f keratin genes (Casanova et a l , 1995), 
labile inhibitors o f transcription (Cremisi and Duprey, 1987), and post-transcriptional 
proteolysis (Kulesh e t a l , 1989) have all been implicated in the cell-specific and 
developmental regulation o f keratin filament formation An important aspect to the 
proteolytic regulation o f keratin filament formation, in which both partners o f the pair 
are required for proteolytic stability and filament expression, is that it would appear 
that the expression o f a type II keratin is sufficient to induce the expression o f a type I 
partner (Giudice and Fuchs, 1987, Knapp and Franke, 1989, Lersch et a l , 1989, 
Rothnagel et a l , 1993) Type I keratin expression has been suggested to be dependent 
on accumulation o f unpolymerised Type II keratin (Giudice and Fuchs, 1987) for 
proteolytic stability for overall filament formation Type I proteolysis may form a 
universal regulatory element while specificity in Type II expression will therefore 
result in Type I induction and tissue-specific Intermediate Filament formation 
(Rothnagel et a l , 1993) Synthesis o f both keratin types can be uncoupled and control 
o f cytokeratin Intermediate Filament formation can occur at different levels (Knapp 
and Franke, 1989), strengthening this suggestion There is substantial evidence for 
additional post-transcriptional regulatory mechanisms (Blouin et a l , 19 9 1, Crowe et 
a l , 1993), including mRNA degradation (Paine et a l , 1992) and the suggestion that 
there is a possible block on the translation o f certain keratin mRNAs, such as K8 
(Tyner and Fuchs, 1984) This speculatively involves translational repression (Su et 
a l , 1994) and even masking o f keratin mRNAs in epithelial squamous cell 
carcinomas (Winter and Schweizer, 1983)
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16  Integrins
The mtegnn receptors consist o f two heterodimer chains, a  and p, both o f which form 
a non-covalently associated complex (Hynes, 1987) The a  subunit family o f 
integrins possesses 15  variants, while the p subunit family contain 8 variants In 
theory these two families could associate to give rise to over 100 integrins However, 
the actual diversity is much more restricted and in reality the subunits combine into 
22 different integrins (Buck and Horwitz, 1987) The integrm family is subdivided on 
the basis o f its P subunit (Newham and Humphires, 1996) For example, the Pi 
integrins are involved principally m the adhesion between the ECM  and the cellular 
cytoskeleton (Buck et a l , 1987), while the P2 mtegnns participate in cell-cell 
interactions (Ruoslahti, 1991) The specificity o f binding is not determined solely by 
integrm pairing, but also by the cell type it is expressed m
Integrins have been implicated in such diverse processes as inflammation, cellular 
growth and differentiation (Albelda and Buck, 1990) For example, the interaction in 
developing lung between the ECM  and the epithelium is mediated by mtegnn 
receptors, and allows normal lung branching to occur (Gumbiner, 1996) As well as 
functioning as cell adhesion molecules, the integrins have signalling functions that 
regulate various aspects o f cell behaviour and differentiation This signalling is 
accomplished through focal adhesion proteins In this study we have chosen the 
increased expression o f both a 2 and pi integrins as markers o f differentiated epithelial 
lung cell differentiation
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Transcriptional Control of Gene Expression
Transcriptional control o f gene expression during both proliferation and 
differentiation has been widely studied Transcription factors such as MyoD and 
Myogemn have been shown to play critical roles in the regulation o f muscle-specific 
differentiation (Wemtraub, 1993, Buckingham, 1994) On the other hand, factors such 
as c-fos, c-jun, and c-myc have long been established as playing roles in the regulation 
o f cellular proliferation, differentiation and transformation o f a wide variety o f cell 
types Selective transcription o f genes such as alcohol dehydrogenase (Adh) during 
development is known to occur through specific sequences in the promoter regions o f 
genes that bind regulatory factors known as transcriptional enhancers (Novina and 
Roy, 1996) Despite this, the process o f transcription and the mechanisms by which 
transcription factors regulate differentiation are still not fully understood
171  The c-myc proto-oncogene
First identified as the transforming gene o f the avian mvelocvtomatosis virus (v-myc) 
(reviewed, Evan, 1990), the myc family o f oncogenes must rank among the most 
widely studied o f all proto-oncogenes Despite this, there is a relative paucity o f direct 
c-myc targets that have been identified to explain the capacity o f this gene to induce 
transformation and malignancy (Ryan and Bimie, 1996) While no direct role for c- 
myc was found in some malignant conversions (DeBenedetti et a l, 1994), c-myc 
expression has been shown to be critical to transformation by both v-abl and BCR- 
A B L, as evidenced using dominant negative c-myc expression (Sawyers et a l , 1992) 
Genetic instability and abnormality is associated with lung cancers (Fong et a l, 1995) 
and c-myc abnormalities are frequently associated with carcinogenesis c-myc 
activation has been shown to occur via gene amplification, chromosomal 
translocation, proviral insertion and retroviral transduction (Ryan and Bimie, 1997)
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1 7.1 1 c-Myc structure and Function
The c-m yc  gene is highly conserved, apart from its first exon, throughout vertebrate 
evolution It first came to notice because o f its homology to the viral oncogene, v-m yc  
While deregulated expression o f c-m yc has been associated with a variety o f 
neoplasms, early studies indicated that introduction o f the c-m yc gene into normal 
fibroblasts was not sufficient to transform cells (reviewed Evan et a l , 1990) The 5 ’ 
region o f the c-m yc gene contains four promoters, termed P0-P3 However, the two 
major promoters, PI and P2 contnbute 75%-90% and 10-25%  o f the cytoplasmic c- 
myc mRNAs, respectively (Ryan and Bimie, 1996, Nanbru et a l , 1997) The 
functional significance o f these promoters remains a mystery They may play roles in 
processes such as proliferation and differentiation, or may simply represent 
evolutionary redundance o f the P0 and P3 promoters The c-Myc protein is a 
phosphoprotein, phosphorylated by casein kinase II (Hagiwara e t a l , 1992) and 
DNA-PK (DNA-activated protein kinase) (Iijima et a l , 1992, Chibazakura et a l ,
1997), and its expression is induced in response to serum and growth factor 
stimulation c-Myc possesses a short cluster o f basic ammo acids that serve as nuclear 
localisation sequences (NLS) (Saphire et a l , 1998), in addition to DNA-binding 
leucine zipper motifs The N-terminal region contains the transcriptional 
transactivation domain (Ryan and Bimie, 1996) There are two isoforms o f the protein, 
c-M ycl and c-Myc2, which differ by 20 ammo acids in their N-terminal region 
(DeBenedetti, personal correspondence)
c-Myc exerts its effects through oligomerisation with other proteins (Figure 1 6), 
characteristic o f other DNA-bmding transcription factors (e g Jun and Fos) 
Originally thought to homodimenze, it is now known that this is untrue Oncogenic 
activation o f c-Myc requires heterodimenzation with activating Max proteins (Amati 
et a l , 1993), which then bind DNA through basic-hehx-loop-hehx-leucine zipper 
motifs Negative regulation o f c-Myc activity occurs through interaction with another 
factor, termed Mad (Ryan and Bimie, 1996), which has no transactivating function 
but competes with Max for binding to the same region o f the c-Myc protein It is, 
therefore, a competitive inhibitor o f c-Myc activation by Max No initial sequence 
specificity o f c-Myc binding was apparent, but it is now understood that c-Myc binds 
through a basic amino acid a-helix region (Fisher et a l , 1993) to what are termed
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myc-binding sequences or “ E-box elements" (CACGTG). These sites require 
association o f Max in addition to c-myc for activation (Ryan and Bimie, 1997). In- 
vivo  activation o f E-box containing genes by Myc/Max heterodimers, including an 
RNA helicase gene belonging to the DEAD-box family, has been demonstrated 
(Grandori et al., 1996). c-Myc/Max complexes, active in transcription, appear to be 
dependent on the levels o f c-Myc available within the cell (Amati et al., 1993), that is, 
Myc synthesis is rate-limiting for Myc-Max dimerisation and activity. Myc 
overexpression activates, while Max overexpression represses transcription through 
E-box sites. This is because Max/Max homodimers do not activate, and so compete 
with Myc/Max complexes when Max is over-expressed (Somer et al., 1998). Max 
overexpressing lines show reduced expression o f transiently transfected Myc- 
responsive genes (Zhang et al., 1997), implying a role for Max expression in the 
regulation o f processes such as differentiation.
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Max appears to be extremely simple and is comprised o f only 160 amino acids, 80 o f  
which constitute the DNA-binding/dimerization domain (Cole, 1991), suggesting that
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transactivation o f basal transcription occurs through the longer N-terminal region o f 
the c-myc portion o f the Myc/Max complex. This explains the lack o f  transactivation 
by Max homodimers and the findings that myc levels are rate limiting in the 
transactivation by Myc/Max heterodimeric complexes. Myc/Max. Max/Max and 
Mad/Myc complexes all bind to the Myc E-box with the same affinity (Somer et a l ,
1998). Therefore, since the transactivation domain o f these complexes lies in the Myc 
N-terminal, complexes lacking a Myc partner act as competitive inhibitors o f 
Myc/Max transactivation.
However, c-Myc has also been shown to exhibit a degree o f “ dual functionality”  in 
that it is capable o f transcriptional repression, as well as activation (Antonson et a l .  
1995), depending upon the position o f the E-box relative to the transcription start site. 
A s such, the role o f c-m yc  in the regulation o f cellular growth and proliferation should 
not be confined to a narrow view o f transcriptional enhancement and stimulation o f 
proliferation. Roles for c-myc in apoptosis and differentiation are evident, but as yet 
unclear. “ It would be naive to assume that the only transcriptional targets o f c-myc arc 
those involved in transformation” (Ryan and Bimie, 1997). Human bronchial 
epithelial cells transformed by overexpression o f c-rafA  and c-m yc  proto-oncogenes 
were capable o f inducing multi-differentiated carcinomas in nude mice (Pfeifer et al., 
1991). This suggests that the role o f c-m yc  in regulating differentiation may be cell- 
specific, and that down-regulation o f myc expression during differentiation (Yen and 
Forbes, 1990; Valy-Nagyi et al.. 1993) may not be a “ universal”  requirement o f all 
cell types, as observed for A P-1. In addition, c-m yc has been shown to play a role in 
the induction o f apoptosis (Harrington et al.. 1994; Kohlhubcr et al.. 1995).
c-Myc has been found to directly interact with a number o f  additional proteins, many 
o f which are novel transcription factors in themselves (Figure 1.7). These interactions 
may form another level at which myc exerts its influence over the transcription 
process. A  novel zinc-finger protein, termed Miz-1 (Myc interacting zinc-finger 
protein-1) has been identified that specifically interacts with Myc, but not with Max 
(Pcukert et al.. 1997). Miz-1 is a transcription factor with potent anti-proliferative 
effcctS. Binding o f Myc to Miz-1 inhibits the promoter activation activity o f M iz-1, 
relieving the anti-proliferative effects o f Miz-1 expression. O f note is the interaction 
between c-myc and the developmental regulator known as Yin-Yang I (Y Y 1) . Y Y 1
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regulates e-Mye levels, while association o f c-Myc and Y Y 1  proteins reduces the 
activity o f  both proteins. This may form the basis o f an auto-regulatory mechanism to 
control the levels/activity o f these two proteins. Such interactions with key 
transcription factors, regulating their activity, may play a significant role in the 
activity o f  c-Myc. This is particularly intriguing in light o f  the lack o f direct 
transcriptional targets identified for c-Myc to date. A  diagram o f the known 
interactions between c-Myc and other enhancer proteins is shown in Figure 1.7
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(reproduced from Ryan and Bimie, 1996):
Figure 1.7 : Regions o f c-Myc interacting with other transcription factors. (Note: 
pi 07 is a member o f the Retinoblastoma family o f  negative regulators. Its association 
with c-Myc inhibits the transactivation activity o f c-Myc).
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CF-1)
17  2 The Yin-Yang Transcription factor, YY1 (NF-E1, NF-5, UCRBP,
Y Y 1  (Yin-Yang 1) is a developmentally important transcription factor, so-named 
because o f its ability to act as both a transcriptional activator and repressor It belongs 
to the GLI-Kruppel family o f negative transcription factors (Licht et a l , 1990, Shi et  
a l , 1991), o f which relatively few are known in eukaryotes The Y Y 1  gene was 
localised to chromosome 14 in humans (Yao et a l , 1998), although pseudogenes or 
additional Y Y 1  genes have been suggested to exist (Zhu et a l , 1994) The promoter 
region o f Y Y 1  lacks consensus TATA or CCAA T boxes, but contains multiple SP-1 
binding sites (Yao et a l , 1998), including a critical promoter region (Safrany and 
Perry, 1993) Four laboratories working independently cloned the Y Y 1  gene in 199 1, 
perhaps highlighting the universally important role o f Y Y 1  in transcriptional 
regulation
1 Park and Atchison (1991) isolated a factor they termed N F -E 1, which was capable 
o f binding to both the immunoglobulin k  3 ’ enhancer and the immunoglobulin 
heavy-chain jiE l site, transcriptionally repressing and activating these promoters, 
respectively The authors also reported that N F-E1 (Common Factor 1, C F 1) was 
capable o f binding the c-m yc promoter The binding o f C F1 was shown to be 
capable o f activating transcription through a c-m yc CF1 site (Riggs et a l , 1991) 
Overexpression o f Y Y 1  was shown to be a strong activator o f murine c-m yc  
expression, with mRNAs increasing from both the PI and P2 promoters o f the 
endogenous c-myc gene (Riggs et a l , 1993) These promoters account for the vast 
majority o f c-m yc transcript present in the cytoplasm
2 NF-8 was found to bind to and activate critical downstream promoter elements in 
the mouse nbosomal protein rpL30 and rpL32 genes (Hanharan et a l , 1991)
3 Flanagan et al (199 1) isolated a negative transcription factor, U CRBP (UCR- 
Bmding Protein) that bound to the upstream conserved region (UCR) o f M M LV 
(Moloney Munne Leukaemia Virus), down-regulating promoter activity A  
negative regulatory region in the HPV-18 (Human Papilloma Virus) was shown to 
bind Y Y 1  with high affinity (Bauknert et a l , 1992) and mutation o f the Y Y 1
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binding site leads to enhanced activity o f the H PV-18 promoter Many viruses that 
cause cancer have been found to have lost Y Y 1  bindmg sites, which may be a 
means o f escaping this negative regulation (Shnvastava and Calame, 1994)
4 Finally, Y Y 1  was isolated and given its more widely used name by Shi et a l (199 1) 
when it was found to associate with the Adenovirus P5 promoter, activated by the 
viral E l A  protein In the absence o f E l A  this promoter is silenced by Y Y 1 ,  and 
only becomes activated in the presence o f E l A  Both E l A  and Y Y 1  were found to 
share overlappmg binding sites m the P5 promoter, but Y Y 1  bindmg is not 
eliminated upon E l A bindmg, suggesting that competition for binding is not the 
means by which regulation occurs ElA-mediated activation is speculated to 
involve unmasking regions o f the Y Y 1  N-termmal involved in activation but 
normally masked in the full-length protein (Lee et a l , 1994) (Figure 1 8)
Consensus activation and repression sequences for Y Y 1  are shown below, although 
these are known to vary giving rise to changes in binding capacity o f these sites for 
Y Y 1  (Hyde-DeRuyscher et a l , 1995)
Activation C G G C C A T C T T G N C T G
Repression CCATN TTN N N A
1.7  2 1  The Structure and Function of Y Y 1
There is evidence that Y Y 1  is a phosphoprotein Eight consensus phosphorylation 
sites are found in the deduced ammo acid sequence and Y Y 1  activity can be abolished 
through the use o f phosphatases (Becker et a l , 1994) The ammo acid sequence o f the 
Y Y 1  protein displays a number o f unique properties to date, including acid nch 
domains similar to transcriptional activators, as well as Ala+Gly-nch and His nch 
sequences common to transcriptional repressors (Park and Atchison, 199 1) The very 
unusual N-termmal region consists o f 1 1  consecutive negatively charged ammo acids 
and 12  consecutive histidines, thought to form two oppositely charged symmetrical 
helices separated by a highly flexible glycine-rich loop (Helix-Loop-Helix, HLH) 
(Hanharan et a l , 199 1) These regions are speculated to be capable o f forming an 
acidic activation domain that could be neutralised or modulated under certain
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conditions to allow interaction with polymerase II before and after transcnption has 
commenced The ammo terminal transactivation domain requires ammo acids 16-29 
and 80-100 for maximal activity (Bushmeyer et a l , 1995)
The C-terminal contains four zinc fingers, characteristic o f DNA-binding 
transcnption factors, while the central region is largely unstructured, consisting of 
large loop and helix regions The Y Y 1  repression domain lies near the carboxy 
terminus and is embedded within the Y Y 1  zinc finger region necessary for DNA- 
binding (Bushmeyer et a l , 1995) Particular importance has been placed upon zinc 
fingers 3 and 4 for repression activity
The functional diversity o f Y Y 1  was conceivably attnbuted to its structural plasticity 
(Hariharan et a l , 1991) It is generally thought that repression o f gene transcnption is 
the usual function o f Y Y 1 ,  with the activating N-terminal region being masked 
Interaction with activating proteins, such as viral E l A, then releases the N-termmal 
region and converts Y Y 1  to an activator o f transcription through the same promoter 
(Figure 1 8) However, it has also been suggested that repression is not the intnnsic 
activity o f Y Y 1  Rather, Y Y 1  acts to bend DNA (Natesan and Gilman, 1993) in a way 
that modulates the interaction o f proteins bound to the two flanking regions When the 
orientation o f the Y Y 1  binding site is reversed or the phasing o f the sites is changed, 
Y Y 1  becomes an activator o f the same promoter (Natesan and Gilman, 1995) Rather 
than bending two proteins away from one another, Y Y 1 now bends them towards one 
another to bring them into closer contact and increase association Therefore, Y Y 1  
will have distinct local effects on protein-DNA and protein-protein interactions 
depending upon the position and orientation o f its binding site within the promoter, 
supporting a general role for Y Y 1  in the building o f highly organised promoter 
complexes This is particularly important in the formation o f promoter structures at 
TATA-less promoters, since Y Y 1  has been shown to bend DNA in a manner suitable 
to provide a site for transcription initiation (Kim and Shapiro, 1996) Both promoter 
orientation-dependent and co-factor-dependent activity o f Y Y  1 was also suggested in 
the human Interferon-y promoter (Ye et a l , 1994) In this case, DNA-binding is a 
required function o f Y Y 1 ,  while in other cases DNA-binding is not required for Y Y 1  
to exert its effects upon promoter formation and activity
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In r  3 ^
Figure 1.8: Diagrammatic Representation o f  E lA-m ediated activation o f  YY1 
Transactivating Potential. Y Y 1  is a repressor o f the P5 promoter (A), but in the 
presence o f EIA, the N-terminal Activating Region (Blue) is unmasked and 
transcription is activated (B).
1.7.2.2 Transcription Factors interact with YY1 to regulate its activity
A Y Y 1  binding site in the c-fos promoter is required for adenovirus E IA  activation o f  
c-fos transcription (Gedrich and Engel, 1995). Rather unusually and almost 
paradoxically, repression by Y Y 1 was also found to be independent o f the presence o f 
Y Y I binding sites in c-fos reporter constructs (Zhou et a l ,  1995). It was shown that 
Y Y 1  repression was mediated through interaction o f Y Y I with C REB (cyclic AM P 
Response Element Binding) Proteins. Thus, within the c-fos promoter alone Y Y I is 
known to interact with E IA  and CREBPs to either increase or decrease transcription, 
respectively, and these functions can be both dependent and independent o f the ability 
o f  Y Y I  to bind DNA. This has lead to claims that Y Y I activity is regulated through 
interactions with other proteins and that it must contain a C-terminal repression 
domain that is independent o f  its ability to bend DNA (Hyde-DcRuyschcr et al.,
1995).
Numerous YYI-associated complexes appear to be targets for E IA  activation (Shi e t  
al., 1991 ;  Gedrich and Engel, 1995; Labrie et a l .  995). In fact, a major role o f viral 
E IA  may be the activation o f genes normally repressed by Y Y I ,  including viral genes 
(Shrivastava and Calame, 1994). SP1 frequently acts as a regulator o f Y Y 1-associated 
complexes (Bennett et a l .  1999), particularly during TATA-lcss promoter complex 
formation. “ Bi-functionality'* is evident in the ability o f Y Y I  to simultaneously up-
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regulate some genes while down-regulating their antagonists. For example, 
transcription o f the LDL (Low-Density Lipoprotein) reccptor gene is inhibited by 
Y Y 1  during high cholesterol (Bennett et ah, 1999), while that o f Cholesterol Esterase 
is enhanced (Gauthier el al., 1999). This was attributed to interactions o f Y Y 1  with 
SP1 in the cholesterol esterase promoter and with SRE-BP in the LDL promoter, 
inhibiting their function. The ability o f Y Y 1 to repress numerous SR E-BP (Serum 
Response Elemement-Binding Proteins) regulated genes has been associated with the 
displacement o f  Factor Y , a positive regulator o f gene transcription (Ericsson el al.,
1999). Similar “ bi-functionality”  is evident during proliferation, in which Y Y 1  up- 
regulates c-myc gene transcription, correlating with cellular proliferation, and inhibits 
muscle actin expression, correlating with differentiation (Lee et a l, 1994). However, 
despite being shown to interact both in-vitro and in-vivo (Lee et al., 1993; Seto eta I,
1993), both Y Y 1  and SP-1 appear to function independently at the surf-1 promoter, 
where the Y Y 1  binding site has been shown to be both necessary and sufficient to 
confer growth-factor inducibility in transcription o f the Surf-1 gene (Cole and Gatson,
1997). Activation o f transcription by Y Y 1 independent o f DNA-binding has been 
shown for the a - 1  acid glycoprotein (AGP) promoter through functional interaction 
with a negative DNA-binding factor, termed Factor B (Lee and Lee, 1994). In the 
human GM -CSF (Granulocyte Macrophage-Colony Stimulating Factor) promoter co­
factors in addition to Y Y 1  were required for activator function and promoter complex 
formation (Ye et al., 1994), but in this case binding o f Y Y 1  to DNA is required (Ye el 
al., 1996),
Additionally, Y Y 1  has been suggested to participate in the stimulation o f 
autonomously replicating human chromosome fragments through interaction with a 
replication-enhancing element, REE1 (Obusc et al.. 1998) and in the regulation o f 
transposable elements o f the genome (Becker et al.. 1993; Satyamoorthy et al., 1993; 
Singer et al., 1993). These elements are thought to be a major source o f functional 
diversity allowing evolution to continue. Overall, Y Y 1  appears to perform a multitude 
o f tasks, many o f which are influenced by its ability to bind to DNA and affect 
promoter structure and formation, as well as interact with numerous transcriptional 
cnhanccrs to modify its own activity. The complexity o f  the regulatory effects o f  Y Y I 
is highlighted by Bushmeyer et al (1995); “ Y Y I  can either activate or repress some
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promoters depending on either promoter architecture or intracellular milieu”  These 
unique properties suggest an unusual and complex role for Y Y 1  in the regulation o f 
gene expression
1 7.2 3 YY1 and TATA-less Transcription
Y Y 1  is thought to play a central role in the formation o f transcription initiation 
complexes at TATA-less promoters Promotion o f TATA-less transcription by Y Y 1  
was initially suggested by the in-vitro  transcription expenments o f Seto et a l ( 1991) 
and Hahn et a l (1992) Y Y 1  has been shown to bend DNA and is thought to play a 
role in the formation o f promoter structures for RN A pol II binding (Natesan and 
Gilman, 1995, Kim and Shapiro, 1996) In an in-vitro transcription reaction, 
supercoiled DNA templates could be transcribed in the presence o f only Y Y 1 ,  TFIIB 
and RNA Pol II (Usheva and Shenk, 1994) Overall, Y Y 1  is thought to be a key 
regulator o f TATA-less promoter initiation, probably m all TATA-less promoters 
(Azizkhan et a l , 1993) Its ubiquitous expression is in agreement with the findings 
that many universally expressed housekeeping genes appear to lack any discernible 
TATA  recognition sequence, including the Y Y 1  gene itself (Yao et a l , 1998) In light 
o f this, a report challenging the concept that TBP-mediated association o f TFIID with 
the TATA-box is limiting in the rate o f transcription initiation is o f interest (Antoniou 
et a l , 1995) Altered transcription was only observed when TBP binding was 
drastically decreased m the promoter o f the P-globin gene However, this promoter 
also contains an active Y Y 1  binding site, the importance o f which may have been 
overlooked by the authors
The ability o f Y Y 1  to interact with TFIIB/D is also thought to be a means by which 
Y Y 1  regulates TATA-less promoter formation, by-passing the requirement for TBP 
in these systems Recently TAFn55 (TATA-Bindmg Protein-Associated Factor), a 
subunit o f TFIID, has been shown to interact directly with the largest subunit, 
TAFn230 through its central region and with multiple activators -  including SP1 ,  
Y Y 1  and Adenoviral E l A  -  through a distinct amino-terminal domain (Chiang et a l ,
1995) This subunit may form the “bridge”  between transcriptional enhancers and the 
actual transcriptional components surrounding RN A polymerase II It is possible that
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Y Y 1  is part of, or is actually the “bridging unit” , particularly in TATA-less promoters 
(since TAF55 is a basal umt, while Y Y 1  appears to be “ in-limbo”  between enhancer 
and basal transcription factor, depending upon the promoter) The effects o f SP1 on 
YY1-m ediated transcription initiation, particularly from TATA-less promoters, may 
reside in its interaction with TA Fn55/230 to guide the initiation complex towards the 
Inr-associated Y Y 1  to begin initiation
Further evidence that Y Y 1  plays a role transcription through TATA-less promoters 
has been provided by Gatson and Fried (1994), Cole and Gaston (1997), Johansson et 
al (1998) and Karantzoulis et a l (1999) In addition, Y Y 1  is thought to play a role in 
the downstream regulation o f transcription (Last et a l , 1999) The majority o f known 
transcriptional enhancers are upstream, since they would interfere with the actual 
transit o f the RN A polymerase II i f  situated downstream, while Y Y 1  appears to 
interact with many o f the basal factors and may form part o f the basal RNA 
holoenzyme m some circumstances
1 7 2 4 YY1 in Differentiation and Development
The unusual nature o f the Y Y 1  protein has led to speculation that it may play a key 
role in the regulation o f differentiation and development Both Chromatin structure 
and methylation are thought to be key mechanisms by which cells control specific 
gene transcription during differentiation The Nuclear Matrix Protein-1 (NMP-1), a 
transcription factor which has been shown to associate with the nuclear matrix to 
mediate gene-matnx interactions withm the nucleus, has been shown to be none other 
than Y Y 1  (Guo et a l , 1995) Sequences necessary for nuclear localisation and 
association with the nuclear matrix have been identified in the C-terminal region o f 
the Y Y 1  peptide (Bushmeyer and Atchison, 1998, McNeil et a l , 1998) Nuclear- 
matrix-associated transcription factors may affect gene regulation by mediating 
transient associations between DNA and the nuclear matrix, locally unravelling 
chromatin structure to allow the transcriptional machinery to access promoters and 
begin transcription, implying roles for Y Y 1  in activating repressed genes during 
development
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Binding o f Y Y 1  to DNA during globin promoter formation is known to be 
methylation-sensitive (Satyamoorthy et a l , 1993, Yost et a l , 1993), which may imply 
a role for Y Y 1  in tissue- and developmental-specific transcription o f genes A  Y Y 1  
binding site is thought to function in the stage-specific expression o f the fetal (gamma) 
globin gene (Zhu et a l , 1999) The human e-globm gene is transcribed in erythroid 
cells only during the embryonic stages o f development A  binding site for Y Y 1 ,  
around nucleotide -269, was identified as critical in the formation o f the £-globin 
repressor complex (Raich et a l , 1995), forming part o f the local regulatory elements 
suggested to be involved in the regulation o f embryonic stage-specific expression o f 
this gene Processes such as these, resulting in the stage-specific switches in gene 
expression, are thought to be associated with methylation o f CpG islands, which 
silence transcription o f developmentally important genes and to which Y Y 1  binding 
is sensitive
In addition, levels o f Y Y 1  have been shown to decrease during differentiation o f 
mouse myoblasts (Lee et a l , 1992) Y Y 1  contains several peptide regions prone to 
proteolytic cleavage, raising the possibility that protease-mediated degradation events 
may contribute to diminished Y Y 1  protein levels during myogenesis (Lee et a l ,
1994) Two proteolytic pathways through which Y Y 1  can be differentially targeted 
under different cell growth conditions have been identified (Walowitz e t a l , 1998), 
identifying a role, at least partially, for protease calpain II (m-calpain) However, in 
serum starvation studies Y Y 1  protein expression was lost only after 24 hours, despite 
the fact that Y Y 1  transcript expression was lost within hours (Flanagan, 1995), 
suggesting that the Y Y 1  protein is relatively stable This does not exclude the 
possibility that proteolytic regulation o f Y Y 1  levels may play a role in different 
processes
Treatment o f myoblasts with the differentiation modulating agent, BrdU results in 
inhibition o f myogenesis, resulting in/from an increase in expression o f Y Y 1  and 
decreased a-actin levels (Lee et a l , 1992) Transfection o f SRF (Serum Response 
Factor), which competes with Y Y 1  for the regulation o f a-actin gene transcription, 
could directly transactivate the actin promoter in BrdU-treated myoblasts Both SRF 
and Y Y 1  are ubiquitously expressed, suggesting that they may have antagonistic
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functions in regulating genes such as c-fos, a-actin and cardiac creatine kinase-M 
(Vincent et a l , 1993, Liu et a l , 1995) during development High levels o f Y Y 1  in 
non-differentiated muscle cells down-regulate the dystrophin promoter, at least in part, 
by interfering with the spatial organisation o f the promoter (Galvagm et a l , 1998) 
Y Y 1  and a positive regulator o f dystrophin, DPBF (dystrophin promoter bending 
factor), induce opposite bends in the CArG element o f this promoter, suggesting that 
their binding induces alternative promoter structures to regulate muscle development
1.8 eukaryotic Translation Initiation Factor, eIF-4E
eIF4E, otherwise known as eIF4a or the small cap binding protein, binds directly to 
the 5' 7-Methyl-Gppp cap in an ATP-dependent manner, and is thought to be the first 
factor to interact with the mRNA to initiate translation eIF-4E is a 25 kDa phospho- 
protem responsible for Cap-binding specificity in eIF-4F complexes during 
eukaryotic translation initiation events eIF-4E consists o f a single aP  domain which 
contains 8 anti-parallel P strands forming a curved p sheet (Sonenberg and Gmgras,
1998) This sheet is backed by three long a-helices The mRNA cap-structure binds 
loosely to an hydrophobic pocket in the concave inner surface o f eIF-4E, across 
which salt-bridges form after phosphorylation to “ lock”  the cap in place 
(Marcotngiano et a l , 1998, CSHL abstracts), while the convex dorsal surface 
interacts in a mutually exclusive manner with either eIF-4G or the 4E-BPs 
Phosphorylation o f eIF-4E occurs as part o f the eIF-4F complex (Tauzon et a l , 1990) 
greatly enhancing and stabilising its association with the cap (Mimch et a l , 1994, 
Joshi e t a l ,  1995)
eIF-4E is widely accepted as the limiting factor in translation initiation, particularly 
for mRNAs with complex 5 ’ UTRs It is present in molar levels significantly lower 
than that o f other initiation factors (DeBenedetti and Rhoads, 1990, Sonenberg, 1996) 
It is the most specifically targeted mRNA-binding elF and is an essential component 
o f the cytoplasmic cap-binding complex The cap-binding activity o f the eIF-4E
28
peptide is thought to reside in a highly evolutionary conserved placement of 
tryptophan residues in both yeast and mammals (Altmann et a l , 1988) This factor 
therefore plays a critical role in the regulation of translation, particularly of specific 
mRNA species, and the levels and activity o f eIF-4E are critical to the control of 
cellular proliferation and differentiation (Jaramillo et a l , 1991) A rather novel and 
as-yet to be proven additional function for eIF-4E has been suggested, namely that it 
may play some part in the transport o f mRNAs from the nucleus The 5’ Cap- 
structure is known to be involved m the process of nucleocytoplasmic transport 
(Sonenberg and Gingras, 1998), already thought to be the function of the novel elF- 
4E homologue protein, eIF-4EHP (Rome et a l , 1998) In light of the Cap-binding 
specificity o f eIF-4E and recent findings o f localisation o f a fraction o f eIF-4E to the 
nucleus (Pollard et a l , 1999), this additional role for eIF-4E is not implausible
Frequently mammalian cells express at least two forms of this factor (Jaramillo et a l , 
1991, Haghighat et a l , 1995) The gene(s) for eIF-4E is thought to lie on 
chromosome 4 in humans (Gao et a l , 1998) Gao et al (1998) isolated two genes for 
eIF-4E from placental genomic libraries, in which case eIF-4El contained six introns 
but the other (eIF-4E2) was mtronless Subtle differences between the two genes were 
identified and both genes were reported to be differentially expressed in four human 
cell lines A notable difference between the two genes was that the eIF-4El promoter 
contained c-myc-binding elements while that of eIF-4E2 did not, suggesting 
constitutive expression of the latter and inducible expression of the former In fact, 
eIF-4E has been identified as one o f the few targets for c-Myc induction (Rosenwald 
et a l , 1993, Jones et a l , 1996) The complexity o f eIF-4E expression patterns in 
eukaryotic cells was highlighted by the findings that m Drosophila a single eIF-4E 
gene could code for three alternatively spliced mRNA transcripts, two of which 
resulted in expression of the same form of eIF-4E, while the other encoded an isoform 
differing at the amino-terminal sequence of the protein (Lavoie et a l , 1996) The 
three eIF-4E transcripts varied greatly in the lengths o f their respective 5’ UTRs, 
suggesting that each was subject to varying degrees o f translational regulation 
themselves This may reflect a means of auto-regulating levels o f eIF-4E expression 
during phases o f hyper- and hypo-proliferation of cells
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Following on from BrdU work that has previously been performed in the laboratory 
(McBride S , et a l , 1999, P Meleady, PhD Thesis, 1997, F O’Sullivan, PhD Thesis, 
1999, D Walsh, PhD Thesis 1999, P Doolan, PhD Thesis, 2001) it was decided to 
investigate the ability of other halogenated thymidine analogues to induce 
differentiation in DLKP and A549 cells In this study it was decided to utilise the 
expression of a 2-, Pi-integrm, EpCAM, cytokeratms 8, 18 and 19 as markers of 
differentiation in the two cell lines The thymidine analogues initially chosen for this 
work were 5-Iodo-2 -deoxyUndine, 5-Chloro-2 -deoxyUndine, 5-FluroUracil, 5- 
Fluro-2 -deoxyUndine, 5-Fluro-5 -deoxyUndine, 5-BromoUndine and 5- 
BromoUracil
Exposure o f the both cell lines to BrdU and the other halogenated thymidine 
analogues investigated also resulted m a morphological change in the treated cells 
These changes included a flattening and stretching of the cells, with the cells doubling 
or quadrupling in size, following treatment Cells treated with 5,2 -FdU exhibited the 
greatest alteration in morphology and the greatest increase m cell size
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1 9 Aims o f Thesis
❖ Previous research performed in this laboratory has demonstrated that the 
halogenated thymidine analogue, Bromodeoxyundine, induces the in vitro 
differentiation o f the lung cell lines DLKP and A549 This differentiation is 
indicated by the induction of cytokeratins 8, 18 and 19 (McBride, et a l , 1999, 
Meleady and Clynes 2001a, Meleady and Clynes, 2001b, O’Sullivan, PhD 
Thesis, 1999) Also shown to be induced by BrdU are the mtegnns a j  and Pi 
(Meleady, PhD Thesis, 1997) and Ep-CAM (O’Sullivan, PhD Thesis, 1999)
❖ The thymidine analogues BrdU has been shown in this laboratory to induce 
the expression of cytokeratin and mtegrin proteins The ability o f other 
halogenated pyrimidine analogues, IdU, CdU, 5,5 -FdU, 5,2 -FdU, 5-FU, 
BromoUracil and Bromoundine, to alter expression of these proteins was also 
to be investigated It was hoped that such investigation would help us gam a 
better understanding of the mechanisms by which differentiation is regulated 
in our in vitro model system
❖ In order to investigate the mechanisms involved in lung cell differentiation in 
our model system initial work examined the effect of the pyrimidine 
analogues had on the cytokeratin and mtegrin proteins in DLKP and A549 cell 
lines This was principally performed by immunocytochemistry
❖ To mvestigate the global transcriptional changes induced in the DLKP cell 
line following exposure to the pyrimidine analogues, DNA microarray 
experiments were employed to help to elucidate genes which may be common 
to the pathway(s) regulating differentiation in our cell system The use of 
such techniques may yield helpful leads to help us understand the overall 
processes o f differentiation involved
♦♦♦ Work performed by Walsh (PhD Thesis, 1999) in our laboratory suggested 
that the transcription factors c-myc and Yin Yang 1 may be key proteins
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involved in the control of differentiation which is induced by BrdU in DLKP 
cells cDNAs coding for these two proteins were transfected into DLKP and a 
clonal subpopulation DLKP-SQ, to asses their ability to induce simple 
differentiation in this poorly differentiated cell line It was hoped that 
compiling results from BrdU-treated cells and transfections would allow us to 
develop a model for the regulation of K8 and K18 synthesis in our lung cell 
line models, with possible implications for understanding the early stages of 
lung development as well as aspects of de-differentiation in lung cancer Such 
models are severely lacking in lung biology
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Section 2.0 Materials & Methods
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2.1 W A TE R
Ultrapure water was used in the preparation o f all media and solutions. This water was 
purified by a reverse osmosis system (Millipore Milli-RO 10 Plus, Elgastat UHP) to a 
standard o f 12 - 18 MQ/cm resistance.
2.2 G L A SSW A R E
Solutions pertaining to cell culture and maintenance were prepared and stored in sterile 
glass bottles. Bottles (and lids) and all other glassware used for any cell-related work 
were prepared as follows:- all glassware and lids were soaked in a 2% (v/v) solution of 
RBS-25 (AGB Scientific) for at least 1 hour. Following scrubbing and several rinses in 
tap water, the bottles were then washed by machine using Neodisher detergent, an 
organic, phosphate-based acid detergent. The bottles were then rinsed twice with 
distilled water, once with ultrapure water and sterilised by autoclaving.
2.3 ST E R IL ISA T IO N
Water, glassware and all thermostable solutions were sterilised by autoclaving at 121 °C 
for 20 minutes (min) under pressure o f lbar. Thermolabile solutions were filtered 
through a 0.22jim sterile filter (Millipore, millex-gv, SLGV-025BS). Low 
protein-binding filters were used for all protein-containing solutions.
2.4 M ED IA  PR EPA RATIO N
Medium was routinely prepared and sterility checked by Joe Carey. The basal media 
used during routine cell culture were prepared according to the formulations shown in 
I'able 2.4.1. 1 Ox media were added to sterile ultrapure water, buffered with HEPES and 
NaHCOj and adjusted to a pH of 7.45 - 7.55 using sterile I.5M NaOH and 1.5M IICI. 
The media were then filtered through sterile 0.22^m bell filters (Gelman, 121-58) and
34
stored in 500ml sterile bottles at 4°C Sterility checks were carried out on each 500ml 
bottle of medium as described in Section 2 5 6
The basal media were stored at 4°C up to their expiry dates as specified on each 
individual lOx medium container Prior to use, 100ml aliquots o f basal media were 
supplemented with 2mM L-glutamine (Gibco, 25030-024) and 6% foetal calf serum 
(Sigma, F-7524 Batch) and this was used as routine culture medium This was stored 
for up to 2 weeks at 4°C, after which time, fresh culture medium was prepared
Table 2 4 1 Preparation of basal media
DMEM
(Gibco, 12501-029)
Hams F12
(Gibco, 21700-109)
10X Medium 500ml Powder
Ultrapure H20 4300ml 4700ml
1M HEPES*
Sigma, H-9136
100ml 100ml
7 5% NaHC03 
BDH, 30151
45ml 45ml
* HEPES = N-(2-Hydroxyethyl)piperazme-N'-(2-ethanesulfomc acid)
For most cell lines, ATCC (Ham’s F I2/ DMEM (1 1)) supplemented with 6% FCS, 1% 
Sodium Pyruvate and 2mM L-glutamine was routinely used
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2 5 C E L L  LIN ES
All cell culture work was carried out in a class II down-flow re-circulatmg laminar flow 
cabinet (Nuaire Biological Cabinet) and any work which involved toxic compounds 
was carried out in a cytoguard (Gelman) Strict aseptic techniques were adhered to at 
all times The laminar flow cabinet was swabbed with 70% industrial methylated spirits 
(IMS) before and after use, as were all items used in the cabinet Each cell line was 
assigned specific media and waste bottles Only one cell line was worked with at a time 
in the cabinet which was allowed to clear for 15mm between different cell lines The 
cabinet itself was cleaned each week with industrial detergents (Virkon, Antec 
International, TEGO, TH Goldschmidt L td ), as were the incubators The cell lines 
used during the course o f this study, their sources and their basal media requirements 
are listed in Table 2 5 1 Lines were maintained in 25cm2 flasks (Costar, 3050), 75cm2 
(Costar, 3075) or 175cm2 flasks (Coming, 431079) at 37°C and fed every two to three 
days
2.5.1 Subculture of Adherent Lines
During routine subculturing or harvesting of adherent lines, cells were removed from 
their flasks by enzymatic detachment
Waste medium was removed from the flasks and rinsed with a pre-warmed (37°C) 
trypsin/EDTA (TV) solution (0 25% trypsin (Gibco, 25090-028), 0 01% EDTA 
(Sigma, EDS) solution in PBS A (Oxoid, BR14a)) The purpose of this was to remove 
any naturally occurring trypsin inhibitor which would be present in residual serum 
Fresh TV was then placed on the cells (2ml/25cm2 flask or 4ml/75cm2 flask) and the 
flasks incubated at 37°C until the cells were seen to have detached (5-10 mm) The 
trypsm was deactivated by addition of a equal volume of growth medium (/ e 
containing 6% serum) The entire solution was transferred to a 30ml sterile universal 
tube (Stenlin, 128a) and centrifuged at 1,000 rpm for 5 mm The resulting cell pellet 
was resuspended in pre-warmed (37°C) fresh growth medium, counted (Section 2 5 3) 
and used to re-seed a flask at the required cell density or to set up an assay
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T able 2 5.1 C ell lines used during the course o f  this study
Cell line Basal medium Cell type Source
DLKP 
(and subpopulation 
SQ)
ATCC1” Human 
poorly-differentiated lung 
carcinoma
Dr Geraldine 
Grant, 
NCTCC
A549 ATCC2 Human lung 
adenocarcinoma
ATCC2
* These cells grow in suspension
1 ATCC = American Type Culture Collection
2 5 3 Cell Counting
Cell counting and viability determinations were earned out using a trypan blue (Gibco, 
15250-012) dye exclusion technique
An aliquot o f trypan blue was added to a sample from a single cell suspension m a ratio 
of 1 5 After 3 mm incubation at room temperature, a sample of this mixture was 
applied to the chamber of a haemocytometer over which a glass coverslip had been 
placed Cells in the 16 squares of the four outer comer grids o f the chamber were 
counted microscopically, an average per comer gnd was calculated with the dilution 
factor being taken into account, and final cell numbers were multiplied by 104 to 
determine the number o f cells per ml The volume occupied by the chamber is 0 1 cm x 
0 lem x 0 01cm í e 0 0001cm3 Therefore cell number x 104 is equivalent to cells per 
ml Non-viable cells were those that stained blue while viable cells excluded the trypan 
blue dye and remained unstained
2 5 4 Cell Freezing
To allow long-term storage o f cell stocks, cells were frozen and cryo-preserved in 
liquid nitrogen at temperatures below -180°C Once frozen properly, such stocks 
should last indefinitely
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Cells to be frozen were harvested in the log phase o f growth (z e actively growing and 
approximately 50 - 70% confluent) and counted as described in Sections 2 5 3 Pelleted 
cells were re-suspended in serum An equal volume of a DMSO/serum (1 9, v/v) was 
slowly added dropwise to the cell suspension to give a final concentration of at least 
5x l06 cells/ml This step was very important as DMSO is toxic to cells When added 
slowly the cells had a period of time to adapt to the presence of the DMSO, otherwise 
cells may have lysed The suspension was then aliquoted into cryovials (Greiner, 122 
278) which were then quickly placed in the vapour phase o f liquid nitrogen containers 
(approximately -80°C) After 2 5 to 3 5 hours, the cryovials were lowered down into 
the liquid nitrogen where they were stored until required
2 5.5 Cell Thawing
Immediately prior to the removal o f a cryovial from the liquid nitrogen stores for 
thawing, a stenle universal tube containing growth medium was prepared for the rapid 
transfer and dilution o f thawed cells to reduce their exposure time to the DMSO 
freezing solution which is toxic at room temperature The suspension was centrifuged 
at 1,000 rpm for 5 mm, the DMSO-containing supernatant removed and the pellet 
re-suspended in fresh growth medium A viability count was earned out (Section 2 5 3) 
to determine the efficacy of the freezing/ thawing procedures Thawed cells were 
placed into tissue culture flasks with the appropriate volume of medium (5ml/25cm2 
flask and 10ml/75cm flask) and allowed to attach overnight After 24 hours, the cells 
were re-fed with fresh medium to remove any residual traces o f DMSO
2.5 6 Sterility Checks
Stenlity checks were routinely carried out on all media, supplements and trypsin used 
for cell culture Samples o f basal media were inoculated into Columbia (Oxoid, 
CM331) blood agar plates, Sabauraud (Oxoid, CM217) dextrose and Thioglycollate 
(Oxoid, CM 173) broths which detect most contaminants including bactena, fungus and 
yeast Growth media (i e supplemented with serum and L-glutamine) were stenlity 
checked at least 2 days prior to use by incubating samples at 37°C, which were 
subsequently examined for turbidity and other indications o f contamination
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2.6 MYCOPLASMA ANALYSIS
Mycoplasma examinations were earned out routinely (at least every 3 months) on all 
cell lines used in this study These analyses were performed by Aine Adams and 
Michael Henry
2 6 1  Indirect Staining Procedure
In this procedure, Mycoplasma-negative NRK cells (a normal rat kidney fibroblast line) 
were used as indicator cells These cells were incubated with supernatant from test cell 
lines and then examined for Mycoplasma contamination NRK cells were used for this 
procedure because cell integrity is well maintained during fixation A fluorescent 
Hoechst stain was utilised which binds specifically to DNA and so will stain the 
nucleus of the cell in addition to any Mycoplasma DNA present A Mycoplasma 
infection would thus be seen as small fluorescent bodies in the cytoplasm of the NRK 
cells and sometimes outside the cells
NRK cells were seeded onto stenle coverslips in sterile Petri dishes at a cell density of 
2x l03 cells per ml and allowed to attach over night at 37°C in a 5% C02, humidified 
mcubator 1ml o f cell-free (cleared by centnfugation at 1,000 rpm for 5 mm) 
supernatant from each test cell line was then inoculated onto a NRK Petri dish and 
incubated as before until the cells reached 20 - 50% confluency (4 - 5  days) After this 
time, the waste medium was removed from the Petri dishes, the coverslips washed 
twice with stenle PBS A, once with a cold PBS/Camoys (50/50) solution and fixed 
with 2ml of Camoys solution (acetic acid methanol-1 3) for 10 mm The fixative was 
then removed and after air drying, the coverslips were washed twice in deionised water 
and stained with 2ml of Hoechst 33258 stain (BDH)(50ng/ml) for 10 min
From this point on, work was carried out in the dark to limit quenching of the 
fluorescent stain
The coverslips were nnsed three times in PBS They were then mounted in 50% (v/v) 
glycerol in 0 05M citric acid and 0 1M disodium phosphate and examined using a
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fluorescent m icroscope w ith  a U V  filter
2.6.2 Direct Staining
The direct stain for Mycoplasma involved a culture method where test samples were 
inoculated onto an enriched Mycoplasma culture broth (Oxoid, CM403) - 
supplemented with 16% serum, 0 002% DNA (BDH, 42026), 2mg/ml fungizone 
(Gibco, 15290-026), 2x103 units penicillin (Sigma, Pen-3) and 10ml of a 25% (w/v) 
yeast extract solution - to optimise growth of any contaminants and incubated at 37°C 
for 48 hours Samples o f this broth were then streaked onto plates o f Mycoplasma agar 
base (Oxoid, CM401) which had also been supplemented as above and the plates 
incubated for 3 weeks at 37°C in a CO2 environment The plates were viewed 
microscopically at least every 7 days, the appearance of small, “fried egg” -shaped 
colonies is indicative o f a Mycoplasma infection
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2 7 DIFFERENTIATION STUDIES
Differentiation studies were earned out using 5-bromodeoxyundine (BrdU) (Sigma, 
B5002), 5-Chloro, 2-deoxyundine (Sigma, C6891) and 5-Iodo, 2-deoxyundine (Simga, 
17125), 5,2 -FdU (Sigma, B5002), 5,5 -FdU (Sigma,F8791), 5-FU (Sigma, F8423), 
5-bromouracil (Sigma, 852473) and 5-bromouridine (Sigma, B9752) For each of the 
analogues, the powder was reconstituted m UHP water to a stock concentration of 
lOmM and the resultant solution was filter sterilised through a stenle 0 22jam filter, 
aliquoted into stenle Eppendorfs and stored at -20°C for up to 1 year
2.7.1 Differentiation Assays
For lmmunocytochemical analysis (Section 2 8), cells were plated onto 6-well plates 
(Costar, 3516) at densities of lx l  04 cells per well 1 ml o f medium was sufficient for 
each well The cells were allowed to attach and form colonies by incubating at 37°C, 
5% CO2 for 24 hours The plates were covered with parafilm to prevent contamination 
After this time the media was replaced with fresh medium containing 10|aM the 
appropnate thymidine Plates were wrapped in parafilm and incubated for up to 7 days 
Medium was replaced every 3-4 days over the course of the assay All waste medium 
was retained for disposal by incineration At the end of the assay the cells were fixed 
with methanol as described in Section 2 8 1 Immunocytochemistry/fluorescence was 
then earned out using a range of antibodies as described in Section 2 8 2
For additional analytical techniques (Western blotting, immunoprecipitation, 
iso-electric focusing, PCR and DNA Microarrays), cells were inoculated into 75cm2 
flasks at a density o f lxlO 5 cells per flask or into 175 cm2 flasks at a density o f 5x l05 
cells per flask, and were incubated for two days at 37°C Analogue containing medium, 
at a concentration of 1 Op,M, was then added to the cells The medium was replaced with 
fresh, drug-containing media every 3-4 days The cells were then harvested by 
trypsimsation, washed in stenle PBS A, counted, pelleted and stored at -80°C until 
required For RNA extraction (section 2 14), pellets were lysed in tri-reagent and stored 
at -80°C
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2 8 IM M U N O C Y T O C H E M IST R Y
2 8 1  Fixation of cells
For fixation, medium was removed from 6-wells plates, cells were rinsed 3 times with 
PBS A and then incubated at -20°C for 7 minutes using ice-cold methanol The 
methanol was then removed from the cells, which were allowed to dry at 37°C for a few 
minutes and then stored at -20°C until required
2 8 2 Immunocytochemical procedure
The avidin-biotm-peroxidase complex (ABC) immunoperoxidase technique combined 
with the diaminobenzidine (DAB) visualisation procedure was employed to indicate 
primary antibody binding The ABC method involves application of a biotin-labelled 
secondary antibody, followed by the addition of avidin-biotin-peroxidase complex 
which results in a high staining intensity due to the formation o f an avidin-biotin lattice 
which contains several peroxidase molecules The peroxidase enzyme reacts with 
DAB solution to give an insoluble, brown-colour precipitate Therefore, observation o f 
a brown precipitate following this procedure is indicative o f primary antibody 
reactivity
The procedure used is as follows
Cell preparations (6-well tissue culture plates) which had been previously fixed in 
methanol and frozen at -20°C were allowed to thaw and equilibrate at room 
temperature A grease pen (DAKO, S2002) was used to encircle cells in tissue culture 
plates to retain the various solutions involved The cells were equilibrated in 
Tns-buffered saline (TBS) (0 05M Tns/HCl, 0 15M NaCl, pH 7 6) for 5 minutes The 
slides were then mcubated for 20 minutes at room temperature (RT) with either normal 
rabbit (DAKO, X092) or goat (DAKO, X0907) serum diluted 1 5 in TBS to block 
non-specific binding, depending upon the host source o f the primary antibody in 
question This was then removed and 25-3 0|il o f optimally diluted primary antibody 
(Table 2 8 1) was placed on the cells The slides and tissue-culture plates were placed 
on a tray containing moistened tissue paper and mcubated at 37°C for 2 hours or 4°C
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overnight The primary antibodies used in the study are listed in Table 2 8 1 The 
slides were then rinsed in TBS/ 0 1% Tween (Sigma, P-1379) for 5min x3 times, and 
then incubated for 30 min with a suitable biotinylated secondary antibody (rabbit 
anti-mouse immunoglobulins (DAKO, E354), goat anti-rabbit (DAKO, E0432) diluted
1 300 in TBS The slides were rinsed as before and incubated with 
strepABComplex/Horse Radish Peroxidase (HRP) (DAKO, K377) for 30 mm at RT, 
after which they were rinsed again in TBS/ 0 1% Tween for 5mm x3 times The cells 
were then incubated with a DAB solution (DAKO, S3000) for 10-15 min The plates 
were then rinsed off with UHP water and counterstained with 2% methyl green 
solution, and samples mounted using a commercial mounting solution (DAKO, 
S3023)
2 8.3 Immunofluorescence
Immunofluorescence was performed using a similar approach to that described in 2 8 
above Cell preparations (6-well tissue culture plates) which had been previously fixed 
in methanol and frozen at -20°C were allowed to thaw and equilibrate at room 
temperature A grease pen (DAKO, S2002) was used to encircle cells in tissue culture 
plates to contain the various solutions involved The cells were equilibrated in 
Tns-buffered saline (TBS) (0 05M Tns/HCl, 0 15M NaCl, pH 7 6) for 5 minutes The 
slides were then incubated for 20 minutes at room temperature (RT) with normal 
rabbit/goat serum (DAKO, X092/Dako, X0907) (depending upon the primary in 
question) diluted 1 5 in TBS to block non-specific binding This was then removed and 
25-3 Ojal o f optimally-diluted primary antibody was placed on the cells and incubated on 
a tray containing moistened tissue paper at 4°C overnight The following day the slides 
were then nnsed in TBS/ 0 1% Tween (Sigma, P-1379) for 5min x3 times All 
subsequent manipulations were performed in a darkened room, and incubations were 
performed in trays covered in tinfoil as a precaution to minimise “quenching” o f 
fluorescence by exposure to light for extended periods Cells were incubated for 60 min 
with FITC-labelled goat anti-rabbit immunoglobulin (Sigma, F-6005) diluted 1 160 in 
TBS/0 l%Tween The slides were then nnsed in TBS/ 0 1% Tween (Sigma, P-1379), 
x3 in 15 m in , air-dned and mounted in fluorescent mounting medium (DAKO, S3023) 
Antibody reactivity was determined by examination under a fluorescent microscope
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Antibody
Dilution/
Concentration
Supplier Catalogue no
Cytokeratin 8 (M) 1/200 Sigma C-5301
Cytokeratin 18 (M) 1/800 Sigma C-8541
Cytokeratin 19 (M) 1/50 Sigma C5301
eIF-4E (M) 1/250
Transduction
Laboratones
E27620
323/A3
(Anti-EpCAM)*
1/150 NeoMarkers MS-181-P1
Ep-CAM Abl 
(VU-1D9)*
1/150 NeoMarkers MS-144-P1
Pi-mtegnn 1/100 Serotech MCA1188
0C2-integnn 1/250 Serotech MCA1186
Nomenclature (M) = Mouse-anti-human IgG 
(R) = Rabbit-anti- human IgG
* These antibodies were used in combination to improve sensitivity 
Table 2 8 1  Primary antibodies used for îmmunocytochemistry/Immunofluorescence
2 9 WESTERN BLOT ANALYSIS
Proteins for western blot analysis were separated by SDS-polyacylamide gel 
electrophoresis (SDS-PAGE)
2.9 1 Sample preparation
Cell pellets (Section 2 7 1) were lysed in TG lysis buffer (20mM Tris-HCl pH 8, 10% 
glycerol, 1% TntonX -100,1 5mMMgCl2,2m M  EDTA, 137mMNaCl, lm M N a3V 0 45 
ImM Pefabloc (Boehnnger, 84500920-22), and IX Protease inhibitor cocktail 
(Boehnnger, 1697498) for 20 mm on ice The extracts were either used immediately 
for western blot analysis or snap frozen in liquid nitrogen and stored at -80°C 
Alternatively, cells were lysed by resuspension in boiling loading buffer (2 5ml
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1 25M-Tris/HCl, 1 Og SDS, 5 8ml glycerol and 0 1% bromophenol blue (Sigma, 
B8026) made up to 25ml with distilled water) and incubated at 100°C for 2-3 m m , 
cooled to room temperature and used immediately for western blot analysis
2 9.2 Gel electrophoresis
Resolving and stacking gels were prepared as outlined in Table 2 9 1 and poured into 
clean 10cm x 8cm gel cassettes which consisted o f 1 glass and 1 aluminium plate, 
separated by 0 75cm plastic spacers The resolving gel was poured first and allowed to 
set The stacking gel was then poured and a comb was placed into the stacking gel in 
order to create wells for sample loading Once set, the gels could be used immediately 
or wrapped m aluminium foil and stored at 4°C for 24 hours
Before samples were loaded onto the stacking gels, equal cell numbers (2xl04 cells per 
lane) were lysed in 2x loading buffer (Section 2 9 1) The samples were then loaded 
alongside molecular weight colour protein markers (Sigma, C-3437) The gels were run 
at 250V, 45mA for approximately 1 5 hours (until the protein was run at least half way 
into the gel as judged by the migration o f colour markers during the electrophoretic 
process All gels were made from a stock of Acrylamide (details below) Sample 
calculations for two different percentage gels are shown in table 2 9 1
Components
Resolving gel 
(7 5% )
Resolving gel 
(12%)
Stacking gel
Acrylamide stock’ 3 75ml 6ml 0 8ml
Ultrapure water 8 0ml 5 75ml 3 6ml
1 875M-Tns/HCl, pH 8 8 3 0ml 3 0ml -
1 25M-Tns/HCl, pH 6 8 - - 0 5ml
10% SDS (Sigma, L-4509) 150fil 150jil 50|il
10% APS (Sigma, A-1433) 60(al 60fjtl \ l \ i \
TEMED (Sigma, T-8133) I0\û 10\d 6 jli1
Acrylamide stock -  Sigma Cat No - 148660
T able 2 9.1 Preparation o f  electrophoresis gels
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2.9.3 W estern blotting
Following electrophorcsis, the acrylamide gels were equilibrated in transfer buffer 
(25mM Tris, 192mM glycine (Sigma, G-7126) pH 8.3-8.5 without adjusting) for 20 
min. Proteins in gels were transferred onto Hybond ECL nitrocellulose (Amersham, 
RPN 2020D) or PVDF (Polyvinyl diflouridc) (Boehringer, 1722026) membranes by 
semi-dry electroblotting. Six sheets o f Whatman 3mm filter paper (Whatman. 
1001824) were soaked in transfer buffer and placcd on the cathode plate o f a semi-dry 
blotting apparatus. Excess air was removed from between the filters by moving a glass 
pipette over the filter paper. Nitrocellulose or PVDF (pre-activated in methanol for 1-2 
min. and washed in UHP for 5 min), cut to the same size o f the gel, was soaked in 
transfer buffer and placcd over the filter paper, making sure there were no air bubbles. 
The acrylamide gel was placed over the nitrocellulose and six more sheets o f presoaked 
filter paper were placed on top o f the gel. Excess air was again removed by rolling the 
pipette over the filter paper. The proteins were transferred from the gel to the 
nitrocellulose/PVDF at a current o f 0.34mA at 15V for 20-30 min. depending upon the 
size o f the protein.
1. Anode buffer 1: (4 sheets o f filter paper; squeeze dry)
33.35gTris, 200ml Methanol in 1 L.
2. Anode buffer 2: (2 sheets o f filter paper; squeeze dry)
3.03g Tris, 200ml Methanol in 1 L.
3. PVDF membrane (pre-activated in methanol as before).
4. Polyacrylamide gel.
5. Cathode Buffer: (4 sheets o f filter paper; squeeze dry)
3.03g Tris, 5.25g 6-amino-n-hcxanoic acid (Sigma, A-2504), 200ml Methanol 
in 1 L.
All incubation steps from now on, including the blocking step, were carried out on a 
revolving apparatus to ensure even exposure o f the membrane blot to all reagents.
The nitrocellulose/PVDF membranes were blockcd for 2 hours at room temperature 
with fresh filtered 5% non-fat dried milk (Cadburys; Marvel skimmed milk) in TBS/ 
0.1% Tween, pH 7.4.
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After blocking, the membranes were rinsed with TBS/0 1% Tween and incubated with 
primary antibody overnight at 4°C Primary antibodies used are listed in table 2 9 2 
The following day the primary antibody was removed and the membranes rinsed 3 
times with TBS/ 0 1% Tween The membranes were incubated in 1/1000 dilution o f a 
suitable HRP-labelled secondary antibody (Mouse, Sigma, A-6782 or Rabbit, Sigma, 
A-4914) in TBS/0 1% Tween for 1 hour at room temperature (R T ) The secondary 
was then removed and blots were washed for 15 mm m TBS/0 l%Tween Bound 
antibody was detected using enhanced chemilummescence (ECL) (Section 2 9 4)
Antibody
Dilution/
Concentration
Supplier Catalogue no.
Cytokeratin 8 (M) 1/400 Sigma C-5301
Cytokeratin 18 (M) 1/800 Sigma C-8541
Cytokeratin 19 (M) 1/50 Sigma C5301
eIF-4E (M) 1/500
Transduction
Laboratories
E27620
c-myc (M) 1/500 Santa Cruz SC-040
YY1 (R) 1/250 Santa Cruz SC-281
ßi-integrm 1/250 Chemicon AB 1937
Madl 1/250 Santa Cruz SC-222
Nomenclature (M) = Mouse anti-human IgG 
(R) = Rabbit anti-human IgG 
Table 2 9 2 Antibodies used for western blot analysis
2 9.4 Enhanced chemilummescence detection
Protein bands were developed using the Enhanced Chemilummescence Kit (ECL) 
(Amersham, RPN2109) according to the manufacturer’s instructions
After blots were washed in TBS/0 1% Tween x3 times for 5 mm, a sheet o f parafilm 
was flattened over a smooth surface, e g  a glass plate, making sure all air bubbles were 
removed The membrane was then placed on the parafilm, and excess fluid removed 
1 5ml o f ECL detection reagent 1 and 1 5ml of reagent 2 were mixed and covered over
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the membrane Charges on the parafilm ensured the fluid stayed on the membrane The 
reagent was removed after one minute and the membrane wrapped in cling film The 
membrane was exposed to autoradiographic film (Kodak, X-OMAT S, 500 9907) in an 
autoradiographic cassette for various times, depending upon the strength of the signal 
obtained The autoradiographic film was then developed The exposed film was 
developed for 5min in developer (Kodak, LX24), diluted 1 6 5 in water The film was 
briefly immersed in water and transferred to a Fixer solution (Kodak, FX-40) diluted
1 5 in water, for 5min The film was transferred to water for 5 mm and then air-dned
2 10 RNA EXTRACTION
RNA was extracted from cells as follows
Cells were trypsinised, washed once with PBS A and the sample was counted 
Approximately 108 cells were pelleted and lysed using 1ml o f TRI REAGENT™ 
(Sigma, T-9424) The samples were allowed to stand for 5 min at RT to allow complete 
dissociation o f nucleoprotein complexes and then snap-frozen in liq N2 and stored at 
-80°C
When thawed, samples were allowed to stand for 5 mm before 0 2ml o f chlorofom was 
added per ml of TRI REAGENT™ used Samples were then shaken vigorously for 15 
sec and allowed to stand for 15 mm at RT Samples were then centrifuged at 13000rpm 
in a microfuge for 15 min at 4°C This step separated the mixture into 3 phases, the 
RNA was contained in the colourless upper aqueous layer This layer was then 
transferred to a fresh Eppendorf and 0 5ml of isopropanol was added The sample was 
mixed and allowed to stand at RT for 10 mm before being centrifuged at 13000rpm in a 
microfuge for 10 min at 4°C The RNA formed a precipitate at the bottom of the tube 
The supernatant was removed and the pellet was washed with 1ml of 75% ethanol and 
centrifuged at 4°C for 5-10 mm at 8500rpm The supernatant was removed and the 
pellet was briefly allowed to air-dry 20-3Ojil o f DEPC-treated water was then added to 
the RNA to resuspend the pellet
Concentrations o f RNA in samples were calculated by determining OD at 260nm and 
280nm and using the following formula -
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OD260nm x Dilution factor x 40 = |ig/|il RNA 
The punty o f the RNA extraction was calculated by determining its OD at 260nm and 
280nm An A260nm A280nm ratio of 2 is indicative of pure RNA Only those samples 
with ratios between 1 7 and 2 1 were used
2 10.1 Qiagen Kit RNA Isolation
Alternatively, high quality RNA was isolated from cells using the Rneasy mini kit 
(Qiagen, 74104) The Rneasy extraction is based on guanidine thiocyanate method o f 
extraction The procedure was performed according to the manufacturer’s instructions
2.11 REVERSE TRANSCRIPTASE REACTION
Reverse transcriptase (RT) reactions were earned out in laminar flow cabinets using 
micropipettes which were specifically allocated to this work
cDNA was formed using the following procedure -
❖ l|al oligo (dT)12“18 primers (l^ig/|il) (Promega, C l 101)
❖ 1 jal total RNA (1 |ig/|il) (section 2 14)
❖ 3 |il water
were mixed in a 0 5ml Eppendorf (Eppendorf, 0030 121 023), heated to 70°C for 10 
mm and then chilled on ice To this, the following were added -
❖ 4jil of a 5x buffer (250mM-Tris/HCl pH 8 3, 375mM-KCl and 15mM-MgCl2)
❖ 2\il DTT (lOOmM) (Gibco, 510-8025 SA)
❖ 1 jil RNasin (40U/|il) (Promega, N 2511)
❖ 1 til dNTPs (lOmM of each dNTP)
6\x\ water
l |i l  Moloney murine leukaemia virus-reverse transcriptase (MMLV-RT) 
(40,000U/|al) (Gibco, 510-8025 SA)
The solutions were mixed and the RT reaction was earned out by incubating the 
Eppendorfs at 37°C for 1 hour The MMLV-RT enzyme was then inactivated by 
heating to 95°C for 2 min The cDNA was stored at -20°C until required for use in PCR 
reactions as outlined m Section 2 16
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2 12 1 PO L Y M E R A SE  CH A IN  R E A C T IO N
A standardised polymerase chain reaction (PCR) procedure was followed in this study 
The Eppendorf tubes used (Eppendorf, 0030 121 023) and the sterile water were 
DEPC-treated All reagents had been aliquoted and were stored at -20°C and all 
reactions were carried out m a laminar flow cabinet
Each PCR tube contained the following -
❖ 24 5|il water
❖ 5|il lOx buffer* (lOOmM-Tris/HCl, pH 9 0, 50mM-KCl, 1% Triton X-100)
❖ 3|il 25mM-MgCl2*
❖ 8|il dNTPs (1 25mM each of dATP, dCTP, dGTP and dTTP) (Promega, U1240)
❖ 1 |il each of first and second strand target primers (250ng/|al)
❖ 1 (il each of first and second strand endogenous control pnmer (250ng/|il) (p-actm)
❖ 0 5\x\ o f 5U/|il Taq DNA polymerase enzyme*
❖ 5|il cDNA 
*(Promega, N1862)
DNA was amplified by PCR as follows
95°C for 5 mm - to denature double-stranded DNA 
30 cycles 95°C for 30 sec - denature 
*°C for 30 sec - anneal 
72°C for 30 sec - extend 
72°C for 7 mm -  extend
❖ the annealing temperature varied with the pnmer set used See Table 2 appropnate 
annealing temperatures
The reaction tubes were then stored at 4°C until analysed by gel electrophoresis as 
described in Section 2 17
Pnmers were K8/18 (McBnde et a l , 1999), K19 (Meleady, PhD Thesis 1997) c-myc 
(NicAomhlimh, R , PhD thesis, 1997) and P-actm (NicAomhlimh, R 5 PhD thesis, 1997)
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Gene Sense Sequence Anti-Sense Sequence
Id2 gacccgatgagcctctatc cgcttattcagccacagtgc
Id3 gtggaaatcctacagcgcgtc gcaccaggtttagtctccagg
FSTL1 gaggcacagaccatgtgtctgg cctgctgacagatgcagtaaa
Spd/Spn tggagagcaccccttttaccac aaccctcttcactggacagatc
TNFSF7 gtcacttgggtgggacgtagc ggcgctgggaggcaatggta
FHL2 acaagcagcaacttctctgtgt cacaaggagtgcttcgtgtgc
HMOX1 cttcttcaccttccccaacatt ctttccagagagaggggcaca
Zyxin ccactccattcafttccaagtc gggctccaggactgaacttgg
GPX3 gtggagggctttgtccctaatttt Atgagacggccttcagttactt
LOXL2 gcaccgtgtgcgatgacga aatccgaatgtgcctccaccgg
eIF2-associated p67 aaacagaccctccctcagttcc aattccaggccttgcattaatc
p21 cctggcacctcacctgctctgc gcagaagatgtagaggggcc
Table 2 12 1 Primer Sequences for PCR amplification 
212  2 Real Time-PCR
RNA was isolated (Section 2 14) cell and cDNA synthesised as per Section 2 15 The 
Taqman® Real time PCR analysis was preformed using the Applied BioSystems Assays 
on Demand PCR Kits, and experiments were preformed in triplicate, following per 
manufacturer’s instructions
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2 13 ELECTROPHORESIS OF PCR PRODUCTS
A 2% agarose gel (NuSieve, GTG) was prepared in TBE buffer (5 4g Tris, 2 75g boric 
acid, 2ml 0 5M-EDTA pH 8 0 in 500ml water) and melted in a microwave oven After 
allowing to cool, 0 003% (v/v) of a lOmg/ml ethidium bromide solution was added to 
the gel which was then poured into an electrophoresis apparatus (BioRad) Combs 
were placed in the gel to form wells and the gel was allowed to set
lOjil loading buffer (50% glycerol, 1 mg/ml xylene cyanol, 1 mg/ml bromophenol blue, 
ImM EDTA) was added to 50jil PCR samples and 20jil was run on the gel at 80-90mV 
for approximately 2 hours When the dye front was seen to have migrated the required 
distance, the gel was removed from the apparatus and examined on a 
UV-transilluminator and photographed
2 14 OVEREXPRESSION STUDIES 
2 14 1 Plasmid Preparation
Cultures were streaked on LB agar containing 50(ig/ml AMP (Sigma, G9516) and 
50jig/ml Ampicillm and incubated at 37°C overnight From these, a single colony was 
inoculated into 10ml of LB AMP (50|ig/ml each) and grown overnight A 2ml sample of 
this suspension was then added to 200ml o f TB AMP 50|ag/ml and left to grow overnight 
at 37°C for large-scale isolation of plasmid from transformed cells The following day the 
cells were pelleted, 15 minutes at 5000 rpm The plasmid DNA was then isolated from 
the cells using the Maxi-Mim Qiagen Plasmid DNA Extraction kit (Qiagen, 12143) The 
DNA concentration was determined by measuring the OD260nm
2 14 2 Lipofectin Transfection of attached mammalian cells
On the day pnor to transfections, cells to be transfected were plated from a single cell 
suspension and seeded into 25cm2 flasks at 3x105 cells per flask On the day of the 
transfection, the plasmids to be transfected were prepared along with the lipid
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transfection reagents according to the manufacturers protocols (Lipofectin - GibcoBRL 
, 18292-011) The cells were transfected for four hours in the absence of serum after 
which the media was supplemented with 10% serum overnight The following morning 
flasks were washed with serum-contaimng medium and re-fed Selection began 12-24 
hours after re-feeding For all transfections the cells were incubated at 37°C
2 14.3 Selection of Transfected cells
After transfection, cells that had taken up the plasmid were selected by feedmg the cells 
with media containing geneticin (Sigma, G9516) - the plasmids used had a 
geneticin-resistance marker, therefore, only those cells containing the plasmid will 
survive treatment with geneticin 2 days after transfection the flask of cells was fed with 
200|ig/ml geneticin in complete media The concentration of geneticin was increased 
step-wise evey 2 days to a final concentration of 800^g/ml Untransfected control flasks 
were killed after 4-5 days From surviving cells, frozen stocks were made and cells were 
prepared for immunocytochemical (Section 2 8) and western blot (Section 2 9) analysis
2 14 4 Transient Transfection of DNA using Fugene 6 Reagent
Cells were seeded mto 25cm2 flasks at a cell density o f 1 5 x 105 cells/ml (in 4 mL 
medium) Fugene 6 reagent DNA complex was used at a 3 2 ratio which was found to be 
an optimal ratio The Fugene DNA complex was made up accordmg to manufacturer’s 
recommendations and with lOOjaL of the complex mixture was added to the cells m a 
drop-wise fashion Cells were returned to the 37°C incubator Cells were harvested for 
RNA and protein at 24, 48 and 72 hours
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2.15 A ffym etrix  G eneC hips®
The microarray gene expression expenments which were performed in this body o f 
work were performed using Affymetrix® Human Genome U133A GeneChips® 
Affymetrix GeneChip probe microarrays are manufactured using technology that 
combines photolithography and combinatorial chemistry Tens to hundreds to 
thousands of different oligonucleotide probes are synthesised and each of these 
oligonucleotides is located in a specific area on the microarray slide, called a probe cell 
Each probe cell contains millions o f copies o f a given oligonucleotide and each feature 
size on the Affymetrix U133 A GeneChip is 18 microns Due to advances in microarray 
design Affymetrix have since launched a new GeneChip, U133 Plus 2, which has 
decreased the feature size o f the probes from 18 microns to 11 microns The new U133 
Plus 2 GeneChips are now comprised o f the old Affymetrix U133A and U133B 
GeneChips on a single slide The reduction in feature size to 11 microns has resulted in 
an increase in feature definition, with improved sharpness and signal uniformity
The most important aspect in efficient probe design is the quality o f the sequence 
information used Probe selection and array design are two major factors in reliability, 
sensitivity, specificity and versatility of expression probe arrays Probes selected for 
gene expression arrays by Affymetrix are generated from sequence and annotation data 
obtained from multiple databases such as GenBank, RefSeq and dbEST Sequences 
from these databases are collected and clustered into groups o f similar sequences 
Using clusters provided by UmGene database as a starting point, sequences are further 
subdivided into subclusters representing distinct transcripts
This categorisation process involves alignment to the human genome, which reveals 
splicing and polyadenylation variants The alignment also extends the annotation 
information supplied by the databases pinpointing low quality sequences These areas 
are usually trimmed for subsequent generation o f high quality consensus sequences or 
alternatively Affymetrix employ quality ranking to select representative sequences, 
called exemplars, for probe design
In general, Affymetrix use 11 to 16 probes which are 25 bases in length for each 
transcript The probe selection method used by Affymetrix for their U 133 GeneChips
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takes into account probe uniqueness and the hybridisation characteristics o f the probes 
which allow probes to be selected based on probe behaviour Affymetrix use a multiple 
linear regression (MLR) model in the probe design that was derived from 
thermodynamic model of nucleic acid duplex formation This model predicts probe 
binding affinity and linearity o f signal changes in response to varying target 
concentrations An advantage o f this type o f model-based probe selection system is 
that it provides a physical and mathematical foundation for systematic and large-scale 
probe selection Also, an essential criterion of probe selection by Affymetrix for 
quantitative expression analysis is that hybridisation intensities o f the selected probes 
must be linearly related to target concentrations
A core element of Affymetnx microarray design is the Perfect/Mismatch probe 
strategy For each probe that is designed to be perfectly complimentary to a given 
target sequence, a partner probe is also generated that is identical except for a single 
base mismatch in its center These probe pairs, called the Perfect Match probe (PM) 
and the Mismatch probes (MM), allow the quantitation and subtraction o f signals 
caused by non-specific cross-hybridisation The differences in hybridisation signals 
between the partners, as well as their intensity ratios, serve as indicators o f specific 
target abundance
2 15 1 Sample and Array Processing
After RNA isolation, quantification and punfication using the Qiagen Rneasy isolation 
method (Section 2 14 1), cDNA was synthesised using the GeneChip T7-01igo (dT) 
Promoter Primer Kit (Affymetnx, 900375) from lOjag total RNA First strand cDNA 
synthesis was then performed using the SuperScnpt Choice Kit (BioSciences, 
11917-010) First strand cDNA synthesis involved ‘primer hybridisation’ where the 
T7-Ohgo (dT) pnmer was incubated with the RNA and DEPC-treated H2O at 70°C for 
10 mins , followed by a short incubation in ice, ‘temperature adjustment’ where 5X first 
strand buffer, DTT and dNTP mix were added to the RNA mix and incubated at 42°C 
for 2 mins , and ‘First Strand synthesis’ where SuperScnpt IIR T  was added to the mix 
and incubated at 42°C for 1 hour Second strand cDNA synthesis was performed and 
punfied using GeneChip Sample Cleanup module (Affymetrix, 900371) as 
recommended by the manufacturers instructions
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cRNA was then synthesised and biotin-labelled using the Enzo BioArray HighYield 
RNA Transcript Labelling Kit (Affymetnx, 900182) Biotm-labelled cRNA was 
punfied using the GeneChip Cleanup Module Kit (Affymetnx, 900371) and quantified 
The value obtained was adjusted to reflect carryover o f unlabelled total RNA A 
sample o f biotin-labelled cRNA was taken for gel electrophoresis analysis The 
labelled cRNA was then fragmented before hybridisation onto the Affymetnx 
GeneChip probe microarrays The aliquot o f fragmented sample RNA was stored at 
-20°C until ready to perform the hybndisation step
Hybndisation of cRNA onto the Affymetnx GeneChip probe human microarrays 
(Affymetnx, HU133A and HU 133 Plus 2) was performed in the Conway Institute, 
University College Dublin, where the Affymetnx Hybndisation Oven and Fluidics 
Station is set up along with the Affymetnx GeneChip Scanner, which exported the data 
directly into the Affymetnx analysis software, Micro Array Suite 5 1 (MAS 5 1)
2.15 2 Microarray Data Normalisation
The purpose of data normalisation is to minimise the effects o f expenmental and 
technical vanation between microarray expenments so that meaningful biological 
comparisons can be drawn from the data sets and that real biological changes can be 
identified among multiple microarray expenments Several approaches have been 
demonstrated to be effective and beneficial However, most biologists use data scaling 
as the method of choice despite the presence o f other alternatives In order to compare 
gene expression results from expenments performed using microarrays, it is necessary 
to normalise the data obtained following scanning the microarray chips There are two 
mam ways in which this type of normalisation is performed, the first o f which is 
4Per-chip’ normalisation This type o f normalisation helps to reduce minor differences 
in probe preparation and hybridisation conditions which may potentially result in high 
intensity o f certain probe sets These adjustments m probe intensity are made to set the 
average fluorescence intensity to some standard value, so that all the intensities on a 
given microarray chip go up or down to a similar degree However, this type of 
normalisation should only be performed on microarrays using similar cell or tissue 
types One drawback from this o f normalisation is that some aspects o f the microarray
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data may potentially be obscured, such as whether the RNA samples or the probe 
preparation steps were equivalent for each sample.
The second way in which most biologist normalise their data sets is by employing ‘per 
gene' normalisation method. The main aim of microarray experiments is to identify 
genes whose expression changes in different conditions, be that tracking gene changes 
across a temporal experiment or when comparing gene expression between normal and 
diseased tissue. Therefore, it is necessary to normalise microarray data sets using ‘per 
gene* normalisation. In ‘Per gene’ normalisation is necessary to find genes that have 
similar expression pattern across an experiment. Analysis o f raw data from microarray 
experiments is useful for identifying genes that are expressed at the same level, for 
example, genes that are highly abundant in the samples.
2.15.3 Probe Logarithmic Intensity’ ERror estimation (PLIER)
The PLIER algorithm (http://www.affVmetrix.com) is a new tool introduced by 
Affymetrix for the use in data analysis o f their GeneChips and has replaced the need to 
normalise microarray data by using the ‘per chip' and ‘per gene' normalisation 
methods. This algorithm incorporates model-based expression analysis and non-linear 
normalisation techniques. PLIER accounts for differences in probes by means o f a 
parameter termed “probe affinity” . Probe affinity is a measure o f how likely a probe is 
to bind to a complimentary sequence, as all probes have different thermodynamic 
properties and binding efficiencies. Probe affinities determine the signal intensities 
produced at a specific target concentration for a given probe, and are calculated using 
experimental data across multiple arrays. By accounting for these observed 
differences, all the probes within a set can be easily compared. An example o f how the 
PIER algorithm works is if one probe is consistently twice as bright as other probes 
with in a set, PLIER appropriately scales the probe intensities. In the case o f a probe 
set, this enables all set numbers to be compared and combined accurately.
PLIER also employs an error model that assumes error is proportional to the probe 
intensity rather that o f the target concentration. At high concentrations, error is 
approximately proportional to target concentration, since most o f the intensity is due to 
target hybridisation signal. However, at the low end, error is approximately
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proportional to background hybridisation intensity, which is the largest component o f 
the observed intensity. Due to this effect, it is inaccurate to treat errors as a proportion 
of target concentration in all circumstances. The PLIER error model smoothly 
transitions between the low end, where error is dependent upon background, and the 
high end, where error is dependent on signal.
The PLIER algorithm supports a multi-array approach that enables replicate sample 
analysis. PLIER ensures consistent probe behaviour across experiments to improve the 
quality o f results in any one given experiment and helps to discount outliers. Benefits 
o f this algorithm include an improved coefficient o f variation o f signals from probe sets 
while retaining accuracy. Also higher differential sensitivity for low expressors maybe 
achieved using PLIER.
2.16 Genomatix Software Suite
One company that is providing software that allows users to explore textual data as well 
as combine sequence analysis, and genome annotation in order to help researchers to 
discover new contexts from biological data; is Genomatix (www.genomatix.de). The 
analysis offered by Genomatix software is aimed to help researchers gain a better 
understanding o f gene regulation at the molecular level. The Genomatix software suite 
is comprised o f six main tools: El Dorado, Gene2Promoter, BiblioSphere, GEMS 
Launcher, Matlnspector and Promtoerlnspector. ElDorado is a gene orientated genome 
search engine which provides the user with information about functional genomic 
elements within a specific region of the genome. This piece o f software compiles and 
integrates information from several sources and includes functional information, 
synonyms and information on gene function and regulatory pathway. In addition, 
information on mRNAs, their exon/intron structure and coding sequences, single 
nucleotide polymorphisms (SNPs) and potential promoter regions maybe retrieved 
using ElDorado.
Since co-regulation o f gene transcription often originates from common promoter 
elements the identification and characterization o f these elements provides a more 
in-depth analysis for expression of microarray clusters. Gene2Promoter allows users to 
automatically extract groups o f promoters for genes that may o f interest. This piece of
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Genomatix software provides access to promoter sequences o f all genes annotated in 
available genomes. Results from Gene2Promoter are presented in a graphical format 
and common transcription factor binding sites are high lighted along the gene input 
sequence.
One powerful member o f the Genomatix Software Suite, which illustrates the emerging 
emphasis on the visual presentation of complex data, is BiblioSphere. BiblioSphere is a 
data-mining tool for extracting and studying gene relationships from literature 
databases and genome-wide promoter analysis. The data-mining strategy allows to 
find direct gcnc-gcne co-citations and even yet unknown gene relations via interlinks. 
BiblioSphere data is displayed as 3D interactive view (Figure 1.?) o f gene 
relationships. Results can be classified by tissue. Gene Ontology and MeSH. Statistical 
rating by z-scores indicates over- and under-representation o f genes in the referring 
biological categories.
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Figure 2.1 Screen shot o f BiblioSphere
Although transcription is regulated by a variety o f DNA sequences, including enhancer 
and matrix attachment regions, promoters can be seen as the most important part o f the 
sequence because any activator or repressor has to act on the promoter to influence 
transcriptional initiation of a particular gene. Promoters are DNA regions o f several 
hundred base pairs that contain the transcription start site o f genes. The most important 
functional elements within promoters are binding sites for specific proteins called 
transcription factors. The control o f gene transcription is a common method used in 
biological systems to regulate protein expression. Transcription regulation in 
eukaryotes depends on a series o f complex signal transduction networks that control
59
gene promoter activity. Genomatix have develop a software packages, GEMS 
Launcher with helps researchers to identify transcription factor binding sites in a given 
gene promoter. GEMS Launcher is divided up into several parts, the first o f which is 
Matlnspector.
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Figure 2.2 Graphical example o f Transcription Factor Binding Sites located in a 
Promoter sequence.
Matlnspector is a tool that employs a library o f matrix descriptions for transcription 
factor binding sites and locates these binding sites on a given promoter sequence. 
Graphical display o f transcription factor binding sites common to a set o f inputted 
promoters is obtained following Matlnspector analysis. FrameWoker software tool 
that allows users to extract a common framework o f elements from a set o f DNA 
sequences. These elements are usually transcription factor binding sites since this tool 
is designed for the comparative analysis o f promoter sequences. FramcWorker 
generates the most complex models that are common to the input sequences. These are 
all elements that occur in the same order and in a certain distance range in all (or a 
subset of) the input sequences.
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Figure 2.3 Screen shot o f Frame Worker Results
Once a model o f transcription factor binding sites is generated using FrameWoker 
software, it is possible using Genomatix Model Inspector program to scan sequence 
databases for regulatory units that match the model which have been generated using 
Matlnspector. Model Inspector provides a library o f experimentally verified promoter 
models against which transcription factor models maybe scanned.
It is with software packages provided by companies such as Genomatix, that scientists 
will have to reply on in order to help them make sense of the vast quantities o f data that 
is being generated by DNA microarray experiments, not only carried out in their own 
laboratories, but also the great wealth o f information that is available in public accesses 
databases. The type information retrieval, visualisation, standardisation and analysis 
offered by Genomatix, is and will receive a great deal o f attention from countless other 
companies and bioinformatics will undoubtedly remain an extremely important and 
ever changing area o f scientific research in the future.
6 1
Section 3.0: Results
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Section 3 1  INVESTIGATION OF THE EFFECT OF PRYMIDINE 
ANALOGUE EXPOSURE IN THE HUMAN LUNG CARCINMOA 
CELL LINES, DLKP AND A549
Pervious studies in this laboratory have shown that IOjiM 5,2 -Bromodeoxyuridine 
(BrdU) induces cytokeratin 8, 18 and 19 protein expression in the DLKP cell line and 
enhances their expression in A549 (McBride, et a l , 1999, O’Sulllivan, PhD Thesis, 
1999, Meleady and Clynes, 2001) Induced ct2-, pi-integrin has been observed in both 
cell lines (Meleady and Clynes, 2001) as well as the protein expression of Ep-CAM 
(O’Sullivan, PhD Thesis, 1999)
In this study we expand the range of pyrimidine analogues investigated in our pervious 
studies in order to determine if all analogues investigated induced a similar pattern of 
differentiation in both the DLKP and A549 cell lines Immunocytochemistry was the 
primary analysis carried on treated cells and was used to qualitatively investigate the 
changes in cytokeratins 8, 18 and 19, a 2-, pi-integnn and Ep-CAM protein expression in 
both cell lines following treatment (Section 2 7) with each analogue investigated 
Western blot analysis was performed on a subset of treatments
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Immunocytochemical analysis of A549 cells treated with IO^ iM BrdU, IdU, CdU, 5-FU,
5,2 -FdU, and 70^M Bromouracil and Bromoundine showed that expression of a 2- 
mtegrin protein to be increased in treated cells The intensity of the observed staining in 
IdU, CdU and 5,2 -FdU treated A549 cells was comparable to that obtained following 
10|iM BrdU treatment In contrast immunocytochemistry analysis showed that cells 
treated with Bromouracil, Bromoundine and 5-FU did not exhibit the same intensity as 
seen with the other analogues
Section 3 1 1  Changes in a 2-integrin expression in A549 cells following trea tm en t
w ith the thym idine analogues
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Immunocytochemical analysis of A549 cells treated with lOjaM BrdU, IdU, CdU, 5-FU,
5,2 -FdU, and 70|iM Bromouracil and Bromouridine showed that expression of pi- 
integrin protein to be increased in treated cells The intensity of the observed staining in 
CdU, 5-FU and 5,2 -FdU treated A549 cells was comparable to that obtained following 
IO^ iM BrdU treatment Immunocytochemical analysis showed that IdU-treated cells to 
have a greater increase in Pi-integrin protein than BrdU-treated cells In contrast 
immunocytochemistry revealed that treatment with Bromouracil and Bromouridine did 
not exhibit the same intensity as seen with the other analogues
Section 3 1 2  Changes m pi-integrin expression in A549 cells following trea tm en t
w ith the thym idine analogues
66
Figure 3.1.2.1 Control
Figure 3.1.2.3 CdU
Figure 3.1.2.2 BrdU
Figure 3.1.2.4 IdU
Figure 3.1.2.5 5-FU
:V%
■ ■
JZà<
Figure 3.1.2.7 Bromouraeil
Figure 3.1.2.6 5,2-FdU
k ì *  . *-.<> i
• " r . ' V *  < 8
Figure 3.1.2.8 Bromouridine
Magnification -  40X
67
Immunocytochemical analysis of A549 cells treated with IOjiM BrdU, IdU, CdU, 5-FU,
5,2 -FdU, and 70|j,M Bromouracil and Bromouridine showed that expression of EpCAM 
protein to be increased in treated cells The intensity of the observed staining in IdU, 5- 
FU and 5,2 -FdU treated A549 cells was comparable to that obtained following 10|^M 
BrdU treatment Immunocytochemical analysis showed that CdU-, Bromouracil- and 
Bromouridine-treated cells to have an only slightly greater level of increase in EpCAM 
expression than the control A549 cells
Section 3 1 3  Changes in EpCA M  expression in A549 cells following trea tm en t w ith
the thym idine analogues
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Immunocytochemical and immunofluorescence analysis of A549 cells treated with 10|oM 
BrdU, IdU, CdU, 5-FU, 5,2 -FdU, and 70jj,M Bromouracil and Bromouridine showed 
that expression of cytokeratms 8 protein to be increased in treated cells The intensity of 
the observed staining in all the analogue treatments was increase in comparison to the 
A549 control cells CdU and 5,2 -FdU treated A549 cells exhibited a greater increase 
cell size in comparison to the other treatments The morphology of 5,2 -FdU treated 
A549 cells were greatly altered in comparison to control cells and the other analogue 
treatments
Section 3 1 4  Changes m CK8 expression in A549 cells following trea tm en t w ith the
thym idine analogues
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Figure 3.1.4.9 Control Figure 3.1.4.10 IdU
Figure 3.1.4.13 BromoUracil
Magnification
Immunocytochemical analysis of A549 cells treated with IOjuM  BrdU, IdU, CdU, 5-FU,
5.2 -FdU, and 70*iM Bromouracil and Bromouridine showed that expression of 
cytokeratm 18 protein to be increased in treated cells The intensity of the observed 
staining in all the analogue treatments was increase in comparison to the A549 control 
cells All treatments displayed a similar increase in CK18 comparable to that observed in 
lOfiM BrdU treated cells CdU and 5,2 -FdU treated A549 cells exhibited a greater 
increase in size o f the cells in comparison to the other treatments The morphology of
5.2 -FdU treated A549 cells were greatly altered in comparison to control cells and the 
other analogue treatments
Section 3 1 5  Changes in CK18 expression m A549 cells following trea tm en t w ith
the thym idine analogues
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Figure 3.1.5.9 Control Figure 3.1.5.10 IdU
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Immunocytochemical analysis of A549 cells treated with 10p,M BrdU, IdU, CdU, 5-FU,
5,2 -FdU, and 70|iM Bromouracil and Bromouridine showed that expression of 
cytokeratin 19 protein to be increased in treated cells The intensity of the observed 
staining in all the analogue treatments was increase in comparison to the A549 control 
cells All treatments displayed a similar increase in CK18 comparable to that observed in 
IOjiM BrdU treated cells IdU, 5-FU and 5,2 -FdU treated A549 cells exhibited a greater 
increase in CK19 than the other treatments CdU and 5,2 -FdU displayed a great increase 
in cell size The morphology of 5,2 -FdU treated A549 cells were greatly altered in 
comparison to control cells and the other analogue treatments
Section 3 1 6  Changes in CK19 expression in A549 cells following trea tm en t w ith
the thym idine analogues
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Control BrdU 5.2’ IdU 5,2’CdU BromoUracil Bromoundme 5- FU 5.2’- FdU
a 2 Integnn + + + + + -H- + + + + +
Pi Integnn + + + + + + + + + ++ + + + + +
Ep- CAM + + + + + + + + + + -H-
CK-8 + + + + +-H- + + + + + + +++ + + + + + +
CK-18 + + + + + + + + + + -H- + + + +-H- +-H-
CK-19 + + + + + + + -H -+ + + + ++ -H -+ +++
Table 1 Summary of results obtained for different marker proteins in A549 treated cells with various thymidine 
analogues
+ - Expression, ++ - Strong Expression, +++ - Intense Expression
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Immunocytochemical analysis of DLKP cells treated with 10|iM BrdU, IdU, CdU, 5,2 - 
FdU and 5,5 -FdU (results not shown) showed that expression of a 2-integrin protein to 
be increased in treated cells The intensity of the observed staining in these analogue 
treatments was increase comparable to that seen in BrdU treated cells In contrast, 
immunocytochemical analysis of DLKP cells treated with 70|¿M Bromouridine and 
Bromouracil revealed that the cells did not exhibit the same increase in a 2-integrin as 
seen with the other analogues
Section 3 1 7  Changes in a 2 -m tegrin expression in D LK P cells following trea tm en t
w ith the thym idine analogues
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Immunocytochemical analysis of DLKP cells treated with lO^M BrdU, IdU, CdU, 5,2 - 
FdU and 5,5 -FdU (results not shown) showed that expression of Pi-integrin protein to be 
increased in treated cells The intensity of the observed staining in IdU, 5,2 -FdU and
5,5 -FdU-treated DLKP cells was comparable to the staining observed in BrdU treated 
cells Immunocytochemistry analysis revealed that cells treated with 70^iM Bromouracil 
and Bromouridine did not exhibit the same intensity as seen with the other analogues
Section 3 1 8  Changes in pi-integrm  expression m D LK P cells following trea tm en t
with the thym idine analogues
82
Figure 3.1.8.1 Control Figure 3.1.8.2 BrdU
Figure 3.1.8.3 CdU
Figure 3.1.8.5 5,2'-FdU
Figure 3.1.8.4 IdU
Figure 3.1.8.6 Bromouracil
Figure 3.1.8.7 Bromouridine
Magnification -  40X
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Immunocytochemical analysis of DLKP cells treated with lO^M BrdU, IdU, CdU, 5,2 - 
FdU, 5,5 -FdU (results not shown), and 70|iM Bromouridine and Bromouracil showed 
that expression of EpCAM protein to be increased in treated cells The intensity of the 
observed staining in all analogue treatments was only slightly greater than that seen in the 
DLKP control
Section 3 1 9  Changes in EpCAM  expression in D LK P cells following trea tm en t
w ith the thym idine analogues
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Figure 3.1.9.1 Control
Figure 3.1.9.2 CdU
Figure 3.1.9.4 5,2’-FdU
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Immunocytochemical analysis of DLKP cells treated with 10|iM BrdU, IdU, CdU, 5,2 - 
FdU, 5,5 -FdU (results not shown), and 70p,M Bromouracil and Bromoundine showed 
that expression of cytokeratin 8 protein to be induced in treated cells The intensity of 
the observed staining 5,2 -FdU-treated DLKP cells to be similar to that of BrdU treated 
cells
Section 3 1 10 Changes in CK8 expression in D LK P cells following trea tm en t
with the thym idine analogues
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Immunocytochemical analysis of DLKP cells treated with IOjjM  BrdU, IdU, CdU, 5,2 - 
FdU, 5,5 -FdU (results not shown), and 70jj,M Bromouridine and Bromouracil showed 
that expression of cytokeratin 18 protein to be induced in treated cells The intensity of 
the observed staining in IdU-, 5,2 -FdU, and 5,5 -FdU-treated DLKP cells was 
comparable to the staining observed m BrdU treated cells Immunocytochemistry 
analysis revealed that cells treated with Bromouracil and Bromouridine did not exhibit 
the same intensity as seen with the other analogues
Section 3 111 Changes in CK18 expression in D LK P cells following trea tm en t
with the thym idine analogues.
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Figure 3.1.11.1 Control
Figure 3.1.11.3 CdU
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Immunocytochemical analysis of DLKP cells treated with 10p.M BrdU, IdU, CdU, 5,2 - 
FdU, 5,5 -FdU (results not shown), and 70jiM Bromouracil and Bromouridine showed 
that expression of cytokeratin 19 protein to be induced in treated cells The intensity of 
the observed staining in IdU, 5,2 -FdU, and 5,5 -FdU-treated cells was comparable to the 
staining observed in BrdU treated cells Immunocytochemistry analysis revealed that 
cells treated with CdU, Bromouracil and Bromouridine did not exhibit the same increase 
intensity as seen with the other analogues
Section 3 112  Changes m CK19 expression in D LK P cells following trea tm en t
w ith the thym idine analogues
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Control BrdU 5.2’ IdU 5,2’CdU BromoUracil Bromouridine
5,2'-
FdU
5,5’- FdU
a2
Integrin
+ -H - ++ ++ + + ++ ++
p.
Integrin
+ ++ +++ + + + + + + + +
Ep-
CAM
- + ++ + + + + +
CK-8 - ++ + + + + ++ +
CK-18 - ++ ++ + ++ + ++ ++
CK-19 - + ++ + + + ++ ++
Table 2 Summary of results obtained for different marker proteins in DLKP treated cells with various thymidine analogues.
- No Expression, + Expression, ++ Strong Expression, +++ Intense Expression.
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Section 3.1.13 INVESTIGATION OF CHANGES IN CYTOKERATIN 8 
AND EIF4E EXPRESSION LEVELS IN TREATED A549 
CELLS
To quantify the changes in expression of cytokeratin 8 protein observed in the 
immunochemical analysis o f treated A549 cells, Western blot analysis was performed 
on cells which had been treated for up to 14 days with a selection o f analogues
An increase in cytokeratin 8 protein levels was demonstrated in A549 cells treated 
with BrdU, IdU, CdU, 5,2 -FdU, 5,5 -FdU and 5-FU An increase in cytokeratin 
expression was observed at day 7 with a great increased noted in cells exposed to 
drug for 14 days
The expression level o f eIF4E in treated A549 cells was also investigated and we 
demonstrate an increase o f this protein m A549-treated cells Western blot analysis 
also revealed that only phosphorylated eIF4E was present in treated cells
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A549 7-day 14-day
Figure 3.2.1 Western Blot analysis o f Keratin 8 protein in A549 cells 
following treatment with 10}iM IdU for 7- and 14-days.
A549 7-day 14-day
Figure 3.2.2 Western Blot analysis o f Keratin 8 protein in A549 cells 
following treatment with lO^M CdU for 7- and 14-days.
A549 7-day 14-dav
Figure 3.2.3 Western Blot analysis o f Keratin 8 protein in A549 cells 
following treatment with lO^M 5-FU for 7- and 14-days.
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A549 7-day 14-day
Figure 3.2.4 Western Blot analysis of Keratin 8 protein in A549 cells 
following treatment with lO^M 5,2'-FdU for 7- and 14-days.
A549 7-day 14-dav
Figure 3.2.5 Western Blot analysis o f Keratin 8 protein in A549 cells following 
treatment with lOpM 5,5'-FdU for 7- and 14-days.
T3
Figure 3.2.6 Western blot analysis for K8 expression in A549 cells treated with 
lO^M BrdU, 5-FU and 5,2'-FdU for 7-days.
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analogues on eIF4E protein expression in AS49 cells.
Section 3.1.14 Sum m ary  o f the effects o f trea tm en t w ith  pyrim idine
A549 cells were treated with IdU, CdU and Bromouracil (Section 2.7) in order to 
investigate the effect these treatments had on the protein expression levels o f eIF4E in 
the A549 cell line. Western blot analysis revealed an increase in the expression of 
phosphorylated eIF4E in the three drug treatments.
Control Day 7
Phospho-eIF4E
eIF4E
GAPDH
Figure 3.2.7 Western Blot analysis o f eIF4E protein in A549 cells following 
treatment with lO^M IdU for 7 days.
Control Day 7
Phospho-elF4E
elF4E
GAPDH
Figure 3.2.8 Western Blot analysis o f eIF4E protein in A549 cells following 
treatment with 1 O^M CdU for 7 days.
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Figure 3.2.9 Western Blot analysis o f eIF4E protein in A549 cells following 
treatment with 70nM BromoUracil for 7 days.
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The change of morphology in both cell lines following 7-days o f treatment with 
IO^ iM  BrdU was investigated Both cell lines an approximate 5- to 10-fold increase 
m cell surface area occurred, with most o f the cells acquiring a stretched, flattened 
appearance
Immunocytochemical analysis for was conducted on treated DLKP and A549 cells to 
investigate if  the observed changes m morphology were accompanied by changes in 
marker protein expression CK8, CK18 or CK19 were not detected by 
immunocytochemistry or western blot analysis m DLKP pnor to treatment with 
BrdU, but following treatment all three cytokeratins were present in approximately 
10% of the treated-DLKP cells Increased number o f keratin-positive cells and 
increased intensity o f staining was evident in DLKP cells treated for 7 days
CK8, CK18 and CK19 filaments were present in A549 cells pnor to BrdU treatment 
Increased keratin synthesis was detected immunocytochemically following BrdU- 
treatment and this was further confirmed for CK8 by western blotting where an 
increase in the cytokeratin proteins where observed after 7-day and 14-day exposure
DLKP and A549 BrdU-treated cells were also examined immunocytochemically to 
determine any alterations in mtegrin expression Analysis revealed that appeared to 
be marked increases both a 2- and pi-mtergrin subunits EpCAM expression levels 
were also up-regulated in both cell lines following BrdU-treatment
Section 3.1 15 S um m ary  of the effects o f 5-B rom o-2 '-deoxyU ridine (B rdU )
on differentiation  status of D LK P and  A549 cell lines
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The ability o f 5-Iodo-2 -deoxyUridine (IdU) to induce differentiation was also 
investigated DLKP and A549 cells treated with IOjiM IdU for 7-days and 
investigated for morphological changes Both DLKP and A549 treated cells became 
very flattened and stretched The observed alteration in morphology after IdU 
treatment was comparable to the observed in BrdU treatments
Analysis of the selected marker proteins by immunocytochemistry revealed that 
cytokeratins 8, 18 and 19 were all increased in A549-treated cells and that they were 
induced in the DLKP cell line, when compared to the control untreated DLKP and 
A549 cells Western blot analysis was performed for CK8 m IdU-treated A549 cells 
exposed for 7- and 14-days Ail three cytokeratins were found to be increased after 7- 
days with a greater increase observed after 14-days by immunocytochemistry
Immunocytochemical analysis for ct2-, Pi-intergnn and EpCAM revealed that 
expression levels of these markers were increase following exposure to IdU for 7- 
days in both DLKP and A549 cell lines Pi-intergnn showed a greater increase than 
the other two markers
Section 3.1 16 S um m ary  o f the effects o f 5 -Iodo-2 '-deoxyU ndine (IdU ) on
the differentiation  sta tus o f D LK P an d  A549
i
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DLKP and A549 cells exposed to CdU for 7-days were investigated for 
morphological changes Treated DLKP and A549 cells became very flattened and 
stretched and an approximately 5- to 10-fold increase in cell surface area occurred 
The morphological changes seen were comparable to those noted m BrdU treatment 
o f these cell lines
Analysis o f the selected differentiation protein markers by immunocytochemistry 
revealed that cytokeratins 8,18 and 19 were induced m DLKP and increased in 
A549 following CdU treatment Increases in the cytokeratin filaments were also 
observed in A549 treated cells Western blot analysis confirmed that A549 cells 
treated with CdU for 7- and 14-days that cytokeratins 8 was increased
DLKP and A549 BrdU-treated cells were also examined immunocytochemically to 
determine any alterations in integnn expression Analysis revealed that appeared to 
be marked increases both a 2- and Pi-intergnn subunits EpCAM expression levels 
were also up-regulated in both cell lines following CdU treatment
Section 3 1 1 7  Sum m ary  of the effects of 5 -C h loro-2 '-deoxyU ndine (CdU )
on the differentiation  status of D LK P an d  A549
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Note the affect o f 5-FU was not investigated in the differentiation status o f DLKP
A549 cells exposed to 5-FU for 7-days were investigated for morphological changes 
Treated A549 cells became flattened and stretched The increase in cell surface area 
observed in BrdU treated cells did not occur to the same extent in 5-FU treated cells
Analysis o f the selected differentiation protein markers by immunocytochemistry 
revealed that cytokeratins 8, 18 and 19 were noted A549 cells following treatment 
with 5-FU Western blot analysis confirmed that A549 cells treated with 5-FU for 7- 
and 14-days that cytokeratins 8 was increased
A549 5-FU-treated cells were also examined immunocytochemically to determine 
any alterations in integnn expression Analysis revealed that appeared to be marked 
increases both cc2- and Pi-intergrin subunits EpCAM expression levels were also up- 
regulated m both cell lines following 5-FU treatment
Section 3 1 18 S um m ary  o f the effects of 5-FIuro-deoxy U rid ine (5-FU) on
the differen tiation  sta tus of A549
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DLKP and A549 cells exposed to 5,2 -FdU for 7-days were investigated for 
morphological changes Treated DLKP and A549 cells became very flattened and 
stretched and an approximately 10-fold increase m cell surface area occurred A549 
cells exhibited a much larger increase in cell surface area than seen in 5,2 -FdU 
treated cells The increase in cell surface area was much greater than that observed in 
BrdU treated DLKP and A549 cells
Analysis o f the selected differentiation protein markers by immunocytochemistry 
revealed that cytokeratins 8, 18 and 19 were induced in DLKP following 5,2 -FdU 
treatment Increases m the cytokeratin filaments were also observed m A549 treated 
cells Western blot analysis confirmed that A549 cells treated with CdU for 7- and 
14-days that cytokeratins 8 was increased
DLKP and A549 BrdU-treated cells were also examined immunocytochemically to 
determine any alterations in integnn expression Analysis revealed that appeared to 
be marked increases both ct2- and Pi-intergnn subunits EpCAM expression levels 
were also up-regulated in both cell lines following 5,2 -FdU treatment
Section 3 1 1 9  S um m ary o f the effects of S -F lu ro ^ -d e o x y U n d in e  (5 ,2 '-
FdU ) on the d ifferen tiation  sta tus of D LK P and  A549.
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The ability o f 5,5 -FdU to induce differentiation was also investigated DLKP cells 
treated with IOjiM 5,5 -FdU for 7-days and investigated for morphological changes 
DLKP treated cells became very flattened and stretched The observed alteration m 
morphology after 5,5 -FdU treatment was comparable to the observed m BrdU 
treatments
Analysis o f the selected differentiation protein markers by immunocytochemistry 
revealed that cytokeratins 8,18 and 19 were induced in DLKP following 5,5 -FdU 
treatment 5,5 -FdU DLKP-treated cells were also examined immunocytochemically 
to determine any alterations in integrin expression Analysis revealed that appeared 
to be a moderate increase both 0C2- and Pi-intergnn subunits EpCAM expression 
levels were also induced m DLKP following 5,5 -FdU treatment
Section 3.1 20 S um m ary  o f the effects o f 5-F luro-5 '-deoxy U rid ine (5 ,5 '-
FdU ) on the d ifferen tiation  sta tus o f D LK P.
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Section 3 121 Summary of the effects of 5-BromorUndine and 5-
BromoUracil on the differentiation status of DLKP and 
A549.
Toxicity profiles (results not shown) for 5-BromoUridme and BromoUracil in both 
DLKP and A549 cells revealed that it did not appear to be very toxic A 
concentration o f 70jaM was chosen for the differentiation studies Investigation of the 
morphological changes in DLKP and A549 cells treated with 5-BromoUndme and 
BromoUracil for 7-days did not reveal any obvious alterations in cell surface area 
The cells did not acquire a flattened and stretched appearance as was seen in some of 
the other analogue treatments
Immunocytochemical analysis o f DLKP cells treated 5-BromoUndme and 
BromoUracil for 7-days appeared to show very little induction o f the CK8, CK18 and 
CK19 Assessment o f immunocytochemistry of the results revealed no major change 
m the expression level of ct2-, pi-integnns or EpCAM
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Section 3.2 DNA Microarrays
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Section 3.2.1 DNA M icroarrays
The success o f the human genome project has allowed biologists to identify 
almost all the genes that are responsible for the genetic makeup of humans. The 
next important task is to assign function to the nearly 40,000 genes sequenced. 
The use o f microarrays to analyse the gene expression on a global level has 
recently received a great deal o f attention. In order to understand the complex 
mechanisms and networks involved in the control processes o f normal and 
disease states o f eukaryotic cells, it is no longer enough to focus on isolated 
pathways or single genetic events. Global transcriptional profiling using 
microarray techniques now offer the chance to develop a more complete 
understanding of gene function, regulation and interactions. The technique o f 
microarray analysis has the huge advantage over other gene profiling methods in 
that mRNA isolated from a given cell, tissue or tumour can be used to prepare a 
labelled sample and hybridised simultaneously to a vast number o f DNA 
sequences. Microarrays now offer great flexibility in the number o f target 
sequences that maybe analysed per microarray. As few as a couple o f probe 
sequences to as many as the nearly 40.000 genes o f the human genome can now 
be analysed on one single microarray slide.
A wide variety o f different microarrays platforms have been developed by both 
academic and commercial companies. The two main groups o f microarrays 
currently in mainstream use; these are complementary DNA (cDNA) and 
oligonucleotides. Probes for cDNA arrays are generally printed onto glass or 
nylon slides at exact locations. The probes for cDNA (spotted) microarrays are 
prepared from products o f the polymerase chain reaction (PCR) generated from 
cDNA libraries. Oligonucleotide microarrays on the other hand, arc mostly 20- 
lOOmers w'hich are synthesised in situ. either by photolithography onto silicon 
wafers or by ink-jet technology. One advantage oligonucleotide microarrays 
have over cDNA microarrays is the fact that the sequence used for the oligos can 
be designed to the most unique part o f  a given transcript, making it possible to 
discriminate between closely related genes or splicc variants. The microarray 
gene expression studies which were performed in this body of work were
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performed using Affymetrix® Human Genome U133A GeneChips® (Section 
2 15)
Section 3 2 2 BrdU Array
Three separate DNA microarray experiments were performed on DLKP cells 
treated with BrdU over a time course These experiments have been labelled 
Exp 1, 2 and 3 for simplicity The initial experiments, Exp 1 and Exp 2, were 
preformed at the same time, therefore, the results from these two experiments 
will be discussed together Also, these initial microarray experiments were 
performed using one biological sample from each time point, whereas, the third 
expenment, Exp 3, was performed in triplicate using biological replicates And 
the results of Exp 3 will be discussed in a separate subsection
Section 3 2 2 1 BrdU Microarrays - Exp 1 and Exp 2
In the preliminary two BrdU-treated DLKP microarray expenments, Exp 1 and 
Exp 2, hybridisations were performed using the Affymetrix U133A chips 
(Section 2 15) Cells were harvested and RNA isolated (as per Section 2 10) at 
the following time points of 0, 1, 3, 7 and 14 days in Exp 1 and 0, 1 and 7 days 
for Exp 2 These microarray experiments were performed using single samples 
from each time point cRNA was prepared (Section 2 15 1) from total RNA 
which had been checked for quality, and shipped to the Conway Institute at 
University College Dublin, where it was hybridised to the Affymetrix® Human 
Genome U133A GeneChips®, and the chips scanned using the Affymetrix Chip 
scanner This data was then sent back to us
The resulting data sets were scaled and normalised as per analysis earned out by 
Rushton, J J , et a l , (2003) In order to compare gene expression results in the 
microarray experiments performed, it was necessary to normalise the data 
obtained following scanning the microarray GeneChips There are two main 
ways in which this type o f normalisation is performed Ter-chip’ and ‘Per-gene’ 
normalisations (Reviewed m Section 2 15 1) This was performed using
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Affymetnx Microarrays Suite v5 0 software, which scales all o f the probe sets so 
that the average is 100 for each GeneChip The average probe signal was 
calculated for each GeneChip and this was adjusted to 100 by multiplying by a 
scaling factor By doing this for each GeneChip it makes the data easier to 
compare across different GeneChips in a given experiment
Additional data analysis was preformed using GeneSprmg (Silicon Genetics) 
The data were normalised to the mean of the day 0 samples and then filtering 
was used to identify genes that were consistently up- or down-regulated in the 
day 1, 3, 7 or 14 day samples The filter used was a 1 5 fold increase or decrease 
and the genes were also filtered using a ‘Present’ or ‘Marginal’ filter A filter of 
1 5-fold up or down was selected in these microarray experiments since it is 
generally thought that the expression levels of transcription factors do not alter 
dramatically in cells It is thought that the control of gene expression is tightly 
controlled by small alterations in transcription factor expression levels Gene 
lists were then generated for each of the two rounds o f microarrays containing 
the gene name, accession number, Affymetnx Probe Id number and the fold 
increase/decrease o f each gene found to be differentially expressed
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Section 3.2 2 2 Validation of Initial DNA Microarrays and Gene
expression changes in BrdU-treated DLKP cells
In order to validate the gene lists which were generated from the expression 
analysis performed using the GeneSpring analysis software package, and to 
demonstrate that the fold increase/decrease observed were real expression 
changes, a set o f genes was selected from the gene lists generated RT-PCR 
analysis was performed on these genes In the majority o f cases the results 
confirmed the trends observed in the microarray analysis The following section 
contains the result for each of the selected genes In each subsection a graph 
illustrating the fold increase/decrease found following microarray analysis, along 
with the corresponding RT-PCR result, is shown
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Section 3 2 2 2 1 FSTL1
FSTL1 is protein with similarity to follistatin, an activin-bmding protein It is 
known to contain an FS module, a folhstatin-hke sequence containing 10 
conserved cysteine residues FST1 is thought to be an autoantigen associated 
with rheumatoid arthritis Following gene expression analysis, using GeneSprmg 
analysis software, the FSTL1 gene was demonstrated to increase in BrdU-treated 
DLKP cells It was noted, that after three days o f exposure o f the cells to BrdU, 
the level o f expression of the gene started to increase to a maximum at 7-days A 
decrease in FSTL1 was observed between day 7 and day 14 samples This result 
was confirmed by RT-PCR analysis (Section 2 11), which showed a similar 
pattern o f expression for the FLST1 gene
FSTL1
Time (days)
M DO D1 D3 D7 D14 NegCtl
603bp
310bp
GAPDH
FSTL1
F igure  3 2.1 M icroarray analysis (top im age) show ing fold increase o f  FSTL1
m R N A  R T -R C R  analysis (low er im age) confirm ing an increase in FSTL1
m R N A  expression  levels
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Section 3.2.2.2 2 FLH 2
FHL2 belongs to the family of LIM proteins, which are known involved in 
protein-protein interaction and transcriptional regulation Recent evidence has 
suggested that FHL proteins may act as co-regulators involved in the modulation 
o f tissue-specific gene expression by interacting with different transcription 
factors Such transcription factors include JUN and FOS and these associations 
have been shown to result in a powerful activation o f AP-1-mediated 
transcription Following gene expression analysis, an increase in the expression 
of FHL2 mRNA was observed in BrdU-treated DLKP cells mRNA levels were 
to dramatically increase at day 7 to approximately 6 5-fold at 7days However, 
this increase was not maintained at day 14 where they were reduced to 4-fold 
higher than control cells This result was confirmed by RT-PCR analysis, which 
showed a similar pattern of expression for the FHL2 gene
FLH2
Time (days)
F igure  3.2 2 M icroarray analysis (top im age) show ing fold  increase o f  FH L2
m R N A  R T-R C R  analysis (low er im age) confirm ing an increase in FH L2
m R N A  expression  levels
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Section 3 2.2.2.3 TN FSF7
TNFSF7 belongs to the tumour necrosis factor (TNF) ligand family and this 
cytokine has been reported to a play a role in the regulation of B-cell activation 
and IgG production Microarray analysis revealed an increase in TNFSF7 
transcript levels in drug-treated cells It was found that after one day of exposure 
o f the cells to BrdU that the level of expression of TNFSF7 mRNA increased 
gradually over the course o f the experiment, to approximately 6 5-fold at day 14 
This result was confirmed by RT-PCR analysis, which showed a similar pattern 
of expression for the TNFSSF7 gene
TNFSF7
0 1 3 7 14
Time (days)
D7 D14 Neg Ctl
GAPDH
TNFSF7
F ig u re 3  2 3 G ene expression  analysis (top im age) sh ow ing fo ld  increase o f
T N FSF7 m R N A  R T-R C R  analysis (low er im age) confirm ing an increase in
T N FSF7 m R N A  expression  levels
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Section 3.2.2 2 4 GPX3
Microarray analysis revealed that an increase in GPX3 mRNA expression levels 
following exposure to DLKP to BrdU It was demonstrated at day 1 the level of 
GPX3 mRNA levels increased by 4-fold to a maximum of approximately 7-fold 
after 3-days o f exposure to the drug A decrease in GPX3 mRNA was observed 
at day 7 and day 14 where mRNA levels had reduced to 5- and 3-fold, 
respectively These results was confirmed by RT-PCR analysis, which showed a 
similar pattern of expression for the GPX3 mRNA expression levels
GPX3
Time (days)
M DO D1 D3 D7 D14 Neg Ctl
603bp
310bp
GAPDH
GPX3
F igure  3 3 4 G ene expression  analysis (top im age) show ing fo ld  increase o f
G PX3 m R N A  R T-RC R analysis (low er im age) confirm ing an increase in G PX 3
m R N A  expression  levels
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Section 3 2 2 2 5 Zyxin
Zyxin is a low abundance phosphoprotein that is concentrated at adhesion 
plaques and along the actin filament bundles near where they insert at adhesion 
plaques Zyxin has features of an intracellular signal transducer and may 
function as a scaffold for the assembly of multimeric complexes These protein 
assemblages could mediate integrm-dependent signalling events that lead to cell 
differentiation or modulation of cyto-architecture Microarray analysis revealed 
that an increase in Zyxin transcript levels in BrdU-treated DLKP cells A 3-fold 
increase in Zyxin mRNA was observed in the day 1 sample and this increase was 
maintained up to day 7, where mRNA levels had to a maximum of approximately 
3 5-fold At day 14 a decrease in Zyxin mRNA expression levels was observed, 
but did not return to control levels This result was confirmed by RT-PCR 
analysis, which showed a similar pattern of expression for the Zyxin transcript 
levels
Z y x in
T ime (days)
M DO D1 D3 D7 D14 NegCtl
Figure 3 2 5 Gene expression analysis (top image) showing fold increase o f 
Zyxin mRNA RT-RCR analysis (lower image) confirming an increase in Zyxin 
mRNA expression levels
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Section 3.2.2.2.6 Spermidine/spermine N -acetytransferase (Spd/Spn)
Spermidine/spermine N-acetytransferase is a highly regulated enzymatic protein 
is known induced by a variety o f toxic agents, hormones and polyamines. It is 
also in belongs to a metabolic pathway which involves ornithine decarboxylase 
and S-adenosylmethionione decarboxylase. The combination o f these enzymes 
fine tune intracellular polyamine concentration, underscoring the important role 
o f these proteins in growth and cell survival. Following microarray analysis, 
Spd/Spn mRNA levels found to remain at a similar expression level as controls 
cells up to three days o f exposure to BrdU. However, microarray analysis 
revealed a 4.5-fold increase in Spd/Spn mRNA levels following 7 days exposure 
to the drug, but this increase in transcript levels was reduced to approximately 3- 
fold at day 14. RT-PCR analysis confirmed the results generated following 
microarray expression analysis using GeneSpring software.
Spd/Spn
Time (days)
Figure 3.2.6 G ene expression  analysis (top im age) sh ow ing  fold increase o f
Spd/Spn m R N A . RT-RCR analysis (low er im age) confirm ing an increase in
Spd/Spn m R N A  expression levels.
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Section 3.2 2 2.7 Id2
The Id family o f four hehx-loop-hehx (HLH) transcription factors (Id l, Id2, Id3 
and Id4) act as dominant negative regulators o f basic HLH proteins Since many 
bHLH proteins positively regulate sets o f genes during cell fate determination 
and cell differentiation, Id proteins are thought to inhibit the ability o f bHLH 
proteins from binding DNA and inhibit cell differentiation Although Id proteins 
traditionally have been viewed as negative regulators of differentiation, recent 
work has revealed much wider biological roles, and they are now thought to be 
important in development, cell cycle control and tumour biology Microarray 
analysis revealed that Id2 transcript levels were increased to approximately 5 5- 
fold following exposure of cells to BrdU for 24 hours However, over the 
remainder o f the experiment Id2 mRNA levels declined to 2 5-fold day 7 and day 
7 By day 14 transcript levels had returned to those of control cells A similar 
pattern o f expression was demonstrated following RT-PCR analysis for Id2 in 
BrdU-treated cells
ID2
Time (days)
Figure 3 2 7 Gene expression analysis (top image) showing fold increase of 
Id2 mRNA RT-RCR analysis (lower image) confirming an increase in Id2 
mRNA expression levels
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Section 3 2 2 2.8 eIF2-associated p67
Initiation of protein synthesis plays a central role in gene expression and is 
largely regulated at the level of formation of the initiation complex with the 
eukaryotic initiation factor 2 (eIF2), Met-tRNA, and the 40S ribosome The rate 
o f protein synthesis is regulated at the level o f phosphorylation of the a-subumt 
of eIF2, which is controlled by the cellular glycoprotein, p67 p67 protects the 
a-subumt from phosphorylation by its kinases Following microarray expression 
analysis, eIF2-associated p67 mRNA expression levels were shown to decrease 
at day 1 and day 3 in BrdU-treated DLKP cells and to increase to near control 
levels at the day 7 However, a decrease at day 14 decrease marginally was 
observed RT-PCR analysis demonstrated a small decrease in eIF2-associated 
p67 mRNA in the day 3 sample, with the remaining time points exhibiting the 
same level of expression as control cells
D14 NegCtl
GAPDH
eIF2-
associated
p67
F igure  3 2 8 G ene expression  analysis (top im age) sh ow ing fo ld  increase o f
eIF 2-associated  p67 m R N A  R T-R C R  analysis (low er im age) confirm ing an
increase in eIF2-associated  p67 m R N A  expression  levels
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Section 3 2 2 2 9 Im m ediate-early  Response fac to r 3 (IER 3)
IER3 is a member of mtermediate-early gene family o f proteins that are thought 
to be critical for the control o f cell proliferation and apoptosis in several cell 
types Following gene expression analysis, using GeneSpnng analysis software, 
the IER3 gene was shown to increase in BrdU-treated DLKP cells It was found 
that after 1 day of exposure o f the cells to drug that the mRNA levels o f IER3 
had increased to approximately 2-fold and increased further to 3 5-fold at day 7 
At day 14 a reduction in transcript levels was observed, but did not return to that 
o f control levels RT-PCR analysis confirmed the microarray expression results 
obtained following GeneSpnng analysis, however a increase in IER3 mRNA 
levels was demonstrated across all samples and no reduction m IER3 signal was 
found at day 14
IER3
Time (days)
M DO D1 D3 D7 D14 NegCtl
603bp
310bp
GAPDH
1ER3
F igure  3 2 9 G ene expression  analysis (top im age) show ing fold  increase o f
IER3 m R N A  R T-R C R  analysis (low er im age) confirm ing an increase in IER3
m R N A  expression  levels
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Section 3 2.2.2.10 LO XL2
A family o f four proteins know as LOXL (LOXL 1-4) were recently identified 
and it has been suggested that these proteins are located in distinct intracellular 
and intranuclear locations, each with related but different functions that include 
cell growth control, tumour suppression, senescence and chemotaxis 
Microarray analysis revealed an increase in LOXL2 transcript levels in drug 
treated DLKP cells It was demonstrated that after 3 days o f exposure o f DLKP 
cells to BrdU mRNA expression levels o f LOXL2 remained at control levels up 
to day 3, after which they were observed to increase to approximately 4-fold 
However, at day 14 mRNA levels were reduced marginally to 3 5-fold This 
result was confirmed by RT-PCR analysis, which demonstrated that LOXL2 
transcript levels increased over the course of the experiment
D7 D14 NegCtl
GAPDH
LOXL2
—►r— ^
F igure  3 2.10 G ene expression  analysis (top im age) show ing fold  increase o f
L O X L2 m R N A  R T-R C R  analysis (low er im age) confirm ing an increase in
L O X L2 m R N A  expression  levels
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Section 3 2.2.2 11 p21
Following microarray expression analysis mRNA expression levels o f CDKN1A 
were found to increase in drug-treated DLKP cells Gene expression and RT- 
PCR analysis revealed a marked increase in CDKN1A mRNA expression levels 
after 24 hours of exposure of cells to BrdU and this increase was maintained over 
the experiment
M DO D1 D3 D7 D14 NegCtI
Figure 3 2 11 RT-RCR analysis (bottom image) shows the level of CDKN1A 
mRNA following exposure o f DLKP to BrdU
603bp _*J
L  GAPDH
310bp ~ H
U— p21
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Section 3 2 2.3 D LK P B rdU  A rray  -  Exp 3
The third DLKP BrdU microarray experiment, Exp 3, was performed using 
Affymetnx U133A GeneChips® RNA was isolated (Section 2 10) from cells 
harvested after 0, 3 and 7 days exposure to BrdU (Section 2 7) This set o f DNA 
microarrays were performed in triplicate using biological replicates The isolated 
RNA was shipped to Affymetnx where the cRNA was prepared and hybndised 
to U133A GeneChips® and the chips scanned using an Affymetnx GeneChip 
scanner The data was received back, and expression analysis was performed as 
descnbed below
The data set was normalised using the Affymetnx PLIER (Probe Logarithmic 
Error intensity Estimate) method in GREX This normalisation method is 
recommended by Affymetnx for use on their GeneChips™ The PLIER method 
(Reviewed m Section 2 15 3) produces an improved signal by accounting for 
experimentally observed patterns in probe behaviour and handling error at the 
appropriately low and high signal values Some of the advantages of using this 
method of normalisation included higher reproducibility o f signal (lower 
coefficient of vanation) without loss o f accuracy and higher differential 
sensitivity for low expressors
Having subjected the data set to the PLIER normalisation method, the data was 
then imported into GeneSpnng analysis software (Silicon Genetics) and a new 
expenment was set up As a result o f using the PLIER method of normalisation, 
the data did not need to undergo ‘Per Chip’ normalisation in GeneSpnng In 
GeneSpnng the samples were then normalised to the mean of the day 0 samples
A filter was then applied to the data to select genes that had a ‘Present’ or 
‘Marginal’ flag in three out of the nine samples The filter also contained a 
condition that selected for genes that crossed a 1 5 fold threshold, up or down, m 
either the day 3 or day 7 samples
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Section 3 2 2.4 V alidation  of the D L K P-B rdU  E xp 3 M icro array s
In order to validate the gene lists, which were generated from the expression 
analysis carried out using GeneSpnng, and to demonstrate that the fold 
increase/decrease observed were actual real expression changes, a set o f genes 
were selected from the gene lists generated RT-PCR analysis was performed on 
these genes The expression patterns which confirmed the results that were 
obtained from the chip expression analysis
The following section contains the result for each of the genes selected In each 
subsection a graph illustrating the fold increase/decrease found following 
expression analysis, along with the confirmation RT-PCR result, is shown
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Section 3 2 2.4 1 Spd/Spn
Spermidine/spermine N-acetytransferase is a highly regulated enzymatic protein 
is known to be inducible by a variety of toxic agents, hormones and polyamines 
It is also in belongs to a metabolic pathway which involves ornithine 
decarboxylase and S-adenosylmethiomone decarboxylase The combination of 
these enzymes fine tune intracellular polyamine concentration, underscoring the 
important role o f these proteins m growth and cell survival Microarray analysis 
revealed an increase in Spd/Spn mRNA expression levels following treatment of 
DLKP cell with BrdU Spd/Spn transcript levels were shown to increase at day 
three to 1 8-fold and to 2 8-fold at day 7 RT-PCR analysis demonstrated an 
increase of several fold in Spd/Spn mRNA expression levels following three 
days exposure o f DLKP to BrdU A slight reduction in Spd/Spn mRNA was 
observed in the day 7 sample in comparison to the day 3, however, Spd/Spn 
mRNA levels were still several fold increased when compared to control 
untreated cells
Spd/Spn
Timo (days)
Neg Ctl
603bp
310bp
GAPDH
Spd/Spn
F igure  3.2 12 The top graph illustrates the fo ld  change in Spd/Spn m R N A
fo llow in g  gene expression  analysis RT-R C R  analysis (bottom  im age) sh ow s the
level o f  Spd/Spn m R N A  fo llow in g  exposure o f  D LK P to
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Section 3.2 2 4 2 HM OX1
HMOX1 is one o f two isoforms of heme oxygenase that is involved in 
catabolizing heme to biliverdin, carbon monoxide and free iron and is thought to 
be involved in iron homeostasis Following gene expression analysis, HMOX1 
mRNA levels were found to increase by approximately 2-fold in the day 3 
sample and the expression level o f this gene was maintained at this level in the 
day 7 sample This result was confirmed by RT-PCR analysis which 
demonstrated a significant increase in HMOX1 mRNA expression levels across 
the experiment in comparison to untreated control cells
Neg Ctl
603bp
310bp
HMOX1
GAPDH
F igure  3 2.13 The top graph illustrates the fold  change in  H M O X1 m R N A
fo llow in g  gene expression  analysis RT-RC R analysis (bottom  im age) sh ow s the
level o f  H M OX1 m R N A  fo llow in g  exposure o f  D LK P to BrdU
124
Section 3.2.2.4 3 Id2
The Id family of four helix-loop-helix (HLH) transcription factors (Id l, Id2, Id3 
and Id4) act as dominant negative regulators o f basic HLH proteins Since many 
bHLH proteins positively regulate sets o f genes during cell fate determination 
and cell differentiation, Id proteins are thought to inhibit the ability o f bHLH 
proteins from binding DNA and inhibit cell differentiation Although Id proteins 
traditionally have been viewed as negative regulators of differentiation, recent 
work has revealed much wider biological roles, and are now thought to be 
important in development, cell cycle control and tumour biology Microarray 
analysis revealed a 4-fold increase in Id2 mRNA transcript levels At day 7 Id2 
expression levels were found to decrease, but still remained approximately 2-fold 
higher than control cells These results were confirmed by RT-PCR analysis 
which demonstrated a significant increase in Id2 mRNA levels in the day 3 and 
day 7 samples, with the day 7 samples slowing a reduction m Id2 signal in 
comparison to the day 3 sample
M Untreated
■MMUKUIV
Nee Ctl
603bp
310bp
F igure  3.2.14 The top graph illustrates the fold  change in Id2 m R N A  fo llow in g
gene expression  analysis R T-R C R  analysis (bottom  im age) sh ow s the lev e l o f
Id2 m R N A  fo llow in g  exposure o f  DLK P to BrdU
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Section 3 2 2 4 4 Id3
The Id family o f four hehx-loop-helix (HLH) transcription factors (Id l, Id2, Id3 
and Id4) act as dominant negative regulators o f basic HLH proteins Since many 
bHLH proteins positively regulate sets o f genes during cell fate determination 
and cell differentiation, Id proteins are thought to inhibit the ability o f bHLH 
proteins from bmdmg DNA and inhibit cell differentiation Although Id proteins 
traditionally have been viewed as negative regulators of differentiation, recent 
work has revealed much wider biological roles, and are now thought to be 
important in development, cell cycle control and tumour biology Microarray 
analysis revealed a dramatic increase in Id3 mRNA transcript levels following 
exposure o f DLKP cells to BrdU A 7 5- and 5 5-fold increase in Id3 mRNA 
expression level was observed m the day 3 and day 7 samples, respectively RT- 
PCR analysis demonstrated a similar pattern o f expression for Id3
Id3
Time (days)
Nee Ctl
603bo
310bp
GAPDH
Id3
F igure  3 2.15 The top graph illustrates the fold  change in Id3 m R N A  fo llo w in g
gene expression  analysis RT-R C R  analysis (bottom  im age) show s the level o f
Id3 m R N A  fo llow in g  exposure o f  DLK P to BrdU
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Section 3 2 2 4 5 FSTL1
FSTL1 encodes a protein with similarity to follistatm, an activin-bindmg protem 
It contains an FS module, a follistatin-like sequence containing 10 conserved 
cysteme residues This gene product is thought to be an autoantigen associated 
with rheumatoid arthritis Following microarray analysis using GeneSpnng 
analysis software, FSTL1 mRNA expression levels were revealed to increase 
several fold after exposure to BrdU Following three days treatment o f DLKP 
with drug FSTL1 mRNA were shown to increase by 1 5-fold and increased 
further to approximately 3-fold by day 7 RT-PCR analysis (Section 2 11) 
confirmed the trend in FSTL1 mRNA expression observed in the microarray 
analysis
FSTL1
Time (days)
Neg Ctl
603bp
3 1 0 b p
GAPDH
FSTL1
F igure  3 2 16 The top graph illustrates the fold  change in FSTL1 m R N A
fo llow in g  gene expression  analysis RT-R C R  analysis (bottom  im age) sh ow s the
level o f  FSTL1 m R N A  fo llow in g  exposure o f  D LK P to BrdU
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Section 3 2 2 4 6 FH L2
FHL2 belongs to the family o f LIM proteins, which are involved in protein- 
protein interaction and transcriptional regulation Recent evidence has suggests 
that FHL proteins may act as co-regulators involved in the modulation o f tissue- 
specific gene expression by interacting with different transcription factors Such 
transcription factors include JUN and FOS and these associations have been 
shown to result in a powerful activation of AP-1-mediated transcription 
Microarray analysis revealed an increase m FHL2 transcript levels in drug- 
treated DLKP cells A 3-fold increase in FHL2 mRNA expression levels was 
observed following three days exposure o f cells to BrdU and expression levels of 
the gene increase further to 5 5-fold m the day 7 sample RT-PCR analysis 
demonstrated a similar increase in FHL2 transcript levels as was observed in the 
microarray analysis
FHL2
Time (days)
M Oil 7 0
603 hn 
310hn
lassie^
GAPOH  
FHT ?
F igure  3 2 17 The top graph illustrates the fold  change in FH L2 m R N A
fo llow in g  gene expression  analysis R T-R C R  analysis (bottom  im age) show s the
level o f  FHL2 m R N A  fo llow in g  exposure o f  D LK P to BrdU
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Section 3 2 2.4 7 TN FSF7
TNFSF7 belongs to the tumour necrosis factor (TNF) ligand family and this 
cytokine has been reported to a play a role in the regulation o f B-cell activation 
and IgG production Following microarray analysis, using GeneSpnng analysis 
software, it was observed that the mRNA expression levels o f TNFSF7 increase 
by approximately 1 5- and 3 3-fold in the day 3 and day 7 samples, respectively 
This results was confirmed by RT-PCR analysis which demonstrated a similar 
increase in TNFSF7 transcript levels
TNFSF7
Time (days)
F igure  3.2 18 The top graph illustrates the fo ld  change in T N FSF7 m R N A
fo llow in g  gene expression  analysis RT-RC R analysis (bottom  im age) sh ow s the
level o f  T N FSF7 m R N A  fo llow in g  exposure o f  D LK P to BrdU
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Section 3.2.2.S Investigation of potentially co-regulated genes in BrdU- 
trcatcd DLKP cells as identified using DNA microarrays
Time coursc microarray experiments reveal information about the temporal 
transcription profile o f spotted genes. Sets o f genes with the same expression 
pattern can be grouped into clusters but the identification o f molecular 
mechanisms responsible for co-expression requires further investigation. By 
using comparative promoter analysis it is possible to identify genes for which co- 
expression may be a result o f co-regulation. The aim of this analysis is to find 
promoter features that may be potentially responsible for co-expression of 
differentiation related genes.
DLKP cells, exposed to the differentiation-modulating agent BrdU, undergo 
morphological change and the several epithelial markers o f lung cell 
differentiations are induced. In order to analyse global changes the 
transcriptional profiles o f BrdU-trcatcd DLKP cells were examined using 
Affymetrix UA133 DNA microarrays. Following DNA microarray analysis the 
data generated was normalised and filtered (Section 2.15.2) and gene lists for up- 
and down-regulated differentially expressed genes were then generated.
Section 3.2.2.5.1 Gene Clustering
Effective comparative promoter analysis requires tightly clustered gene 
expression profiles. To generate tight clusters the gene lists were subjected to 
ANOVA analysis and the data from this microarray experiment was grouped into 
13 clusters (Figure 3.2.19). In theory' from analysis o f  clustered data sets it is 
possible to identify genes that are co-regulated and promoter models that are 
involved in the regulation o f these clustered genes. One software package which 
is currently available for this type o f analysis is the Genomatix Software Suite 
(www.genomatix.de).
Clustering algorithms may be performed on microarray data sets to help identify 
genes that have similar patterns o f gene expression and the results can be easily 
visualised. Hierarchical clustering has become one of the most widely used
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techniques for the analysis o f gene expression data Clustering is an 
agglomerative approach in which single expression profiles are joined together 
until the process had been carried to completion Simplified, hierarchical 
clustering works on the basis where a pair o f genes that have the most similar 
expression pattern are found, these two genes are joined together and then the 
method identifies the next most similar pair of genes This process continues 
until all o f the genes are joined into one large cluster Clustering of microarray 
data may only be carried out on data sets that have been normalised and there are 
several different variations on hierarchical clustering
An alternative to hierarchical cluster is k-means clustering In k-means 
clustering objects are partitioned into a fixed number o f clusters This process 
may be computationally intensive K-means clustering is particularly useful 
when used with other techniques such as principal component analysis Principal 
component analysis allows visual estimation of the number o f clusters 
represented by the data
The hypothesis behind clustering techniques is that genes in a cluster may share 
some common function or regulatory elements However, classifications based 
on clustering algorithms are dependent on the particular methods used, the 
manner m which the data are normalised, and the manner in which similarity is 
measured All o f these factors can have a huge effect on the outcome of 
clustenng analysis Therefore, no single method of clustering is more or less 
appropnate to use on a given data set Furthermore, use o f one of more methods 
o f clustenng may in fact highlight differentiation relationships within a data set 
which consequently may be found to be important Tools and techniques for 
analysis data sets are under continual development and the ultimate guide to the 
use o f any data analysis method must be our biological understanding of the 
experiment under investigation
A worked example for the identification o f co-regulated genes in the BrdU Exp 
3 microarray expenment is detailed in Section 4 6
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Figure 3.2.19 Heat map of 732 differentially regulated genes in BrdU DNA 
microarray. Following gene expression analysis o f the DNA microarrays, the 
data set was subjected to statistical analysis and the gene lists then clustered. 13 
clusters were then selected for further analysis. Clusters were choscn so that not 
more than approximately 150 genes were contained in each cluster.
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Section 3 2 3 D L K P 5,2-FdU  A rray s  DNA M icroarrays
Affymetnx U133A human expression DNA microarrays were probed with RNA 
isolated from 5,2 -FdU-treated DLKP cells from a time course expenment Cells 
were harvested after 0, 3 and 7 days exposure to the modulating agent (Section 
2 7) and RNA isolated (Section 2 10) cRNA was then prepared (Section 2 15 1) 
and transported to the Conway Institute at Umversity College Dublin, where it 
was hybndised to the U133A GeneChips™, and the chips were scanned using 
the Affymetnx Gene Chip scanner The raw data was retrieved from the Conway 
Institute and the following analysis was performed on the data set
The data set was normalised and filtered as has been described for in the BrdU 
Exp 3 microarray expenment (Section 3 2 2 3) using the Affymetnx PLIER 
(Probe Loganthmic Error intensity Estimate) method in GREX and using 
GeneSpnng gene expression analysis software
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Section 3.2 3 1 V alidation of the 5 ,2 '-FdU  DNA M icro array s
In order to validate the gene lists, which were generated from the expression 
analysis earned out using GeneSpnng, and to demonstrate that the fold 
increase/decrease observed were actual real expression changes, a set of genes 
were selected from the gene lists generated RT-PCR analysis was performed on 
these genes The expression patterns which confirmed the results that were 
obtained from the chip expression analysis
The following section contains the result for each of the genes selected In each 
subsection a graph illustrating the fold increase/decrease found following 
expression analysis, along with the confirmation RT-PCR result, is shown
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Section 3.2 3 1 1 Id2
The Id family of four helix-loop-helix (HLH) transcription factors (Id l, Id2, Id3 
and Id4) act as dominant negative regulators o f basic HLH proteins Since many 
bHLH proteins positively regulate sets of genes during cell fate determination 
and cell differentiation, Id proteins are thought to inhibit the ability o f bHLH 
proteins from binding DNA and inhibit cell differentiation Although Id proteins 
traditionally have been viewed as negative regulators o f differentiation, recent 
work has revealed much wider biological roles, and are now thought to be 
important in development, cell cycle control and tumour biology Following 
microarray analysis m DLKP cells treated with 5,2 -FdU a significant increase in 
Id2 mRNA expression levels was observed Id2 transcript levels increased to a 
maximum of 7 5-fold in the day 3 sample, and declined slightly to 4 8-fold at day 
7 RT-PCR analysis confirmed the results o f the microarray analysis performed 
and demonstrated a similar increase in Id2 mRNA levels
Id2
Time (days)
Neg Ctl
603bp 
310bp
GAPDH
ID2
Figure 3 2 20 Top graph illustrates the fold change in Id2 mRNA following 
gene expression analysis RT-PCR analysis (bottom image) shows the actual 
level o f Id2 at the various time points
135
Section 3.2.3.1.2 Id3
The Id family o f four helix-loop-hehx (HLH) transcription factors (Id l, Id2, Id3 
and Id4) act as dominant negative regulators of basic HLH proteins Since many 
bHLH proteins positively regulate sets o f genes during cell fate determination 
and cell differentiation, Id proteins are thought to inhibit the ability o f bHLH 
proteins from binding DNA and inhibit cell differentiation Although Id proteins 
traditionally have been viewed as negative regulators o f differentiation, recent 
work has revealed much wider biological roles, and are now thought to be 
important m development, cell cycle control and tumour biology Microarray 
analysis revealed an increase in Id3 mRNA levels following exposure DLKP to
i
5,2 -FdU A 7 5- and 6 4-fold increase in Id3 mRNA levels was observed in day 
3 and day 7 samples, respectively RT-PCR analysis confirmed this results and 
revealed a similar increase in Id3 transcript levels
M Untreated 3D 7D Neg Ctl
V i iMhrnint>TM^
F igure  3 2 21 Top graph illustrates the fold change in  Id3 m R N A  fo llo w in g
gene expression  analysis R T-PCR  analysis (bottom  im age) show s the actual
level o f  Id3 at the various tim e points
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Section 3.2 3 1 3 H em e O xygenasel (H M O X 1)
HMOX1 is one o f two isoforms of heme oxygenase that is involved in 
catabolismg heme to biliverdin, carbon monoxide and free iron and is thought to 
be involved in iron homeostasis Following microarray analysis a 2 5-fold 
increase in HMOX1 mRNA expression levels was observed following three days 
o f exposure o f cells to drug A further increase in FHL2 expression was found in 
the day 7 sample where the genes mRNA levels had increased to nearly 3-fold 
RT-PCR analysis demonstrated a similar pattern o f transcript levels for HMOX1
HMOX1
Time (days)
F igure  3 2 22 Top graph illustrates the fold  change in  H M O X1 m R N A
fo llo w in g  gene expression  analysis R T-PCR  analysis (bottom  im age) sh ow s the
actual level o f  H M OX1 at the various tim e points
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Section 3.2 3 1 4 FH L2
FHL2 belongs to the family o f LIM proteins, which are involved in protein- 
protein interaction and transcriptional regulation Recent evidence has suggests 
that FHL proteins may act as co-regulators involved in the modulation o f tissue- 
specific gene expression by interacting with different transcription factors Such 
transcription factors include JUN and FOS and these associations have been 
shown to result in a powerful activation of AP-1-mediated transcription 
Following gene expression analysis, using GeneSpnng analysis software, the 
FL1 gene was shown to increase in 5,2 -FdU-treated DLKP cells Microarray 
analysis revealed an increase in FHL2 transcript levels in drug-treated cells In 
the day 3 sample FHL2 mRNA levels were found to increased by 2 2-fold and 
levels were further increased to 2 9-fold in the day 7 sample Confirmation of 
this result was demonstrated following RT-PCR analysis with revealed a similar 
increase in FHL2 mRNA expression levels in the day 3 and day 7 samples
FHL2
Ttme (days)
Neg Ctl
Figure 3 2 23 The top graph illustrates the fold change m FHL2 mRNA 
following gene expression analysis RT-RCR analysis (bottom image) shows the 
level o f FHL2 mRNA following exposure o f DLKP to 5,2 -FdU
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Section 3 2 3 1 5 TN FSF7
TNFSF7 belongs to the tumour necrosis factor (TNF) ligand family and this 
cytokine has been reported to a play a role in the regulation o f B-cell activation 
and IgG production Following microarray analysis the expression of TNFSF7 
was demonstrated to increase to 1 5-fold in the day 7 sample, with a little change 
in mRNA expression levels at day 3 However, RT-PCR analysis reveal a 
signification increase in TNFSF7 mRNA transcription levels in both the day 3 
and day 7 samples
TNFSF7
Time (days)
Figure 3 2 24 The top graph illustrates the fold change in TNFSF7 mRNA 
following gene expression analysis RT-RCR analysis (bottom image) shows the 
level o f TNFSF7 mRNA following exposure of DLKP to 5,2 -FdU
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Section 3.2.4 D LK P IdU  DNA M icro array
Affymetnx U133 Plus 2 human expression DNA microarrays were probed with 
RNA from IdU-treated DLKP cells from a time course experiment Cells were 
harvested after 0 and 7 days exposure to the thymidine analogue (Section 2 7) 
and RNA isolated (Section 2 10) This experiment was set up in triplicate using 
biological replicates The RNA was quantified and shipped to Affymetnx where 
cRNA was prepared, hybridised to the GeneChips® and scanned using the 
Affymetnx Gene Chip scanner The data was received back from Affymetnx for 
gene expression analysis
As mentioned above, this experiment used the Affymetnx U133A Plus 2 whole 
genome GeneChips™ rather than the Affymetnx U133A GeneChips™, which 
had been used in the previous BrdU and 5,2 -FdU DNA microarrays It is 
therefore more difficult to compare the results from the BrdU and 5,2 -FdU 
microarrays with data generated from the IdU microarrays In order to get over 
this chip vanation issue the IdU data sent was not put through the PLIER 
normalisation in GREX and an alternative normalisation method was applied
The Gene Chip data was normalised ‘Per Chip’ by using the 50th percentile, 
using genes flagged as anything but ‘Absent’ in the calculation of the 50th 
percentile The samples were then normalised ‘Per Gene’ to the mean of the day 
0 samples The data was then imported into the GeneSpnng analysis software 
where a new expenment was setup
A filter was then applied to the data to select genes that had a ‘Present’ or 
‘Marginal’ flag in 3 out o f the 6 samples The filter also contained a condition 
that selected for genes that crossed a 1 5 fold threshold, up or down in day 7
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Section 3 2 5 Comparison of Up Regulated Genes between BrdU, 5,2'-FdU 
and IdU
The BrdU, and 5,2 -FdU microarrays experiments were performed on 
Affymetrix human U133A GeneChips™, whereas the IdU experiment was 
performed using the U 133 Plus 2GeneChips™ In order to compare these arrays 
a different form of normalisation was performed on the IdU data set than was 
described for the BrdU Exp 3 and 5,2 -FdU microarray expenments
Since the chip types were different, they could not be combined in GREX for 
PLIER normalisation (as described in Section 2 15 3) and an alternative 
normalisation was used The GeneChips® were normalised to the 50th 
percentile, using genes flagged as anything but ‘Absent’ in the calculation o f the 
o f the 50th percentile The samples on the U133 A GeneChips™ (BrdU and 5,2 - 
FdU microarrays) were then normalised to the mean o f the day 0 samples 
Because the IdU microarrays were earned out on a different Gene Chip type, the 
samples on this Gene Chip were normalised to the mean day 0 on the U 133 Plus 
2 chip, and not to the day 0 o f the U133A Gene Chip
Three pair-wise comparison expenments were then created, one for each of the 
three treatments and the appropnate day 0 sample Gene lists were then 
generated and called ‘Present’ or ‘Marginal’ in three of the nine samples, in each 
pair-wise expenment, and that went either 1 5-fold up or down with drug 
treatment The resulting gene lists from each drug treatment were then divided 
into up- and down-regulated differentially expressed genes
In the BrdU expenment a total o f 1,093 genes were identified as being 
differentially expressed 812 of these genes were found to be up-regulated, and 
of 281 were to be down regulated
In the 5,2 -FdU DNA microarrays a total o f 2,147 genes were identified as being 
differentially expressed O f this number 1,186 gene were found to be up- 
regulated, whereas 961 genes were found to be down-regulated
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In the case of the IdU DNA microarray experiment a total o f 722 genes were 
identified as being differentially expressed O f this number 471 genes were 
identified as being up-regulated, whereas 251 genes where found to be down- 
regulated In the IdU DNA microarrays only two time points were chosen for 
analysis, 0 and 7 days This may explain why a smaller number, 722 genes, were 
found to be differentially expressed in comparison to the BrdU and 5,2 -FdU 
microarrays where 1,093 and 2,147 differentially expressed genes were 
identified, respectively
From analysis o f the differentiation studies preformed in the early part o f this 
thesis (Section 3 1 and Section 4 2) it appeared that all the pynmidme analogues 
investigated induced a similar pattern o f differentiation To explore these earlier 
studies further, it was decided to investigate common genes that that may be 
potentially involved in the regulation of differentiation in the BrdU, 5,2 -FdU 
and IdU treatments In order to identify common differentially expressed genes 
m these three drug treatments, up/down-regulated gene lists from the three 
microarray experiments (Apendix 7 1, Appendix 7 3 and Appendix 7 4) were 
overlapped using Venn diagrams (Figure 3 2 25 and Figure 3 2 26)
In the case o f the up-regulated gene list it was fond that a total o f 179 genes were 
common to both the BrdU and 5,2 -FdU microarrays 29 genes were identified 
as common to only the 5 ,2 '-FdU and IdU microarrays, and 132 genes common to 
only the BrdU and IdU microarrays A total o f 93 up-regulated genes were 
found common between the BrdU, 5,2 -FdU and IdU microarrays
In the case of the down-regulated gene lists it was found that a total of 105 genes 
were common to both the 5,2 -FdU and BrdU microarrays 15 genes were 
common only to the 5,2 -FdU and IdU microarrays A total 24 genes were 
identified as being common to both the BrdU and IdU microarrays Only 9 
genes were determined to be commonly down-regulated between the BrdU, 5,2 - 
FdU and IdU microarrays
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Up from PorM 1.5FUD 52FdU Up from PorM 1.5FUD BrdU
Up from PorM 1.5UD fdU
20340 
afl genes
Figure 3.2.25 Venn Diagram of Genes Identified as being Up-regulated in 
the BrdU, 5,2'-FdU and IdU DNA Microarrays. The above Venn diagram 
illustrates the overlap o f the genes determined to be up-regulated in all three 
microarrays experiments. The number in each overlapping section represents the 
number o f up-regulated genes common to that section.
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Figure 3.2.26 Venn Diagram of Genes Identified as being Down-regulated in 
the BrdU, 5,2'-FdU and IdU DNA Microarrays. The above Venn diagram 
illustrates the overlap o f the genes determined to be down-regulated in all three 
microarrays experiments. The number in each overlapping section represents the 
number o f down-regulated genes common to that section.
Further analysis of these results is described in the discussion.
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Section 3.3 Transfections
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Section 3 3 1  O verexpression o f the tran sc rip tio n  facto r, c-myc
Several attempts were made to transfect DLKP and DLKP-SQ cell lines, both 
transiently (Section 2 14 4) and stably (Section 2 14 2), with an expression 
plasmid containing human c-myc cDNA insert
The plasmid appeared to readily transfect into both cell lines In the case o f the 
stable transfections, several clones were isolated from the mixed population o f 
transfected cells The clones were then assayed for up-regulation o f c-myc 
mRNA and protein, however, no increase in either c-myc mRNA or protem 
levels were observed It was thought that during the selection process the clones 
lost the overexpression of c-myc and that the surviving cells were as a result of 
resistance to geneticin c-myc is widely known to induce apoptosis when up- 
regulated in many cell types, and this may also be a reason for the lack of 
overexpression seen in each round of stable clones generated
Several rounds of c-myc transient transfections were also earned out RNA and 
protem were harvested from the transfected cells at the following time points - 0, 
24, 48 and 72 hours In these transfections an increase in c-myc mRNA and a 
marginal increase in c-Myc protem were noted However, the up-regulation o f c- 
myc appeared to have a negative effect on all the other genes assayed for It was 
suspected that the transient up-regulation o f c-myc was inducing apoptosis, 
hence, shutting off these genes
Gene Investigated Transient Stable
c-myc fmRNA |  Protem - mRNA/Protein
YY1 t  Protein îProtein
M adl t  Protem
eIF4E t  Protein
Cytokeratin 8 ImRNA
(3i integrin -mRNA
Table 3 3.1 Summary of Alterations in mRNA and Protein levels o f genes 
investigated in c-myc Stable and Transient Transfections T= increase in 
expression, |=  decrease in expression, - = no change in expression
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Section 33.1.1.1 RT-PCR analysis of c-myc Stable Transfections
Section 3.3.1.1 c-myc stable transfections
I 2 3 4 5 6 7 8 9 10 11 12
c-myc 
fi-actin
Lane 1: Marker. Lane 2: DLKP, Lane 3: DLKP::c-myc Mixed Population, Lane 4: DLKP-SQ, 
Lane 5: DLKP-SQ:\c-myc Mixed Population. Lane 6: DLKP-SQ::YY I Mixed Population, Lane 
7: DLKP-SQ::c-myc Clone I, Lane 8: DLKP-SQ::c-m>’c Clone 2, Lane 9: DLKP-SQ::c-myc 
Clone 5, Lane 10: DLKP-SQ::c-m>r Clone 6. Lane 11: DLKP-SQ::c-myc Clone 7, Lane 12: 
DLKP-SQ: :c-myc Clone 8.
c-m ve
(J-actin
Lane I: Marker. Lane 2: Blank, Lane 3: DLKP. Lane 4: DLKP^c-myc Mixed Population. Lane 
5: DLKP-SQ. Lane 6: DLKP-SQ::c-myc Mixed Population. Lane 7: DLKP-SQ::YY1 Mixed 
Population
1 2  3 4 5 6 7 8
c-mvc 
B-actin
Lane 1: Marker. Lane 2: DLKP-SQ, Lane 3: DLKP-SQ::c-myc Clone 1, Lane 4: DLKP-SQ::c- 
myc Clone 2. Lane 5: DLKP-SQ::c-myc Clone 5. Lane 6: DLKP-SQ:: c-myc Clone 6, Lane 7: 
DLKP-SQ:\c-myc Clone 7, Lane 8: DLKP-SQ::c-/nvc Clone 8
Figure 3.3.1 Expression of c-myc in DLKP and DLKP-SQ Stable 
Transfections. DLKP and DLKP-SQ cell lines were both stably transfected 
with a human c-myc expression plasmid and several stable clones were isolated 
from a mixed population of transfected cells. RT-PCR analysis revealed that 
there was no change in c-myc mRNA levels in any o f  the stable clones. 30^g of 
total protein was loaded per gel lane.
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Section 3.3.1.1.2 W estern Blot Analysis of c-myc Stably Transfected Clones
(A )
1 2 3 4 5 6  7 8 9
Lane I: Positive Control. Lane 2: DLKP. Lane 3: DLKP::c-/nvc Mixed Population, Lane 4: 
DLKP::c-myc Clone 1. Lane 5: DLKP::c-m>c Clone 2, Lane 6: DLKP::c-myc Clone 3, Lane 7: 
DLKP::c*/nvc Clone 4, Lane 8: DLKP::c-mv't: Clone 5. Lane 9: DLKP::c-ro.ycClonc6.
(B)
c-Myc
I^ne 1: DLKP-SQ. Lane 2: DLKP-S::c-mvc Mixed population. Lane 3: DLKP-SQ::YY1 Mixed 
Population, Lane 4: DLKP-SQ::c-myc Clone 4. Lane 5: DLKP-SQ::c-myc Clone 5, Lane 6: 
DLKP-SQ::c-myc Clone 7, Lane 7: DLKP-SQ::c-/nyc Clone 8.
Figure 3.3.2 Expression c-Myc in DLKP and DLKP-SQ Stable 
Transfections. c-Myc expression in DLKP and DLKP-SQ clones transfected 
with a full length human c-myc expression plasmid. Western blot analysis 
revealed that there was no up-regulation o f c-Myc protein levels in any o f the 
stable clones generated. 30^g o f total protein was loaded per gel lane.
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Section 3.3.1.1.3 Western Blot analysis of YY1 protein levels in
DLKP::cmyc and DLKP-SQ: :c-myc stably transfected 
Clones.
1 2 3 4 5 6 7 8
Y Y I
Lane I: DLKP. Lane 2: DLKP::c-m>r Mixed Population, Lane 3: DLKP::c-mj-c Clone 1, Lane 
4 :DLKP::c-/t»>c Clone 2, Lane 5: DLKP::c-myc Clone 3, Lane 6: DLKP::c-myc Clone 4, Lane 
7: DLKP::c-m>c Clone 5, Lane 8:DLKP::c-myc Clone 6.
YYI
Lane I: DLKP-SQ, Lane 2: DLKP-SQ: :c-myc Mixed population. Lane 3: DLKP-SQ::YYI 
Mixed Population, Lane 4: DLKP-SQ:\c-myc Clone 4, Lane 5: DLKP-SQ::c-myc Clone 5, Lane 
6: DLKP-SQ::c-myc Clone 7, Lane 7: DLKP-SQ::c-myc Clone 8, Lane 8: Blank, Lane 9: 
DLKP::c-myc Clone 8
Figure 3.3.3 Expression of YYI in DLKP and DLKP-SQ Stably 
Transfected with c-myc. YYI expression in DLKP and DLKP-SQ cells stable 
transfected with a full length c-myc cDNA expression plasmid. An increase in 
YYI protein levels was observed in some o f the stable c-myc clones generated. 
30ng o f total protein was loaded per gel lane.
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Section 3.3 1 2 c-myc T ran sien t T ransfections
Several attempts at transiently transfecting a full length human c-myc expression 
plasmid into the DLKP-SQ cell line were carried out Time points o f 0, 24, 48 
and 72 hours were selected for analysis In order to investigate the effect the up- 
regulation o f c-myc had in the cell line, several different genes were assayed for 
and the results are listed in the following sections
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Section 3.3 1 2.1 R T -PC R  analysis show ing the increase in c-myc expression  
in D L K P-SQ  cell line transiently transfected  w ith  the 
pC M V  • c-myc plasm id
(A)
1 2  3 4
c-m yc
P-actin
L ane  1 D LKP-SQ, L an e  2 D LKP-SQ c-m yc  24h, L an e  3 D LKP-SQ c-m yc 48h, L ane  4 
DLKP-SQ c-m yc  72h
Figure 3 3 4 E xpression o f c-M yc in D L K P-SQ  T ransiently T ransfected  
w ith  c-myc. (A) PCR analysis for c-myc expression demonstrate an increase in 
c-myc mRNA after 24 hours o f  transfection This increase in c-myc was 
maintained over the course o f  the 72 hour transfection (B) W estern blot 
analysis showed that the c-Myc protein level was increased after 24h o f 
transfection and was demonstrated to increase further at 72h 30|ig o f  total
protein was loaded per gel lane
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Section 3 3 1 .2  2 C hange m expression o f M ad protein in D L K P -SQ  
transiently transfected w ith the pC M V .. c-myc p lasm id.
Figure 3 3.5 E xpression o f  M ad m  D L K P-SQ  T ransiently T ransfected w ith  
c-m yc W estern blot analysis for Mad expression in DLKP-SQ cells transiently 
tranfected with the pCM V c-myc plasmid showed that the up-regulation o f  c- 
Myc resulted in the reduction o f  Mad protein in the transfected cells It was 
observed from the analysed transfected cells that after 24h the level o f Mad 
protem  had been greatly reduced m comparison to the control untransfected 
DLKP-SQ cells However, after 72h the level o f  M ad protem was beginnig to 
return, but its expression was still very much reduced in comparison to control 
untransfected cells 30|ig o f  total protem was loaded per gel lane
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Section 3 3.12 3 Change in expression of YY1 protein m DLKP-SQ
transiently transfected with the pCMV. c-myc plasmid
Figure 3 3 6 E xpression o f  YY1 in D L K P-SQ  T ransiently T ransfected w ith  
c-myc Western blot analysis for YY1 expression levels in DLKP-SQ cells 
transiently transfected with the pCMV c-myc plasmid showed that the YY1 
protein slightly increased after 24h This increase was noted also after 48 and a 
greater increase in YY1 was seen following 72 hours o f  transfection 30jig o f 
total protein was loaded per gel lane
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Section 3 3 1 2  4 Change in expression of eIF4E RNA in DLKP-SQ cell line
transiently transfected with the pCMV c-ntyc plasmid
> eIF-4E
L ane  1 DLKP-SQ, L ane  2 24h, L ane  3 48h, L ane  4 72h
F ig u r e 3  3 7 E xpression o f eIF4E in D L K P-SQ  T ransiently T ransfected  
w ith  c-myc Western blot analysis for eIF4E protein expression showed that 
there was an initial increase in the level o f  eIF4E protein in the transfected cells 
when compared to the untransfected DLKP-SQ control cells However, after 48h 
this increase in eIF4E expression had return to the levels observed in the control 
cells
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Section 3 3 1 2  5 Change in expression of cytokeratin 8 RNA in DLKP-SQ
transiently transfected with the pCMV c-myc plasmid
p-actin
CK-8
L an e  1 DLKP-SQ, L ane  2 DLKP-SQ c-m yc 24h, L ane  3 DLKP-SQ c-m yc  48h, L ane  4 
DLKP-SQ c-m yc  72h
Figure 3 3 8 E xpression o f  C ytokeratin 8 in D L K P-SQ  T ransiently  
T ransfected w ith c-myc RT-PCR analysis o f  DLKP-SQ c-myc transiently 
transfected cells showed that upon the up-regulation o f c-myc, the levels o f  CK8 
where found to be decreased It was noted after 48h the eIF4E signal has more 
or less been turned o ff and that following 72h the CK8 levels started to increase 
once again
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Section 3 3 1 2  6 Change in expression of Pi-integnn RNA in DLKP-SQ
transiently transfected with the pCMV* c-myc plasmid
310bp
Pi-integrin
P-actin
L an e  1 M arker, L ane  2 DLKP-SQ, L ane  3 DLKP-SQ c-myc  24h, L ane  4 D L K P -SQ  c- 
m yc 48h, L an e  5 D L K P -S Q  c-m yc  72h
Figure 3 3.9 E xpression o f  Pi-integrin in D L K P-SQ  T ransiently  
T ransfected w ith  c-myc RT-PCR analysis o f  DLKP-SQ c-myc transiently 
transfected cells showed that upon the up-regulation o f  c-myc, the levels o f  pi- 
m tegnn where found to be decreased It was noted that after 48h and 72h the 
level o f  Pi-integrin had been reduced to nearly half that o f  the control 
untransfected cells
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Section 3.3.2 Overexpression o f Yin Yang 1, YY-1
A plasmid encoding the human transcription factor, YY1 was transfected into the 
DLKP-SQ cell line and proved reasonably efficient to transfect. This plasmid 
was transfected both stably and transiently into the DLKP-SQ cell line.
Several stable highly over-expression clones were generated in two separate 
transfections experiments. From the initial experiment three over-expression 
clones were isolated from a mixed population o f  transfected DLKP-SQ cells. 
And from the second experiment several more stable clones were isolated. 
Overexpression o f  YY1 in the three clones was shown to up-regulate c-Myc at 
the protein level (Figure 3.3.11), however, c-myc mRNA levels appeared 
unaffected by the overexpression o f  YY1. An increase in M adl (Figure 3.3.12), 
a member o f  the c-M yc/Max/Mad network, was observed.
An increase in the translation factors eIF4E (Figure 3.3.13) and eIF 2a (Figure 
3.3.19) was also noted in the three overexpressing clones. A significant increase 
in eIF4E protein levels was noted; however, due to problems with RT-PCR 
analysis o f  eIF4E, the effect o f  overexpression o f  YY1 on eIF4E RNA levels are 
not shown. Overexpression o f  YY1 also appeared to have an effect on the 
translation factor eIF2a. A slight increase in eIF2a was noted in the three stable 
clones generated (Figure 3.3.19). PCR analysis for eIF4e-binding protein-1 
showed that there was no alteration in the expression o f  mRNA levels for this 
gene in any o f  the clones analysed.
The effect o f  overexpression o f  YY1 on cytokeratin expression was also 
investigated and it was found that there was no effect on the mRNA levels o f 
cytokeratin 8 (Figure 3.3.14). However, some changes in the expression levels 
o f  both cytokeratins 18 (Figure 3.3.15) and cytokeratin 19 (Figure 3.3.16) were 
noted.
Unfortunately for some unknown reason, the YY1 clones lost all ovcr-cxprcssion 
o f  YY1 during the freeze thaw back o f  the stable YY1 clones and due to time
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the YY1 plasmid and in order to investigate further the role which YY1 plays m 
the regulation o f  differentiation in our cell system
constraints towards the end of this thesis it was not possible to generate more
stable over-expression clones Therefore, it was decided to transiently transfect
i
G ene Investigated Transient Stable
YY1 s tm R N A tProtein
c-myc ¿mRNA tProtein -mRNA tProtein
M adl ; î  Protein tProtein
eIF4E , Î Protein tProtein
Cytokeratin 8 ¿mRNA -mRNA
Cytokeratin 18 J,mRNA at 24 h only -mRNA
Cytokeratin 19 i  -mRNA tm R N A
bi integrm ¿mRNA -mRNA ¿Protein
eIF4E-BPl ! -m R N A -mRNA
eIF2cc i ¿mRNA tProtein
Mnk2 -mRNA
FHL1 TmRNA
FSTL1 -mRNA
HMOX1 tm RN A
Id2 tm R N A
Id3 • t mRNA
T able 3 3 2 Summary o f  the results obtained for the YY1 transient and stable
f
transfection experiments \=  increase in expression, J,= decrease in 
expression, - = no change in expression
Section 3.3.2.1 Stable Over-expression YY1 Clones
Section 3.2.2.1.1 Investigation of the increase o f YYI protein levels in
DLKP::YY1 stably transfected cells.
(A)
1 2  3 4 5
L ane 1: YYI Control Peptide. L ane 2: DLKP-SQ, L ane 3 : DLKP-SQ::YYI C lone 2, L ane 3: 
DLKP-SQ::YY1 Clone 4. L ane 4: DLKP-SQ::YY1 Clone 13.
(B)
1 2 3 4 5 6 7 8
L ane 1: DLKP-SQ, L ane 2: Clone 6. L ane 3: Clone 4. L ane 4: C lone 13. L an e  5: C lone 14, 
L ane 6: Clone 7D, L ane 7: C lone8D , L ane 8: Positive Control.
Figure 3.2.10 Expression o f Y Y I in D LK P-SQ  YYI Stable T ransfections.
Western blot analysis was carried out on the DLKP-SQ::YYI stable clones. (A) 
Level o f  YYI protein overexpression in the initial round o f  YYI stable 
transfections. (B) Level o f  YYI protein overexpression in clones isolated from 
the second round o f  YYI transfections. 30^g o f  total protein was loaded per gel 
lane.
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(A)
Section 3.2 2 1 2 Investigation of c-myc RNA and protein levels in
DLKP YY1 stably transfected cells
 ^ c m^c 
234 bp  _____________________
(3-actin
L an e  1 M arker, L ane  2 DLKP-SQ, L ane  3 Clone 2, L ane  4 Clone 4, L an e  5 Clone 13
(B)
1 2  3 4 5 6  7 8 9
c-myc
P-actin
L an e  1 M arker, L an e  2 DLKP-SQ, L ane  3 Clone 6, L ane  4 Clone 8, L an e  5 Clone 13, 
L an e  6 Clone 14, L ane  7 Clone 7D, L ane  8 Clone8D, L ane  9 N eg Control
(C)
i t e  mm m mW  VP
c-M yc
p-actin
L an e  1 DLKP-SQ, L ane  2 Clone 2, L ane  3 Clone 4, L ane  4 Clone 13
Figure 3 3.11 E xpression o f c-m yc in Stable YY1 transfections (A) and (B)
RT-PCR analysis for c-myc RNA in the stably transfected DLKP-SQ YY1 
clones showed that there was no apparent change in expression in any o f  the 
isolated clones in the first and second round o f  transfections, respectfully (C) 
W estern blot analysis was earned out on the DLKP-SQ YY1 stable clones 
revealed that all three clones had increased levels o f  c-Myc when com pared to 
the untransfected DLKP-SQ cells 30|ig o f  total protein was loaded per gel lane
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I
Section 3 2 2 1 3 Investigation of Mad protein levels in DLKP* YY1
stably transfected cells
i
1 2 * 3 4 5
Mad
L an e  1 DLKP-SQ, L ane  2 DLKP-SQ YY1 Clone 2, L ane  3 DLKP-SQ YY1 Clone 4, L an e  
4 DLKP-SQ YY1 Clone 13, L an e  5 A549
i
i
i
i
Figure 3 3 12 M ad W estern expression in YY1 overexpressing D L K P-SQ
i
W estern blot analysis was earned out on YY1 stable clones revealed that all 
three clones had increased levels o f  Mad, with Clone 4 exhibiting the greatest 
increase
Section 3.2.2.1.4 Investigation o f eIF4E protein levels in DLKP::YY1
stably transfected cells.
(A)
1 2  3 4
eIF4E
L ane I : DLKP-SQ, L ane 2: DLKP-SQ::YY1 Clone 2, L ane 3: DLKP-SQ::YY1 Clone 4, L an e  
4: D LKP-SQ ::Y Y I Clone 13.
(B)
L ane I : DLKP-SQ, L ane 2: Clone 6, L ane 3: C lone 4, L ane 4: C lone 13, L ane 5: C lone 14, 
L ane 6: Clone 7D, L ane 7: Clone8D
Figure 3 .3.13 eIF4E expression in YY1 O verexpressing D L K P-SQ . (A )
Western blot analysis was carried out initial YY1 stable clones isolated showed 
that there was a significant increase in eIF4E. (B) The increase in eIF4E was 
also repeated in the second round o f YY1 transfections and was confirm ed by 
western blot analysis. 30jig o f  total protein was loaded per gel lane.
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Section 3 2 2 15  Investigation of cytokeratin 8 expression levels in
DLKP..YY1 stably transfected cells.
2 3 4 5 6 7 8 9
310bp
234bp
194bp
CK8
(3-actin
L ane  1 M arker, L ane  2 DLKP-SQ, L ane 3 Clone 6, L ane  4 Clone 8, L ane  5 Clone 13, 
L an e  6 Clone 14, L ane  7 Clone 7D, L ane 8 Clone8D, L ane  9 N eg Control
Figure 3 3 14 Cytokeratin 8 mRNA Expression in YY1 Oversexpression DLKP- 
SQ R T -P C R  analysis o f the stably transfected D L K P -SQ . YY1 clones for  
alterations in the expression o f  CK 8 RN A revealed that there w as no  
apparent change m  the level o f  CK 8 R N A  m  any o f  the stab le clones 
isolated
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II
Section 3 2 2 1 1 6  Investigation o f  cytokeratin 18 expression levels in
D LK P: YY1 stably transfected  cells
[
603bp
310bp
194bp
L ane  1 M arker, L an e  2 DLKP-SQ, L ane  3 Clone 6, L ane  4 Clone 8, L an e  5 Clone 13,
\
L ane 6 Clone 14, L ane  7 Clone 7D, L ane  8 CIone8D, L an e  9 N eg Control
iii
i
ii
Figure 3.3 15 C ytokeratin 18 m R N A  E xpression in YY1 O verexpressing  
D L K P-SQ  RT-PCR analysis o f the stably transfected DLKP-SQ YY1 clones 
for alterations in the expression o f  CK18 RNA revealed that there was no 
apparent change in the level o f CK18 RNA in any o f  the stable clones isolated
i
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f
!
I
ISection 3 2.2 1 1 7 Investigation o f  cytokeratm  19 expression levels m  
D L K P YY1 stably transfected cells
Lane 1 M arker, Lane 2 DLKP-SQ, Lane 3 Clone 6, Lane 4 Clone 8, Lane 5 Clone 13,
t
Lane 6 Clone 14, Lane 7 Clone 7D, Lane 8 Clone8D, Lane 9 N eg Control
Figure 3.3.16 C ytokeratm  19 m R N A  E xpression in YY1 O verexpression  
D L K P-SQ  RT-PCR analysis o f  the stably transfected DLKP-SQ YY1 clones 
for alterations in the expression o f  CK19 RNA revealed that Clones 4, 13, 14, 7D 
and 8D all showed an increase in CK19 RNA when compared to the DLKP-SQ
i
untransfected cells 1
i
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i
i
DLK P::YY1 stably transfected cells.
Section 3.2.2.1.1.8 Investigation o f pr integrin expression levels in
(A)
4 5 8 9
873bp 
603 bp
310bp
P,-intcgrin
3-actin
L ane 1: M arker. L ane 2: D LKP-SQ, L ane 3: C lone 6, L ane 4: Clone 8. L ane 5: Clone 13, 
L ane 6: Clone 14, L ane 7: C lone 7D . L ane 8: Clone8D, L an e  9: Neg. Control.
(B)
P,-integrin
L ane 1: DLKP-SQ. L an e  2: Clone 2. L ane 3: Clone 3, L ane 4: C lone 13.
Figure 3.3.17 Expression o f p r integrin in YY1 O verexpressing DLK P-SQ .
(A ) R T -PC R  analysis o f the YY1  stably transfections for Pi-integrin m R N A  
expression levels revealed that there was no apparent change. (B) Western blot 
analysis carried out on the three initial clones showed a reduction (Vintegrin 
protein levels when compared to untransfected cells. 30^g o f total protein was 
loaded per gel lane.
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ISection 3 2 2 1.1 9 Investigation o f  eIF4E -binding protein  1 expression
levels in D L K P ..Y Y 1 stably transfected cells
603bp
310bp 
194bp
L an e  1 M arker, L an e  2 DLKP-SQ, L ane  3 Clone 6, L ane  4 Clone 8, L ane  5 Clone 13, 
L an e  6 Clone 14, L an e  7 Clone 7D, L an e  8 Clone8D, L an e  9 N eg Control
ii
i
i
I
I
Figure 3 3 18 E xpression o f  ieIF4E -binding protein -1 m R N A  in YY1  
O verexpressing D L K P-SQ  RT-PCR analysis o f  the stably transfected YY1 
clones revealed that there was no apparent change in the level o f  eIF4E-BPl 
mRNA in any o f  the stable clones isolated
i
i
1 6 8
Section 3.2.2.1.10 Investigation o f eIF-2a protein levels in DLKP::YY1
stably transfected cells.
Figure 3.3.19 Expression o f  eIF 2a  in YY1 O verexpression DLK P-SQ .
Western blot analysis was carried out on  YY1 stable clones. A slight increase in 
eIF -2a protein levels was observed in clone 4. The other two clones exhibited 
similar eIF -2a as the DLKP-SQ control cells. 30ng o f  total protein was loaded 
per gel lane.
1 6 9
IIII
Section 3 2 2.2 A nalysis RNA^ and protein changes in D L K P -SQ  cells 
transiently transfected w ith  the YY 1 plasm id
i
As mentioned earlier, the stable YY1 expressing clones generated from the 
transfection o f the DLKP and DLKP-SQ cell lines lost YY1 over-expression for 
unknown reasons during cell freezing/thaw back process Therefore, it was 
decided to further characterise the role that YY1 plays in our model system by 
transiently transfecting both cell lines with the YY1 plasmid
j
DLKP and DLKP-SQ cells were transiently transfected with two different YY1 
plasmids The transfected cells were also analysed for alterations in expression 
levels o f  other proteins to elucidate what the effect the up-regulation o f  YY1 had
I
Due to historical miss-labelling o f  the YY1 plasmid stocks these transfections 
were performed using two different YY1 vectors, each containing a full length 
human YY1 cDNA sequence The initial transient transfections were performed
i
using the plasmid described in Section 2 14, transfected into the DLKP-SQ cell 
line, while second set o f experiments were performed using the His-tagged YY1i
plasmid, transfected into DLKP ( The reasoning behind the use o f two different 
YY1 plasmids was due to historical miss-labelling o f  plasmids stocks in the
i
laboratory Both YY1 vectors used in this study contained a full length human 
YY1 cDNA sequence and only differed in the fact that one contained an added 
His-tag sequence |
IIij
From analysis o f  these transfections we demonstrate that transient YY1 over- 
expression up-regulated c-Myc protein levels, which is in agreement w ith the
r
stable over-expression o f YY1 in our earlier work mRNA levels o f  c-myc were 
down-regulated in the transient transfections, whereas in the stable transfections 
the over-expression o f YY1 was shown to have no effect o f  c-myc mRNA 
expression levels
We also demonstrate that the transient over-expression o f  YY1 also has a 
negative effect on the mRNA o f the translation initiation factor eIF4a, but does
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not affect the expression o f  other translation initiation factors such as eIF4E- 
binding protein-1 and Mnk2, a known kinase o f eIF4E
mRNA levels o f  cytokeratin 8 and 18 were also investigated and it was 
demonstrated that a slight decrease m cytokeratin 8 mRNA expression in DLKP- 
SQ cells after 24 hours o f  transfection with YY1 The transient over-expression 
o f  YY1 did not appear to have an effect on the mRNA levels o f cytokeratin 18 
Pi-integrin levels were also investigated and mRNA levels o f  this gene were 
revealed to be significantly down-regulated after 24 and 48 hours o f  transfection 
However, expression levels for this gene and returned to near control levels after 
72 hours o f transfection
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Section 3.2.2.2.1 Change in expression of YY1 mRNA in DLKP-SQ
transiently transfected with the YY1 plasmid.
DLKP-48 DI.KP-72 DLKP NTC
Figure 3.3.20 YY1 m RNA Fold change in DLKP cells transiently  
transfected with YY1
Taqman Real Time-PCR analysis for YY1 expression was preformed on YY1 
transiently transfected DLKP cells. It was demonstrated that following 
transfection YY1 mRNA transcript levels were 15.35-fold increase after 48 hours 
and had decreased to 6.75-fold at 72 hours.
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(A)
Section 3.2.2.2.2 Change in expression of c-myc RNA in DLKP-SQ
transiently transfected with the YY1 plasmid.
c-m yc  
(5-actin
L ane I : M arker, L ane 2: DLKP-SQ. L ane 3: DLKP-SQ::YYI 24h, L ane 4: DLKP-SQ::YY1 
48h, L ane 5: DLKP-SQ::YY1 72h.
(B)
1 2 3 4
c-M yc
L ane I: DLKP- SQ, L ane 2: DLKP-SQ::YYI 24h. L ane 3: DLKP-SQ::YYI 48h, L ane 4: 
D LKP-SQ ::Y Y I 72h.
Figure 3.3.21 E xpression o f c-myc in YY1 Transient Transfected D L K P-SQ .
(A) RT-PCR analysis for c-myc mRNA revealed that c-myc was dowTi-regulated 
after 24h and following 48h c-myc message had been fully turned off. However, 
after 72h the level o f  c-myc RNA was found to be increasing once again, but not 
back to control levels. (B) Western blot analysis showed no increase in c-M yc 
protein after 24h, however, an increase was seen at 48 h and this was maintained 
at 72 h o f  transfection. 30fig o f  total protein was loaded per gel lane.
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Section 3.2 2 2 3 Change in' expression of eIF2a RNA in DLKP-SQ cells
transiently^transfected with the YY1 plasmid
1 2 3 4 5 6I
610bp ------ ►
310bp ------ ►
194bp ------ ►
L an e  1 M arker, L an e  2 DLKP-SQ, L ane  3 DLKP-SQ Y Y 1 2 4 h ,L a n e 4  DLKP-SQ YY1 
48h, L ane  5 DLKP-SQ YY1 72h, L ane 6 N eg Control
Figure 3 3 22 E xpression o f  eIF 2a  in YY1 T ransiently T ransfected D LK P-
SQ  RT-PCR analysis for eIF2a showed that eIF2a was markedly down- 
regulated after 24h and 48h, when compared to the untransfected cells It was 
noted that after 72h the level o f  eIF2a had returned to that o f  the control
i
untreated DLKP-SQ cells Control GAPDH mRNA levels did not amplify m this 
reaction, and due to time constraints this PCR was no repeated
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Section 3 2 2.2 4 C hange in expression o f eIF4E -binding protein 1 R N A  in 
D L K P-SQ  transiently transfected w ith  the YY1 plasm id
1 2 3 4 5 6
Lane 1 M arker, Lane 2 DLKP-SQ, Lane 3 DLKP-SQ YY1 24h, Lane 4 DLKP-SQ YY1 
48h, Lane § DLKP-SQ YY1 72h, Lane 6 Neg Control
Figure 3.3.23 E xpression o f  eIF4E -binding protein-*! in YY1 Transiently  
T ransfected D L K P-SQ  PCR analysis for 4E-BP1 mRNA showed no changed 
in expression levels following the overexpression o f  YY1
175
Section 3 2 2 2 5 Change in expression of Mnk2 RNA in DLKP-SQ
transiently transfected with the YY1 plasmid
2 3 4 5 6
603bp ------ ►
310bp ------ ►!
194bp ------ ^
Mnk2
P-actin
Lane 1 M arker, Lane 2 DLKP-SQ, Lane 3 DLKP-SQ YY1 24h, Lane 4 DLKP-SQ  YY1 
48h, Lane 5 DLKP-SQ Y Y 1 72h, Lane 6 N eg Control
Figure 3 3.24 E xpression o f M nk2 in YY1 T ransiently T ransfected D L K P-
SQ  PCR analysis o f  Mnk2 levels in showed that there was no change in the 
expression o f  Mnk2 mRNA levels following the overexpression o f  YY1
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Section 3 2 2 2 6 Change in expression of cytokeratm 8 RNA in DLKP-SQ
cells transiently transfected with the YY1 plasmid
2 3 4 5 6
194bp ------ ►
3 1 0 b p ------ ►
CK8
p-actm
L an e  1 M arker, L an e  2 DLKP-SQ, L ane  3 DLKP-SQ YY1 24h, L ane  4 D LKP-SQ YY1 
48h, L an e  5 DLKP-SQ YY1 72h, L an e  6 N eg Control
Figure 3.3 25 E xpression o f C ytokeratm  8 in YY1 T ransiently T ransfected  
D L K P-SQ  RT-PCR analysis for CK8 RNA in YY1 transiently transfected cells 
revealed that the level o f  CK8 RNA was down-regulated after 24h However, 
after 48h the CK8 message had returned to that o f  the control untransfected 
cellstransfected cells
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Section 3.2.2.2 7 Change in expression of cytokeratin 18 RNA in DLKP-SQ
cells transiently transfected with the YY1 plasmid
603bp
310bp 
194bp
L an e  1 M arker, L ane  2 DLKP-SQ, L an e  3 DLKP-SQ YY1 24h, L ane  4 DLKP-SQ  YY1 
48h, L ane  5 DLKP-SQ YY1 72h, L ane 6 N eg  Control
Figure 3 3.26 E xpression o f  C ytokeratin 18 m R N A  in YY1 T ransiently  
T ransfected D L K P-SQ . PCR analysis o f CK18 mRNA showed that there was 
no significant change in expression following transient transfection with Y Y 1
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Section 3.2 2 2 8 Change m expression of (3i-mtegnn RNA m DLKP-SQ
transiently transfected with the YY1 plasmid
872bp
610bp
2 3 4 5 6
310bp
194bp
Pi-Integrin
p-actin
L an e  1 M arker, L ane  2 DLKP-SQ, L ane  3 D LKP-SQ Y Y 1 2 4 h ,L a n e 4  DLKP-SQ YY1 
48h, L an e  5 DLKP-SQ YY1 72h, L ane 6 N eg Control
Figure 3 3 27 E xpression o f  P i-integrm  m R N A  in YY1 Transiently  
T ransfected D L K P-SQ  RT-PCR analysis for Pi-integnn mRNA revealed that 
the level o f  pi-integrin RNA was significantly down-regulated after 24h In cells 
transfected for 48h the pi-integnn message had nearly been fully switched o ff 
However, after 72h the pi-integnn message had almost returned to that o f  the 
control untransfected cells
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Section 3.2.2.3 C hange in expression o f G enes found regulated in B rdU  
Array in D L K P transiently transfected w ith  the YY1  
plasm id
Following the DNA microarray experiments which were performed towards the 
end o f  this thesis, it was decided to investigate if  YY1 played a role in the 
regulation o f  some o f the genes demonstrated to be differentially expressed in the 
microarray experiments
Following RT-PCR analysis we demonstrate that transient over-expression o f 
YY1 did in fact have a positive effect on some o f the genes identified in the 
DNA microarray experiments We show that the mRNA levels o f  FHL1, Id2, 
Id3 and HMOX1, to be increased While YY1 over-expression did not appear to 
have an effect on FSTL1 mRNA levels
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Section 3.2.2.3.1 FHL1
M Control 48h 72h Neg Ctl
603bp
310bp FHL1
Figure 3 3 28 E xpression o f  FHL1 m R N A  in YY1 T ransiently T ransfected  
D L K P RT-PCR analysis for domonstreated that transcript levels for FHL1 were 
significantly up-regulated after 48 hours o f transfectioin with YY1 This 
increase in FHL1 was maintained at 72 hours o f transfection
Section 3 2 2 3 2 FSTL1
Figure 3 3 29 E xpression o f FSTL1 m R N A  in YY1 T ransiently T ransfected  
D L K P RT-PCR analysis for revealed that the transient over-expression o f  YY1 
had no effect on the mRNA levels o f FSTL1
M  C o n tro l 48h 72h Neg C tl
310bp
603bp
L _  GAPDH
L FSTLl
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Section 3 2 2.3 3 HMOX1
M Control 48h 72h Neg Ctl
603bp —H
310bp - H
L _  HMOX1 
k “  GAPDH
Figure 3 3 30 E xpression o f H M O X1 m R N A  in YY1 T ransiently  
T ransfected D L K P RT-PCR analysis for domonstreated that transcript levels 
for HOMX1 were significantly up-regulated in DLKP cells after 48 hours o f 
transfectioin with YY1 This increase in HMOX1 was maintained at 72 hours o f 
transfection
Section 3 2 2 3.4 Id2
Figure 3 3 31 E xpression o f Id2 m RNA in YY1 T ransiently T ransfected  
D L K P. RT-PCR analysis for demonstarted a significant increase in Id2 
transcript levels after 48 hours o f  transfection with YY1 This increase in Id2 
was maintained at 72 hours o f  tranfection
M  C o n tro l 48h 72h Neg C tl
6 0 3 b p _ *
3 1 0 b p _ *
L _  GAPDH
L _  Id2
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Section 3 2.2.3 5 Id3
M
603 bp 
310bp
Control 48h 72h Neg Ctl
,*f ^  iff** < ' ■> " • < ? 1 • ■* \ i ';■ 'w*‘jj?£ % "9fc■,/-* ' '' V^ -'"  ^?•.
^  VVJlV' r^ rV ' " ' ’v!  V'“ ’ v  ,"' '"> -“■'
GAPDH
Id3
Figure 3.3.32 E xpression o f  Id3 m RNA in YY1 T ransiently T ransfected  
D L K P RT-PCR analysis for revealed a large increase in Id3 mRNA expression 
leveles m transiently tranfected cells
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Section 4.0 Discussion
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4.1 General Introduction
The lung is a complex organ consisting o f  over 40 different cell types (Plopper, 
1996). whose development has been divided into four chronological stages; I) the 
pseudoglandular stage, II) the canalicaular stage, III) the terminal sac stage and 
IV) the alveolar stage. While progress has been m ade in the developmental 
genetics in general, aided by huge developments in DNA microarray analysis and 
proteomic tools, the genetics o f  lung morphogenesis, the differentiation pathway 
and the genes involved in development o f  specific cell types are still largely 
unknown. The failure to identify a stem cell(s) o f  the lung (Emura. 1997) and 
the relative infancy o f  developmental genetics are part o f  the main problems in 
understanding the mechanisms regulating early development o f  the lung. We 
have been afforded the opportunity to study an in vitro model for early 
development using a very poorly differentiated lung cancer cell line, DLKP, 
which was isolated here at the NICB (Law, et a l 1992).
DLKP is a poorly differentiated squamous carcinoma cell line which does not 
express keratin proteins or other epithelial markers such as epithelial-specific 
antigen or desmosomal proteins; despite being o f  epithelial origins (McBride, el 
al., 1998). DLKP cells may represent a stem cell-like cell line o f  lung epithelial 
lineage which has the potential for both proliferation and differentiation. Also, 
the cells appear to be at a very early stage o f  differentiation, shown by the lack o f  
expression o f  the simple epithelial keratins 8, 18 and 19, and can theoretically 
progress towards several different phenotypes.
Bromodeoxyuridine (BrdU) is a halogenated thymidine analogue that competes 
with thymidine for incorporation into DNA. BrdU has been found to modulate 
differentiation in a number o f  different cell types (Harding et a l 1978). 
Specifically, BrdU has been reported in the literature to modulate differentiation 
in neuronal, muscle and haematopoietic lineages (Feyles et al., 1991; Tapscott et 
al., 1989; Yen et al., 1987). It has been shown previously that this differentiation 
modulating agent is capablc o f  inducing differentiation in our m vitro DLKP 
model system, and the lung adenocarcinoma cell line, A549, (M cBridc, et al., 
1999; Mclcady, PhD Thesis, 1997; O 'Sullivan. PhD Thesis, 1999; Walsh, PhD
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Thesis 1999, Doolan, PhD Thesis, 2001) Associated with this alteration in 
differentiation status o f these two cell lines was an alteration in the expression 
levels o f various proteins Protein expression o f  cytokeratins 8, 18 and 19, 
integrins ct2 and pi (Section 3 1), the eukaryotic initiation factors eIF4E (Section 
1 8  and Section 3 114) and eIF2a (Doolan, PhD Thesis 2001) and the 
transcription factors Yin Yang 1 (Section 1 7 2) and c-myc (Section 1 7 1) were 
all up-regulated in DLKP and A549 cells when induced to differentiate by 
exposure to BrdU (Walsh, PhD Thesis, 1999) BrdU-induced differentiation o f 
DLKP and A549 also resulted in the alteration o f Ep-CAM  protein expression 
(Section 3 1), along with global changes in the transcription profiles o f  the cells, 
which were investigated by DNA microarray experiments
In addition, immunocytochemical analysis o f  DLKP treated with BrdU for 7 days 
and then grown in the absence o f  BrdU for up to three months showed that these 
cells retained the pattern o f  keratin expression observed in BrdU-treated cells 
(Walsh, PhD, 1999) This result suggests that BrdU induces a pathway that 
causes irreversible differentiation o f these cells
In this study, BrdU and other halogenated thymidine analogues, namely IdU, 
CdU, Bromoundme, Bromouracil, as well as 5-FU, 5,2 -FdU and 5,5-FdU, were 
investigated to determine if  they had an effect o f  the differentiation status o f  both 
DLKP and A549 cell lines
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4.2 Thymidine analogue-induced differentiation in epithelial cell lines
5-Bromo-2‘-dcoxyUridine (BrdU) has been reported to modulate differentiation 
in a number o f  different cell types, particularly its role in modulating 
differentiation in neuronal, muscle and haematopoietic lineages has been 
documented (Yen el al., 1987; Sugimoto el al.. 1988; Valyi-Nagy el a l.  1993). 
We have demonstrated in our laboratory that BrdU treatment o f  DLKP and A549 
cells induce these cells to differentiate. The mechanism(s) by which BrdU exerts 
its differentiation-modulating effects has not been elucidated. Several different 
theoretical models have been suggested to date (Section 1.4.1). It appears that 
the incorporation o f  BrdU into DNA is critical.
Results presented in this thesis demonstrate that following exposure o f  both 
DLKP and A549 cell lines to BrdU and the various other halogenated pyrimidine 
analogues a similar increase in the differentiation markers investigated was 
observed. Induction o f  cytokeratin expression was demonstrated in the DLKP 
system, with an up-rcgulation o f  cytokeratins observed in A549. However, not 
all the analogues induced/up-regulated the cytokeratins and integrins to the same 
level and a summary o f  these results are contain in Table 3.1 and I'able 3.2.
In the DLKP and A549 systems, treatment with BrdU, IdU and CdU appeared to 
have a similar pattern o f  differentiation, with cytokeratins -8, -18 and -19 
showing induction in expression. In DLKP cells increased expression o f  
integrins, 012 and Pi, were also demonstrated in our differentiation experiments.
Treatment o f  DLKP and A549 with 5,2'-FdU  resulted in a dramatic alteration in 
the cell morphology, with the cells increasing in size to 3-4 tim es that o f  the 
control untreated cells. Induction o f  cytokeratin protein expression was noted in 
the DLKP system and an up-regulation found in A549 treated cells. Integrin and 
Ep-CAM protein expression was also noted in the two cell systems.
Bromouridine and Bromouracil did not seem to induce the differentiation 
markers to the same extent as the other halogenated thymidine analogues, though
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some induction o f  cytokeratins was noted in treated DLKP cells Interestingly, 
toxicity assays for these two analogues revealed that treatment with high 
concentrations o f  these drugs, o f up to 70^g/|il, had no effect on the growth o f 
DLKP cells (results not shown) A small increase in expression o f  the 
cytokeratin proteins was seen in A549 treated cells with little change m ot2-and 
Pi - integrm observed (Section 3 2 21)
In order to ensure that the alteration o f the differentiation status o f  both DLKP 
and A549 was not as a result o f  simple toxic exposure, both cell lines were 
treated with A dnam ycin for 7 days Treatment with Adnam ycin did not produce 
the same differentiating-modulatmg effects as was seen with BrdU and its 
analogues (Data not shown)
In summary, all the thymidine analogues investigated exhibited a similar 
induction in differentiation as was demonstrated previously with treatment o f  
DLKP and A549 cells with BrdU (O ’Sullivan, PhD 1999) The exact 
mechamsms(s) by which these analogues induced the expression o f  the set o f 
differentiation markers investigated in this study remain unclear A surprising 
find was that all the analogues investigated demonstrated a similar overall pattern 
o f cytokeratin and integrm protem expression 5,5 -FdU, 5,2 -FdU and 5-FU are 
known to have a different biological mode o f  action than BrdU, and are known to 
inhibit DNA synthesis However, treatment o f  DLKP and A549 with 
A dnam ycin revealed no induction o f  cytokeratins or integrm proteins following 
7 days exposure o f cells to this drug Therefore, it was concluded that the 
induction o f the selected differentiation markers investigated by BrdU and the 
other pyrimidine analogues in our cell system was not as a result o f  toxic shock 
in the cells In order to investigate these differentiation assays further DNA 
microarray analysis was preformed on a subset o f treatments and the results o f 
these studies will be discussed in Section 4 5
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4.3 c-Myc Over-expression Studies
Epithelial cell proliferation and differentiation is a complex process The 
regulation o f  genes encoding structural proteins, such as cytokeratins, during 
epithelial cell growth and differentiation is relatively well known However, less 
is known about the roles o f specific transcription factors (Lymboussakia, et al, 
1996) Since the discovery o f  c-myc, the myc gene family and the proteins they 
encode have formed part o f  the research programme o f many cancer research 
laboratories worldwide However, despite the numerous studies performed or 
currently under investigation, the role and mechanism o f action o f  the c-myc 
proteins still remain enigmatic In fact, although recently large advances in 
understanding the role played by this oncogene and some o f  its binding partners 
have been achieved the data obtained appears extremely complex and m some 
cases contradictory Many authors believe that oncogenes simply promote cell 
growth or cell death, and that they block cellular differentiation Studies 
performed in this laboratory have shown results that contradict this view In our 
differentiation model system we have shown that up-regulation o f the c-myc 
oncogene may be o f  importance in the lung cell differentiation process and it is 
possible that critical genes such as c-myc, may play different roles depending on 
cell type
Our research group has previously demonstrated that an increase in c-Myc 
expression is associated with the induction o f  differentiation, in both the DLKP 
and A549 cell lines, following treatment with BrdU (Walsh, PhD 1999) 
Western blot analysis revealed a significant increase in the levels o f  c-Myc 
protein during the differentiation o f  both epithelial cell lines Along with the 
increase in c-Myc, an increase in eIF4E was also observed eIF4E has been 
identified as one o f  the few known transcriptional targets o f the c-myc proto­
oncogene (Jones et a l , 1996) Studies have shown that eIF-4E expression 
correlates with c-myc levels following growth induction and that overexpression 
o f  c-myc in rat embryo fibroblasts leads to an up-regulation o f  eIF-4E expression 
(Makhlouf, et a l , 2001)
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It may appear contradictory that both c-Myc and eIF4E are up-regulated during 
epithelial lung differentiation in the DLKP model since there have been 
extensive reports in the literature o f  the down-regulation o f  c-myc expression 
during differentiation (Yen and Forbes, 1990, Valyi-Nagy et a l , 1993, Shimizu 
et a l , 1994) correlated with growth arrest (Bennet et a l , 1994) However, the 
roles o f  oncogenes such as c-myc and eIF4E in cellular differentiation are poorly 
understood
4 3 1  Stable O ver-expression o f  c-myc m DLK P
In light o f  our earlier studies, which showed that there was a significant increase 
in c-Myc protein levels in both DLKP and A549 cells treated with BrdU (Walsh, 
PhD 1999), it was decided to transfect the DLKP and A549 cell lines with a full 
length human c-myc expression vector A549 is known to be a difficult cell line 
to transfect, following several attempts using different transfection techniques 
(Section 2 14 2 and Section 2 14 4) it was not possible to obtain over-expressing 
clones
DLKP and a clonal subpopulation o f  DLKP, DLKP-SQ, were both transfected 
(Section 2 14 2) with a full length human c-myc expression vector Several 
attempts were made to generate c-Myc over-expressing clones The plasmid 
appeared relatively easy to transfect into both the DLKP and DLKP-SQ cell 
lines Several stable clones were isolated from a mixed population, however, 
none o f  the clones isolated appeared to overexpress c-myc at the mRNA (Section 
3 3 1 1 1) or protein level (Section 3 3 1 1 2 )  One possible reason for the lack o f 
overexpression o f c-myc may be due to the possible induction o f  an apoptosis 
pathway in cells over-expressing c-Myc and the clones isolated from the mixed 
population were cells that had become resistant to geneticm, but did not greatly 
over-express c-Myc
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4 3 2 Transient Transfection of DLKP-SQ with c-myc
As a result o f the inability to generate stable over-expressing c-M yc clones in 
both the DLKP and DLKP-SQ cell lines, we decided to attempt to investigate the 
role that c-myc plays in differentiation o f  lung cells by transiently transfecting 
(Section 2 14 4) the DLKP-SQ cell line The DLKP-SQ cell line was selected 
for the transient transfections simply because this subpopulation o f  DLKP is 
known to be easier to transfect, than DLKP
RT-PCR analysis o f transiently transfected DLKP-SQ cells revealed that the 
mRNA level o f  c-myc was significantly increased after 24h, 48h and 72h time 
points when compared to the untransfected DLKP-SQ parental cells (Section
3 3 1 2  1) An increase in c-Myc protein levels after 48 hours o f transfection and 
a further increase at 72 hours was demonstrated (Section 3 3 1 2  1) 
Investigation o f  mRNA and in some cases protein levels o f  potential c-myc target 
genes was then performed, the results are described in the following subsections
4 3 2 1 YY1 E xpression in c-myc transient transfections
The YY1 transcription factor possess the unusual ability to both positively and 
negatively regulate the expression o f a number o f genes which are thought to be 
important m  cellular differentiation (Riggs et al, 1991) (reviewed m Section 
1 7 2) and we have previously (Walsh, Phd Thesis, 1999) have identified this 
transcription factor as an important factor in our differentiation assays The 
unusual properties exhibited by this transcription factor allow it to regulate the 
expression o f  different genes m opposing fashion, making it a pivotal factor in 
the regulation o f developmental gene expression We have previously 
demonstrated in that YY1 is up-regulated in DLKP and A549 cells treated with 
BrdU (Walsh, PhD Thesis 1999) suggesting that this transcription factor may 
indeed be a cntical factor m the induction o f  differentiation on our in vitro cell 
systems
Investigation o f YY1 protein expression in the c-myc transient transfection 
expenm ents revealed an increase in this protein following the over-expression o f
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c-myc A t 24 hours following transfection with the c-myc expression vector a 
increase in YY1 protein expression was demonstrated and this increase was 
maintained at 72 hours (Section 3 3 1 2 3) Due to problems with RT-PCR 
analysis for the YY1 gene, it was not possible to ascertain if  the mRNA levels o f 
YY1 were altered in these experiments These results demonstrate that c-Myc 
had positive effect on the expression levels o f  Y Y 1 in cell system
4 3.2 2 eIF4E E xpression in c-myc transient transfections
eIF4E is a 25 kDa phospho-protein responsible for Cap-binding specificity in 
eIF4F complexes during eukaryotic translation initiation events eIF4E is widely 
accepted as the limiting factor in translational initiation, particularly for mRNAs 
with complex 5 ’ U TR’s The core promoter region o f the eIF4E gene contains a 
pan  o f  E-box consensus sequences, CACGTG, which corresponds to the c-myc 
binding sequence The eIF-4E gene is one o f the few known targets o f the c-Myc 
protein Studies have shown that eIF-4E expression correlates with c-myc levels 
following growth induction and that over-expression o f  c-myc in rat embryo 
fibroblasts leads to an up-regulation o f eIF-4E expression (Makhlouf, et a l , 
2001) which is in agreement with studies that we have performed in this 
laboratory and results presented in this thesis Examination o f  the transient over- 
expression o f  c-myc in DLKP-SQ revealed that eIF4E protein levels increased 
after 24 hours o f  transfection, but reverted back to levels o f  control cells 
following 48 hours (Section 3 3 1 2 4)
4.3 2 3 M ad expression in c-myc transient transfections
The M yc/M ax/M ad family o f  transcription factors plays a fundamental role in 
the regulation o f  cell proliferation, oncogenic transformation, and cell 
differentiation However, it remains unclear whether different heterodimers, such 
as M yc/Max and Mad/Max, recognize the same or different target genes in vivo 
c-M yc and M adl belong to a superfamily o f interacting proteins that regulate cell 
growth and differentiation Myc, Max M adl, Mad2 (M xil), Mad3 Mad4 and 
M nt are all members o f  this family In order for Myc to exert is cellular function 
it requires dim enzation with another protein Blackwood and Eiseman (1991)
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undertook a study to try and uncover a binding partner required for c-myc 
functionality and subsequently they identified a small, novel protem which they 
named Max Sequence analysis showed that M ax was similar to myc in that is 
also contained a bHLH and leucine zipper motifs The structure o f  Max 
appeared to be extremely simple, com pnsing o f  only 160 ammo acids, 60 o f 
which constitute the DNA-bindmg/dimenzation domain (Cole, 1991) Max has 
been found to be a very stable protein and appears to be constitutively expressed 
m resting as well as proliferating cells In proliferating cells, all newly 
synthesised c-myc is found associated with Max, suggesting that c-myc is rate- 
limiting in the formation o f  c-myc-Max dimers
Further work was carried out by Ager and Eiseman (1993) to investigate M yc’s 
and M ax’s ability to interact with other proteins The fact that the highly stable 
Max protein is present at times when myc is not expressed, prompted Eiseman 
and Ager to examine further the possibility that Max might associate w ith other 
proteins This group isolated a Max-binding protein which in turn the named 
Mad (Ager and Eisenman, 1993)
The Mad protem is made up o f  a family o f  four closely related proteins M adl, 
Mxi 1 (Mad2), Mad3 and Mad4 When Mad proteins are over-expressed in cells, 
they inhibit proliferation and apoptosis and suppress cell transformation not only 
by myc, but also by a variety o f  oncogene factors (Zhou and Hurlin, 2001) 
Transcriptional repression function o f  Mad proteins corresponds to its biological 
activity which is in direct opposition to that o f  myc proteins
The expression levels o f Max were not investigated in the c-myc transfection 
experiments, nor how the DLKP-treated with BrdU affects the expression levels 
o f  Max or Mad proteins Results presented in this thesis demonstrate that c-Myc 
protem over-expression has negative effect on the expression o f  M adl protein 
(Section 3 3 1 2 2) The reason why overexpression o f c-Myc decreased the 
expression levels o f M adl proteins is not clear However, in terms o f  cell 
function it is not surprising that increased expression o f  c-Myc would have a 
negative effect on the expression levels o f  Mad proteins, given that these two
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proteins have been demonstrated to have conflicting roles in cellular 
differentiation.
4.3.2.4 p i-In tegrin  Expression in c-myc transient transfections
Integrins form a large family o f  heterodimeric transmembrane glycoproteins that 
bind to components o f  the extracellular matrix. They are versatile adhesion 
receptors expressed by almost every cell type. In addition to mediating cell 
adhesion, integrins are known to function as signalling receptors, participating in 
a diverse array o f  cellular events including spreading, migration, proliferation, 
differentiation and apoptosis (Debhar. 1999). Integrins also appear to be 
important for normal differentiation in most cell types. Their role in 
differentiation o f  epidermal stem cells has been well established (Watt, 1998).
Cell adhesion promotes cellular proliferation through the regulation o f  gene 
expression, including the immediate early genes. However, the precise role o f  
cell adhesion in the regulation o f  the c-Myc proto-oncogene is not clear, and the 
adhesion-dependent signalling pathway(s) regulating the expression o f  c-Myc 
has yet to be defined.
Our research group has previously demonstrated that treatment o f  DLKP and 
A549 with the differentiation-modulating agent, BrdU, resulted in increase 
expression o f  Pi-integrin protein (Meleady, and Clynes, 2000). An increase in c- 
Myc was also observed in these cells (W alsh, PhD, 1999). Interestingly, in the 
transient transfection o f  the DLKP-SQ cell line with c-myc, a slight decrease in 
the mRNA levels o f  p|-integrin was observed. It has been previously been 
reported in the literature that constitutive expression o f  c-Myc in keratinocytes 
causes a reduction in P)-integrin expression levels. Our study o f  the transient 
over-expression o f  the c-myc gene agrees with these studies (Section 3.3.1.2.6). 
However, this does not explain how the expression levels o f  Pi-integrin are 
increased in BrdU-treated DLKP and A549 cells in which c-Myc levels are 
increased. It is possible that the treatment o f these cell lines w ith BrdU induces 
Pi-integrin proteins via some other pathway way w'hich is independent o f
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regulation o f  c-Myc Another reason for this disparity between the BrdU- 
treatments and the c-myc transient over-expression studies potentially could be 
related to c-Myc phosphorylation In these experiments the phosphorylation 
status o f  c-Myc has not been investigated Future work is required to examine if  
the activity o f  c-Myc is a result o f kinase-related effects in BrdU-treated cells
In summary, we have found that it was not possible to generate stably over­
express c-Myc in the DLKP cell line, but we have demonstrated that the transient 
over-expression o f  c-Myc increased levels o f YY1 and eIF4E protein expression 
levels were increased in these transient experiments Our results agree with 
published data where up-regulated c-Myc expression levels have been reported to 
increase the expression o f  eIF4E protein levels (Makhlouf, et a1, 2001) Further 
work is required to investigate the exact role c-myc plays our model 
differentiation system The over-expression o f  c-myc may indeed be involved in 
the regulation o f  other important differentiation-related genes not investigated in 
these studies Genes that may warrant further investigation maybe those which 
we have identified as being differentially expressed and thought important in the 
regulation o f differentiation by BrdU, 5,2 -FdU and IdU, following DNA 
microarray analysis (Section 3 2 and Section 4 5) In view o f  the fact that the 
microarray experiments performed in this thesis were conducted after this set o f 
c-myc over-expression studies, and due to time constraints, it was not possible to 
investigate if  c-myc was involved in their regulation o f  expression
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4 4 Yin Yang 1 Over-expression Studies
The Yin Yang 1 (YY1) transcriptional regulator is thought to be o f cntical 
importance in the control o f  normal development (Riggs et a l , 1991) (reviewed 
in Section 1 7 2) YY1 possesses the unusual property o f  regulating transcription 
in three ways In different cellular contexts, YY1 has been shown to activate, 
repress or initiate transcription o f a number o f cellular genes These opposing 
roles in the regulation o f  gene expression make YY1 a pivotal factor in the 
regulation o f developmental gene expression YY1 is ubiquitously expressed 
transcription factor that is thought to play an important role in the regulation o f  
many cellular and viral genes through the consensus cis recognition sequence 
(Yao, et al, 1998) It has been reported previously to up-regulate genes such as 
c-myc (Riggs el a l , 1993, Lee et a l , 1994) Previous investigation in our 
laboratory o f  the DLKP and A549 cell lines showed elevated expression o f YY1 
protein upon treatment with BrdU m both cell lines (Walsh, PhD 1999) BrdU 
has also been shown to up-regulate the levels o f  YY1 in embryonic myoblasts 
(Lee et a l , 1992), further confirming work previously performed in this 
laboratory It appears that YY1 may play an important role in the control o f 
normal differentiation and development, due to its unusual ability to 
differentially regulate expression o f various genes
Despite the large number o f  genes found to be potentially regulated by YY1 and 
the increasingly large number o f proteins that are claimed to interact w ith YY1, 
little is known concerning how YY1 itself is regulated YY1 has also been 
linked to cellular growth and differentiation One study by Lee et al (1992) 
demonstrated that the level o f  YY1 activity changes during myoblast 
differentiation It has been shown that YY1 levels increase rapidly in quiescent 
NIH3T3 cells in response to serum and insulin-like growth factor 1 treatment 
(Shi, et al, 1997) YY1 DNA binding activity has also been shown to be 
regulated during differentiation For example, YY1 DNA binding decreases 
during differentiation o f  human teratocarcinoma cells (Liu, et a l , 1994)
In view o f its pleiotropic activities, it is not surprising that association o f  YY1 
with other proteins appears to be important in determining the activity o f  YY1
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YY1 was first cloned because o f  it was found to bind to an E l A  sensitive site m 
the Adenoassociated virus (AAV) P5 promoter YY1 has also been shown to 
associate with another transcriptional activator S p l, YY1 and Spl together 
activate transcription in a synergistic manner (Lee, et a l , 1993, Seto, et a l , 
1993) Also, studies using the P5 promoter in an in vitro system indicated that 
YY1 TFIIB and Pol II are sufficient to initiate transcription
YY1 has been demonstrated to increase the transcription from the PI and P2 
promoter o f  the c-myc gene (Riggs et a l , 1993) In addition, it has been revealed 
that YY1 associates with the c-Myc protein itself (Shenvastava, et a l , 1993) In 
co-transfections earned out by Shnvastava, et al (1993), over-expression o f c- 
Myc inhibits both the transcnptional activation and repression abilities o f  YY1 
YY1 is thought to compete with Max (Section 1 7  1 1), excluding it from 
association with c-Myc (Shnvastava et a l , 1994) Since the 201-343 amino acid 
region o f YY1 is required for association with c-Myc and is also required for 
association with Spl and E l A, c-Myc may inhibit YY1 activity by m terfenng 
with its ability to associate with other transcnption proteins Studies have shown 
that c-Myc interferes w ith the ability o f YY1 to contact the basal transcription 
factors TATA-binding protein (TBP) and TFIIB
c-Myc levels vary in response to many mitogens and growth signals and it may 
be that the varying levels o f  c-Myc modulate YY1 activity in vivo There has 
been some speculation that one function o f  the c-Myc oncogene is to modulate 
the expression o f  YY1-dependent developmental genes by virtue o f  is association 
with YY1 (Liu, et a l , 1996) In co-transfection expenm ents, c-myc expression 
was able to reduce YY1 activating function from eight-fold m  the absence o f  co­
expressed c-myc to two-fold m its presence (Shnvastave, et a l , 1993) In light o f 
Y Y ls  ability to activate c-myc gene transcription, association between these two 
proteins may form the basis o f an auto-regulatory mechanism that controls the 
expression and activity o f  both proteins (Gngnani, et a l , 1990), preventing 
excessive loss o f growth control dunng periods o f  elevated c-M yc expression
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4.4.1 Role for YY1 in regulation o f differentiation in DLKP
Previous work performed by our research group showed that the differentiation- 
modulating agent. BrdU, was capable o f  inducing differentiation in our in vitro 
DLKP cell system and the lung adenocarcinoma cell line, A549(M cBride S., et 
a/., 1999; Meleady P., PhD Thesis 1997; O ’Sullivan F., PhD Thesis 1999; Walsh 
D., PhD Thesis 1999; Dolan P., PhD Thesis 2001; Meleady and Clynes, 2001a; 
Meleady and Clynes. 2001b). It was also proposed by work performed by Walsh 
(PhD Thesis, 1999) that YY1 may play a critical role in the control and induction 
o f  differentiation in our model system. To investigate if  YY1 is indeed a critical 
factor in this model differentiation process it was decided to transfect the cell 
line, DLKP, and a colonal subpopulation, DLKP-SQ, with an YY1 expression 
vector.
Stable highly over-expression Y Y 1 clones were generated from the transfection 
o f  DLKP-SQ cells with a full length YY1 expression vector. Preliminary 
characterisation on the effect o f  the over-expression o f  the YY1 transcription 
factor was performed on these clones. Unfortunately, during the freezing and 
thaw-back, the cells lost the over-expression o f  YY1 gene.
Western blot analysis o f  the isolated over-expressing YY1 clones revealed a 
significant increase in expression o f  YY1 protein in comparison to the 
untransfected parental cell line (Section 3.2.2.1.1). As a result o f  difficulties 
experienced generating effective RT-PCR primers, it was not possible to 
investigate the YY1 mRNA levels in the isolated over-expression clones.
In order to characterise the DLKP-SQ YY1 clones, the expression levels o f 
several genes were investigated at both the mRNA and protein level in an 
attempt to determine if  the over-expression o f  YY1 plays an important role in our 
differentiation system. In studies performed by W alsh (PhD Thesis, 1999), it 
was demonstrated that BrdU-treatment o f  DLKP increased the expression o f  
YY1 and c-Myc proteins; indicating that these two proteins maybe two important 
transcription factors in this differentiation model system. Also, YY1 has been 
reported in the literature to associate with c-Myc; therefore, we investigated the
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expression levels o f c-Myc m our YY1 to determine if  YY1 played a role in the 
regulation o f c-myc RT-PCR analysis for c-myc was performed on the clones 
(Section 3 2 2 1 2) revealing no change in expression o f  c-myc However, 
W estern blot analysis demonstrated that there was a marked increase in c-Myc 
protein levels within the YY1 clones (Section 3 2 2 1 2) It appears that the up- 
regulation o f  YY1 had no effect on c-myc expression at the RNA level, but did 
cause an increase in c-Myc protein expression
In addition to c-Myc, M adl protein levels were investigated in the YY1 over- 
expressing clones M adl protein is reported to be expressed in resting and 
differentiating cells and is a known antagonist o f c-Myc The expression o f c- 
Myc and Mad proteins is tightly controlled and their relative concentrations are 
critical parameters in the regulation o f  cell growth W estern blot analysis for 
M adl protein in the YY1 clones revealed that the level o f M adl was increased, 
with Clone 4 exhibiting the greatest increase in expression (Section 3 2 2 1 3)
The effect o f  over-expression o f  YY1 on members o f  the family o f  eukaryotic 
translation factors (elFs) were also investigated in this study It was found that 
over-expression o f  YY1 up-regulated the mRNA expression levels o f  eIF 2a 
(Section 3 2 2 1 10) in all clones when compared to the untransfected parental 
cell line, DLKP-SQ mRNA levels o f  Mnk2, a known eIF4E kinase, were 
examined It was demonstrated that over-expression o f YY1 in this cell model 
system had no effect o f the mRNA levels o f Mnk2
W estern blot analysis for eIF4E in the YY1 clones was performed revealing that 
a substantial increase in the level o f  eIF4E protein (Section 3 2 2 1 4) All clones 
exhibited a marked increased in eIF4E protein, however, Clone 4 showed the 
greatest change Immunocytochemical analysis o f the clones revealed that the 
over-expression o f YY1 also increased the expression o f  Ornithine 
Decarboxylase (results not shown) which is known to be translationaly regulated 
by eIF4E over-expression Due to problems with RT-PCR primers it was not 
possible to investigate if the mRNA levels o f e ir4 E  were altered in these clones 
An increase in the expression o f  eIF4E protein levels was also demonstrated in
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BrdU-treated DLKP cells eIF4E has also been reported as a target for c-M yc 
and over-expression o f  c-Myc has previously been shown to up-regulate eIF4E 
protein levels (Makhlouf, et a l , 2001), which was confirmed here Also, an 
increase m  eIF4E protein expression was demonstrated in the treatment o f  A549 
cell lines (Section 3 1 14) with BrdU and this further confirms the fact that YY1 
maybe playing role in this differentiation system
Other members o f  the translationaly machinery were investigated, these included 
Mnk2, eIF4E~BPl and eIF2a RT-PCR analysis o f  eIFF4E-binding protein-1 
revealed that there was no change in mRNA expression in any o f  YY1 over­
expressing clones RT-PCR analysis for eIF2a revealed an increase in mRNA 
levels in the clones Western blot analysis also demonstrated an increase in 
eIF2a protein levels
In our studies we demonstrate that the over-expression o f  YY1 in our system had 
an effect on some o f  the translation machinery o f  the cell In particular, a major 
increase in the expression eIF4E protein levels was demonstrated along with an 
increase in the expression o f  eIF2a mRNA and protein levels eIF2a is a subunit 
o f eIF2 and is involved in the recruitment o f  the initiator tRNA (Met-tRNA) to 
the 40S Ribosomal subunit, in the initiation process o f  translation (Colhurst et al 
1987) It has been suggested that eIF2a, along with eIF4E, may possibly be a 
limiting factor in initiation o f  protein synthesis Under conditions o f  elevated 
eIF4E expression, translation o f complex or repressed mRNAs have been shown 
to be initiated more frequently, and can compete more efficiently for eIF2a, 
becoming translated at the same rate as ‘norm al’ mRNAs The over-expression 
o f  these two important initiation factors may thus be playing important roles in 
the induction o f  cytokeratin protein expression in the YY1 over-expressing 
clones
We also examined by RT-PCR analysis Pi-mtegrin mRNA expression levels in 
the YY1 over-expressing clones and demonstrated that there was no change in 
the level o f  expression o f Pi-integrin mRNA (Section 3 2 2 1 1 8) However, 
Western blot analysis revealed that upon up-regulation o f  YY1 protein, p i-
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integrin protein levels appeared to be down-regulated (Section 3 2 2 1 1 8) As 
m entioned earlier up-regulation o f c-Myc protein has been shown to have an 
inhibitory effect on the expression levels o f  pi-integrin In our in vitro system 
we have demonstrated that associated with the over-expression o f  YY1 protein, 
is an associated up-regulation in the expression levels o f  c-Myc protein This up- 
regulation in c-Myc protein may explain why a decrease Pi-integnn was 
observed in the YY1 over-expression experiments Also, as for c-Myc, YY1 
over expression may have a different affect on the expression o f  certain genes, 
and the expression pattern o f these genes may vary when compared to BrdU- 
treatment o f cells
Immunocytochemical analysis performed by Derek W alsh (PhD Thesis, 1999) 
demonstrated that the over-expression o f  YY1 in DLKP induced cytokeratm 
expression in the cell line In order to investigate if  YY1 over-expression altered 
the mRNA expression o f  these proteins, RT-PCR analysis was performed for 
cytokeratins 8, 18 and 19 This analysis revealed that the level o f  mRNA o f 
cytokeratm 8 remained unaffected by the over-expression o f  YY1 (Section 
3 2 2 1 5) However, the mRNA levels o f  both cytokeratm 18 and 19 (Section 
3 2 2 1 1 6and Section 3 2 2 1 1 7) were both increased, indicating that YY1 
maybe involved in the regulation o f  their expression For some unknown reason 
the stable YY1 clones generated in this study lost their YY1 over-expression 
during freeze/thaw back Several clone stock banks were prepared, however 
when these stocks were re-cultured, W estern blot analysis revealed that the 
clones had lost all over-expression o f  YY1 protein Due to time constraints in 
this thesis, it was not possible to ascertain if  the protein levels o f  these three 
cytokeratins were also altered and some further work needs to be performed to 
address this
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Section 4.4 2 Transient Over-expression of YY1
Due to time constraints towards the end o f  thesis and problems with the YY1 
plasmid, it was not possible to generate more stable over-expressing YY1 clones 
Therefore, it was decided to transiently transfect the DLKP and DLKP-SQ cell 
lines w ith a YY1 expression vector for up to 72 hours in order to further 
investigate the potential role that YY1 plays in our model differentiation system 
The initial transient transfections where performed with the YY1 expression 
vector described m Section 3 2 2 2 while the DLKP YY1 transient transfections 
were earned out using the vector described in Section 3 2 2  2 Both YY1 
plasmids contain a full length human cDNA gene
From analysis o f the transient over-expression o f  YY1 expenm ents it was found 
the YY1 mRNA levels were increased several fold following 72 hours o f 
transfection (Section 3 2 2 2 1) Unfortunately, due to continual problems 
sourcing anti-YY l antibody from Santz B io tec , it was not possible to examine 
the protein levels o f  YY1 in these experiments Transient over-expression o f 
YY1 appeared to have a negative effect on the expression levels o f  c-myc 
mRNA, and analysis revealed that the c-myc signal was complete shutoff after 48 
hours, but were found to increase again after 72 hours, but not back to control 
levels (Section 3 2 2 2 2) However, Western blot analysis demonstrated that c- 
Myc protein levels were increased upon the over-expression o f  the YY1 gene 
(Section 3 2 2 2 2 )  From analysis o f  the stable over-expression YY1 
experiments in DLKP-SQ cells (Section 4 4 1), results demonstrated that the 
mRNA levels o f  c-myc were unchanged by the over-expression o f  YY1 protein, 
however c-Myc protein expression levels were increased in the YY1 clones
The YY1 transient over-expression studies performed confirmed that YY1 up- 
regulation in our cell system is capable o f increasing c-Myc protein expression 
The dispanty in the effect o f YY1 over-expression on c-myc mRNA levels 
maybe explained by dosage levels o f  the YY1 gene in the transfected cells The 
over-expression o f  YY1 achieved in the transient expenm ents maybe much 
higher than the levels obtained in the stable clones, and the differences m the
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The effect o f  transient over-expression o f  YY1 on members o f  the translation 
initiation factors was also investigated These expenm ents confirmed results o f 
the stable over-expression experiments where YY1 was demonstrated to have no 
effect on expression levels o f  eIF4E-bindmg protein-1 and Mnk2 (Section 
3 2 2 2 4 and Section 3 2 2 2 5) In the stable YY1 clones it was found that the 
protein expression levels o f eIF 2a were increased, however, the mRNA levels 
for this gene were not investigated The results from the transient over- 
expression o f  YY1 revealed that the mRNA levels for eIF 2a were greatly 
reduced after 24 hours o f  transfection, but after 72 hours returned to control 
levels Unfortunately, due to time constraints it was not possible to investigate 
the protein levels o f  eIF2a in these transient expenm ents
pi-in tegrm  mRNA levels in the YY1 transient transfection experiments were 
also investigated The results o f  this analysis revealed a marked reduction in the 
expression o f pi-integrm  mRNA upon up-regulation o f  YY1, with virtually all 
pi-integrm  mRNA signal shutoff following 48 hours o f  transfection with YY1 
However, 72 hours after transfection the mRNA expression levels o f p l-in tegrin  
had almost returned to that o f  the control, untransfected cells These results in 
part contradicted the RT-PCR analysis performed on the YY1 stably over- 
expression clones, which showed no apparent change in p i-in tegnn  mRNA 
levels (Section 3 2 2 2 8) Western blot analysis demonstrated a marked 
reduction in p i-in tegral protein levels In both the YY1 stable and transient 
over-expression studies we have demonstrated that YY1 is cable o f  up-regulating 
c-M yc protein levels in your system Therefore, it is plausible to assume that this 
up-regulation in c-Myc protein levels may potentially be regulating the levels o f 
p i-in tegrm  The regulation o f  p i-in tegnn  by c-Myc has previously been 
reported
The effect o f  YY1 over-expression on the mRNA expression o f cytokeratin 8 and 
18 was examined It appeared that YY1 over-expression had no major impact
levels o f YY1 expression may have a bearing on the expression of c-myc mRNA
in these experiments Further analysis is required to confirm this hypothesis
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the mRNA levels o f  these two cytokeratins These experiments were preformed 
at the end o f  this thesis and due to time constraints it was no possible to 
investigate if  transient YY1 over-expression induced cytokeratin protein 
expression, as was demonstrated by our research group in stable YY1 over- 
expression clones (Walsh, PhD Thesis, 1999)
In summary, we have demonstrated that the stable and transient over-expression 
o f the YY1 transcription factor in our cell system is capable o f  inducing a similar 
pattern o f  genes as were found altered in BrdU-treated DLKP cells We 
demonstrate that both BrdU-treatment o f  DLKP and the over-expression o f  YY1 
protein both increased the expression levels o f  c-Myc and eIF4E proteins These 
results suggest that these two genes may be playing a critical role in the 
regulation o f  the differentiation pathway induced in DLKP by BrdU
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4.5 DNA Microarray Analysis
Temporal and spatial control o f  gene expression by transcription factors is the 
hallmark o f  development The program of lung development from the beginning 
is directed by the activity o f key transcriptional factors DNA microarrays which 
permit assessment o f  gene expression patterns on a global level have become 
increasingly available Initial work in this study demonstrated that a range o f 
thymidme analogues, including BrdU, IdU and 5,2 -FdU (Section 4 2), were 
capable o f  inducing differentiation-related proteins in our DLKP and A549 cell 
line model systems Analysis o f  DLKP cells treated with these three thymidine 
analogues illustrated that they all induced a similar pattern o f  differentiation- 
related genes (Section 4 2) All three analogues altered the morphology o f 
DLKP upon treatment for 7 days In particular, the expression o f  cytokeratins 8, 
18 and 19 proteins were induced following exposure o f  cells to the thym idme 
analogues (Section 3 1) To investigate the global changes that occurred in 
DLKP cells treated with BrdU, 5,2 -FdU and IdU, DNA microarray analysis was 
performed using Affym etnx U133A GeneChips® (Section 2 15) The aim o f 
this analysis was to identify patterns o f gene expression changes in all three 
thymidine analogue treatments and also to identify common gene alterations 
between the three DNA microarrays performed, thereby possibly identifying 
genes which maybe potentially regulatory m the pathway o f differentiation 
induced by these three analogues
The first DNA microarrays to be performed were microarrays on BrdU-treated 
DLKP cells Three separate microarray experiments, labelled Exp 1, Exp 2 and 
Exp 3, were performed In the initial experiments, Expt 1, time points at 0, 1,3,  
7 and 14 days and in the Expt 2 experiment time points o f  0, 1 and 7 days were 
chosen for analysis (Section 3 2 2 1) These initial microarray expenm ents were 
earned out using single samples from each time point Gene expression analysis 
on data sets was carried out as per Rushton et a l , (2003) In Exp 1 over 9,100 
genes were identified as being differentially expressed in the experiment, 
whereas in Exp 2 approximately 3,500 genes were identified A large difference 
in the numbers o f  genes identified as being differentially expressed between
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these two experiments maybe due to the fact that 5 experiment time points were 
chosen in Exp I In Exp 2 only time points at 3 and 7 days were chosen
Following gene expression analysis on these data sets, a list o f  differentially 
expressed up- and down-regulated genes was created From this list, ten genes 
were selected and RT-PCR analysis was performed in order to verify the gene 
expression analysis results The genes were selected on the basis o f  being the 
most robust and the most reliably consistent in the two expenm ents The ten 
selected genes were then confirmed by RT-PCR analysis in order to validate the 
microarray data sets
Expt 3 was preformed in triplicate using biological replicates and time points o f 
0, 3 and 7 days were chosen (Section 3 2 2 3) Since this expenm ent was 
performed using biological triplicates, the promoter analysis (Section 3 2 2 5 and 
Section 4 6) for this thesis was focused on this expenm ent In this experiment 
following gene expression analysis a total o f 1,093 genes were identified as 
being differentially expressed (Appendix 7 1) 812 o f  which were demonstrated 
as being up-regulated, whereas 281 genes were identified as being down- 
regulated at day 7
In the 5,2 -FdU microarray expenment, total o f 2,240 genes were identified as 
being differentially expressed across the experiment (Appendix 7 3) At day 7, 
1,186 o f  these genes were shown to be up-regulated and 961 genes down- 
regulated The total number o f  differentially expressed genes identified in the
5,2 -FdU array found to be almost twice that Epx 3 BrdU array In the case o f 
the IdU microarray 722 genes were identified as being differentially expressed, 
471 o f  which were found to be up-regulated at day 7, with a further 251 down- 
regulated
Exp 3 o f  the BrdU mtcroarrays, the 5,2 -FdU and IdU microarrays were 
performed towards the end o f this thesis and as a result time did not allow for
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RT-PCR validation o f  wide set o f genes identified as being differentially 
expressed However, the ten genes used to validate the initial BrdU arrays, Exp 
1 and Exp 2, also emerged following analysis o f  the third BrdU microarray, Exp 
3, and the 5,2 -FdU microarray These ten genes were used to validate the BrdU 
(Exp 3) and 5,2-FdU However, not all o f these ten were found up-regulated in 
the IdU microarrays, therefore only a subset o f  these were used to validate this 
microarray
4 5 1  C om parison o f the BrdU , 5,2 -FdU M icroarray and IdU  D N A  
M icroarrays
Venn diagrams o f differentially expressed genes were created in order to identify 
genes that that were commonly up-regulated at 7 days between the Exp 3 BrdU,
5,2 -FdU and IdU microarrays (Section 3 2 5) 179 up-regulated genes were
shown to be common to BrdU and 5,2 -FdU only 132 up-regulated genes were 
found common to BrdU and IdU only, and a further 29 genes common only to 
IdU and 5,2 -FdU A total o f 93 up-regulated genes (Appendix 7 5) were 
identified as being common to all three treatments
Similar to the up-regulated genes, the lists o f  differentially expressed down- 
regulated genes from the BrdU, 5,2 -FdU and IdU microarrays were overlapped 
using a Venn diagram in order to identify genes that are commonly down- 
regulated between the three treatments From the Venn diagram 105 down- 
regulated genes were found to be common to both the BrdU and 5,2 -FdU 
microarrays It was observed that 24 genes were commonly down-regulated 
between BrdU and IdU, with a further 15 genes common to 5,2 -FdU and IdU 
only A total o f  9 genes were identified as being down-regulated between all 
three microarray experiments
It should also be noted that BrdU treatment o f  DLKP cells differentiate in 
response to treatment with BrdU Therefore one would expect some ‘noise’ from 
undifferentiated cells Also, the low percentage o f  cells induced to differentiate
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in the BrdU differentiation assays agrees with the finding o f  relatively few genes 
found to overlap between the three microarray experiments.
4.5.2 Identification o f biological themes with EASE
High density microarray experiments have enabled the discovery o f  global 
patterns o f  biological responses to experimental conditions. Huge am ounts o f  
effort have been placed on issues such as data normalisation and statistical 
testing o f  genes that are significantly clustered on the basis o f  expression 
profiles. The net result o f  these efforts is the creation o f  one or more often very 
long lists o f  differentially expressed genes. However, one area o f  microarray 
analysis that requires attention in trying to make biological sense o f  these lists is 
o f  identification o f  biological themes from the gene lists. Annotating genes from 
such lists can be extremely laborious using internet-based databases or manual 
literature searches. Even after performing such searches, it can be difficult to 
identify biological themes from the gene list in order to makes sense o f  the 
microarray data. Expression Analysis Systematic Explorer (EASE) is a publicly 
available software application (http://david.niaid.nih.aov/david) that can used for 
the determination o f  biological themes from lists o f  genes.
The main focus o f  the differentiation studies performed in this body o f  work was 
to identify genes that were common to all three thymidine analogues, BrdU, 5,2 - 
FdU and IdU, since all three induce similar patterns o f  differentiation. A total o f 
93 genes (Appendix 7.5) were identified as being up-regulated between the three 
microarray experiments. In order to identify biological themes within this set o f  
93 genes, they were entered into EASE.
Not surprisingly, due to the effect these thymidine analogues have on the cell, 
some o f  the categories that featured strongly in this analysis included cell death 
and apoptosis categories. However, other groups which featured heavily in the 
statistical scoring in the EASE analysis were the categories o f  morphogenesis, 
organogenesis and development (Table 4.1).
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Common Name Affymetnx Id
ID3 207826 s at
LY6H 206773 at
PHLDA2 209803 s at
GBX2 210560 at
CYP1B1 202436 s at
ID1 208937 s at
F2R 203989 x at
TPM1 206116 s at
GPC4 204983 s at
CSRP2 207030 s at
PAPSS2 203058 s at
HMOX1 203665 at
MCAM 209087 x at
EPB41L2 201719 s at
KLF4 221841 s at
TAGLN 205547 s at
DPYSL2 200762 at
DKK3 214247 s at
FGF2 204422 s at
DTR 203821 at
Table 4.1 This table details the 20 genes categorised by EASE has being 
involved in ‘Developm ent’
A total o f 20 (Table 4 1) o f  the 93 (Appendix 7 5) up-regulated genes common to 
all three microarrays fell into the development category, a subset o f  the more 
interesting genes are descnbed m the following subsections
4 5 2 1  Id fam ily
The Id family o f  four helix-loop-hehx (HLH) transcription factors (Id l, Id2, Id3 
and Id4) act as dominant negative regulators o f  basic HLH proteins The four Id 
proteins share a homologous HLH domain, but lack the basic DNA binding 
domain Id proteins act to sequester bHLH proteins by forming inactive dimers 
to prevent binding o f bHLH proteins to E-box sites (Chaudhary et a l , 2000)
Two genes from the Id family o f transcription factors, Id l and Id3, were found 
following EASE analysis, in the development category and were common to all 
three DNA microarray experiments The expression o f I d l  m R N A  w as found
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to be up-regulated in all three microarray experiments: 4.8-fold in BrdU, 
3.6-fold in 5,2'-FdU and 1.6-fold in the IdU microarray. The mRNA 
expression levels o f the Id3 family member was increased by 7.5-fold in the 
BrdU microarray, 7.9-fold and 1.6-fold in the 5,2'-FdU and IdU 
microarrays, respectively.
Two other Id family members, Id2 and Id4, were also found up-regulated in the 
DNA microarray experiments. However, EASE did not classify these two family 
members in to the ‘Development’ category. The expression of Id2 mRNA was 
increased to 3.9-fold in both the BrdU and 5*2-'FdU microarray and 1.5 fold 
in the IdU microarray. The expression levels o f Id4 mRNA were increased 
to 4.4-fold and down to 2.7-fold at day 3 and day 7, respectively, in the BrdU 
microarray. In the 5,2'-FdU microarray experiments the mRNA levels of 
Id4 were found to be 3.2-fold and 3.9-fold at day 3 and day 7 respectively. 
And in the IdU microarray the expression of Id4 mRNA was found to 
increase to 2.1-fold following 7 days o f  exposure to the analogue.
The different Id members have been localised to different chromosomes and 
show marked differences in their pattern o f  expression and function (Fong et al., 
2003). Although the family members are similar in the HLH domain, the regions 
outside this sequence are distinct from each other. It is thought that this variance 
between the four family members may determine their tissue specific function, as 
well as the binding specificity for particular bHLH proteins. Since many bHLH 
proteins positively regulate sets o f  genes during cell fate determination and cell 
differentiation. Id proteins are thought to inhibit the ability o f  bHLH proteins 
from binding DNA and inhibit cell differentiation.
Although Id proteins traditionally have been viewed as negative regulators o f  
differentiation, recent work has revealed much wider biological roles, and are 
now thought to be important in development, cell cycle control and tumour 
biology. In general, the Id proteins are expected to have overlapping function 
because o f  their ability to form non functional dimers with differentiation- 
inducing bHLH proteins. Recent studies suggest that his may not be true, and 
some Id proteins may, in fact, be required to induce and maintain the
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differentiation state o f  a particular cell (Lui, et a l , 2000, Cooper and Newburger, 
1998) It has been demonstrated that Id2 may act as inhibitor o f proliferation and 
is required for the determination and maintenance o f  the differentiated state o f 
alveolar epithelial cells (Liu et a l , 2000) The constitutive expressions o f Id2 
and Id3 mRNA in Sertoli cells suggests that these proteins may have a significant 
role in maintaining Sertoli cell function (Chaudhary et a l , 2000) Chaudhary et 
al (2000) have shown that post-mitotic and differentiated Sertoli cells express 
high levels o f  Id proteins This pattern o f  Id2 and Id3 expression agrees w ith the 
results presented in this study, where we show a signification increase o f  both 
genes in differentiating lung epithelial cells
In several epithelial cell types, the expression o f this family o f proteins has been 
positively correlated with proliferation (Barone et a l , 1994) They are often up- 
regulated m proliferating and undifferentiated cells, and down-regulated upon 
induction o f differentiation (Norton et a l , 1998) Ectopic expression o f Id 
proteins has also been shown to block differentiation functions in a number o f 
cell types by sequestering cell-specific bHLH transcription factors (M elnikova 
and Christy 1996, Shoji et a l , 1994) Experiments presented in our study show 
that mRNAs for the Id family members are up-regulated in DLKP cells induced 
to differentiate following treatment w ith halogenated pyrimidine analogues 
Therefore, we suggest that the Id family o f  transcription factors may potentially 
play an important role in the control o f  differentiation-related genes in our model 
cell system However, further work is required to elucidate the exact role this 
family o f  proteins plays in our differentiation system
4 5.2 2 G lypicans
Glypicans are a family o f  six glycosylphosphatidylmositol-anchored cell surface 
heparan sulfate proteoglycans implicated in the control o f  cellular growth and 
differentiation, which have been localized to rafts and caveolae (Fransson 2003) 
Glypicans are selective regulators o f ligand-receptor binding and have been 
reported to control cellular growth and development In recent years it has 
become apparent that proteoglycans serve in several major developmental 
signaling-pathways It is now thought that several secreted and cell surface
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molecules participate indirectly in growth-factor signaling, by influencing the 
interactions between growth factors and receptors The evidence is particularly 
strong for the pathways supported by FGFs, Wnts and BMPs, which all involved 
in a wide variety o f  developmental pathways (De Cat and David, 2001)
Proteoglycans are proteins, substituted with glycosaminoglycans These 
glycosaminoglycans bind to growth factors, extracellular matrix molecules, 
enzymes, protease inhibitors and many other proteins They are predominantly 
located on the cell surface Two major families o f proteoglycans have been 
identified the syndecans and the glypicans Syndecans are transmembrane 
proteoglycans, whereas glypicans are attached to the cell surface Syndecans and 
glypicans show differential expression and have been found to be highly 
regulated during development The structures o f  the individual glypicans are 
extremely well conserved across the species It is not currently known if  the 
glypican family members share common functions (De Cat and David, 2001)
Given the ability o f  glypicans to regulate the activity o f  cellular growth, this 
family o f  proteins has also been associated with some cancers Recent reports 
have showed that changes in their expression patterns maybe linked with tumour 
progression One such study established a connection between glypican 1 and 
pancreatic cancer, where the expression o f this protein was significantly up- 
regulated (K leef et a l , 1998) In our study w e found that the expression o f  
glypican-4 m R N A  w as increased by 1 6-fold at day 7 in the BrdU  
m icroarray, to 1.7-fold in both the 5 ,2 '-FdU  and IdU  m icroarrays, 
respectively The exact role that the glypicans play in our differentiation system 
remains unclear and further work is required to ascertain their exact role in the 
control o f  differentiation m the DLKP cell line
V
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4 5 2 3 Kruppel-like factor 4
Following EASE analysis o f the BrdU, 5,2 -Fdu and IdU microarray data sets, 
one interesting gene identified in the development category was KLF4 Analysis 
of the microarray experiments revealed that the expression of KLF4 mRNA 
was increased 1 8-fold in BrdU-treated DLKP cells, 2 8-fold in 5,2'-FdU and 
2 2-fold in IdU-treated DLKP cells following 7 days exposure
Kruppel-like factors (KLFs) are DNA-binding transcriptional regulators that play 
a diverse role during differentiation and development The KLFs are zinc finger 
transcription factors, expressed in the epitheha of the skin, lungs and 
gastrointestinal tract as well as in many other organs Members o f this family 
include erythroid (EKLF), lung (LKLF), basic (bKLF) and gut (GKLF, also 
known as KLF4)
KLF4 has been the most thoroughly investigated family member with respect to 
its role in cellular differentiation This gene has been shown to be important in 
the gastrointestinal tract and colon epithelium, where the gene is thought to 
regulate cell growth and differentiation Shie et al (2000) demonstrated that the 
expression of KLF4 mRNA is significantly decreased in neoplastic colomc 
tissues including adenoma and carcinoma and they have suggested that down- 
regulation of KLF4 may contribute to malignant transformation of the colon In 
this study, Shie et al (2000) showed that constitutive over-expression of KLF4 in 
human adenocarcinoma cells resulted in a decrease in [3H]thymidine uptake, 
whereas inhibition of KLF4 led to an increase in DNA synthesis, suggesting that 
KLF4 may play an essential role in controlling growth arrest in the colon This 
trend in KLF4 expression was confirmed in another study by Sheilds et al 
(1996) who demonstrated that KLF4 mRNA levels were significantly decreased 
in proliferating NIH 3T3 cells The exact mechanism by which KLF4 exerts its 
effect in is not fully understood Shei et al (2000) reported that the expression 
of KLF4 is closely related to that o f CD1 and CD 1-associated kinase activity and 
that KLF4 in fact suppresses the CD1 promoter activity
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Earlier work in this study examined the effect o f the differentiation modulating 
agent, BrdU, and the various other halogenated thymidine analogues (Section 3 1 
and Section 4 2) had on the differentiation status o f both DLKP and A549 
Markers of differentiation that were investigated in these assays included a group 
of intermediate filaments known as cytokeratins These proteins are known to be 
important in cellular differentiation and cytoskeleton organisation and have been 
subdivided into two main types The acidic type I is composed of cytokeratins 
9-20, whereas the basic type II include 1-8 (Section 1 5) One cytokeratin in 
particular, K19, has no known basic type II keratin partner, although its 
expression is often found in cells that express K8 (Qumlan et a l , 1985) We 
have also demonstrated that the expression of K8 and K19 protein levels are 
induced our differentiation studies of both DLKP and A549 cells (Section 4 2)
Regulation of cytokeratin expression in the differentiating stratified squamous 
epithelium is governed by a complex interplay of both ubiquitous and tissue- 
specific transcription factors Little is known about the regulation of K19 
expression Brembeck and Rustig (2000) reported that KLF4 and Spl modulate 
K19 promoter activity in a tissue-specific manner The role o f Spl in the 
regulation of cytokeratins has been descnbed previously The promoter of 
corneal-specific K3 gene is regulated by an overlapping Spl/Ap2 site and 
endogenous levels o f Spl and Ap2 define K3 gene transcription in differentiating 
corneal epithelial cells (Chen et a l , 1996) The transcription of K5, K16, K17 
and K18 has ail been shown to be under the control of Spl (Ohtsuki et al 1993, 
Magnaldo et a l , 1993, Gunther et a l , 1995)
The KLF family o f transcription factors had been phylogenetically linked to the 
Spl family Brembeck and Rustig (2000) in their study revealed that both Spl 
and KLF4 act positively on an overlapping Spl/KLF4 site in the K19 promoter 
with preferential binding by KLF4 and postulated that the endogenous levels o f 
Spl and KLF4 are important determinants in binding to this element In their 
study they showed that KLF4 contributes to the tissue-specific transcriptional 
regulation of K19 expression KLF4 appears to play an important role in cell- 
specific differentiation by activating K19 expression, which they demonstrated to 
be influenced by Spl in stratified squamous epithelial cells but is relatively
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independent o f Spl m pancreatic ductal epithelial cells Therefore, it is possible 
that KLF4 and Spl modulate K19 expression differently, m that Spl is important 
developmentally and KLF4 directs cell fate decisions during differentiation
Jenkins et al (1998) also reported that KLF4 increased the transcriptional 
activity o f keratin 4 and Epstein-Barr virus ED-L2 promoters and suggested that 
KLF4 may function as a transcriptional activator in the oesophageal squamous 
epithelium to regulate cell differentiation It is also possible that KLF4 may 
function as either an activator or repressor of transcription and that this property 
is promoter or cell type specific (Yet et a l , 1998) Is it possible that KLF4 is 
involved in the regulation of cytokeratm expression levels in our cell system9 In 
order to answer this question the factors involved in the regulation of KLF4 itself 
require investigation
4 5 2 31 Regulation of KLF4
The transcriptional regulation of KLF4 itself is poorly understood and it was 
recently shown by Chen et a l , (2000) that IFN-y enhanced its expression IFN-y, 
a pleiotropic cytokine with antiproliferative and lmmuno-modulating activities, 
has been shown to exert its functions by enhancing transcription of IFN-y- 
responsive genes such as IRF-1, FcrRl and Ly6-1A/E These genes, in general, 
share many common features, for example, their expression is mediated by 
tyrosine phosphorylation of latent pre-existing STAT1 and their promoters 
contain an IFN-y-activation sequence that binds specifically to phosphorylated 
STAT1 (Chen et al 2002) A study performed by Chen et al (2002), established 
the molecular mechanism by which IFN-y induced KLF4 expression in colon 
cancer cells This was accomplished by demonstrating that IFN-y increased 
KLF4 and IFR-1 mRNA levels in a similar fashion Wong et al (2002) 
demonstrated that the induction of IRF-1 by IFN-y was STATI -dependent and 
that the expression of the ST ATI gene depended on IRF-1 Together, these data 
suggest that IFN-y-induced KLF4 expression was mediated through STAT1 and 
this theory was further supported by findings showing that the effect o f IFN-y on 
KLF4 or IRF-1 gene expression was completely abolished in STAT1-deficient 
cells
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4 5 2 3 2 STATI regulation of gene expression in response to IFN-y
The transcription factor STAT-1 is activated by the tyrosine phosphorylation 
mediated by JAK family kinases during cellular responses to cytokine or growth 
factor signalling STAT-1 directly regulates the expression of key proteins in 
controlling the cellular processes o f growth arrest o f p21 (also known as 
CDKN1 A) and cell death via expression of caspases (Wong et a l , 2002) In our 
study it was observed that p21 mRNA was up-regulated 4 9-fold in the BrdU 
microarray, 2.5-fold in 5,2'-FdU microarray and 2.2-fold in IdU-treated 
DLKP cells, after 7 days exposure STAT-1 is also thought to be an essential 
element in a range of different transcription factor complexes The two most 
commonly identified are GAF and ISGF3, which are involved in the signal 
transduction pathways o f type I and II INFs, respectively (Stark et a l , 1998, 
Decker et a l , 1997)
Genetic and biochemical analyses have revealed the importance of the protein 
tyrosine kmase Jakl and Jak2 and the transcription factor STAT1 in IFN-y- 
depended signalling Upon ligand binding, the receptor oligomerises and Jakl 
and Jak2 are activated, leading to the phosphorylation of tyrosine 440 of the IFN- 
y receptor subunit 1 (INFGR1) o f the receptor, which provides a docking site for 
STAT1 STAT1 then is phosphorylated on tyrosine 701, leading to its 
dimensation and translocation to the nucleus, where it binds to the gamma- 
activated sequence (GAS) elements of promoters to regulate expression of 
downstream genes (Rama et a l , 2001) In our study we found the that 
expression of Jak2 was increased by 1.7-fold in the DLKP IdU microarray 
experiment and increased by 1 8- and 2 2-fold at day 3 and day 7 in the 5,2- 
FdU microarray experiment, respectively Therefore, Jak2 potentially may be 
involved in the phosphorylation of ST ATI in our model system
Wong et al (2002) proposed a role o f IRF-1 in the regulation of STAT-1 
expression They found that STAT-1 regulates the IRF-1 gene promoter and 
suggested that both gene products form a feedback loop that acts to regulate 
cellular responses to INFs, such as IFN-y In this study we found that STAT-1 
mRNA was increased 1.8-fold in both the BrdU and IdU microarrays and
216
1.6-fold m the 5,2'-FdU-treated DLKP cells These results indicate that 
STAT-1 may indeed be playing a role m the regulation of IFN-y which in turn 
may potentially be controlling the expression levels o f KLF4 m our 
differentiation model system The expression levels o f IFN-y are in the BrdU, 
5,2 -FdU and IdU microarray experiments are unknown One proposed reason 
that they may not have been identified by microarrays analysis may be as result 
of less than optimal probe design by Affymetrix Affymetrix do not quality 
control each probe set and we know from other experiments that genes which we 
know are up-regulated at the mRNA levels are not detected by Affymetrix 
GeneChips However, from analysing the microarray data sets it would seem 
probably that IFN-y is in fact up-regulated in treated DLKP cells The 
expression of other genes that are know targets o f IFN-y, such as IRF-1 and 
Interleukin 18 have been demonstrated as being increased several fold in the 
microarray experiments
It should be noted here that the Affymetrix GeneChip system has many 
advantages over other platforms currently available on the market However, 
this system does have some drawbacks Through out this study we have 
identified some failing in probe design, where the system has not identified genes 
that we know from previous studies to be altered following exposure of DLKP 
cells to BrdU Some of these genes include YY1, c-myc and a 2-integrin We 
have previously shown these genes in particular have increased mRNA and 
protein levels following treatment with drug
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Figure 4.1 Schem atic o f the proposed regulation o f  cytokeratin  
expression in BrdlJ-, 5 ,2'-FdU - and IdU -treated DLKP C ells. STAT-1 is 
activated by phosphorylation mediated by the Jak kinases. Phosphorylated 
STAT-1 translocates to the nucleus where it is proposed to be involved in the 
regulation o f KLF4 and IRF-1 gene expression. It is suggested that up-regulation 
of KLF4 increases the transcription of certain genes such as the cytokeratins. 
IRF-1 and STAT-1 form a feedback loop that acts to regulate the cellular 
responses to stimuli such as INF-y.
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4 5 2 3 3 Potential role for YY1 in regulation of IFN-y
The nuclear factor o f activated T cells (NFAT) originally described as an 
essential transcription factor for IL-2 gene expression in T cells, is thought to 
play a major role in the coordinating transcription of a number of cytokines 
Recent studies have demonstrated that the cytoplasmic NFAT components 
belong to a large family of regulatory transcription factors comprised o f at least 
four members, NFAT 1-4, which are differentially expressed In T cells NFAT1 
is expressed in both unstimulated and stimulated cells, whereas NFAT2 is 
expressed primarily in activated cells (Sweetser et al 1998)
Some studies have shown that NFAT1 (also know as NFATC2) may function m 
the regulation of the IFN-y promoter Sweetser et al (1998) demonstrated that 
two strong NFAT binding sites were required for maximal expression o f the IFN- 
y reporter construct containing 538 bp of the IFN-y promoter Also in this work, 
the group showed that YY1 did not mediate inhibition of basal IFN-y expression 
Previous studies suggested that YY1 suppresses IFN-y promoter function in 
Jurkat T cells by interacting at two regions within a silencer element located 
between the NFAT-binding sites (Ye et a l , 1996) In contrast to this Yen et al 
(1996), Sweetser et al (1998) demonstrated that proteins binding to the NFAT 
and YY1 sites on the IFN-y promoter may serve to initiate expression of IFN-y in 
primary splenocytes Although YY1 has been shown to interact with many other 
transcriptional regulators, interaction with NFAT proteins has not yet been 
demonstrated
The mechanisms by which YY1 induces transcriptional activation of cellular 
genes such as c-myc and how proteins modulate the activating and repressive 
activities o f YY1 remain yet unclear And this is the case o f the effect o f YY1 
on the IFN-y promoter, however, this transcription factor is thought to play a 
complex and context-dependent role in the regulation of IFN-y expression
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4 5.2.3 4 YY1 transient over-expression versus BrdU-treatment in 
DLKP cells
Following DNA microarray analysis performed on DLKP-treated cells with 
BrdU, 5,2 -FdU and IdU (Sections 3 2 and Section 4 5) it was decided to 
investigate if  some of the differentially expressed genes identified m these 
microarrays experiments were also altered following the transient over- 
expression of YY1 RT-PCR analysis revealed that the transient over-expression 
of YY1 did in fact up-regulate the expression of Hmoxl, Id2, Id3 and FHL1 
mRNAs (Section 3 2) However, further RT-PCR analysis for FSTL1 mRNA 
expression demonstrated that YY1 over-expression had no effect on expression 
levels o f FSTL1 (Section 3 2)
Promoter analysis on these four genes was also performed (Section 2 16) 
Interestingly, this analysis demonstrated that the promoter sequences of the Id2 
and FHL1 genes both contained binding motifs for the Spl and KLF4 
transcription factors Analysis on the BrdU, 5,2 -FdU and IdU microarrays 
demonstrated that KJLF4 and the Id family o f transcription factors may 
potentially play an important role in the induction of differentiation in our DLKP 
model system We have earlier discussed (Section 4 5 2 3 3) how YY1 has been 
shown to regulate the expression levels of IFN-y in certain cell types and how in 
turn IFN-y, as well as STAT-1, are involved in the regulation of KLF4 In 
previous studies, YY1 has been demonstrated to associate with the transcription 
factor Spl and the association of these two factors as been shown to activate the 
transcription of a number of cellular genes (Section 17  2) Therefore, it is 
plausible to hypothesise that YY1 is in fact a major controlling factor in the 
regulation of differentiation induced in our DLKP model system by BrdU, as 
previously suggested (Walsh D , PhD Thesis, 1999)
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Figure 4.2 H ypothesised Involvem ent o f  YYI in the R egulation o f  INFy
It is hypothesised that YYI may be involved in the regulation of expression of 
IFN-y, and that IFN-y then stimulates the phosphorylation of STAT-1, mediated 
by Jak, which results in the activation of transcription o f KLF4.
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4 5 2 3 5 Other genes identified in the development category included 
FGF-2 and LY6H 
Fibroblast Growth Factor-2
Fibroblast growth factors (FGF) make up a large family o f polypeptide growth 
factors that are found in a wide variety o f organisms In vertebrates, 22 members 
have been identified and are thought to be highly conserved in both gene 
structure and amino acid sequence Most FGF genes are found distributed 
around the geneome (Omitz and Itoh, 2001) The members of this family of 
proteins are differentially expressed in many tissue types, but the patterns and 
timing of expression differ Some FGFs are expressed exclusively during 
embryonic development (FGF 3, 4, 8, 15, 17, and 19), whereas others are 
expressed in embryonic and adult tissues (FGFs 1, 2, 5-7 16, 18 and 20-23)
In our differentiation system, DNA microarray analysis revealed that FGF-2 
mRNA levels were increased in the BrdU, 5,2 -FdU and IdU microarrays The 
expression of FGF-2 mRNA was found to be increased to 1 6-fold in all three 
arrays The expression patterns of FGFs suggest that they have important roles 
in development They are often involved in the direct signalling across 
epithelial-mesenchymal boundaries (Hogan 1999), the expression of each family 
member is thought to be tightly controlled However, the exact mechanisms 
regulating FGFs activity in vivo are not yet fully understood The roles which 
FGFs play m development have also yet to be determined
LY6H
The ly6 family of molecules was first identified in mouse and are a class of  
glycosylphosphatidylinositol-anchored cell surface glycoproteins Highly 
restrictive patterns of expression of Ly6 genes in specific subpopulations of 
munne myeloid and lymphoid cells established Ly6 molecules as markers for T- 
cell differentiation and for hematopoietic stem cells
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Murine Ly-6 molecules are a family of cell surface glycoproteins which have 
interesting patterns of tissue expression during haematopoiesis from 
multipotential stem cells to lineage committed precursor cells, and on specific 
leucocyte subpopulations in the peripheral lymphoid tissues These interesting 
patterns of tissue expression suggest an intimate association between the 
regulation of Ly-6 expression and the development and homeostasis of the 
immune system Ly-6 molecules are low molecular weight phosphatidyl mositol 
anchored glycoproteins with remarkable ammo acid homology throughout a 
distinctive cysteine nch protein domain that is associated predominantly with O- 
lmked carbohydrate These molecules are encoded by multiple tightly linked 
genes located on chromosome 15 which have conserved geneomic organization 
The in vivo functions of Ly-6 molecules are not known although in vitro studies 
suggest a role in cellular activation
Ly6H appeared to play a role in the differentiation pathway induced in DLKP 
suggestion that following the treatment with BrdU, 5,2 -FdU and IdU It was 
observed that the mRNA expression levels of this gene was increased to 2 0- 
and 1 9-fold m the BrdU and 5,2'-FdU microarrays, and to 1 7-fold in the 
IdU experiment following 7 days exposure of DLKP to each of the 
analogues
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4.6 Investigation of potentially co-regulated genes in BrdU-treated cells
Time course microarray experiments reveal information about the temporal 
transcription profile o f genes. Sets o f genes with the same expression pattern can 
be grouped into clusters but the identification o f  molecular mechanisms 
responsible for co-expression requires further investigation. By using 
comparative promoter analysis it is possible to identify genes for which co- 
expression maybe a result o f re-regulation. The aim o f  this analysis was to find 
promoter features that are potentially responsible for co-expression of different 
genes.
DLKP cells exposed to the differcntiating-modulating agent, BrdU, undergo 
morphological change and several cpithelia markers o f  lung cell differentiation 
are induced. In order to analyse global changes, the transcriptional profiles o f  
BrdU-treated DLKP cells were examined using Affymetrix U133A DNA 
microarray GeneChips®. Following DNA microarray data was normalised and 
passed through various filters, as described in Section 3.2.2.3. Effective 
comparative promoter analysis requires tightly clustered gene expression 
profiles. To generate tight clusters the gene lists were subjected to ANOVA 
analysis (Section 3.2.2.5).
It is beyond the scope of this thesis to analyse all the clusters from the BrdU 
array for co-regulated set o f differentially expressed genes. Therefore, it was 
decided to select one cluster and to demonstrate how it is possible to identify 
potentially co-regulated genes using the Genomatix Suite software 
(www.genomatix.de). In this worked example genes contained in Cluster 5 were 
chosen. The decision to choose Cluster 5 was made because genes contained in 
this cluster where found to be up-regulated following three days exposure to 
BrdU and remained at this level after 7 days.
A total o f 115 genes were contained in Cluster 5 and were imported into the 
Genomatix BiblioSphere software package (Section 2.16) and were filtered using 
‘Biological Processes’ Gene Ontology filter. After applying GO filter the genes 
were categorised as illustrated in figure 4.3 and ranked according o z-score. 15
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genes (Table 4.2) were found to be classified into the ‘Development’ category 
and had a z-scoring o f 1.68. These were chosen for further analysis. The 
hypothesis behind is experiment was that co-expressed genes that are involved in 
the same biological process may potentially be co-regulated at a promoter level. 
We could have classified the genes based on involvement in other cellular 
processes such as disease or molecular function alternatively, but since the 
overall aim of this thesis in the investigation o f genes involved in cellular 
differentiation it was decided to select the ‘Development’ category.
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Figure 4 .3  B io lo g ic a l F ilter o f  genes contain  in C lu ster 5.
225
C o m m o n  N am e L o c u s ld A ffy m e tn x  Id
EPA S1 endothelial PA S dom ain  protein  1 2034 200878  at
SCM L1 sex  com b on m id leg-like 1 (D rosophila) 6322 218793 s at
M Y H 9
m yosin , heavy po lypeptide 9, non­
m uscle
4627 2 1 1926_s_at
P H L D A 2
p leck stn n  hom ology-like dom ain, 
fam ily  A , m em ber 2
7262 209803_s_at
T PM 2 tropom yosin  2 (beta) 7169 212654  at
TPM 1 tropom yosin  1 (alpha) 7168 206117  at
SM TN sm oothehn 6525 209427  at
C X C R 4 chem okine (C -X -C  m otif) recep to r 4 7852 217028 at
CO L1A 1 collagen, type I, a lpha  1 1277 202310  s at
P A P SS 2
3-p h o sp h o ad en o sin e  5 '-phosphosulfa te 
syn thase 2
9060 203060_s_at
ET S2
v-ets ery throblastosis v irus E26 
oncogene hom olog  2 (avian)
2114 201329_s_at
H M G A1 high m obility  g roup A T -hook 1 3159 206074  s at
R P S6K A 6
ribosom al pro tein  S6 k inase, 90kD a, 
po lypep tide 6
27330 22073 8_s_at
A D O R A 2A adenosine A 2 a  receptor 135 205013 s at
G PR 64 G  pro tein -coup led  recep tor 64 10149 206002 at
Table 4 2 15 genes contained in ‘Development’ Category
The promoters for each of these 15 genes were retrieved using Genomatix 
Gene2Promoter software packages and the promoter regions of the 15 genes 
were then searched for a common framework of transcription factor binding 
sites 500 bps upstream o f the transcriptional start site, for each of the genes was 
analysed Following this analysis, several models were identified The model 
illustrated below (Figure 4 4) was chosen on the basis that it contained an E box 
transcription factor matrix Previous work in this laboratory has suggested that 
c-myc may play an important role in the control o f the differentiation pathway of 
BrdU-treated DLKP cells (Walsh, PhD Thesis 1999) c-Myc is known to contain 
an E box binding motif (Section 17  11)
The model chosen (Figure 4 4) contains three transcription factor elements 
MAZF, ZBPF and Ebox, were found in 6 (40%) (Figure 4 4) o f the 15 gene 
promoters from the ‘Development’ category
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Figure 4.4 Binding sites for MAZF, ZBPF and Ebox in the upstream 
promoter regions of EPAS1, MYH9, TMP1, TMP2 COLA1 RPS6KA6.
4.6.1 Role for M AZF, ZPF and EBO X  R egulation o f  other hum an  
prom oter sequences
In order to investigate the specificity o f the promoter model containing MAZF, 
ZBPF and E box this model was searched for in all known human promoter 
regions. This was performed by using Genomatix Modellnspector program. 
From this analysis it was found that the promoter model occurs in 94 human gene 
promoter sequences, two of which are involved in regulation o f protein 
biosynthesis (elFGl and PRKAA1). Another set o f genes whose promoters also 
contain this model transcription factor framework are these involved in the 
protein kinase cascade. Included in this list o f genes were STK.17B, ADRA2C, 
PRKAA1, F2R and RPS6KA2 (Figure 4.5).
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Figure 4.5 Evaluation o f Model Inspector Matches
Interestingly, one gene, STK17A. whose closely related family member STK17B 
promoter region was found to contain the proposed transcription factor model 
motif; was also found in cluster 5. From DNA microarray analysis we found 
that STK17A mRNA expression levels were increased by 1.7- and 1.9-fold at 
day 3 and day 7, respectively, in the BrdU Exp. 3 microarray experiments. 
STK17B expression levels were also found increased in the DLK.P BrdU Exp. 3 
microarray experiment. At day 3 and day 7 the mRNA expression levels o f this 
gene was found to be 1.7- and 1.8-fold increased, respectively. This may be 
further evidence that the transcription factor model system that we have 
identified in this example may indeed be biologically relevant.
Further experimental work is required to confirm the model transcription factor 
framework identified in this example. Also, in this example only one cluster 
from the BrdU Exp. 3 microarray data set was investigated and genes contained 
in this cluster were found up-regulated at day 3 and remained up-regulated at day 
7. Genes whose expression levels increase and decrease across the experiment 
and genes that are down-regulated at day 3 and day 7 may be investigated for co­
regulation. The work required to investigate further potentially co-regulated 
genes in the differentiation experiments, is beyond what is possible in the time 
allotted for this thesis and further work may identify other interesting models
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systems that are responsible for the gene expression patterns observed in our in 
vitro  differentiation model system
In light of this it is clear that the results generated m these microarray 
experiments could be extensively mined in the manner demonstrated to reveal 
countless groups of potentially co-regulated genes The breath of this analysis 
was beyond the scope o f this thesis, therefore, it was decided to illustrate the 
powerful use o f this type of analysis in one cluster o f the DLKP BrdU microarray 
experiment The process just described is an iterative one and further work could 
potentially generate additional interesting transcription factor frameworks
4 7 Sum m ary
Experiments performed in this study have demonstrated that the pyrimidine 
analogues investigated induce a very similar gene expression changes and 
differentiation pattern, in drug-treated DLKP and A549 cell lines These 
alterations in gene expression are reflected in a common set of transcriptional 
gene changes, as well as drug-specific changes We have identified a whole host 
of additional differentially expressed genes following BrdU exposure, as well as 
in 5,2 -FdU and IdU-treated DLKP cells by DNA microarray analysis And have 
validated some of these gene expression alternations by RT-PCR
It has also been shown in this thesis that YY1 is directly capable of regulating 
some, but not all, o f the genes altered following BrdU exposure The results of 
these studies further the hypothesis put forward by Walsh (PhD Thesis, 1999), 
which suggested that YY1 potentially plays a key role in the regulation of 
differentiation in our in vitro  model system
We have analysed all these results and discussed some possible models for the 
observed transcriptional alternations induced in our cell systems upon induction 
of differentiation and suggest some experiments to future work
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Section 5.0 Conclusions and Future Work
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51 Conclusions
❖  Pyrim dine A nalogues Induce D ifferentiation m D L K P and A 549 cell 
lines
This project began, as an investigation into the mechamsm(s) by with the 
differentiating modulating agent, BrdU, is able to alter the differentiation status 
of epithelial lung cells A range of pyrmidine analogues, as well as BrdU, 
namely IdU, CdU, BromoUracil, BromoUridine, 5-FU, 5,2 -FdU and 5,5 -FdU, 
were also investigated to determine if similar differentiation affects were seen 
with these analogues as was seen with BrdU-treated DLKP and A549 cells
Our results demonstrate a common differentiation effect o f all the pyrmindine 
analogues in both the DLKP and A549 cell lines The ability o f these analogues 
to induce differentiation in both cell lines was assessed by examining their effect 
on protein expression levels of cytokeratin 8, 18 and 19, a2-mtegrin, Pi-integrm 
and Ep-CAM This study has shown that these proteins are induced in DLKP 
cells and are increased A549 cells following exposure to these analogues
❖ cD N A  T ransfection o f  c-m yc  and YY1 into DLK P
In light of work performed in our laboratory which demonstrated that BrdU 
treatment of DLKP and A549 cells significantly increases in the expression of c- 
Myc and YY1 (Walsh, PhD Thesis, 1999) It has been suggest that these two 
transcription factors may potentially be important key regulators of 
differentiation in our cell system Therefore, it was decided to transfect full 
length human c-m yc  and YY1 cDNAs into the DLKP cell line in order to 
determine if their over-expression induced similar patters o f gene expression as 
was demonstrated in BrdU-treatment of DLKP
Attempts to stably over-express the c-m yc expression vector in our DLKP cell 
line proved unsuccessful Clones isolated from a mixed population of cells did
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not exhibit any significant up-regulalion in either c-m yc  mRNA or protein levels. 
Therefore, it was decided to transiently transfect the vector in order to determine 
if c-m yc  was a key regulator o f differentiation. We demonstrated that the 
transient over-expression o f c-m yc  had a positive effect on YY1 and eIF4E 
protein expression levels which is in agreement with results obtained from the 
treatment o f DLKP cells with BrdU.
Over-expression o f the transcription factor YY1, into DLKP cells also resulted in 
a significant increase in the expression levels o f c-Myc and eIF4E proteins. Also 
associated with the transient increase in YY1 levels was a increase in genes 
which were identified as differentially expressed in the DNA microarrays 
performed in this study. We show that mRNA levels for FHL1, Id2, Id3 and 
HMOX1 are all increased in YY1 transiently transfected cells. This provides 
further evidence that YY1 is indeed an important factor in the regulation of  
differentiation and that YY1 transfection and BrdU treatment o f the DLKP cell 
line may induce a similar pattern o f differentiation in our cell system.
❖ DNA Microarray Experiments
DNA microarrays were also performed on DLKP cells treated with 5,2'-FdU. 
IdU and BrdU in order to examine global transcriptional changes which occur in 
DLKP cells following exposure to these differentiation-inducing drugs. 93 up- 
regulated differentially expressed genes were identified as common to all three 
microarray experiments. These genes were further investigated in order to 
determine their involvement in the process o f differentiation in our cell system. 
These 93 genes were subjected to EASE analysis, which we used, helped to 
identify biological patterns in the gene list. Following this analysis we narrowed 
our focus on a subset o f the 93 genes which are thought to be involved in cellular 
development. We propose that the Id family o f transcription factors may be 
important regulators o f differentiation in our cell models. This family o f helix- 
loop-helix transcription factors has also been demonstrated as being a central 
regulator in the differentiation of other types o f epithelial cells, besides the lung. 
These studies provide evidence that Id proteins may in fact be significant
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controllers in our system and we suggest that these transcription factors may 
indeed have a wider role to play in cellular process than traditionally thought
Another finding from the microarray experiments performed in this thesis was 
the involvement o f the transcription factor, KLF4 KLF4 has been shown to be 
important in the gastrointestinal tract where the gene is thought to regulate cell 
growth and differentiation This gene has also been associated with the 
regulation of cytokeratin expression m other cell systems and from the results of 
this thesis we hypothesis that this transcription factor could potentially be 
involved in the regulation of cytokeratin expression in BrdU-treated DLKP cells
From our microarray experiments we propose a role for KLF4 in the regulation 
of cytokeratin expression in our differentiation system We hypothesis that 
KLF4 mRNA levels are increase mediated by the phosphorylated STAT-1 and 
IFNy and IRF-1 We also suggest a possible role for YY1 involvement in the 
regulation o f IFNy within the cell The involvement o f YY1 in this model is 
further strengthen following promoter analysis o f a subset of genes identified as 
differentially expressed in the DNA microarray experiments As mentioned 
earlier we have shown that YY1 is capable of inducing the expression o f FHL1, 
Id2, Id3 and HMOX1 in DLKP cells following transient over-expression studies 
We demonstrate that the promoter sequences o f Id2 and FHL1 genes both 
contain binding motifs for Spl and KLF4 transcription factors, which provides 
further evidence for important roles for both YY1 and KLF4 in our proposed 
model
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Future Work.
The work described in this thesis has identified a number of key factors and the 
mechamsm(s) that maybe critical in the control o f differentiation of lung 
epithelial cells Areas that would be o f interest for further study may include
1 YY1 T ransfections
>  DNA Arrays and Protein Arrays Perform DNA arrays on stable YY1 
clones Investigate o f YY1 over-expressing clones by DNA 
microarray analysis may provide further leads and help to identify 
gene targets for this unusual transcription factor Comparison of the 
results o f YY1 and the microarray experiments preformed on 
pyrmidine-treated DLKP cells may identify common regulatory genes 
in our in vitro  lung differentiation model Investigate on the altered 
protein profiles in YY1 transfected cells may also be of interest The 
use of new protein arrays, as provided Ciphergen SELI-TOF system, 
may generate interesting leads for further investigation
> DIGE 2D electrophoresis Analysis experiments on stable YY1 clones 
using DIGE analysis may also aid m the identification of proteins 
thought to be under either the activation or repression control o f YY1
>  Immunocytochemical and in-situ  hybridisation studies using tissue 
sections from early lung and carcinoma samples may be used to 
identify the in-vivo  relevance of factors, such as YY1, shown to be 
involved in differentiation in our in-vitro  model
>  In order to determine the percentage of transfect cells in the YY1 
transient transfections co-transfection of the YY1 plasmid along with 
GFP or P-Gal should be preformed
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2. c-Myc Transfections
>  In order to investigate further the role which c-m yc plays in our model 
differentiation system and to overcome the difficulties experienced in 
this study with stably transfecting the c-m yc  vector into the DLKP 
cell line, transfection with an inducible c-m yc plasmid may offer an 
alternative approach
>  Further work is required to confirm the hypothesis that 
overexpression of c-m yc  in our model system does in fact induce 
apoptosis RT-PCR and Western blot analysis for pro-apoptotic 
factors should be performed
3 T hym idine A nalogues and D N A  M icroarrays
> Quantitative RT-PCR analysis confirm the microarray results using 
Real Time-PCR
> Transfection of KLF4 into the DLKP cell line From the results 
presented in this thesis it appears that KLF4 may be an important 
transcription factor in the regulation of cytokeratin expression in our 
cell system Therefore, it would be interesting to transfect a full 
length human cDNA for this gene into DLKP cells to investigate if it 
is possible to mimic the gene expression pattern with KLF4 over- 
expression as was demonstrated in pynmidine-treated DLKP cells
>  DNA microarray analysis generates vast amounts o f data, analysis of  
some of which is only possible in the time provided for the 
completion of this thesis In this study only up-regulated genes where 
investigated Down-regulated genes may also play an important role 
in the regulation of cellular process and differentiation, therefore, 
warrant further investigation It is possible that the microarray data 
sets generated in this body of work could yet reveal more interesting
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genes and pathways involved m the regulation early lung 
differentiation, if re-mined
>  Further microarray analysis could reveal interesting targets for siRNA 
experiments It would be interesting to known-down key genes that 
are potentially regulating the process o f differentiation in our cell 
system
> Promoter analysis in this study we demonstrated the possible use of  
promoter analysis software for the identification of potentially co­
regulated genes in the BrdU microarray experiments As mentioned, 
this process is iterative, and is beyond the scope of this thesis to fully 
mine the data to its full potential Similar analysis o f clusters is 
possible for the 5,2'-FdU and IdU microarray experiments In light of  
the model transcription factor framework identified in this thesis, it is 
clear that other framework models of more significant importance 
may yet be identified from the microarray data sets
>  DIGE 2D electrophoresis and protein Arrays Comparison of control 
versus treated cells, using DIGE 2D electrophoresis and protein arrays 
may help to identify proteins that may be up- or down-regulated in 
our model system for lung cell differentiation Unknown proteins 
may then be tentatively identified using Mass Spec analysis
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Section 7.0 Appendices
7 1 Appendix A -  Differentially Expressed Genes Identified in BrdU Exp 3 
DNA Microarray Experiment
List o f differentially expressed genes identified from microarray analysis o f BrdU 
Exp 3 DNA microarrays Genes listed are sorted by Affymetnx ID number
l i
AfTy metri* 
Id
Day 0 Dav 3 Day 7 Common NameLocus Link Normalized Flags Normalized Flags Normalized Flags
1405 i at 6352 1 A 12.878 P.A 67.626 P CCL5
200600 at 4478 1 P 1.354 P 1.630 P MSN
200606 at 1832 1 P 1.275 P 1.626 P DSP
200609 s at 9948 1 P 1.529 P 1.480 P WDRI
200611 s at 9948 1 P 1.537 P 1.500 P WDR1
200621 at 1465 1 P 1.570 P 1.708 P CSRP1
200632 s at 10397 1 P 1.329 P 1.531 P NDRG1
200677 at 754 1 P 1.252 P 1.515 P PTTG1IP
200678 x at 28% 1 P 0.643 P 0.859 P GRN
2006% s at 2934 1 P 1.411 P 1.860 P GSN
200697 at 3098 1 P 1.415 P 1.532 P HKI
200715 x at 23521 1 P 0.637 P 0.783 P RPLI3A
200742 s at 1200 1 P 0.572 P 0.826 P CLN2
200743 s at 1200 1 P 0.559 P 0.784 P CLN2
200760 s at 10550 1 P 1.309 P 1.761 P JWA
200761 s at 10550 1 P 1.191 P 1.738 P JWA
200762 at 1808 1 P 1.699 P 2.095 P DPYSL2
200770 s at 3915 1 P 1.234 P 1.717 P LAMC1
200779 at 468 1 P 0.423 P 0.453 P ATF4
200785 s at 4035 1 P 1.290 P 1.521 P LRP1
200787 s at 8682 1 P 1.506 P 1.940 P PEA 15
200788 s at 8682 I P 1.486 P 1.880 P PEAI5
200790 at 4953 1 P 1.551 P 1.213 P 0DC1
200802 at 6301 1 P 0.652 P 0.659 P SARS
200808 s at 7791 1 P 1.880 P 1.962 P ZYX
200838 at 1508 1 P 1.093 P 2.031 P crsB
200839 s at 1508 1 P 1.062 P 1.769 P CTSB
200841 s at 2058 1 P 0.633 P 0.742 P EPRS
200872 at 6281 1 P 1.473 P 2.429 P SI00A10
200878_at 29952 1 A 2.247 P.M.A 2.708 P EPASI
200887 s at 6772 1 P 1.627 P 2.377 P STATI
200897 s at 23022 1 P 1.398 P 1.836 P KIAA0992
200904_at 3133 1 P 1.118 P 1.758 P HLA-E
200905_x_ at 3133 1 P 1.209 P 1.655 P HLA-E
200907 s at 23022 1 P.A 1.217 P 1.710 P KIAA0992
200923_at 3959 1 A 1.150 M.A 2.423 P LGALS3BP
200931 s at 7414 1 P 1.474 P 1.745 P VCL
200965 s at 3983 1 P 0.544 P 0.800 P ABLIMI
200983 x at 966 1 P 1.362 P 1.767 P CD59
200984 s at 966 1 P 1.501 P 1.931 P CD59
200985 s at 966 1 P 1.581 P 2.0% P CD59;
200986 at 710 1 P.A 1.259 P 1.908 P SERPINGI
200988 s at 10197 1 P 1.665 P 1.565 P PSME3
200989 at 3091 1 P 1.537 P 1.423 P HIF1A
201010 s at 10628 1 P 0.584 P 1.402 P TXNIP
201015_s_at 3728 1 A 2.589 P.M 4.411 P JUP
201037 al 5214 1 P 1.790 P 1.679 P PFKP
201041 s at 1843 1 P 1.355 P 1.848 P DUSP1
201042 at 7052 1 P,A 13.556 P 22.821 P TGM2
20l058_s_at 10398 1 P 1.658 P 1.843 P MYL9
Affymetrix
Id
Day 0 Day 3 Day 7 Common NameLocusLink
Normalized Flags Normalized Flags Normalized Flags
201060 x at 2040 1 P 1.433 P 1.743 P ST0M
201061 s at 2040 1 P 1.314 P 1.669 P STOM
201085 s at 6651 1 P.A 1.374 P 1.570 P SON
201110 s at 7057 1 A 10.648 P 8.768 P.A TUBS 1
201116 s at 1363 1 P 1.085 P 1.537 P CPE
201140 s at 5878 1 P 1.487 P 1.703 P RAB5C
201141 at 10457 1 P 1.287 P 1.578 P GPNMB
201142 at 1965 1 P 1.386 P 1.509 P EIF2SI
201144 s at 1965 1 P 1.530 P 1.376 P EIF2SI
201147 s at 7078 1 A 2.093 A 3.727 P.M TIMP3
201149 s at 7078' 1 P 1.905 P 2.995 P TIMP3
201150 s at 7078 1 A 1.292 P.A 2.131 P TIMP3
201156 s at 5878 1 P 1.355 P 1.592 P RAB5C
201161 s at 8531 1 P 1.241 P 1.555 P CSDA
201162 at 3490 1 A 1.383 A 3.143 P IGFBP7
201163 s at 3490 1 P 1.634 P 3.422 P IGFBP7
201170 s at 8553 1 P 1.254 P 1.671 P BMLIIB2
201189 s at 3710 1 P.A 1.362 P 1.681 P ITPR3
201195 s at 8140 I P 0.680 P 0.553 P SLC7A5
201206 s at 6238 I P 1.327 P 1.537 P RRBP1
201214 s at 5510 1 P 1.516 P 1.411 P PPP1R7
201216 at 10961 1 P 0.593 P 0.717 P ERP28
201232_s_at 5719 I P 1.576 P 1.478 P PSMD13
201233 at 5719 1 P 1.513 P 1.425 P PSMD13
201263 at 6897 I P 0.587 P 0.632 P TARS
201266 at 7296 1 P 1.646 P 1.680 P TXNRD1
201278 at I A 1.467 M.A 1.567 P.A
201315_x_at 10581 I P 0.870 P 1.524 P IF1TM2
201329 s at 2114 1 A 1.617 P.A 1.713 P ETS2
201348_at 2878 1 P 3.924 P 4.117 P GPX3
201397 at 26227 I P 0.436 P 0.417 P PHGDH
201401 s at 156 1 P 0.595 P,M,A 0.705 P.A ADRBK1
201410 at 1 P 1.538 P 1.312 P PLEKHB2
201416 at 1 P 1.303 P 1.740 P S0X4
201417 at 1 P 1.198 P 1.571 P S0X4
201422 at 10437 1 P 1.367 P 1.522 P IFI30
201425 at 217 1 P 0.599 P 0.574 P ALDH2
201427 s at 6414 1 A 1 808 P.A 2.178 P.M SEPPI
201460 at 9261 1 P 1.472 P 1.528 P MAPKAPK2
201464 x at 3725 1 A 2.573 P.M 3.470 P JUN
201466 s at 3725 1 A 2.201 P 2.898 P JUN; API
20l473_at 3726 1 P 1.369 P 1.899 P JUNB
201475 x at 4141 1 P 0.521 P 0.556 P MARS
201482 at 5768 1 P 1.364 P 1.561 P QSCN6
201489 at 10105 1 P 1.485 P 1.688 P PPIF
201490 s at 10105 1 P 1.493 P 1.827 P PPIF
201498_at 7874 1 P 1.530 P 1.293 1’ USP7
201502 s at 4792 1 P 1.915 P 2.399 P NFKBIA
201505 at 3912 1 P.A 1.903 P 2.354 P LAMBI
201531 at 7538 1 P 1.184 P 1.773 P ZFP36
Affymetrix
Id
LocusLink
Day 0 Day 3 Day 7
Common Name
Normalized Flags Normalized Flags Normalized Flags
201539_s_at 2273 1 P 1 4 5 4 P 2 417 P FHL1
201540_at 2273 1 P 1485 P 2 255 P FHL1
201546_at 9320 1 P 1 577 P 1 540 P T R IP 12
201557_at 6844 1 P 0 6 1 7 P 0 790 P V A M P2
201564_s_at 6624 1 P 1 496 P 1 609 P FSCN1
201565_s_at 3398 1 P 3 928 P 1 901 P ID2
201566 x at 3398 1 P,M 5 879 P 2 464 P ID2
201578_at 5420 1 M ,A 1 188 M ,A 1 558 P ,M PO D X L
201596_x_at 3875 1 A 2 751 P,M 4 8 1 3 P KR T18
201601_x_at 5805 1 P 0 833 P,M 1 587 P IFITM1
201631_s_at 8870 1 P 2 594 P 3 867 P IER3
201648_at 1 P 1 420 P 1 577 P KIA A 1579
201649_at 9246 1 P 1 161 P 1 818 P U B E2L6
201655_s_at 3339 1 A 1 074 A 1 610 P H SPG 2
201666_at 7076 1 P 1 201 P 1 954 P T IM PI
201673_s_at 2997 1 P 1 6 9 0 P 1 503 P GYS1
201693_s_at 1958 1 P 1 0 0 9 P,A 1 554 P E G R I
201695_s_at 4860 1 P 1 642 P 1 375 P N P
201700_at 896 1 P 1 810 P 1 7 0 6 P CCND 3
201710_at 4605 1 P 1 687 P 1 163 P M Y B L2
201718_s_at 2037 1 P 1 446 P 1 651 P EPB 41L2
2 01719_s_at 2037 1 P 1 328 P 1 509 P EPB 41L
201739_at 6446 1 P 4 350 P 6 3 1 2 P SGK
201744_s_at 4060 1 P 1 428 P 1 879 P LUM
201762_s_at 5721 1 P 1 311 P 1 660 P PSM E2
201765_s_at 3073 1 P 0 592 P 0 840 P H EX A
201798_s_at 26509 1 P,A 5 459 P 13 058 P FER1L3
201810_s_at 9467 1 P 1 813 P 2 115 P SH 3BP5
20181 l_ x _ at 9467 1 P 2 037 P 2 081 P SH 3BP5
201841_s_at 3315 1 P 1 636 P 1 720 P HSPB1
201860_s_at 5327 1 A 1658 M ,A 2 3 1 2 P,A PLA T
201865_x_at 2908 1 P 1 479 P 1 561 P NR3C1
201866_s_at 2908 1 P M 1 441 P 1 529 P NR3C1
201877_s_at 5527 1 P 0 638 P 0 714 P PPP2R 5C
201891_s_at 567 1 P 1 282 P 1 598 P B2M
201900_s_at 10327 1 P 0 521 P 0 748 P AKR1A1
2 01915_at 11231 1 P 0 640 P 0 734 P SEC63
201925_s_at 1604 1 P 0 6 1 1 P 0 771 P DAF
201926_s„at 1604 1 P 0 627 P 0 722 P DA F
201951_at 214 1 P 1 600 P 2 764 P A LC A M
201952_at 214 1 P 1 483 P 2 448 P A L C A M
201959_s_at 23077 1 P,A 1 408 P 1 698 P M Y C B P2
201960_s_at 23077 1 P 1 402 P 1 742 P M Y C B P2
201971_s_at 523 1 P 1 559 P 1 595 P A T P6V 1A
201972_at 523 1 P 1458 P 1 614 P A T P6V 1A
201998_at 6480 1 P,M 1 529 P 1 496 P SIA TI
202007_at 4811 1 P 1 340 P 2 095 P N ID
202008_s_at 4811 1 P 1 243 P 1 839 P N ID
2 02016_at 4232 1 P 1 862 P 1 731 P M E ST
202017_at 2052 1 P 1 519 P 1 532 P EPHX1
V
Affymetrix
Id
LocusLink
Day 0 Day 3, Day 7
Common Name
Normalized Flags Normalized Flags Normalized Flags
202023_at 1942 1 A 1 509 P,M,A 2 268 P EFNA1
202052_s_at 26064 1 P 1 594 p 2 242 P RAI14
202055_at 1 P,M A 1 533 p 1 546 P KPN Al
202056_at 1 P 1 650 p 1 539 P KPNA1
20205 8_s_at 3836 1 P 1 537 p 1 427 P KPN Al
202059_s_at 3836 1 P 1 619 p 1493 P KPNA1
202069_s_at 3419 1 P 1 615 p 1 367 P 1DH3A
20207 l_at 6385 1 P 2310 p 2 260 P SDC4
202074_s_at 10133 1 P 1 143 p 1 560 P OPTN
202080_s_at 22906 1 A 1 158 M,A 1 555 P,A OIPIO6
202086_at 4599 1 A 2 340 P,M 6 578 P MX1
202105_at 3476 1 P 0 645 P 0 722 P IGBP1
202122_s_at 10226 1 P 1 468 P 1 635 P M6PRBP1
202132_at 25937 1 M,A 1 536 P,M 1656 P,M TAZ
202133_at 25937 1 P 1 231 P 1 613 P TAZ
202180_s_at 9961 1 P,A 1 104 P 1 649 P MVP
202193_at 3985 1 P 1 711 P 1 601 P LIMK2
202196_s_at 27122 1 A 3 642 P,A 4 850 P,M DKK3
20224 l_at 10221 1 P 2 804 P 3 234 P TRIB1
202258_s_at 10443 1 P 0 585 P 0 678 P PFAAP5
202259_s_at 10443 1 P 0 629 P 0 787 P PFAAP5
202272_s_at 23219 1 P 1 532 P 1 412 P FBX028
202284_s_at 1026 1 P 4 476 P 4 940 P P21
202307_s_at 5696 1 P 1 881 P 2 580 P TAPI
202310_s_at 1277 1 A 2 670 PjA 2 989 P,A COL1A1
202328_s_at 5310 1 P 0 597 P 0 657 P PKD1
202350_s_at 4147 1 P 1 668 P 1 884 P MATN2
20236 l_at 9632 1 P 1 333 P 1503 P SEC24C
202370_s_at 865 1 P 1 601 P 1 336 P CBFB
202389_s_at 3064 1 A 1 568 P 1 638 P HD
20239 l_at 10409 1 P 3 198 P 4 368 P BASPl
202402_s_at 833 1 P 0 560 P 0 602 P CARS
202422_s_at 2182 1 P 1 501 P 1 625 P ACSL4
202425_x_at 5530 1 P,M,A 1 237 P 1 524 P PPP3CA
20243 0_s_at 5359 1 P 1 447 P 2 452 P PLSCRl
202435_s_at 1545 1 A 1 335 P 1 670 P,A CYP1B1
202436_s_at 1545 1 P,A 1 418 P 1 647 P CYP1B1
20243 7_s_at 1545 1 A 1 486 P 2 040 P CYP1B1
202446_s_at 5359 1 P 1 293 P 2 069 P PLSCRl
202458_at 11098 1 A 3 120 P,M,A 6 194 P SPUVE
202462_s_at 9879 1 P 1 543 P 1 268 P DDX46
202468_s_at 8727 1 P 1 567 P 1 731 P CTNNAL1
20248 l_at 9249 1 P 1 124 P 1 520 P DHRS3
202524_s_at 9806 1 P 0 542 P 0 594 P SPOCK2
20253 l_at 3659 1 P 1 909 P 2 375 P IRF1
202575_at 1382 1 A 2 672 M,A 2516 P,M,A CRABP2
202598_at 6284 1 P 1430 P 2 083 P S100A13
202620_s_at 5352 1 P 1 826 P 2 047 P PLOD2
202628_s_at 5054 1 A 17716 A 55 277 P SERPINE1
20263 0_at 10513 1 P 0 651 P 0 866 P APPBP2
V I
A ffym ctm  
' Id LocusLink
DavO Day 3 Day 7
Common Name
Normalized Flags Normalized Flags Normalized Flags
202637 s at 3383 1 P 1.367 P 2.120 P ICAM1
202638 s at 3383 1 P 1.482 P 2.282 P ICAM1
202643 s at 7128 1 A 1.678 P.A 2.349 P TNFAIP3
202644 s at 7128 1 P 1.788 P 2.315 P TNFAIP3
202656 s at 9792 1 P 1.594 P 1.556 P SERTAD2
202660 at 23526 1 P 1.418 P 1.575 P HA-1
202662 s at 3709 1 P.M.A 1.343 P 1.679 P 1TPR2
202672 s at 467 1 P 1.366 P 1.620 P ATF3
202684 s at 8731 1 P 1.883 P 1.362 P RNMT
202686 s at 558 1 M.A 1.259 P.M 1.829 P AXL
202693 s at 9263 1 P 1.691 P 1.690 P STK17A
202695 s at 9263 1 P.A 1.734 P 1.915 P STKI7A
202716 at 5770 1 P 1.583 P 1.633 P PTPNI
202728 s at 4052 1 P 0.577 P.A 0.844 P LTBP1
202729 s at 4052 1 P 0.652 P 0.914 P LTBPI
202732 at 11142 1 P 1.085 P 1.566 P PKIG
202743 at 8503 1 P 1.988 P 1.995 P PIK3R3
202746 at 9452 1 P 2.315 P 3.499 P ITM2A
202759 s at 11217 1 A 1.472 P.A 1.842 P.A PALM2
202760 s at 11217 1 P,A 1.545 P.M.A 1.993 P.A AKAP2
202761 s at 23224 1 P 0.987 P 1.563 P SYNE2
202766 s at 2200 1 P 1.182 P 1.767 P FBN1
202769 at I P 0.572 P 0.630 P CCNG2
202794 at 3628 1 P 1.450 P 1.549 P INPPI
20280 l_at 5566 1 P 1.590 P 1.454 P PRKACA
202812 at 2548 1 P 0.515 P 0.759 P GAA
202819 s at 6924 1 P 1.762 P 1.460 P TCEB3
202822 at 4026 1 P 1.414 P 1.735 P LPP
202830 s at 2542 1 P 0.497 A 0.630 P.A SLC37A4
202846 s at 5279 1 P 0.605 P 0.690 P PIGC
202847 at 5106 1 P 0.382 P 0.381 P PCK2
202854 at 3251 1 P 1.497 P 1.527 P HPRT1
202870 s at 991 1 P 1.511 P 1.3% P CDC20
202883 s at 5519 1 P 1.565 P 1.515 P PPP2R1B
202887 s at 54541 1 P 0.429 A 0.474 A DDIT4
202934 at 3099 1 A 1.917 P.A 1.845 P.A HK2
202948 at 3554 1 P.A 1.099 P.A 1.595 P.M.A IL1R1
202949 s at 2274 1 P 3.214 P 5.650 P FHL2
202962 at 23303 1 M.A 1.689 P.A 1.867 P KIFI3B
202998 s at 4017 1 P 1.214 P 2.216 P L0XL2
203002 at 51421 1 P 1.636 P 1.783 P AM0TL2
203023_at 51491 1 P 1.611 P 1.585 P HSPCIII
20305 l_at 22893 1 P 1.431 P 1.584 P BAHDI
203058 s_at 9060 1 P 2.594 P 3.299 P PAPSS2
203059_s_at 9060 1 P.M 1.694 P 2.184 P PAPSS2
203060_s_at 9060 1 P 3.572 P 4.9% P PAPSS2
203062 s at 9656 1 P 1.511 P 1.563 P MDCI
203065 s at 857 1 P 1.411 P 1.629 P CAV1
203066 at 51363 1 P 1.656 P 1.645 P GALNAC4S-6ST
203072 at 4643 1 A 2.026 P 2.157 P MY01E
Affymetrix
Id
LocusLink
Day 0 Day 3 Day 7
Common Name
Normalized Flags Normalized Flags Normalized Flags
203074_at 244 1 A 1 185 P,A 1 664 P ANXA8
203102_s_at 4247 1 P 1 591 P 1 451 P MGAT2
203119_at 79080 1 P 1 364 P 1 501 P MGC2574
203140_at 604 1 P 1 299 P 2 011 P BCL6
203148_s_at 9830 1 P 1 551 P 2 105 P TRIM14
203153_at 3434 1 A 2 969 P,A 8 524 P IFIT1
203158_s_at 2744 1 A 1 579 P 1 648 P GLS
203178_at 2628 1 P 1 544 P 1 337 P GATM
203184_at 2201 1 P 1 873 P 2 503 P FBN2
20321 l_s_at 8898 1 P 1 550 P 1 336 P MTMR2
203212_s_at 8898 1 A 1 565 P 1 536 P>A MTMR2
203216_s_at 4646 1 P 1 547 P I 323 P M Y06
203242_s_at 10611 1 P,M 1471 P 1 604 P LIM
203243_s_at 10611 1 P 1 642 P 1 942 P LIM
203252_at 10263 1 P 1 512 P 1 421 P DOC-1R
203304_at 25805 1 P,M 2 356 P 2 293 P BAMBI
203336_s_at 9270 1 P 1 559 P 1 518 P ITGB1BP1
203359_s_at 26292 1 P 1 943 P 1 520 P MYCBP
203360_s_at 26292 1 P 1 734 P 1 317 P MYCBP
20338 l_s_at 348 1 P,M 1 376 P 2 272 P APOE
203382_s_at 348 1 P,A 1 507 P 2 557 P APOE
203386_at 9882 1 P,A 1 553 P 1 726 P TBC1D4
203413_at 4753 1 P 1253 P 1 852 P NELL2
203423_at 5947 1 P 1 287 P 1 812 P RBP1
203439_s_at 8614 1 P 0 674 P 0 609 P,A STC2
20345 5_s_at 6303 1 P 1 713 P 2 535 P SAT
203485_at 6252 1 P 1 575 P 1 516 P RTN1
203504_s_at 19 1 P 1 913 P 2 457 P ABC Al
203505_at 19 1 P 2 218 P 3 080 P ABCA1
203526_s_at 324 1 P 1 347 P 1 584 P APC
203558_at 9820 1 P 0612 P M 0914 P CUL7
203563_at 60312 1 A 1 187 P,A 1 569 P,M,A AFAP
203578_s_at 9057 1 P,M 1 746 P 1 392 P SLC7A6
203585_at 7739 1 P 1631 P 1 707 P ZNF185
203592 s at 10272 1 PM 1 896 P 1 801 P FSTL3
203603_s_at 9839 1 P,A 1 574 A 1 463 P,A ZFHX1B
203607_at 22876 1 P 1 591 P 1 529 P INPP5F
203650_at 10544 1 P 1 335 P 1 510 P PROCR
203657_s_at 8722 1 P 0 540 P 0 741 P CTSF
203665_at 3162 1 P 2 443 P 2 435 P HMOX1
20367 l_at 7172 1 P,A 1 647 P,M 1 565 P TPMT
203674_at 9931 1 P 1 472 P 1 593 P HELZ
203675_at 4925 1 P 1 180 P 1 626 P NUCB2
203701_s_at 55621 1 P 1 548 P 1 424 P FLJ20244
203710_at 3708 1 P 1 811 P 1 661 P ITPR1
203725_at 1647 1 P 1 452 P 1 861 P GADD45A
203728_at 578 1 P 1 507 P 1 486 P BAK1
203736_s_at 8496 1 M,A 1 375 P 1 616 P PPFIBP1
203743_s_at 6996 1 P 1606 P 1 410 P TDG
203767_s_at 412 1 P 2 006 P | 1691 P STS
Vlll
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203787 at 23635 1 P 1.717 P 2.234 P SSBP2
203810 at 11080 1 P 1.593 P 1.458 P DNAJB4
203811 s at 11080 1 P.M.A 1.666 P 1.648 P DNAJB4
203821 at 1839 1 A 3.276 P 2.477 P.M DTR
203836 s at 4217 1 A 1.462 P.A 1.899 P.A MAP3K5
203843 at 6197 1 P 1.349 P 1.585 P RPS6KA3
203851 at 3489 1 P.A 1.972 P 2.426 P IGFBP6
203876 s at 4320 1 P.A 0.573 P.M.A 0.695 P.A MMP11;
203889 at 6447 1 M.A 1.463 P 2.005 P SGNEI
203895 at 1 P 1.334 P 1.558 P PLCB4
203910 at 9411 1 P 2.144 P 3.560 P PARGI
203921 at 9435 1 P 0.439 P 0.546 P CIIST2
203927 at 4794 1 P.M 1.652 P 2.040 P NFKBIE
203936 s at 4318 1 P 1.434 P 1.608 P MMP9
203946 s at 384 1 P.A 2.360 P 2.222 P ARG2
203951 at 1264 I A 12.155 P 12.597 P CNN1
203964 at 9111 1 P 1.874 P 1.995 P NMI
203973 s at 1052 1 P 1.188 P 1.604 P CEBPD
203980 at 2167 1 P 1.538 P 1.611 P FABP4
203981 s at 5826 1 P 0.585 P 0.711 P ABCD4
203986_at 8987 1 P 1.663 P 1604 P GENX-3414
203989 x at 2149 1 A 1.891 P.A 2.739 P F2R
204005 s at 5074 1 P 1.501 P 1.615 P PAWR
204024 at 734 1 P 1.539 P 1.159 P C8orfl
204029 at 1952 1 P 0.616 P 0.643 P CELSR2
204030 s at 29970 1 P 1.948 P 2.721 P SCIUPI
204035 at 7857 1 P 0.803 P 0.416 P SCG2
204048 s at 9749 1 P 1.321 P 1.539 P C6orf56
204049 s at 9749 1 P 1.515 P 1.693 P C6orf56
204070 at 5920 1 P.A 1.431 P,A 2.723 P RARRES3
204081 at 4900 1 P 2.118 P 1.856 P NRGN
204082 at 5090 1 P 1.467 P 1.858 P PBX3
204083 s at 7169 1 P 1.545 P 1.656 P TP M2
204094 s at 9819 1 P 1.573 P 1.601 P KIAA0669
204109 s at 4800 1 P 1.530 P 1.251 P NFYA
204135 at 11259 1 P 1.623 P 2.851 P D0C1
204139 x at 7593 1 P 0.602 A 0.762 P,A ZNF42
204141 at 7280 1 P 2.284 P 2.008 P TUBB
204159 at 1031 1 P 1.550 P 1.388 P CDKN2C
204184 s at 157 1 P 1.536 P 1.358 P ADRBK2
204210 s at 5130 1 P.A 1.534 P.A 1.414 P PCYT1A
204218 at 25906 1 P 1.514 P 1.254 P DKFZP564M082
204224 s at 2643 1 P 1.961 P 1.709 P GCHI
204238_s_at 10591 1 P 0.642 P 0.808 P C6orf108
204260 at 1114 1 P 0.189 P 0.220 P CHGB
204268 at 6273 1 A 2.756 P 4.154 P SI00A2
204279 at 5698 1 P 2.180 P 3.303 P PSMB9
204284 at 5507 1 P 1.259 P.A 1.672 P PPPIR3C
204313 s at 1385 1 P 1.541 P 1.436 P CREBI
204326.x at 4500 1 P 2.032 P 2.455 P MTIL
A ffym etm
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204332 s at 175 1 P 0.600 P 0.718 P AGA
204333 s at 175 1 P 0.570 P 0.611 P AGA
204347 at 205 1 P 1.642 P 1.952 P AK3
204348 s at 205 1 P 1.606 P 1.835 P AK3
204358 s at 23768 1 P 0.625 P.A 0.939 P FI.RT2
204359 at 23768 1 P 0.620 P 0.909 P FLRT2
204360 s at 4669 I P 0.647 P 0.742 P NAGLU
204368 at 6578 1 A 1.442 P,M,A 2.032 P SLC02AI
2043% s at 2869 1 P 1.589 P 1.584 P GRK5
204398 s at 24139 1 P 0.643 P 0.825 P.M EML2
204412 s at 4744 1 P 1.572 P 1.257 P NEFH
204416 X at 341 1 A 1.584 P 1.572 P.M AP0C1
204420 at 8061 1 P 1.580 P 1.869 P DIPA
204421 s at 2247 1 P 1.488 P 1.563 P FGF2
204422 s at 2247 1 P 1.667 P 1.646 P FGF2
204423 at 4289 1 P 1.696 P 1.558 P MKLNI
204425 at 393 I P 0.583 P.A 0.738 P ARHGAP4
204455 at 667 1 A 1.901 P.A 3.900 P BPAG1
204462 s at 6567 1 P 1.414 P 1.766 P SLC16A2
204465 s at 9118 I P 1.915 P 1.894 P INA
204475 at 4312 I P 3.658 P 6.287 P MMP1
204485 s at 10040 1 P 0.653 P 0.781 P TOM ILI
204490 s at 960 I P.A 2.166 P.A 4.040 P.A CD44
204493 at 637 1 P 1.569 P 1.427 P BID
204514 at 1802 I P 1.505 P 1.600 P DPH2L2
204527 at 4644 1 P 1.519 P 1.513 P MY05A
204530 s at 9760 1 P,A 1.481 A 1.702 P TOX
204540 at 1917 1 P 1.556 P 1.229 P EEF1A2
204567_s_at 9619 1 P 1.555 P 1.144 P ABCG1
204616_at 7347 1 P 1.549 P 1.454 P UCHL3
204627_s_at 3690 1 A 1.485 P.A 2.100 P ITGB3
204632 at 8986 1 P 1.832 P 1.669 P RPS6KA4
204646_at 1806 1 P 0.547 P 0.606 P DPYD
204647 at 9454 1 P 1.685 P 2.199 P H0MER3
204653_at 1 P.A 1.274 P 1.608 P TFAP2A
204655 at 6352 1 A 2.186 P.A 7.657 P CCL5
204665_at 80143 1 P 0.825 P 0.626 P FU21I68
204682 at 4053 1 P.A 1.357 P 2.179 P LTBP2
204745 X at 4495 1 P 1.463 P 1.882 P M il  G
204748 at 5743 1 M.A 3.283 P 4.991 P COX2
204749_at 4675 1 P 1.535 P 1.564 P NAP1L3
204759 at 1102 1 P 1.684 P 1.274 P CHC1L
204780 s at 355 1 A 1.375 P.A 1.754 P TNFRSF6
204788 s at 5498 1 P 0.546 P 0.617 P PPOX
204790_at 4092 1 P 1.807 P 1.313 P SMAD7
204792 s at 9742 1 P.A 0.594 P 0.819 P.A KIAA0590
204806 x_at 3134 1 P 1.034 P 1.558 P IILA-F
204811 s at 9254 1 P 0.644 P 0.651 P CACNA2D2
204859_s_at 317 1 P 1.512 P 1.599 P APAF1
204865 at 761 1 A 1.506 P.A 1.757 P CA3; CAII1
X
Affymetrix
Id
Day 0 Day 3 Day 7
Common NameLocusLink
Normalized Flags Normalized Flags Normalized Flags
204875_s_at 2762 1 P 1 377 P 1 725 P GMDS
204880 at 4255 1 P 0 655 P 0 764 P MGMT
204897_at 5734 1 P 2 197 P 2 832 P PTGER4
204908 s at 602 1 P 1 734 P 2 267 P BCL3
204928 s at 8273 1 P 1 590 P 1 331 P SLC10A3
204935_at 5771 1 P,A 1 546 P 1 237 P>A PTPN2
204937 s at 10782 1 P 1 525 P 1 349 P ZNF274
204948_s_at 10468 1 A 1 305 P 1 701 P FST
20495 5_at 8406 1 P 1 854 P 1 797 P SRPX
204983_s_at 2239 1 P 1 249 P 1 621 P GPC4
204985_s_at 79090 1 P 0 632 P 0 772 P MGC2650
20499 l_s_at 4771 1 A 1 583 P,A 1 809 P,M NF2
204995_at 8851 1 P 0 707 P 0 625 P,A CDK5R1
204998_s_at 22809 1 P 0 532 P 0 660 P ATF5
204999_s_at 22809 1 P 0 420 P 0 507 P ATF5
205005_s_at 9397 1 P 1 593 P 1 426 P NMT2
205006_s_at 9397 1 P 1 605 P 1 718 P NMT2
205013 s at 135 1 P,A 1 864 P 2 098 P ADORA2A
205016 at 7039 1 A 2 225 P 2 039 P TGFA
205034_at 9134 1 P 1 702 P 1 461 P CCNE2
205047_s_at 440 1 P 0 279 P 0 271 P ASNS
20508 l_at 1396 1 P 1 803 P 1 343 P CRIP1
205088_at 10046 1 M 1 433 P 1 612 P CXorf6
205097_at 1836 1 P 1 363 P 1 622 P SLC26A2
205110_s_at 2258 1 P,A 1482 P 1 643 P FGF13
20511 l_s_at 51196 1 P 1 548 P 2 134 P PLCE1
205112 at 51196 1 P,A 1 636 P 2 470 P PLCE1
205115_s_at 9904 1 A 1 552 P 1 353 P,M RBM19
205126_at 7444 1 P 1 504 P 1 542 P VRK2
205172_x_at 1212 1 P 1 550 P 1 597 P CLTB
205174_s_at 25797 1 P 2 687 P 3 129 P QPCT
205192_at 9020 1 P,M 1 501 P 1 575 P MAP3K14
205193_at 23764 1 P,M 1 594 P 1 360 P MAFF
205196_s_at 1174 1 P,M 1 432 P,A 2 059 P,A AP1S1
205205_at 5971 1 P 1 867 P 2 271 P RELB
205214_at 9262 1 A 2 069 P,M,A 1 846 M,A STK17B
205249_at 1959 1 P 1 041 P 1 649 P EGR2
205280_at 2743 1 P 0 651 P 0 722 P GLRB
205286_at 7022 1 A 2 102 P 3 094 P TFAP2C
205288_at 8556 1 P 1 548 P 1 322 P,M CDC14A
205350_at 1381 1 P 1 976 P 2 301 P CRABP1
205352_at 5274 1 P,A 1 428 P 1 956 P SERPINI1
205358_at 2891 1 P 0 622 P 0 774 P GRIA2
205379_at 874 1 A 1 967 P,A 2 206 P CBR3
20540 l_at 8540 1 P 1 522 P 1 327 P AGPS
205407_at 8434 1 P 0 604 P 0 835 P RECK
205423_at 162 1 P 1 614 P 1 524 P APIB1
205428_s_at 794 1 P»A 1 529 P 1 484 P CALB2
205434_s_at 22848 I P \ 576 P 1 496 P AAK1
205443_at 6617 1 P 1 845 P 1 582 P SNAPC1
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205479 s at 5328 1 A 2 913 P 6 454 P PLAU
205483_s_at 9636 1 P 1 597 P 2 631 P G1P2
205493_s_at 10570 1 P 1 691 P 1 379 P DPYSL4
205497_at 7728 1 P,A 0 649 M,A 0 781 M,A ZNF175
205498_at 2690 1 P,M,A 1 635 P 1 803 P GHR
205534_at 5099 1 A 1 711 PjA 2 180 P PCDH7
205543_at 22824 1 P 1 395 P 1 560 P APG-1
205547_s_at 6876 1 P 5 771 P 6 351 P TAGLN
205569_at 27074 1 P 1 142 P 1 881 P LAMP3
205606_at 4040 1 P 0 577 P 0 722 P LRP6
205619 s at 4222 1 A 1 342 P,A 2 228 P MEOX1
205625 s at 793 1 A 3 079 P 4 556 P CALB1
205626_s_at 793 1 P,A 1 401 P 1 643 P CALBI
205660 at 8638 1 M,A 1 247 P,A 2 008 P OASL
205676_at 1594 1 P,A 1 479 P 1 575 P CYP27B1
205715_at 683 1 M,A 1 517 P,M,A 1 399 M,A BST1
205729_at 9180 1 P 1035 P 1 544 P OSMR
205777_at 1852 1 P 1 564 P 1 326 P DUSP9
205807 s at 7286 1 P 1 437 P 1 504 P TUFT1
205828_at 4314 1 P 1 590 P 1 338 P MMP3
205829_at 3292 1 P,A 1 885 P 1 625 P HSD17B1
205830_at 1047 1 P 0 605 P 0 780 P CLGN
205848_at 2620 1 P 0 656 P 0 514 P,M GAS2
205876_at 3977 1 P,M 2 037 P 2 162 P LIFR
205896_at 6583 1 P 1 458 P 1 508 P SLC22A4
205899_at 8900 1 A 1 684 P,A 1 730 P,M CCNA1
205924_at 5865 1 A 2 627 P 3 222 P RAB3B
205925 s at 5865 1 P 1 998 P 2 138 P RAB3B
20593 7_at 10669 1 P 0 572 P 0 792 P CGREF1
205973_at 9638 1 P,A 1 314 P 1 514 P FEZ1
205986_at 9625 1 P,A 0 600 A 0 689 M,A AATK
206002_at 10149 1 A 1 796 M,A 1 849 P A GPR64
206023_at 10874 1 P 1 387 P 1 535 P NMU
20603 6_s_at 5966 1 P 1 555 P 1 453 P RELB
206067 s a t 7490 1 A 2 297 P,M,A 1 863 P,A WT1
206068_s_at 33 1 M,A 1 636 P 1 448 P ACADL
206074_s_at 3159 1 P 1 526 P 1 582 P HMGA1
206100_at 1368 1 P,A 1 582 P 1 924 P CPM
206103_at 5881 1 P 0 576 P 0 674 P RAC3
206104_at 3670 1 P>A 1 864 P 1 713 P ISLl
206116_s_at 7168 1 P 3 588 P 5 110 P TPM1
206117_at 7168 1 A 3 077 P,A 4 184 P TPM1
206128_at 152 1 P 0 621 P,A 0816 P ADRA2C
206137_at 9699 1 P,M 1 908 P 2 182 P RIMS2
206142_at 7694 1 P,M 0613 A 0 737 A ZNF135
206157_at 5806 1 P 2 010 P 1 241 P PTX3
206279_at 5616 1 P;A 1 471 P 1 573 P,M PRKY
206295_at 3606 1 P,A 1 653 P 2 355 P IL18
206343_s_at 3084 1 P 2 177 P 1623 P NRG1
206355_at 2774 1 P 0 623 P 0 645 P GNAL
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20640 l_s_at 4137 1 P 0 652 P,A 0 626 P,M,A MAPT
206404_at 2254 1 P 0 695 P 0 652 P FGF9
206424_at 1592 1 P 1 763 P 1 461 P CYP26A1
20646 l_x_at 4496 1 A 1 974 P,A 2 623 P» A MT1H
206463_s__at 10202 1 A 2 838 P,A 2 716 M,A DHRS2
206504_at 1591 1 A 3 766 P,M 5 333 P,M,A CYP24A1
206506_s_at 8464 1 P,A 0 640 P,A 0811 M,A SUPT3H
206508_at 970 1 P,A 1 738 P,A 3 310 P TNFSF7
206580_s_at 30008 1 P 1 848 P 1 712 P EFEMP2
206632_s_at 9582 1 P 1 920 P 2 098 P APOBEC3B
206662_at 2745 1 P 1 832 P 2 075 P GLRX
206675_s_at 6498 1 P,A 1 890 P 1 265 P,A SKIL
206693_at 3574 1 P,M 1 108 P,A 1 915 P IL7
206699_x_at 4861 1 P,A 1 553 P 1 429 P,M NPAS1
206748_s_at 9043 1 P 1 599 P 1 443 P SPAG9
206765_at 3759 1 P 0 629 P 0611 P KCNJ2
206773_at 4062 1 P,A 1 954 P 1 786 P LY6H
206788_s_at 865 1 P 1 761 P 1 411 P CBFB
206805„at 10371 1 P 1 173 P 1 859 P SEMA3A
206825_at 5021 1 A 2 427 P 3 962 P OXTR
206850_at 10633 1 P,A 1 882 P 1 420 P RRP22
206907_at 8744 1 P 1 624 P 1 882 P TNFSF9
207014_at 2555 1 P,M 1 312 P 1 718 P GABRA2
207030_s_at 1466 1 P 2 743 P 2 341 P CSRP2
207050_at 781 1 A 1 491 P,A 1 633 P,M,A CACNA2D1
207147_at 1746 1 P 1 790 P 0 731 P,M DLX2
207180_s_at 10553 1 p ,m ,a 1 511 P 1 248 P HTATIP2
207196_s_at 10318 1 P 1 511 P 1 648 P TNIP1
207219_at 65243 1 P 0 600 P 0 655 P LOC65243
20728 l_x_at 51480 1 P 2 237 P 3 607 P VCX2
207290_at 5362 1 P 0 385 P,A 0 403 A PLXNA2
207302_at 6445 1 P 0 428 P 0 400 P SGCG
207304_at 7596 1 P 2 175 P 1 509 P ZNF45
207324_s_at 1823 1 P,M 0 597 A 0 528 A DSC1
207332_s_at 7037 1 P 1 500 P 1 539 P TFRC
207357_s_at 55568 1 P 1 161 P 1 527 P GALNT10
207390_s_at 6525 1 P 1 523 P 1 530 P SMTN
207415_at 22925 1 P,A I 303 PM ,A 1 716 P PLA2R1
207535_s_at 4791 1 P 1 625 P 1 878 P NFKB2
207563_s_at 8473 1 P 0 643 P 0 780 P OGT
207574_s_at 4616 1 P 2 255 P 2 443 P GADD45B
207643_s_at 7132 1 A 1 083 P,M 1 619 P TNFRSF1A
207700_s_at 8202 1 P 1 456 P 1 560 P NCOA3
207714_s_at 871 1 P 2 408 P 2 214 P SERPINH1
207768_at 1961 1 A 3 446 P 3 661 P EGR4
207813_s_at 2232 1 P 0 646 P 0 741 P FDXR
207826_s_at 3399 1 P 7 473 P 4 465 P ID3
207876_s_at 2318 1 P 1 365 P 1 739 P FLNC
208003_s_at 10725 1 P 0 988 P 1 502 P NFAT5
208018_s_at 3055 1 A 1 611 P,A 1 393 P,A HCK
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208055 s at 26091 1 P 1.551 P 1.726 P HERC4
208112 x at 10938 1 P 1.504 P 1.679 P EHD1
208116 s at 4121 1 A 1.661 P.M.A 1.889 P MANI Al
208117 s at 81887 1 P 1.630 P 1.524 P F U  12525
208178 x at 7204 1 P.M.A 1.454 P 1.645 P TRIO
208186 s at 3991 1 P.M.A 1.847 P 1.823 P LIPE
208309 s at 10892 1 P 1.875 P 2.052 P MALTI
208359 s at 3761 1 P 0.497 P.A 0.569 P.A KCNJ4
208370 s at 1827 1 P 1.427 P 1.610 P DSCRI
208433 s at 7804 1 P 0.616 P 0.698 P LRP8
208436 s at 3665 1 P 1.157 P 1.636 P IRF7
208456 s at 22800 1 P 1.631 P 1.682 P RRAS2
208576 s at 8358 1 A 1.1% P.A 1.569 P.M.A HIST1H3B
208581 x at 4501 1 P 1.869 P 2.465 P MT1X
208621 s at 7430 1 P 1.501 P 1.603 P VIL2
208622 s at 7430 1 P 1.530 P 1.643 P VIL2
208633 s at 23499 1 P 1.191 P 1.635 P MACFI
208637 x at 87 1 P 1.511 P 1.704 P ACTNI
208650 s at 934 1 P.M.A 3.016 P 4.522 P CD24
208651 x at 934 1 P.A 2.132 P 2.999 P.A CD24
208693 s at 2617 1 P 0.558 P 0.562 P GARS
208711 s at 595 1 M.A 1.445 M.A 1.972 P CCND1
208712 at 595 1 P.A 1.765 P 2.199 P CCND1
208729 x at 3106 1 P 1.113 P 1.955 P HLA-B
208740 at 10284 1 P 1.352 P 1.635 P SAP 18
208779 x at 780 1 P 1.342 P 1.583 P DDR1
208782 at 11167 1 P 1.714 P 3.062 P FSTL1
208789 at 22939 1 P 2.200 P 2.707 P PTCF
208790 s at 22939 1 P 1.590 P 2.630 P PTRF
208791 at 1191 1 P 1.628 P 2.677 P CLU
208792 s at 1191 1 P 1.559 P 2.485 P CLU
208813 at 2805 1 P 0.617 P 0.619 P GOTI
208866_at 1452 1 P 1.301 P 1.633 P CSNK1AI
208872 s at 7905 1 P 1.521 P 1.377 P DPI
20889 l_at 1848 1 P 0.518 P 0.753 P DUSP6
208892 s at 1848 1 P 0.522 P 0.720 P DUSP6
208893 s at 1848 1 P 0.391 P 0.656 P DUSP6
208898_at 51382 1 P 2.051 P 1.758 P ATP6V1D
208899 x at 51382 1 P 2.028 P 1.817 P ATP6VID
208933 s at 55127 1 P 1.257 P 1.724 P F U  10359
208934 s at 3964 1 P 1.900 P 2.448 P LGALS8:
208935 s at 3964 1 P 1.185 P 1.857 P LGALS8
208936 x at 3964 1 P 1.626 P 1.911 P LGALS8
208937_s_at 3397 1 P 4.800 P 2.532 P IDI
208944 at 7048 1 P 1.585 P 2.663 P TGFBR2
208949 s at 3958 1 P 1.459 P 1.628 P LGALS3
208950 s at 501 1 P 0.631 P 0.722 P ALDH7AI
20895l_at 501 1 P 0.658 P 0.744 P ALDH7A1
208989 s at 22992 1 P.M 1.250 P 1.508 P FBXLI1
208991 _at 1 P 1.704 P 2.387 P STAT3
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208992_s_at 6774 1 P,A 1 536 P 2315 P STAT3
208997_s_at 7351 1 P 1 438 P 1 589 P UCP2
208998_at 7351 1 P 1 524 P 1 742 P UCP2
20901 l_at 7204 1 P 1 414 P 1 536 P TRIO
209015_s_at 10049 1 P 1 549 P 1 491 P DNAJB6
209017_s_at 9361 1 P 0 646 P 0 691 P PRSS15
209025_s_at 10492 1 P 1 379 P 1 517 P SYNCRIP
209040_s_at 5696 1 M,A 2 224 P 3 927 P PSMB8
209083_at 11151 1 A 2 468 P 2216 P CORO 1A
209087_x_at 4162 1 P,A 2 137 P 1 898 P MCAM
209098_s_at 182 1 P 0 588 P 0 621 P JAG1
209099_x_at 182 1 P 0 597 P 0 626 P JAG1
209102_s_at 26959 1 P 0 614 P 0 816 P HBP1
209124_at 4615 1 P 1 413 P 1 580 P MYD88
209131 s at 8773 1 M,A 1 433 P,A 1 605 P>A SNAP23
209140_x_at 3106 1 P 1 234 P 1900 P HLA-B
209155_s_at 22978 1 P 1 453 P 1 604 P NT5C2
209166_s_at 4125 1 P 1 200 P 1 530 P MAN2B1
209173_at 10551 1 P 0 598 : a 0 549 A AGR2
209188_x_at 1810 1 P 1 536 p 1358 P DR1
209189_at 2353 1 P 1 346 p 2 745 P FOS
209191_at 84617 1 P 1 599 p 1 610 P MGC4083
209193_at 5292 1 P 1 789 p 1942 P PIM1
209209_s_at 10979 1 P 1 811 p 1 712 P PLEKHC1
209210_s_at 10979 1 P 1 619 p 1 599 P PLEKHC1
20921 l_at 688 1 P 1 213 p 1 620 P KLF5
209212_s_at 688 1 P 1 017 p 1 568 P KLF5
209220_at 2719 1 P 0 550 P,A 0 718 P GPC3
209260_at 2810 1 A 1 464 p,A 2 035 P,M SFN
209267_s_at 64116 1 P,M 2 978 p 3 693 P SLC39A8
209268_at 11311 1 P 1 446 p 1 540 P VPS45A
209276_s_at 2745 1 P,M 1 660 p 1 565 P GLRX
209277_at 7980 1 P 2 483 p 2 593 P TFPI2
209278_s_at 7980 1 P 2 378 p 3 167 P TFPI2
209288_s_at 10602 1 P 1 232 p 1 644 P CDC42EP3
20929 l_at 3400 1 P 4 766 p 2 901 P ID4
209292_at 3400 1 P 2515 p 1 942 P ID4
209293_x_at 3400 1 P 4 372 p 2 725 P ID4
209304_x_at 4616 1 A 1 886 p 1 887 P,A GADD45B
209305_s__at 4616 1 P,A 1 756 p 1 656 P GADD45B
209340_at 6675 1 P 2 091 p 2 136 P UAP1
209348_s_at 4094 1 P,A 1 513 P,A 1 958 P,M,A MAF
209356_x_at 30008 1 P 2 008 P 1 941 P EFEMP2
209366_x_at 1528 1 P 1 467 P 1640 P CYB5
209372_x_at 7280 1 P 1 619 P 1 625 P TUBB
209383_at 1649 1 P 0 573 P,M 0 591 P,M,A DDIT3
209407_s_at 10522 1 P 0 491 P,A 0710 P DEAF1
209420_s_at 6609 1 P,M 1 848 P 1 874 P SMPD1
209427_at 6525 1 P,A 1 556 P 1 661 P SMTN
20943 2_s_at 10488 1 P 1 598 P 1 600 P CREB3
X V
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209453 at 6548 1 A 1.660 P 1.727 P SLC9AI
209457 at 1847 1 P 2.416 P 3.400 P DUSP5
209459 s at 57416 1 A 4.488 P 5.435 P ABAT
209478 at 201254 1 P 1.684 P 1.429 P STRA13
209487 at 11030 1 A 2.105 P 2.085 P RBPMS
209506 s at 7025 1 P 0.641 P 0.777 P NR2FI
209536_s_at 10916 1 P 1.810 P 2.176 P MAGED2
209543 s at 947 1 P 0.631 P 0.681 P CD34
209560 s at 8788 1 A 1.323 A 1.636 P DLK1
209561 at 7059 1 P 1.170 P 1.595 P T11BS3
209574 s at 753 1 P 1.409 P 1.547 P C 18orf1
209598 at 10687 1 P 1.568 P 1.861 P PNMA2
209620 s at 22 1 P 0.620 P 0.797 P hABC7
209631 s at 1 A 1.990 P.A 1.8% P.M.A
209635 at 1174 1 P 1.474 P 2.123 P API SI
209636 at 4791 1 P 1.876 P 2.559 P NFKB2
209651 at 7041 1 P 1.739 P 1.698 P TGFB11I
209653 at 3840 1 P 1.709 P 1.728 P KPNA4
209656 s at 83604 1 P 1.613 P 1.497 P TM4SF10
209666 s at 1147 1 P 1.541 P 1.478 P CHUK
209682 at 868 1 P 1.543 P 1.702 P CBLB
209710 at 84724 1 P 2.005 P 0.954 P GATA2
209715 at 23468 1 P 1.726 P 1.956 P CBX5
209716 at 1435 1 P.M.A 1.173 P 1.713 P CSF1
209758 s at 8076 1 P 0.841 P 1.766 P MFAP5
209759 s at 1632 1 P 0.616 P 0.602 P DC I
209771 X  at 934 I P 2.774 P 4.169 P CD24
209772 s at 934 1 A 1.873 P.A 2.306 P CD24
209773 s at 6241 1 P 1.619 P 1.253 P RRM2; R2
209788_s_at 51752 1 P 1.218 P 1.550 P ARTS-1
209803 s at 7262 1 P.M 5.997 P 6.779 P PHLDA2
209818 s at 22927 1 P 1.844 P 1.608 P HABP4
209835 X  at 960 1 A 1.667 P.M 2.588 P CD44
209846 s at 11118 1 P.A 0.860 P.A 1.574 P BTN3A2
209852 X  at 10197 1 P 1.647 P 1.621 P PSME3
209853 s at 10197 1 P 1.606 P 1.606 P PSME3
209875_s_at 66% 1 A 1.714 P.A 2.386 P.A SPP1
209894 at 3953 1 P.A 1.227 P 2.008 P.M LEPR
209897 s at 9353 1 P 1.021 P 1.533 P SLIT2
20992 l_at 23657 1 P 0.513 P 0.703 P SLC7A1I
209960 at 3082 1 P 0.636 P 0.745 P HGF
209967 s at 1390 1 P 0.709 P 0.619 P CREM
209969 s at 6772 1 P 1.7% P 3.525 P STATI
210008 s at 6183 1 P 1.762 P 1.545 P MRPSI2
210017 at 10892 1 P 1.764 P 1.728 P MALTI
210018 X at 10892 1 P 1.692 P 1.614 P MALTI
210026 s at 29775 1 P.A 1.518 P 1.440 P CARDIO
210050 at 7167 1 P.M 1.510 P 1.275 P TPI1
210057 at 23049 1 P 1.206 P 1.702 P SMGl
210074 at 1515 1 P 1.176 P 1.784 P CTSL2
x v i
Affymetrix
Id LocusLink
Day 0 Day 3 Day 7
Common Name
Normalized Flags Normalized Flags Normalized Flags
210095_s_at 3486 1 P 1 570 P 1 793 P IGFBP3
210100_s_at 20 1 P,M 0 658 A 0 871 PjA ABCA2
210102_at 4013 1 P 1 014 P 1 527 P LOH11CR2A,
210117_at 6674 1 P 1 783 P 1 224 P SPAG1
210145_at 5321 1 M,A 1 545 P,A 1693 P PLA2G4A
210148_at 10114 1 P,A 1 980 P 1492 P HIPK3
210163_at 6373 1 A 1 927 A 2 936 P CXCL11
210171_s_at 1390 1 P 0 598 P,M 0 577 P,A CREM
210220_at 2535 1 P 0 587 P 0 703 P FZD2
210221_at 1136 1 P,A 1 817 P 1234 P,A CHRNA3
210222_s_at 6252 1 P,A 1 365 P 1 503 P RTN1
210233_at 3556 1 P,A 2 966 P 1 892 A IL1RAP
210240_s_at 1032 1 P 1 578 P 1 086 P CDKN2D
210298_x_at 2273 1 P 1406 P 2 671 P FHL1
210299_s_at 2273 1 P 1698 P 3 269 P FHL1
210336_x_at 7593 1 P 0 643 A 0 686 P,A ZNF42
210358_x_at 84724 1 A 1895 P,A 1 144 P,M,A GATA2
210385_s_at 51752 1 P 1205 P 1 669 P ARTS-1
210396_s_at 1 P 1 666 P 1 321 P
210410_s_at 4439 1 P 0 645 P)A 0 708 P MSH5
210415_s_at 4957 1 P,M 1612 P 1 356 P ODF2
210457_x_at 3159 1 P 1 506 P 1 298 P HMGA1
210463_x_at 55621 1 P 1 560 P 1 325 P FLJ20244
210480_s„at 1 P»A 1 682 P 1970 P M Y06
210512_s_at 7422 1 P 0 617 P 0 543 P VEGF
210514_x_at 3135 1 P 1 020 P 1 513 P HLA-G
210538_s_at 330 1 P,A 10 016 P 9 540 P BIRC3
210560_at 2637 1 P,M 3 388 P 2 070 P GBX2
210570_x_at 5601 1 P 1 524 P 1 193 P MAPK9
210592_s_at 1 P 1 817 P 2 819 P SAT, SSAT
210605_s_at 4240 1 P 1403 P 2 404 P MFGE8
210612_s_at 8871 1 P,A 1 267 P,A 1 900 P SYNJ2
210715_s_at 10653 1 P 1 934 P 3 224 P SPINT2
210732_s_at 3964 1 P 1 928 P 2 242 P LGALS8
210756_s_at 1 P 1 220 P 1630 P NOTCH2
210793_s_at 4928 1 P 1 813 P 1 575 P NUP98
210797_s_at 8638 1 P 1 521 P 3 982 P OASL
210829_s_at 1 P 1 629 P 2 203 P SSBP2
210845_s_at 5329 1 P 2 671 P 3 584 P PLAUR,
2l0869_s_at 4162 1 P,A 2 460 P 2019 P MCAM
210876_at 303 1 P,A 1 724 P 1 739 P ANXA2P1
210926_at 1 P 1 447 P 1 531 P,M FKSG30
210935_s_at 1 P 1 602 P 1 480 P WDR1
2l0976_s_at 5213 1 P 0 655 P 0 848 P PFKM
210986_s_at 7168 1 P 3 399 P 4 636 P TPM1
210987_x_at 7168 1 P 3 168 P 4 265 P TPM1
211003_x_at 7052 1 A 9192 M A 13 843 P A TGM2
211016_x_at 3308 1 P 1 516 P 1 391 P HSPA4
21103 l_s_at 7461 1 P,A 1 320 P 1 654 P CYLN2,
211043_s_at 1212 1 P 1 584 P 1 564 P CLTB
X V I I
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211061 _s__at 4247 1 P 1 858 P 1 770 P MGAT2
211091_s_at 4771 1 P,A 1 508 P 1 496 P NF2
211094_s_at 4763 1 P 0 997 P 1 583 P NF1
211126_s_at 1466 1 P 2 302 P 2 088 P CSRP2
211160_x_at 87 1 P,A 1 403 P,A 1 566 P ACTN1
211162_x_at 6319 1 P 1 573 P 1 331 P SCD
211340_s_at 4162 1 P,M,A 2 877 P 2 346 P MCAM
211352_s_at 8202 1 A 1 204 P,A 1 526 P CAGH16
211403_x_at 51481 1 P 1 991 P 2 939 P VCX2
211456_x_at 1 P,A 1 744 P 2 486 P
211527_x_at 7422 1 P 0 660 P 0 657 P,A VEGFA
211528_x_at 3135 1 P 1 086 P 1 827 P HLA-G
211529_x_at 3135 1 P 1 142 P 1 871 P HLA-G
211530_x_at 3135 1 P 1 112 P 1 705 P HLA-G
211538_s_at 3303 1 P 1 912 P 2 114 P HSPAIA
211564_s_at 8572 1 P 1343 P 1633 P PDLIM
211573_x_at 7052 1 A 1 795 P 2 031 P TGM2
211600_at 1 P 0 938 P 0 534 P PTPRO
21165 l_s_at 3912 1 A 1608 P,A 2 073 P LAMB1
211668_s_at 5328 1 P,M 2 528 P 5 235 P PLAU, UPA
211671_s_at 2908 1 P 1 534 P 1 466 P NR3C1
211725_s_at 1 P 1 700 P 1 575 P
211792_s_at 1031 1 P 1 617 P 1458 P CDKN2C
211799_x_at 3107 1 P 0 962 P 1 664 P HLA-C
211864_s_at 26509 1 A 3 119 P,M 6 485 P FER1L3
21191 l_x_at 3106 1 P 1 121 P 2 071 P HLA-B
211924_s_at 5329 1 P 2 665 P 3 589 P PLAUR
211926_s_at 4627 1 P 1 555 P 1 717 P MYH9
211928_at 1778 1 P 1 192 P 1 504 P DNCH1
211950_at 23352 1 P 1493 P 1 769 P RBAF600
211962_s_at 677 1 P 1239 P 1 834 P ZFP36L1
211982_x_at 23214 1 P 1 607 P 1 516 P XP06
211986_at 195 1 P 1 915 P 2 401 P MGC5395
211992_at 65125 1 P 1 282 P 1 535 P PRKWNK1
211994_at 1 P 1 469 P 1 516 P PRKWNK1
212010_s_at 55573 1 P 1 436 P 1 524 P H41
212012_at 1 A 1 280 P,A 1 541 P,A D2S448
212014_x_at 960 1 P,M 1 549 P,M,A 2 119 P CD44
212022_s_at 1 P 1 619 P 1 656 P MKI67
212023_s_at 1 P 1 549 P 1 521 P MKI67
212032_s_at 53635 1 P 0611 P 0 802 P PTOV1
212061_at 23350 1 P 0 477 P 0 566 P SRI 40
212063_at 960 1 A 1 971 P,A 3 607 P CD44
212069_s_at 23121 1 P,M,A 1440 P 1 544 P KIAA0515
212076_at 1 P 1 130 P 1 559 P MLL
212092_at 23089 1 P 2 584 P 3 170 P PEG 10
212094_at 23089 1 P 2 664 P 2 873 P PEG 10
212097_at 857 1 P 1 353 P 1 633 P CAV1
212099_at 1 P 2 434 P 1 716 P RHOB
212125_at 5905 1 P 1 450 P 1 624 P RANG API
X V 111
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212126 at 1 P 1.405 P 1.502 P
212127 at 5905 1 P 1.589 P 1.903 P RANGAP1
212135 s at 493 1 P 1.354 P 1.919 P ATP2B4
212136 at 493 1 P 1.290 P 1.860 P ATP2B4
212143 s at 3486 1 P 1.726 P 2.072 P IGFBP3
212154 at 6383 1 P.M 1.757 P 1.761 P SDC2
212158 at 6383 1 P.M 1.715 P 1.586 P SDC2
212162 at 57498 1 P 1.333 P 1.513 P KIDINS220
212171 x at 7422 1 P 0.626 P 0.637 P VEGF
212176 at 25957 1 P 0.623 P 0.685 P C6orfl 11
212177 at 1 P 0.492 P 0.598 P C6orf111
212179 at 25957 1 P 0.579 P 0.699 P C6orf111
212185 x at 4502 1 P 1.963 P 2.823 P MT2A
212186 at 31 1 P 1.565 P 1.734 P ACACA
212190 at 5270 1 P 1.880 P 1.499 P SERPINE2
212192 at 115207 1 A 4.360 P.M 3.016 A KCTD12
2121% at 1 P 1.385 P 1.513 P IL6ST
212225 at 10209 1 P 0.558 A 0.821 P.A SUM
212249 at 5295 1 P.M,A 1.465 P 1.554 P P1K3R1
212253 x at 667 1 A 1.617 M.A 2.087 P.A BPAG1
212254 s at 667 1 P 1.535 P 2.146 P BPAG1
212259 s at 57326 1 P 0.521 P 0.701 P PBXIPI
212268 at 1992 1 A 1.968 M.A 1.753 P.M.A SERPINB1
212276 at 23175 1 P 1.346 P 1.536 P LPIN1
212290 at 1 P 0.609 P 0.7% P SLC7A1
212294 at 55970 1 P 1.322 P 1.740 P GNG12
212295 s at 1 P 0.634 P 0.686 P SLC7AI
212307 s at 8473 1 P 0.636 P 0.753 P OGT
212312 at 598 1 P 1.588 P 1.623 P BCL2LI
212325 at 22998 1 M.A 1.330 P.A 1.656 P.A KIAA1102
212333 at 25940 1 P 1.598 P 1.443 P DKFZP564F0522
212364 at 4430 1 P.A 1.678 P 1.866 P MY01B
212384 at 7919 1 P 0.655 P.A 0.774 P BATI
212387 at 1 P 0.648 P 0.771 P TCF4
212412 at 1 P 1.489 P 1.652 P L1M
212463 at I P 1.189 P 1.911 P CD59
212470 at 9043 1 P 1.567 P 1.433 P SPAG9
212473 s at 1 P 1.365 P 1.964 P
212501 at 1051 1 P 0.642 P 0.699 P CEBPB
212511 at 1 P 1.594 P 1.461 P PICALM
212527 at 27351 1 P 1.625 P 1.474 P D15Wsu75e
212538 at 23348 1 P 1.225 P 1.563 P DOCK9
212548 s at 23045 1 P 1.504 P 1.674 P KIAA0826
212565 at 23012 1 P.A 1.109 A 1.518 PA STK38L
212574 x at 91304 1 P 0.688 P 0.628 P R 32I843
212590 at 22800 1 P 1.672 P 1.611 P RRAS2
212593_s_at 27250 1 P 0.643 P 0.740 P PDCD4
212599 at 26053 1 P 1.378 P 1.623 P AUTS2
212601 at 23140 1 P.M 1.362 P 1.655 P ZZEFI
212624 s at 1123 1 P 1.516 P 1.329 P C11NI
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212636 at 1 P 1 277 P 1 581 P QKI, QK3
212638_s_at 11059 1 F 1 627 P 1 605 P WWP1
212641_at 3097 1 P 1 265 P 1 550 P HIVEP2
212646_at 23180 1 A 4 120 P 4 448 P RAFTLIN
212654_at 7169 1 P,A 1 842 P 2 106 P TPM2
212662_at 5817 1 P 1 508 P 1 483 P PVR
212665 at 25976 1 P 1 805 P 1 892 P TIP ARP
212693 at 23195 1 P 1266 P 1 530 P MDN1
212706_at 10156 1 P 1 617 P 1 485 P RASA4
212708 at 1 P 0 565 P 0 686 P CASC3
212714_at 113251 1 P 1 507 P 1426 P LOCI 13251
212722 s at 23210 1 P 1 820 P 1 535 P PTDSR
212723_at 23210 1 P 1 627 P 1 448 P PTDSR
212748_at 57591 1 P 1 377 P 1 667 P MKL1
212775 at 23363 1 P 1 634 P 1 636 P KIAA0657
212776_s_at 23363 1 P 1 585 P 1 510 P KIAA0657
212780 at 6654 1 P 1 525 P 1 345 P SOS1
212786_at 23274 1 P,A 1 343 P 1 652 P KIAA0350
212812_at 1 P 1 246 P 1 507 P
212815_at 10973 1 P 1 684 P 1 789 P HELIC1
212816_s_at 875 1 P 0 504 P 0 503 P CBS
212828_at 1 P 1 378 P 1 755 P SYNJ2
212829_at 1 P 1 501 P 1 689 P
212845_at 23034 1 P 1 576 P 1 551 P SAMD4
212848_s_at 84909 1 A 2 385 P 2 786 P C9orf3
212859_x_at 1 P 1 746 P 2 152 P MT2A
212884_x_at 348 1 P 1242 P 1 771 P APOE
212923_s_at 1 P 1 451 P 1 617 P C6orfl 45
212944_at 1 P 1 201 P 2 249 P MRPS6
212971_at 833 1 P 0 567 P 0 575 P CARS
212980_at 23021 1 P 0 627 P,A 0 663 PjA AHSA2
212990_at 8867 1 P 1 627 P 1 470 P SYNJ1
213030_s_at 5362 1 P 0 474 P 0 501 P PLXNA2
213069_at 1 M A 1 297 P,A 1 624 P HEG
213096_at 9911 1 A 1 397 P,A 1 556 P,M HUCEP11
213107_at 23043 1 P 1 449 P 1 907 P TNIK
213115_at 115201 1 P 1 718 P 1 659 P COL4A6
213118_at 23074 1 P 1 559 P 1 350 P KIAA070I
21313 5_at 1 P 1 653 P 2 296 P TIAM1
213164_at 1 P 1 183 P 2 589 P MRPS6
213167_s_at 1 P,A 1 111 P 1 715 P MRPS6
213191_at 148022 1 P,M,A 1 583 P 1 704 P TRIF
213194_at 6091 1 P 1 514 P 1 827 P ROBOl
213199_at 26005 1 P,M 1 333 P 1 579 P DKFZP586P0123
213220_at 27250 1 P 0 657 P 0 652 P LOC92482
213258_at 1 P 0 612 P 0 846 P,M TFPI
213274_s_at 1508 1 P 1 152 P 2 165 P CTSB
213275_x_at 1508 1 P 1 096 P 2 138 P CTSB
213281_at 3725 1 P 2 050 P 3 041 P JUN
213283_s_at 6297 1 P 0 603 P 0 768 P SALL2
XX
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213313 at 23637 1 P 0.647 P 0.758 P GPR21
213338 at 25907 1 A 1.660 P 1.726 P RISI
213361 at 23424 1 P 1.263 P 1.558 P TDRD7
213368 x at 8541 1 P.A 1.530 P 1.350 P PPF1A3
213373 s at 841 1 P 0.728 P 0.651 P CASP8
213411 at 1 P 0.536 M.A 0.617 P A ADAM22
213427 at 10799 1 P 1.669 P 1.374 P RPP40
213438 at 1 P 0.609 P 1.038 P
213449 at 10940 1 P 1.453 P 1.676 P.M.A POPI
213469 at 1 P 1.283 P 1.604 P F U 12377
213506 at 2150 1 A 13.406 P.M.A 28.093 P F2RLI
213558 at 27445 1 P 2.389 P 2.403 P PCLO
213568 at 116039 1 P 1.810 P 1.926 P OSR2
213572 s at 1992 1 P.A 1.964 P 2.107 P SERPINB1
213591 at 1 P 0.572 P 0.606 P AI.DH7AI
213618 at 116984 1 P 1.675 P 1.695 P CENTD1
213622 at 1298 1 P 1.566 P 1.394 P COL9A2
213629 x at 1 P 1.950 P 1.916 P MTIF
213650 at 23015 1 P 0.604 P 0.660 P GOLGIN-67
213671 s at 4141 1 P 0.478 P 0.526 P MARS
213672 at 4141 1 P.A 0.828 P.A 0.636 P.A MARS
213675 at 1 P.A 1.230 P 1.675 P
213698 at 1 P 0.629 P 0.773 P MGC14276
213712 at 1 M.A 1.294 P.A 1.894 P CTNNAL1
213716 s at 6398 1 M.A 3.568 P 3.135 P SECTM1
213721 at 6657 1 P 0.528 P 0.543 P SOX2
213722 at 6657 1 P.M 0.604 A 0.529 A SOX 2
213741 s at 3836 1 P 1.609 P 1.536 P KPNAI
213764 s at 1 P 0.769 P 1.749 P MFAP5
213765 at 1 P 0.941 P 1.879 P MFAP5
213793 s at 9456 1 P 1.893 P 2.020 P HOMER 1
213804 at 1 P 0.627 M.A 0.641 P.M.A INPP5B
213832 at 1 P 1.592 P 1.948 P
213859 x at 8467 1 P 1.576 P 1.514 P SMARCA5
213899 at 10988 1 P 1.548 P 1.359 P METAP2
213906 at 4603 1 P 1.962 P 2.273 P MYBL1
213924 at 65258 1 P 0.649 P 0.847 P MPPEI
213926 s at 1 P 1.591 P 1.480 P HRB
213931 at 3398 1 M.A 8.131 P 2.690 P.A ID2
213956 at 9857 1 P 1.274 P 1.537 P CAP350
213984 at 23244 1 P 1.526 P 1.120 P KIAA0648
213988 s at 6303 1 P.A 1.661 P.M.A 2.970 P SAT
2139% at 29799 I P 0.356 P 0.487 P YPEL1
213998 s at 10521 1 P 0.513 P 0.735 P DDX17
214022 s at 5805 1 P 1.113 P 1.831 P IFITMI
214023 x at 7280 1 P 1.816 P 1.784 P MGC8685
214030 at 131544 1 P 1.311 P 1.529 P MINA
214053 at 1 P 0.521 P 0.641 P
214071 at 65258 1 P 0.594 P 0.726 P GNAL.
214077 x at 4213 1 P 0.646 P 0.722 P MEIS4
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214079 at 1 P,M,A 11 801 P 8 179 P DHRS2
214091 s at 2878 1 P 3 385 P 3 445 P GPX3
214097 at 6227 1 P 1 463 P 1 702 P RPS21
214155 s at 113251 1 P 1 844 P 1 271 P LOCI 13251
214175 x at 8572 1 A 1 411 P,A 1 823 P,M PDLIM4
214176_s_at 57326 1 P,A 0 629 PjA 0 934 P,A PBXIP1
214196 s at 1200 1 P 0 655 P 0 818 P CLN2
214212 x at 10979 1 P 1 405 P 1 526 P PLEKHC1
214247_s_at 10530 1 M,A 2019 P 3 501 P DKK3
214368 at 10235 1 M,A 1 491 M,A 2 067 P,A RASGRP2
214414_x_at 3039 1 A 2 589 P 2 073 P,M,A HBA2
214437 s at 6472 1 P 0 694 P 0 660 P SHMT2
214505 s at 2273 1 P 1 370 P 2 323 P FHL1
214578 s at 6093 1 P 1 552 P 1 466 P ROCK1
214657 s at 1 P 0510 P,A 0 739 P,A
214690_at 9014 1 P 0 649 P 0 834 P TAF1B
214696_at 84981 1 P,A 1 945 P 1 641 P MGC 14376
214697_s_at 9991 1 P 1 733 P 1 499 P RODI
214722 at 1 P 1 168 P 1 758 P LOC376745
214752 x at 2316 1 P 1 315 P 1 524 P FLNA
214764 at 1 P,A 0 594 P,A 0 784 P,A KIAA0507
214784_x_at 23214 1 P 1 589 P 1 715 P X P06
214909_s_at 23564 1 P 1 500 P 1 267 P DDAH2
214924_s_at 22906 1 P 1 243 P 1 712 P OIPIO6
214930_at 26050 1 P 1 506 P 1 615 P SLITRK5
214954_at 26032 1 P 2 460 P 2 485 P KIAA0527
215014_at 1 A 3 565 P 5 117 P
215016_x_at 667 1 P 1 415 P 1 993 P BPAG1
215047_at 25893 1 P 1 553 P 1 332 P DKFZp434C091
21513 6_s_at 11340 1 P 0 647 P 0 702 P EXOSC8
215222_x_at 23499 1 P 1 272 P 1 528 P MACF1
215313_x_at 3105 1 P 1 041 P 1 550 P HLA-A
215446_s_at 114990 1 P,M A 1 575 P 1 510 P LOX
215485_s_at 3383 1 P>A 1 287 P 1 814 P ICAM1
215489_x_at 9454 1 P 1 539 P 2 194 P HOMER3
215495_s_at 23034 1 P,A 2 971 P 2 475 P SAMD4
215498_s_at 5606 1 P 1 415 P 1 566 P MAP2K3
215499_at 5606 1 P 1 406 P 1 788 P MAP2K3
215506_s_at 9077 1 P,A 1 211 P,M,A 1 670 P ARHI, NOEY2
215629_s_at 79469 1 P 1 822 P 1 288 P BCMSUNL
215643_at 1 P 0 491 p 0 541 P SEMA3D
215684_s_at 84164 1 P 1 514 p 1 603 P ASClplOO
215695_s_at 8908 1 P 1 396 P,M 1 571 P,A GYG2
215706_x_at 7791 1 P 2 157 P 2 230 P ZYX
215719_x_at 355 1 P 1 784 P,A 2 585 P TNFRSF6
215780_s_at 1 P 0 702 P 0 633 P
215783_s_at 1 P 1 356 P 1 774 P ALPL
21604I_x_at 2896 1 P 0 660 P 0911 P GRN
216060_s_at 23002 1 P A 1 451 P 1 591 P DAAM1
216061_x_at 5155 1 P»A 1 583 P 1 763 P PDGFB
XXII
A ffym etm
Id
Day 0 Day 3 Day 7
Common Namel.ocusl.ink
Normalized Flags Normalized Flags Normalized Flags
216064 s at 175 1 P 0.550 P 0.623 P AGA
216230 x at 6609 1 P,A 1.850 P 1.693 P SMPD1
216231 s at 567 1 P 1.334 P 1.683 P B2M
216247 at 6224 1 P 0.578 P 0.724 P RPS20
216252 x at 355 1 A 1.664 P.A 1.814 P.A TNFRSF6
216264 s at 3913 1 P 0.523 P 0.737 P LAMB2
216268 s at 182 1 P 0.614 P 0.649 P JAGI
216338 s at 25844 1 P 0.648 P 0.790 P KLIP!
216379 x at 934 1 P 2.582 P 3.826 P NaGLTl
216620 s at 9639 1 P 1.237 P 1.552 P ARHGEF10
216804 s at 1 P 1.879 P 1.932 P LIM
216870 x at 8847 I P 1.869 P 1.430 P DLEU2
216975 x at 4861 1 A 2.074 P.M 1.853 P.M.A NPAS1
216983 s at 1 P.A 0.656 P.A 0.705 P.A ZNF224
217028 at 7852 1 A 2.416 P 2.644 P.A CXCR4
217122 s at 9906 1 P 0.593 P 0.750 P MMP23B
217124 at 23288 1 P 1.566 P 1.029 P KIAAI023
217165 x at 1 A 1.862 P 1.965 P MTIF
217168 s at 9709 1 P 0.629 P 0.649 P HERPUDI
217234 s at 7430 1 P 1.425 P 1.547 P VIL2
217270 s at 1 P.A 0.648 P.A 0.701 M.A
217289 s at 2542 1 P 0.534 P 0.590 P G6PC
217383 at 1 P.A 1.379 P.A 1.548 P PGKI
217427 s at 7290 1 P 0.651 P 0.858 P HIRA
217436 x at I P 1.076 P 1.678 P HLA-J
217456 x at 3133 1 P 1.218 P 1.624 P HLA-E
217478 s at 3108 1 P 1.367 P 1.611 P HLA-DMA
217494 s at 11191 1 A 1.501 P.A 1.255 P.A PTENPI
217678_at 1 P 0.521 P 0.666 P SLC7A11
217682 at 1 P 1.565 P 1.419 P PROOI49
217728 at 6277 1 A 2.135 P 5.558 P S100A6
217733 s at 9168 1 P 1.387 P 1.675 P TMSBIO
217744 s at 64065 1 P 1.460 P 1.738 P PERP
217755 at 51155 1 P 1.683 P 1.535 P HN1
217761 at 55256 1 P 1.741 P 1.408 P SIPL
217792 at 27131 1 P 0.640 P 0.879 P SNX5
217809_at 28969 1 P 1.530 P 1.731 P BZW2
217835 x at 55969 1 P 1.597 P 1.412 P C20orf24
217841 s at 51400 1 P 1.671 P 1.978 P PME-I
217853 at 64759 1 A 1.601 P 3.073 P TENSI
217867 x at 25825 1 P 0.625 P 0.684 P BACE2
217890 s at 55742 1 A 2.583 P 2.377 P PARVA
217892 s at 51474 1 P 1.791 P 2.131 P EPLIN
217897 at 53826 1 P.A 2.284 P 3.047 P FXYD6
217904 s at 23621 1 P 1.610 P 1.824 P BACE1
217915 s at 51187 1 P 0.653 P 0.659 P C15orfl5
217923 at 23578 1 P 1.517 P 1.418 P PEF
217924 at 64771 1 P 1.512 P 1.592 P C6orfl06
217977 at 51734 1 P 1.540 P 1.326 P SEPX1
217985 s at 11177 1 P 1.943 P 1.717 P BAZ1A
x x i i i
Aflymetrix
Id
DavO Dav 3 Day 7
Common Namel,ocusLink
Normalized Flags Normalized Flags Normalized Flags
217986 s at 11177 1 P 1.718 P 1.513 P BAZIA
217989 at 51170 1 P 0.633 P 0.705 P DHRS8
217995 at 58472 1 A 1.242 A 1.761 P SQRDL
2179% at 22822 1 P 2.021 P 2.062 P PHLDAI
217997 at 22822 1 P 1.856 P 1.792 P PHLDA1
218012 at 64061 1 P 1.544 P 1.413 P SE20-4
218022 at 51231 1 P 0.624 P.A 0.760 P VRK3
218029 at 79567 1 A 1.501 P.M.A 1.543 P.A F U  13725
218035 s at 54502 1 A 1.961 P.A 3.047 P FU20273
218060 s at 7%50 1 P.A 1.581 P 1.536 P F U  13154
218076 s at 55114 1 P 1.404 P 1.517 P ARHGAP17
218091 at 3267 1 P 1.426 P 1.539 P HRB
218092 s at 3267 I P 1.642 P 1.4% P HRB
218113 at 23670 1 A 1.791 P 1.937 P.A TMEM2
218129 s at 4801 1 P 1.526 P 1.462 P NFYB
218145 at 57761 1 P 0.310 P 0.290 P TR1B3
218181 s al 54912 1 P 1.464 P 1.565 P MAP4K4
218199 s at 65083 1 P.A 1.833 P 1.962 P N0L6
218217 at 59342 1 P 0.591 P 0.698 P SCPEPI
218273 s at 54704 1 P 1.236 P 1.661 P PPM2C
218284 at 25856 1 P 1.203 P 1.640 P DKFZP586N072I
218298 s at 80017 1 P 0.551 P.A 0.769 P C14orfl 59
218380 al 60368 1 P 2.194 P 2.337 P NALP1
218400 at 4940 1 P 1.212 P 1.703 P OAS3
218417 s at 55652 1 P.M.A 1.661 P 1.811 P F U 20489
218526 s at 29098 1 P 0.633 P 0.798 P RANGNRF
218532 s at 54463 1 A 1.570 P.M 1.456 P.A FU20I52
218543 s at 64761 1 P 1.179 P 1.679 P ZC3HDCI
218574 s at 29995 1 P 1.330 P 1.778 P I.MCDI
218591 s at 79954 1 P.A 1.522 P.A 1.324 P.A F U  14075
218611 at 51278 1 P 1.6% P 2.128 P IER5
218625 at 51299 1 P 2.877 P 2.1% P NRNI
218642_s_al 79145 1 P.M 2.139 P 2.043 P CHCHD7
218691 s at 8572 1 A 1.968 P.A 2.322 P.M.A PDLIM4
218693 at 23555 ! A 1.344 P.A 2.011 P.A NET-7
218706 s at 65983 1 P 1.210 P 1.649 P NS3TP2
218723 s at 28984 1 P 0.558 P 0.677 P RGC32
218736 s at 54873 1 P 0.645 P 0.629 P.A PALMD
218764 at 5583 1 A 1.927 P.A 1.891 M.A PRKCH
218773_s_at 22921 1 P 0.657 P 0.828 P MSRB
218793 s at 6322 1 P 1.490 P 1.512 P SCMLI
218826_at 54733 1 P 1.614 P 1.679 P SLC35F2
218848 at 79228 1 P 0.608 P 0.713 P MGC2655
218849 s at 10848 1 P 1.692 P 1.601 P RAI
218880 al 2355 1 P 1.436 P 1.660 P F0SL2
218885 s at 79695 1 P 0.542 P 0.583 P GALNT12
218915 at 51219 1 P 1.485 P 1 697 P NF2
218951 s at 55344 1 P 0.654 P 0.666 P F U I 1323
218961 s al 11284 1 P 0.645 P 0.765 P PNKP
218974 at 55084 1 P 1.503 P 1.680 P FU10I59
x x i v
Affymetrix
Id
LocusLink
Day 0 Day 3 Day 7
Common Name
Normalized Flags Normalized Flags Normalized Flags
218986 s at 55601 1 M,A 1 277 P,M 2 224 P FLJ20035
218997_at 64425 1 P 1 505 P 1 467 P PAF53
219014_at 51316 1 P 1 583 P 2 032 P PLAC8
219026 s at 9462 1 P 1 571 P I 747 P RASAL2
219039 at 54910 1 P,A 0 632 M,A 0 722 P,M,A SEMA4C
219073_s_at 114884 1 P,A 1 510 P 2 049 P OSBPLIO
219083 at 55164 1 A 1 597 P 1 594 P,A FLJ10539
219094_at 29067 1 P,A 1618 P 1 355 P HSPC056
219119_at 51691 1 P 0 713 P 0 636 P LSM8
219152 at 50512 1 P,M 0 454 A 0 550 P,M,A PODLX2
219158_s_at 80155 1 P 1492 P 1 576 P TBDN100 i
219170_at 79187 1 P 0 578 P,A 0 658 P,A FSDl
219174_at 80173 1 P 0 594 P 0 713 P CCDC2
219188_s_at 28992 1 P 0 463 P 0 647 P LRP16
219209 at 64135 1 A 1 765 P,A 4 172 P MDA5
21921 l_at 11274 1 P 1 252 P 1 676 P USP18
219250_s_at 23767 1 A 1 127 P,M 1 629 P,M FLRT3
21925 8_at 54962 1 P 1 566 P 1 491 P FLJ20516
219263_at 79589 1 P,A 1921 P 2 275 P RNF128
219270_at 79094 1 P 0 252 A 0 230 A MGC4504
219306_at 56992 1 P 0 660 P 0 709 P KNSL7
21932 l_at 64398 1 P 1 548 P 1 351 P MPP5
219326_s_at 10678 1 P 0 591 P 0 568 P B3GNT1
219352 at 55008 1 M,A 1 488 P 1 786 P FLJ20637
219353_at 54835 1 P 0 639 P 0 748 P NHLRC2
219361_s_at 64782 1 A 1 513 P,M 1 505 P,M,A FLJ12484
219366_at 57099 1 P,A 1 610 P 1 472 P AVEN
219410_at 55076 1 P 1 373 P 1 540 P FLJ10134
219427_at 79633 1 P 1 387 P 1 585 P FATJ
219477_s_at 55901 1 M,A 1 240 P,A 1 855 P,M THSD1,
219493 at 79801 1 P 1 534 P 1 333 P SHCBP1
219500_at 23529 1 P 1 286 P 1 525 P CLC, BSF3
219522_at 24147 1 P,A 1 277 P 1 524 P FJX1
219557_s_at 56675 1 P 1 600 P 1 677 P NR1P3
219612_s_at 2266 1 A 1 585 P,M 2 257 P FGG
219628_at 64393 1 P 1 604 P 1 524 P WIG1
219634_at 50515 1 P 1 300 P 1 508 P CHST11
219690_at 79713 1 P 1 684 P 1 539 P FLJ22573
219692_at 79412 1 P 1 643 P 1 554 P KREMEN2
219700_at 57125 1 P 0 682 P 0617 P PLXDC1
219705_at 79832 1 P 1 560 P 1 181 P FLJ21924
219763_at 57706 1 P 1340 P 1 506 P KIAA1608
219825_at 56603 1 P,A 2 205 P 1 888 P CYP26B1
219869_s_at 64116 1 P,A 1 882 P 1 861 P SLC39A8
219895_at 55026 1 A 1631 P,A 2 125 P FLJ20716
219926_at 64208 1 P 0 654 P 0 733 P POPDC3
219938_s_at 9050 1 PA 2 250 P 2 363 P PSTPIP2
219944_at 79745 1 P,A 1 064 A 1 730 P FLJ21069
219992_at 6866 1 P,M,A 1 436 P 1 770 P TAC3
220033_at 1 P 1 0 634 P 0 700 P
XXV
Affymetrix
Id
LocusLmk
Day 0 '  Day 3 Day 7
Common Name
Normalized Flags Normalized Flags Normalized Flags
220038 at 23678 1 P 1384 P 1 502 P SGKL
220085 at 3070 1 P 1 222 P 1 627 P HELLS
220092 s at 84168 1 P,A 2 559 P 3 188 P ANTXR1
220104 at 56829 1 M,A 1346 P,M,A 1 672 P,A ZC3HAV1
220134 x at 55194 1 P 1 579 P 1 518 P FLJ10647
220145 at 79884 1 P,M 0 694 P,A 0 656 P FLJ21159
220217 x at 64663 1 A 1453 P>A 2 299 P SPANXC
220321 s at 79635 1 P 0 646 P 0 772 P FLJ13646
220327 at 51159 1 P 0 646 P 0 681 P FLJ38507
220358 at 55509 1 P,A 1 892 P 1 994 P SNFT
220393 at 51557 1 P 0 629 P 0 901 P GLULD1
220520 s at 54830 1 M,A 1 540 P 1 336 P FLJ20130
220534 at 79097 1 P,A 1850 P 1 799 P TRIM48
220551 at 57084 1 P 0518 P 0 437 P SLC17A6
220617 s at 55205 1 P 0 628 P 0 745 P ZNF532
220661 s at 55657 1 P 0 623 P 0 789 P FLJ20531
220668 s at 1789 1 P 1 574 P 1389 P DNMT3B
220684_at 30009 1 P,A 1 518 P 1257 P TBX21
220703 at 55853 1 P,A 1 657 P 1 308 P,A ClOorfl 10
220738 s at 27330 1 A 1 661 M,A 1 844 M,A RPS6KA6
220794 at 64388 1 P 0 598 P,M 0 664 P,A PRDC
220800_s_at 29766 1 P,M 1 521 P 1 345 P TMOD3
220892_s_at 29968 1 P 0 367 P 0 334 P PS ATI
220922_s_at 30014 1 A 1 103 A 1 739 P SPANXA1
220954_s_at 29990 1 P 0 635 P 0 772 P PILRB
220987_s_at 81788 1 P 1 810 P 1953 P SNARK
221009_s_at 51129 1 P,A 1890 P 2 686 P ANGPTL4
22101 l„s_at 81606 1 P 4211 P 9 513 P LBH
221039_s_at 50807 1 P 1416 P 1 545 P DDEF1
221059_s_at 4166 1 P 2 224 P 2 377 P CHST6
221078_s_at 55704 1 P 1 525 P 1 393 P FLJ10392
221123_x_at 55893 1 P 0 627 A 0 858 P,A ZNF395
221195_at 51136 1 P 0 657 P,A 0 784 A LOC51136
221213_s_at 54816 1 P,A 0 642 P,A 0 873 P,M,A FLJ20086
221234_s_at 60468 1 A 1 650 P 1366 P A BACH2
221261_x_at 81557 1 P 0 627 P 0613 P MAGED4
221484_at 9334 1 P 1 320 P 1 522 P B4GALT5
221489_s_at 81848 1 P 1 595 P 1675 P SPRY4
221510_s_at 2744 1 P 1602 P 1 956 P GLS
221539_at 1978 1 P 0 600 P 0 600 P EIF4EBP1
221561_at 6646 1 P 1 525 P 1 319 P SOAT1
221645_s_at 55769 1 P 0 640 P 0 838 P ZNF83
221657_s_at 140459 1 P»A 1 585 P 1 455 P ASB6
221664_s_at 50848 1 P 1 069 P 1 542 P F11R
221676_s_at 23603 1 P 1 673 P 1 541 P CORO 1C
221710_x_at 55194 1 P 1 569 P 1 313 P FLJ 10647
221718_s_at 11214 1 P 1 582 P 2 189 P AKAP13
221760_at 1 A 1 997 P 2 902 P MAN1A1
221766_s_at 55603 1 P,M,A 1 621 P 1 962 P C6orf37
221779_at 85377 1 P 1 529 P 1 594 P MIRAB13
XXVI
Affymetrix
Id
Locus Link
Day 0 Day 3 Day 7
Common Name
Normalized Flags Normalized Flags Normalized Flags
221810 at 1 P,A 1 857 P 1 769 P
22183 l_at 1 A 1 504 M A 1 482 P A LUZP1
221841_s_at 1 A 1 690 P,M 1 837 P KLF4
221865_at 203197 1 P 0713 P 0 637 P C9orf91
221875 x at 3134 1 P 1 219 P 2 057 P HLA-F
221892_at 1 P 0 564 P,A 0 705 P H6PD
221893 s at 90956 1 P 1 511 P 1 333 P ADCK2
221899_at 10443 1 P 0 624 P 0 792 P,A PFAAP5
221911 at 1 P 0 647 P 1 097 P ETV1
22195 l_at 1 P 0 537 P,A 0 652 P LOC283232
221986_s_at 54800 1 P 0 643 P,A 0 627 P,M DRE1
221998 s at 51231 1 P 0 521 P 0 663 P LOC51231
222024_s_at 11214 1 P 1 368 P 1 754 P AKAP13
222028_at 7596 1 P 1948 P 1 303 P ZNF45
222043 at 1191 1 P 1 660 P 2 393 P CLU
222074 at 7389 1 P,A 2 213 P 1 840 P,A UROD
222108 at 1 P 1 990 P 2 402 P
222125_s_at 54681 1 P 0 591 P 0 673 P PH-4
222126_at 3668 1 M,A 1 506 P 1 446 P HRBL
222154_s_at 26010 1 P 1496 P 1 727 P DNAPTP6
222204_s_at 54700 1 P 1 559 P 1 584 P RRN3
222258_s_at 23677 1 P 1 613 P 1 953 P SH3BP4
222305_at 1 P>A 1 747 P 1 573 P,M HK2
22235 l_at 5519 1 A 1 765 P,A 1 680 P,A PPP2R1B
266_s_at 934 1 P,A 3 273 P 4 303 P CD24
32042_at 10495 1 P 1 298 P 1 572 P COVA1
33322_i_at 2810 1 P 1 427 P 1 969 P SFN
33323_r_at 2810 1 P 1 536 P 2 165 P SFN
33767_at 1 P 1 548 P 1 327 P NEFH
34697_at 4040 1 P 0 625 P 0 688 P LRP6
36552 at 26005 1 P 1481 P 1 630 P DKFZP586P0123
38037_at 1839 1 P,A 2 201 P 1 886 P DTR
39966 at 10675 1 P 0 568 P 0 564 P CSPG5
40093_at 4059 1 P 1 153 P 2 270 P LU,
41469_at 1 A 1 227 P,A 1 592 P PI3
45297_at 115273 1 A 1 467 P 1 572 P EHD2
48106_at 55652 1 P 1 452 P 1 534 P FLJ20489
49077_at 51400 1 P 1 410 P 1 606 P PME-1
54970_at 83637 1 P 1 721 P 1 814 P DKFZp761I2123
5508 l_at 85377 1 P 1 507 P 1 423 P MIRAB13
57540_at 64080 1 P 1 737 P 1 825 P RBKS
59697_at 1 P 1 734 P 1 701 P
61732_r_at 80173 1 P 0 602 P 0 734 P,A CCDC2
64432_at 51275 1 P 0 626 P 0712 P FLJ39616
65630_at 1 P 0 641 P 0 760 P LOC283232
XXV11
Affymetrix Id
Day 0 Day 3 Day 7 Common
NameNormalised F,aS Normalised FIafi Normalised Flag
AFFX-HUMISGF3A/M97935 3 at 1 P 1 805 P 2 543 P STATI
AFFX-HUMISGF3A/M97935 5 at 1 P 1 610 P 2 380 P STATI
AFFX-HUMISGF3A/M97935 MA at 1 P,M 1 726 P 2 600 P STATI
AFFX-HUMISGF3A/M97935 MB at 1 P 1 796 P 2 751 P STATI
XXV111
7 2 Appendix B -  C luster 5 BrdU Exp. 3
List o f  genes contained in Cluster 5 o f  the BrdU Exp 3 D N A  microarray experiment
x x i x
Cluster 5 -  B rdli Exp. 3
Common Name AfTymctrix Id Common Name AfTymctrix Id
SMARCD 204099_at FU22028 219802 at
FAMIIB 219253.« LOC56901 214096_s_at
AUH 205052_at C20ort3l 2l8282_at
TSFM 212656_a* DECR2 2l9664_s_at
FASTK 210975 x at PIGO 209998_at
ILVBI.; AH AS 202993JU QARS 2l7846_at
ZNF580 220748_s_at CGI-143 2l9345_at
WARP 2l873l_s_at C6orfl08 204238_s_at
FU20758 217895 al MOSPD3 219070_s_at
TRIAD3 2l8426_s_at G6PC3 22l759_at
FIJI 1822 2l5090_xja STATI 209969 *_at
NAGA 202944_at dJ222EI3 1 2l7284_x_at
EBP; CPX 202735 at MAPBPIP 218291 _ai
KIAA0974 213896_x_at MYSTI 221820_s_at
DLGAPI 2l0750_s.ai SGSII; HSS; 35626_at
PPGB 20066 l_at INSIGI; CL-6 20l627_s_at
ACP2 202767_at PTPNI8 203555_at
LOC55974 2l9125_s_at ATP5D 213041_s_at
PKiQ; GPU 204l44_s_*t GGCX 214006_s_at
RABL2A 220500 $ at ATF5; ATFX 2W999_s_at
SLC25AII 207088_s_at LLGL2; HGL 2037l3_l_at
MBTPSI 2l7543_s_at DHPS 202802 _at
FIJI 0496 221934 s at LRP8 208433_s_at
F1J35827 2l2969_x_at FASTK 214114_x_at
RFXANK 202758_s_at KIAA1I64 37802_r_al
NAGA 202943 s at TAGLN 56256_at
INPP5A 203006_at LEPREL2 204854_al
DKFZp762CI86 9l703_at SLC25A1 2l0010_*_at
FIJI 2681 46142 at PCCA 203860_at
IXKT5I337 218500 at CI9orf27 22l267_s_at
SUCLG2 2l4835_s_at NFIB; NFIB2 211467_s_at
PMMI 203467_at FAIM; FAIMI 220643_S_at
DIIX9 2l2105_s_at MAPT 20640 l_s_at
AFFX-l.yjX.Hjrt AD-017 218146_al
NDUFS7 211752_s_at IJROS 20303 l_s_at
C3F 202793_at CPSFI 33l32_at
TGFB1 203085_$_at DEAFI; SPN 209407_s_at
DKFZP586BI62I 218688 al CORO IB 64486 at
II2AFX 2l2525_*_at PLEKHJ1 218290 al
irrATIP 206689_x_at CREM; KER 21017 l_s_at
LOLR 202067j_ a t MSRB; CBSI 218773_$_at
PIR 207469_$_at
MPG; AAG 203686_at
C6orfl08 39817_$_at
ACYP2 206833 s at
VPS28 218679 ( at
NASP 201970_s_at
CPSF4 206688_s_at
ACLY 2l0337_s_at
XXX
7 3 Appendix C -  Differentially Expressed Genes Identified in 5,2"-FdU DNA 
Microarray Experiment
List o f  differentially expressed genes identified from microarray analysis o f  5,2 -FdU  
microarray experiment Genes listed are sorted by A ffym etnx ID number
x x x i
AfTymctrix
Id
Day 0 Day 3 Day 7
Common NameLocusLink
Normalized Flags Normalized Flags Normalized Flags
1053 at 5982 1 P 1.509 P 1.140 P RFC2
1598 j  al 10609 1 P 0.751 P 0.644 P GAS6; AXSF
177 at 5337 1 P 0.711 P 0.646 P PLDI
200020 at 23435 1 P 1.520 P 1.569 P TARDBP
200023 s at 8665 1 P 0.873 P 0.609 P clF3-p47
200036 s at 4736 1 P 0.747 P 0.612 P RPLIOA
200050 at 7705 1 P 1.556 P 1.569 P ZNFI46; 0ZF
200054 at 8882 1 P 1.937 P 1.743 P ZNF259; ZPR1
200079 s at 3735 1 P 1.519 P 1.500 P KARS
200090 at 2339 1 P 1.593 P 1.518 P FNTA
200597 at 1 P 1.209 P 1.509 P EIF3SI0
200609 s at 9948 1 P 1.689 P 1.526 P WDR1; NORI-1
200615 s at 163 1 P 1.630 P 1.567 P AP2BI
200635 s at 5792 1 P 0.660 P 0.822 P PTPRF
200646 s at 4924 1 P 0.577 P 0.511 P NUCB1
200661 at 5476 1 P 0.723 P 0.507 P PPGB; GSL
200670 at 7494 1 P 0.630 P 0.585 P XBP1; XBP2
200678 x at 28% 1 P 0.631 P 0.778 P GRN; PEPI
200685 at 9295 1 P 1.205 P 1.552 P SFRS11
200697 at 3098 1 P 1.4% P 1.577 P HK1; HK1
200715 x at 23521 1 P 0.450 P 0.349 P RPL13A
200719 at 6500 1 P 2.144 P 2.713 P SKP1A
200730 s at 7803 1 P 1.968 P 1.484 P PTP4A1
200731 s at 7803 1 P 1.632 P 1.389 P PTP4A1
200732 s at 7803 1 P 1.601 P 1.372 P PTP4A1
200733 s at 7803 1 P 1.698 1' 1.365 P PTP4A1; HH72
200742 s at 1200 1 P 0.449 P 0.409 P CLN2
200743 s at 1200 1 P 0.482 P 0.415 P CLN2; TPPI
200747 s at 4926 1 P 0.579 P 0.607 P NUMAI
200762 at 1808 1 P 1.026 P 1.698 P DPYSL2
200779 at 468 1 P 0.591 P 0.602 P ATF4; CREB2;
200786 at 5695 1 P 1.509 P 1.170 P PSMB7; Z
200787 s at 8682 1 P 1.621 P 1.952 P PEA 15; PED
200788 s at 8682 1 P 1.744 P 1.999 P PEA 15; PED
200789 ut 1891 1 P 0.625 P 0.594 P ECHI; HPXEL
200790 at 4953 1 P 1.770 P 1.758 P 0DC1
200796 s  at 4170 1 P 0.623 P.A 0.581 P MCL1; TM;
200802 al 6301 I P 0.697 P 0.633 P SARS; SERS;
200808 s al 7791 1 P 1.756 P 1.469 P ZYX
200810 s at 1153 1 P 0.563 P 0.439 P CIRBP; CIRI»
200811 at 1153 1 P 0.545 P 0.402 P C1RBP; CIRP
200813 s at 5048 1 P 1.168 P 1.517 P PAFAHIB1
200814 at 5720 1 P 0.644 P 0.582 P PSME1; PA28A
200821 at 3920 1 P 1.176 P 1.511 P LAMP2
200833 s at 5908 1 P 1.522 P 1.555 P RAP1B
200841 s at 2058 1 P 0.592 P 0.468 P EPRS
200868_s_at 55905 1 P 1.541 P 1.429 P ZNF3I3
200872_at 6281 1 P 1.427 P 1.626 P SIOOAIO
200873 s at 10694 1 P 1.571 P 1.395 P CCT8; Cctq
200887_s_at 6772 1 P 1.329 P 2.005 P STATI
xxxii
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200897 s at 23022 1 P 1.562 P 1.976 P KIAA0992
200898 s al 10724 1 P 1.409 P 1.698 P MGEA5
200899 s at 10724 1 P 1.242 P 1.740 P MGEA5; MEA5
200907 s at 23022 1 P,A 1.473 P 1.615 P KIAA0992
200908 s at 6181 1 A 1.524 P.A 1.522 P.A RPLP2; RPP2
200911 s at 6867 1 P 1.594 P 1.585 P TACCI; Ga55
200916 at 8407 1 P 1.618 P 1.697 P TAGLN2
200917 s at 6734 1 P 0.744 P 0.573 P SRPR
200922 at 10945 1 P 0.735 P 0.608 P KDELR1; ERD2
200962 at 1 P 1.256 P 1.803 P RPL3I
200976 s at 8887 1 P 1.309 P 1.504 P TAXIBPI;
200977 s at 8887 1 P 1.371 P 1.534 P TAXIBP1; T6BP
200979 at 1 P 1.492 P 1.592 P
200988 s at 10197 1 P 2.141 P 2.318 P PSME3; K¡
200995 at 10527 1 P 1.360 P 1.559 P IP07
201006 at 7001 1 P.A 0.865 P.A 0.603 A PRDX2; PRP
201013 s at 10606 I P 1.619 P 1.495 P PAICS
201014 s at 10606 1 P 1.768 P 1.524 P PA1CS; AIRC
201020 at 7533 1 P 1.508 P 1.392 P YWHAH
201022 s at 11034 1 P 1.433 P 1.528 P DSTN; ADF
201024 x at 9669 1 P 1.516 P 1.215 P EIF5B; IF2
201027 s at 9669 1 P 1.727 P 1.482 P E1F5B; IF2
201041 s at 1843 1 P 1.469 P 1.598 P DUSPI
201042 at 7052 1 P.A 3.942 P 4.238 P TGM2
201043 s at 8125 1 P 0.718 P 0.603 P ANP32A
201046 s at 5886 1 P 1.535 P 1.313 P RAD23A
201050 at 23646 1 P 0.686 P 0.644 P PLD3; HU-K4
201058 s at 10398 1 P 1.547 P 1.111 P MYL9; LC20
201060 x at 2040 1 P 1.364 P 1.672 P STOM
201061 s at 2040 1 P 1.207 P 1.636 P STOM; BND7
201065 s at 2969 1 P 0.678 P 0.625 P GTF2I; DIWS;
201093 x at 6389 1 P 0.859 P 0.609 P SDHA; FP
201097 s at 378 1 P 1.478 P 1.512 P ARF4
201099 at 1 P 1.527 P 1.544 P USP9X
201100 s at 8239 1 P 1.623 P 1.602 P USP9X; DFFRX
201102 s at 5211 1 P 1.067 P 0.660 P PFKL; PFK-B
201123 s at 1984 1 P 0.692 P.A 0.447 A EIF5A; EIF-5A
201139 s at 6741 1 P 1.502 P 1.497 P SSB
201142 at 1965 1 P 1.789 P 1.637 P EIF2SI
201143 s at 1965 1 P 1.616 P 1.666 P EIF-2alpha
201144 s at 1965 1 P 1.783 P 1.655 P EIF2SI; EIF-2
201145 at 10456 1 P 0.724 P 0.638 P HAX1
201153 s at 4154 1 P 1.226 P 1.559 P MBNLI; EXP
201167 x at 396 1 P 0.978 P 0.585 P ARHGD1A
201193 at 3417 1 P 0.659 P 0.516 P IDH1; IDP; PICD
201195 s at 8140 1 P 0.641 P 0.520 P SLC7A5
201211 s at 1654 1 P 0.812 P 0.561 P DDX3X; UBX
201214 s at 5510 1 P 1.570 P 1.358 P PPPIR7
201216 at 10961 1 P 0.615 P 0.585 P C 12orl8
201219_at 1488 1 P 1.390 P 1.657 P CTBP2
x x x i i i
Affymetrix
Id
LocusLink
Day 0 Day 3 Day 7
Common Name
Normalized Flags Normalized Flags Normalized Flags
201247 at 6721 1 P 0 538 P 0 489 P SREBF2
201248 s at 6721 1 P 0 629 P 0 482 P SREBF2
201275 at 2224 1 P 0 680 P 0 502 P FDPS, FPS
201282 at 4967 1 P 1640 P 1 195 P OGDH, Elk
201284_s_at 327 1 P 0 667 P 0 325 P APEH
201295 s at 26118 1 P 0514 P,A 0515 P,M,A WSB1
201307 at 55752 1 P 1 465 P 1 598 p FLJ10849
201323_at 10969 1 P 1 550 P 1 336 p EBNA1BP2
201325_s_at 2012 1 P 1 668 P 1 592 p EMPI
201326_at 908 1 P 1 566 P 1 627 p CCT6A
201329_s_at 2114 1 A 1 529 P>A 1 558 P,A ETS2
201331 s at 6778 1 P 0 623 P 0 638 P STAT6
201337 s at 9341 1 P 0 854 P 0 590 P VAMP3, CEB
201344 at 7322 1 P 1417 P 1 916 P UBE2D2
201367 s at 678 1 p ,m ,a 0 798 P,A 0 568 A ZFP36L2
201370 s at 8452 1 P 1 380 P 1 640 P CUL3
201397_at 26227 1 P 0 479 P 0 443 P PHGDH
201401 s at 156 1 P 0 689 P,M 0 466 P,A ADRBK1
201416_at 1 P 1421 P 2110 P SOX4, EVI 16
201417_at 1 P 1 211 P 1 721 P SOX4, EVI16
201421 s at 79084 1 P 1 508 P 1 299 P MEP50
201425_at 217 1 P 0 501 P 0 408 P ALDH2
201432_at 847 1 P 0 593 P 0 484 P CAT
201436_at 1977 1 P 1 650 P 1 585 P EIF4E,
201446_s_at 7072 1 P 0 741 P 0 648 P TIA1
201454_s_at 9520 1 P 0 738 P 0 639 P NPEPPS
201460_at 9261 1 P 1 586 P 1 527 P MAPKAPK2
201464_x_at 3725 1 A 3 589 P 4 645 P JUN
201466_s_at 3725 1 A 3 794 P 5 536 P JUN, API
201475_x_at 4141 1 P 0 624 P 0 508 P MARS
201478_s_at 1736 1 P 1628 P 1 574 P DKC1
201479_at 1736 1 P 1 519 P 1 444 P DKC1,
201489_at 10105 1 P 1 616 P 1 101 P PPIF, CYP3
201498_at 7874 1 P 1 772 P 1 813 P USP7
201501_s_at 2926 1 P 1 434 P 1 682 P GRSF1
201502_s_at 4792 1 P 1 600 P 1 591 P NFKBIA
201516_at 6723 1 P 1 677 P 1249 P SRM
201534_s_at 5412 1 P 1 253 P 1 500 P UBL3
201535_at 5412 1 P 1 285 P 1 729 P UBL3
201536_at 1845 1 P 1 693 P 1 561 P DUSP3
201537_s_at 1845 1 P 2311 P 1 843 P DUSP3, VHR
201539_s_at 2273 1 P 1 160 P 1637 P FHLl, KYO-T
201540_at 2273 1 P 1354 P 1 943 P FHL1, KYO-T
201546_at 9320 1 P 1 506 P 1 436 P TRIP 12
201554_x_at 2992 1 P 1 569 P 1 422 P GYG
201559_s_at 25932 1 P 0 656 P 0 707 P CLIC4
201565_s_at 3398 1 P 4 103 P 3 504 P ID2, ID2A
201566_x_at 3398 1 P,M 5 836 P 4 596 P ID2, ID2A
201571_s_at 1635 1 P 1 547 P 1 451 P DCTD
201572_x_at 1635 1 P 1 588 P 1 626 P DCTD
XXXIV
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201576 s at 2720 1 P 0.664 P 0.515 P GLB1
201579 at 2195 1 P 1.465 P 1.648 P FAT; ME5;
201582 at 10483 1 P.M 1.718 P 1.377 P SEC23B
201587 s at 3654 1 P 1.505 P 1.527 P IRAKI; pcllc
201594 s at 9989 1 P 1.477 P 1.541 P PPP4RI
201595 s at 55854 1 P 1.513 P 1.380 P LEREPCM
201600 at 11331 1 P 0.905 P 0.653 P REA; BAP
201607 at I I 137 1 P 1.851 P 1.853 P PWP1
201608 s at I I 137 1 P 1.581 P 1.388 P PWP1;
201625 s at 3638 1 P 0.609 P 0.421 P INS1G1
201626 at 3638 1 P 0.657 P 0.468 P INSIGl
201627 s at 3638 1 P 0.708 P 0.468 P INSIGI
201629 s at 52 1 P 1.560 P 1.593 P ACPI
201630 s at 52 1 P 1.386 P 1.500 P ACPI
201632 at l% 7 1 P 1.671 P 1.516 P EIF-2Balpha
201639 s at 29894 1 P 0.913 P 0.617 P CPSF1
201642 at 3460 1 P 0.768 P 0.629 P IFNGR2; AF-I
201668 x at 4082 1 P.A 0.541 A 0.798 P.A MARCKS
201677 at 56941 1 P 1.469 P 1.622 P ELF3
201688 s at 7163 1 P 1.456 P 1.570 P TPD52
201689 s at 7163 1 P 1.609 P 1.669 P TPD52
201690 s at 7163 I P 1.541 P 1.672 P TPD52
201691 s at 7163 1 P 1.551 P 2.199 P TPD52; N8L
201704 at 955 1 P 0.917 P 0.601 A ENTPD6
201708 s at 8508 1 P 0.818 P 0.640 P N1PSNAPI
201709 s at 8508 1 P 0.773 P 0.632 P NIPSNAPI
201710 at 4605 1 P 1.765 P 1.248 P MYBL2; BMYB
201712 s at 5903 1 P 1.432 P 1.5% P RANBP2
201739 at 6446 1 P 3.163 P 4.549 P SGK; SGKI
201744 s at 4060 1 P 1.555 P 1.623 P EUM; LDC
201790 s at 1717 1 P 0.699 P 0.522 P DHCR7
201791 s at 1717 1 P 0.705 P 0.557 P DHCR7; SLOS
201794 s at 9887 1 P 1.6% P 1.500 P EST1C
2017%  s at 7407 1 P 0.711 P 0.524 P.A VARS2
201798 s at 26509 1 P.A 3.222 P 5.656 P FERIL3
201805 at 5571 1 P 0.702 P 0.545 P PRKAGI
201814 at 9779 1 P 1.247 P 1.552 P TBCID5
201816 s at 2631 1 P 0.879 P 0.532 P GBAS
201823 s at 9604 1 P 1.461 P 1.615 P RNF14
201824 at 9604 1 P 1.714 P 1.907 P RNF14
201830 s at 10276 1 P 1.378 P 1.517 P NETI
201865 x at 2908 1 P 1.507 P 1.598 P NR3C1
201872 s at 6059 1 P 1.763 P 1.551 P ABCE1
201873 s at 6059 I P 1.586 P 1.598 P ABCEI
201890 at 6241 1 P 1.591 P 1.475 P RRM2; R2
201896 s at 1 P 0.644 P 0.794 P
201900 s at 10327 1 P 0.608 P 0.522 P AKR1AI
201913 s at 80347 1 P 0.894 P 0.642 P COASY
201920 at 6574 1 P 1.742 P 1.362 P SLC20A1;
201937_s_at 23549 1 P.M 1.511 P 1.203 P DNPEP
XXXV
A ffvm ctm
Id
DavO Day 3 Day 7 Common Namelx)cusLink
Normalized Hags Normalized Flags Normalized Flags
201939 at 10769 1 P 1.986 P 1.431 P PLK2; SNK
201948 at 29889 1 P 1 967 P 1.598 P HUMAUANTIG
201951 at 214 1 P 1.484 P 2.712 P ALCAM; MEMD
201952 at 214 1 P 1.467 P 2.398 P ALCAM; MEMD
201959 s at 23077 1 P.A 1.600 P 1.665 P.M MYCBP2
201963 at 2180 1 P 1.532 P 1.505 P ACSLI
201966 at 4720 1 P 1.008 P 0.643 P NDUFS2
201970 s at 4678 1 P 0.829 P 0.638 P NASP
201985 at 9897 1 P 0.590 P 0.692 P KIAA01%
202014 at 23645 1 P 2.393 P 3.054 P PPPIR15A
202015 x at 10988 1 P.A 1.231 P.M.A 1.535 P.A METAP2; p67
202016 at 4232 1 P 0.704 P 0.651 P MEST; PEGI
202017 at 2052 1 P 1.456 P 1.742 P EPHX1 ; MEH
202030 at 10295 1 P 0.917 P 0.629 P BCKDK
202052 s at 26064 1 P 1.963 P 3.139 P RAI 14; RAI 13
202056 at 1 P 1.421 P 1.540 P KPNAI; RCH2
202059 s at 3836 1 P 1.511 P 1.429 P KPNAI; RCH2
202066 at 85(X) 1 P 1.351 P 1.511 P PPF1A1; L1PI
202067 s at 3949 1 P 0.764 P 0.527 P.A LDLR
202068 s at 3949 1 P 0.777 P 0.523 P LDLR; FH; FHC
202070 s at 3419 1 P 1.711 P 1.660 P 1DH3A
202071 at 6385 1 P 1.977 P 1.860 P SDC4; SYND4
202073 at 10133 1 P 1.301 P 2.089 P OPTN
202074 s at 10133 1 P 1.481 P 2.040 P OPTN; NRP
202076 at 329 1 P 1.569 P 1.711 P BIRC2; API 1 ;
202079 s at 22906 1 P 0.740 P.A 0.638 P OIP106
202083 s at 6397 1 P 1.728 P 1.632 P SEC 14L 1
202085 at 9414 1 P 1.400 P 1.758 P TJP2; Z02; XI04
202105 at 3476 1 P 0.713 P 0.620 P IGBPI; IBP1
202121 s at 27243 1 P 0.713 P 0.580 P BC-2
202129 s at 8780 1 P.M 1.971 P 2.200 P RI0K3
202130 at 8780 1 P 1.948 P 2.448 P RI0K3
202131 s at 8780 I P 2.061 P 2.389 P R10K3; SUDD
202135 s at 10120 1 P 0.868 P 0.623 P ACTRIB
202141 s at 10920 1 P 1.642 P 1.686 P COPS8
202142 at 10920 1 P 1.513 P 1.541 P C0PS8; C0P9
202146 at 3475 1 P 2.868 P 3.711 P IFRDI
202147 s at 3475 1 P 2.728 P 3.227 P IFRDI
202148 s at 5831 1 P 0.738 P 0.619 P PYCRI; P5C
202149 at 1 P 1.464 P 1.676 P dJ76112.1
202172 at 1 P 1.301 P 1.561 P ZNF161; DBI
202174 s at 5108 1 P 1.329 P 1.641 P PCM 1 ; PTC4
202180 s at 9961 1 P.A 0.642 P.M.A 0.529 A MVP; LRP
202181 at 9766 1 P 1.374 P 1.556 P K1AA0247
202188 at 9688 1 P 1.655 P 1.222 P NUP93
202193 at 3985 1 P 1.565 P 1.4% P LIMK2
202205 at 7408 1 P 0.720 P 0.593 P VASP
202209 at 27258 1 P 2.117 P 2.262 P LSM3; SMX4
202212 at 23481 1 P 1.679 P 1.406 P PESI
202218 s at 9415 1 P 0.522 P 0.431 P FADS2; D6D
xxxvi
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202240 at 5347 1 P 0 653 P 0 785 P PLK1, STPKI3
202241 at 10221 1 P 1 614 P 2 539 P TRIB1, C8FW
202245 at 4047 1 P 0 672 P 0 563 P LSS
202251 at 9129 1 P 1 459 P 1 552 P PRPF3, PRP3
202253 s at 1785 1 P 0 853 P 0 654 P,A DNM2, DYNII
202265 at 648 1 P 1 416 P 1 846 P B M ll, RNF51
202272 s at 23219 1 P 1 593 P 1 611 P FBX028
202279 at 9556 1 P 1 535 P 1 434 P C14orf2, MP68
202284 s at 1026 1 P 2 609 P 2 528 P CDKN1A, P21
202290 at 11333 1 P 0 657 P 0 499 P PDAP1, PAP
202307_s_at 5696 1 P 1286 P 1 510 P TAPI, APT1
202308 at 6720 1 P 0 455 P 0315 P,A SREBF1
202313 at 5520 1 P 1 649 P 1 658 P PPP2R2A
202328 s at 5310 1 P 0 646 P 0612 P PKD1, PBP
202329 at 1445 1 P 1 511 P 1 359 P CSK
202330 s at 7374 1 P 1 611 P 1 552 P UNG, DGU
202331 at 593 1 P 0 797 P 0 458 P BCKDHA
202340 x at 3164 1 P,A 1679 P 1 078 P,A NR4A1, HMR
202341 s at 23321 1 M,A 1 456 P 1 906 P TR1M2
202342_s_at 23321 1 P 1 288 P 1 602 P TRIM2, RNF86
202344 at 3297 1 P 1 590 P 1 186 P HSF1, HSTF1
202345_s_at 6181 1 P 1 822 P 1 544 P FABP5, EFABP
202352_s_at 5718 1 P 1 520 P 1 263 P PSMD12
202366_at 35 1 P 0 798 P 0 646 M,A ACADS, SCAD
202375_at 9871 1 P 0 966 P 0 634 P SEC24D
202384_s_at 6949 1 P 1 721 P 1 254 P TCOF1, MFD1
202389_s_at 3064 1 A 1 506 P 1 045 M,A HD, IT15
20239 l_at 10409 1 P 2 916 P 8 624 P BASP1, CAP23
202393_s_at 7071 1 P 1 429 P 1 746 P TIEG, EGRA,
202400_s_at 6722 1 P,A 1 589 P 1 747 P SRF
202402_s_at 833 1 P 0615 P 0 570 P CARS, CYSRS
202407_s_at 26121 1 P 0 905 P 0 604 P PRPF31
202413_s_at 7398 1 P 1 510 P 1 536 P USP1
202425_x_at 5530 1 P,M,A 1 620 P 2 130 P PPP3CA
202429_s_at 5530 1 P 1 404 P 2 009 P PPP3CA
202444_s_at 10613 1 P 0 618 P 0 450 P C10orf69,
20245 l_at 2965 1 P 1 526 P 1 840 P GTF2H1
202457_s_at 5530 1 P 1 286 P 1 842 P PPP3CA
202462_s_at 9879 1 P 2 138 P 1 961 P DDX46
202464_s_at 5209 1 P 1 768 P 1 761 P PFKFB3
202468_s_at 8727 1 P 1 911 P 2 094 P CTNNAL1
202470_s_at 11052 1 P 1 225 P 1 633 P CPSF6, CFIM
202472_at 4351 1 P 0818 P 0 616 P,M,A MPI, PMI, PMI1
202476_s_at 10844 1 P 0 809 P 0 636 P TUBGCP2
202492_at 79065 1 P 0 761 P 0 635 P FLJ22169
202498_s_at 6515 1 P 1 600 P 1 348 P SLC2A3
202499_sat 6515 1 P 1 885 P 1634 P SLC2A3
202500_at 3300 1 P 1 900 P 1 886 P DNAJB2
20253 l_at 3659 1 P 1 552 P 1 624 P 1RF1
202532_s_at 1719 1 P 1 885 P 1 962 P DHFR
XXXV11
Affymetrix
Id
Day 0 Day 3 Day 7
Common NameIsOcusLink
Normalized Flags Normalized Flags Normalized Flags
202533 s at 1719 1 P 1.511 P 1.345 P DHFR
202534 X at 1719 1 P 1.601 P 1.717 P DHFR
202536 at 25978 1 P 1.565 P 1.704 P DKFZP5640I23
202541 at 9255 1 P 1.812 P 1.832 P SCYE1
202542 s at 9255 1 P 1.802 P 1.735 P SCYEI; p43;
202580 X at 2305 1 P 1.316 P 1.502 P F0XM1; MPP2
202581 at 3304 1 P 0.772 P 0.586 P HSPA1B
202583 s at 10048 1 P 1.509 P 1.551 P RANBP9
202594 at 23484 1 P 1.349 P 1.608 P LEPROTU
202599 s at 8204 1 P 1.347 P 1.687 P NRIP1; RIP140
202600 s at 8204 1 P 1.138 P 1.589 P NR1P1
202611 s at 9282 1 P 1.351 P 1.557 P CRSP2
202613 at 1503 1 P 2.057 P 1.811 P CTPS
202620 s at 5352 1 P 1.189 P 1.957 P PL0D2
202644 s at 7128 1 P 1.335 P 1.654 P TNFA1P3; A2
202645 s at 4221 1 P 0.811 P 0.610 P MENI
202656 s at 9792 1 P 1.519 P 1.910 P SERTAD2
202657 s at 9792 1 P 1.564 P 1.828 P TRIP-Br2
202671 s at 8566 1 P 1.176 P 0.640 P PDXK; PKH
202672 s at 467 1 P 1.140 P 1.533 P ATF3
202676 X at 10922 1 P.A 0.720 P.A 0.554 M.A FASTK
202678 at 2958 1 P 1.552 P 1.615 P GTF2A2
202682 s at 7375 1 P 0.837 P 0.659 P USP4; UNP
202693 s at 9263 1 P 1.509 P 1.481 P STK17A
202695 s at 9263 1 P.A 1.673 P 2.224 P STK17A
202702 at 7726 1 P 1.780 P 1.577 P TRIM26; AFP
202706 s at 7372 1 P 1.518 P 1.352 P UMPS; OPRT
202712 s at 1159 1 P 0.702 P 0.589 P CKMTI;
202725 at 5430 1 P 1.538 P 1.505 P P0LR2A
202727 s  at 3459 1 P 1.647 P 1.741 P IFNGR1; CD119
202730 s at 27250 1 P 0.606 P 0.544 P PDCD4; H731
202731 at 27250 1 P 0.526 P 0.546 P PDCD4; H731
202735 at 10682 1 P 0.763 P 0.573 P EBP; CPX
202740 at 95 1 P 0.570 P 0.399 P ACYI
202743 at 8503 1 P 1.835 P 2.000 P P1K3R3
202746 at 9452 1 P 1.435 P 3.389 P ITM2A; E25A
202758 s at 8625 1 P 0.551 P 0.285 P RFXANK; BLS
202759 s at 11217 1 A 1.462 P 1.784 P PALM2
202760 s at 11217 1 P.A 1.402 P.A 2.073 P AKAP2
202764 at 6786 1 P 1.548 P 1.636 P SIIM I
202767 at 53 1 P 0.673 P 0.437 P ACP2
202769 at 1 P 0.435 P 0.537 P CCNG2
202770 s at 901 1 P 0.513 P 0.611 P CCNG2
202777 at 8036 1 P 1.378 P 1.516 P SH0C2
202779 s at 27338 1 P 0.833 P 0.652 P UBE2S
202785 at 4701 1 P 0.958 P 0.608 P.M NDUFA7
202792..3_oi 9701 1 P 0.696 P.M 0.618 M.A KÌAA068S
202793 at 10162 1 P 0.696 P 0.419 P.A C3F
202794 at 3628 1 P 1.468 P 1.688 P INPP1
202802 at 1725 1 P 0.719 P 0.447 P Dl IPS
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202812 al 2548 1 P 0.572 P 0.562 P GAA; LYAG
202819 s at 6924 1 P 1.585 P 1.418 P TCEB3; SI 11
202823 at 6921 1 P 1.554 P 1.425 P TCEB1
202830 s at 2542 1 P 0.527 M.A 0.299 A SLC37A4
202838 at 2517 1 P 0.558 P 0.356 P FUCAI
202847 at 5106 1 P 0.261 P 0.203 M.A PCK2;
202852 s al 79719 I P 1.590 P 1.519 P F U I 1506
202855 s at 9123 1 P 0.636 P 0.483 P SLCI6A3
202856 s at 9123 1 P 0.830 P 0.649 P SLC16A3;
202867 s at 54788 1 P 0.730 P 0.568 P DNAJB12;
202868 s al 10775 1 P 1.521 P 1.252 P POP4; RPP29
202883 s at 5519 1 P 1.529 P 1.174 P PPP2R1B
202887 s at 54541 1 P 0.401 M.A 0.358 A DDIT4; Dig2;
202900 s at 4927 1 P 1.743 P 1.625 P NUP88
202903 al 23658 I P 1.364 P 1.690 P LSM5
202904 s at 23658 1 P 1.557 P 1.493 P LSM5;
202906 s at 4683 1 P 1.615 P 1.409 P NBSI
202912 at 133 1 P 1.545 P 1.325 P ADM; AM
202930 s al 8803 1 P 1.518 P 1.409 P SUCLA2
202934 at 3099 1 A 2.805 P 2.985 P HK2
202937 x at 27341 1 P.M 1.612 P 1.138 P CGI-96
202939 at 10269 1 P 1.385 P 1.502 P ZMPSTE24
202943 s at 4668 1 P 0.748 P 0.546 P NAGA
202944 at 4668 1 P 0.783 P 0.618 P NAGA
202945 at 2356 1 P 0.927 P 0.596 M.A FPGS
202949 s at 2274 1 P 2.215 P 2.887 P FHL2; DRAL
202951 at 11329 1 P 1.480 P 1.643 P STK38
202962 at 23303 1 M.A 1.326 P 1.671 P KIF13B; GAKIN
202978 s at 58487 1 P 1.524 P 1.627 P ZF
202979 s at 58487 1 P 1.470 P 1.580 P ZF
202993 at 10994 I P 0.774 P 0.597 P ILVBL
202994 s al 2192 1 P 1.026 P 1.606 P E46L;
202998 s at 4017 1 P 1.150 P 1.980 P L0XL2; WS9-14
203002 at 51421 1 P 1.373 P 1.526 P AM0TL2
203006 at 3632 I P 0.810 P 0.644 P INPP5A
203018 s at 22892 1 P 1.411 P 1.545 P SSX2IP
203019 x at 22892 1 P 1.564 P 1.819 P SSX2IP
203023 al 51491 1 P 1.726 P 1.295 P H s p c m
203027 s at 4597 1 P 0.634 P.M.A 0.518 A MVD
203031 s at 7390 1 P 0.809 P 0.642 P UROS
203038 al 5796 1 M.A 1.512 P 1.783 P PTPRK
203041 s at 3920 1 P 1.197 P 1.678 P LAMP2;
203042 at 3920 1 P 1.395 P 1.932 P LAMP2
203053 at 10286 1 P 1.513 P 1.419 P BCAS2; DAM1
203058 s at 9060 1 P 1.635 P 2.323 P PAPSS2
203060 s at 9060 1 P 1.942 P 3.318 P PAPSS2; SK2
203062 $ at 9656 1 P 1.290 P 1.504 P MDC\
203068 at 9903 1 P 1.570 P 1.514 P KIAA0469
203075 at 4087 1 P 1.645 P 1.674 P SMAD2
203077 s at 4087 1 P 1.337 P 1.516 P SMAD2; JVI8
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203078 at 8453 1 P 1.703 P 1.648 P CUL2
203085 s at 7040 1 P 0.839 P 0.644 P TGFB1;
203095 at 4528 1 P 1.576 P 1.464 P MTIF2
203113 s at 1936 1 P 1.003 P 0.650 P EEFID;
203116 s at 2235 1 P 0.792 P 0.649 P FECH
203119 at 79080 1 P 1.850 P 1.648 P MGC2574
203122 at 51112 1 P.A 0.860 P.A 0.571 A TTCI5; CGI-87
203125 x at 4891 1 P.M.A 0.792 M.A 0.649 A SLCIIA2
203126 at 3613 1 P 0.861 P 0.649 P IMPA2
203139 at 1612 1 P.A 1.428 P 1.541 P DAPK1
203140 at 604 1 P 1.268 P 2.302 P BCL6: BCL5
203150 at 10244 1 P 1.641 P 1.613 P RAB9P40; p40
203154 s at 10298 1 P 1.551 P 1.351 P PAK4
203156 at 11215 1 P 1.646 P 1.670 P AKAP1I
203185 at 9770 1 P 1.276 P 1.605 P RASSF2
203188 at 11041 1 P 0.634 P 0.511 P B3GNT6
203192 at 10058 1 P 0.902 P 0.613 M.A ABCB6
203197 s at 54987 1 P 0.945 P 0.626 P FU20580
203198 at 1025 1 P 0.814 P 0.577 P.A CDK9; TAK
203200 s at 4552 1 P 1.461 P 1.623 P MTRR; MSR
203202 at 11103 1 P 2.083 P 2.042 P HRB2
203203 s at 11103 1 P 1.802 P 1.720 P HRB2; RIP-I
203204 s at 9682 1 P 0.620 P 0.632 P JMJD2A
203205 at 9682 1 P 0.621 P 0.600 P JMJD2A;
203211 s at 8898 1 P 1.784 P 1.634 P MTMR2;
203212 s at 8898 1 A 1.899 P 2.085 P MTMR2
203215 s at 4646 1 P 1.375 P 1.638 P MY06
203216 s at 4646 1 P 1.484 P 1.679 P M Y06
203228 at 5050 1 P 0.865 P 0.607 P PAFAHIB3
203234 at 7378 1 P 1.639 P 1.910 P 1JPPI; UPASE
203239 s at 4849 1 P 0.846 P 0.625 P CN013
203252 at 10263 1 P 0.786 P 0.559 P DOC-1R
203259 s at 51020 1 P 1.573 P 1.631 P C6orf74
203264 s at 23229 1 P 0.675 P 0.597 P ARHGEF9
203267 s at 1819 1 P 0.914 P 0.644 P DRG2
203272 s at 11334 1 P 1.825 P 1.548 P TUSC2
203292 s at 55823 1 P 1.371 P 1.544 P VPS1I
203294 s at 3998 1 P.A 0.867 P.A 0.656 P.A LMAN1; MR60
203299 s at 8905 1 P.A 1.481 P 1.805 P APIS2; DC22
203304 at 25805 1 P.M 2.048 P 3.419 P BAMBI; NMA
203312 x at 382 1 P 1.507 P 1.410 P ARF6
203314 at 8225 1 P 1.522 P 1.037 P PGPL
203315 at 8440 1 P.M.A 1.235 P 1.590 P NCK2; GRB4
203320 at 10019 1 P 0.799 P 0.569 P LNK
203336 s at 9270 1 P 1.799 P 1.350 P ITGB1BP1
203338_at 5529 1 P 1.373 P 1.506 P PPP2R5E
203341 at 10153 1 P 1.554 P 1.415 P CEBPZ
203344 s at 5932 1 P 1.566 P 1.380 P RBBP8
203359 s at 26292 1 P 1.657 P 1.294 P MYCBP
203360 s at 26292 1 P 1.682 P 1.219 P MYCBP
x!
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203361 s at 26292 1 A 1.714 P 1.692 P,M MYCBP
203365 s at 4324 1 P 0.728 P.A 0.607 A MMPI5
203367 at 11072 1 P 1.517 P 1.846 P DUSP14
203368 at 78987 1 P 0.699 P 0.551 P CREED1
203381 s at 348 1 P.M 0.827 P 1.712 P APOE
203382 s at 348 1 P.A 1.007 P.A 2.208 P APOE
203386 at 9882 1 P.A 1.512 P 1.988 P TBCID4
203388 at 409 1 P 0.751 P 0.650 P ARRB2
203392 s at 1487 1 P 0.690 P 0.523 P CTBP1
203394 s at 3280 1 P 1.091 P 1.598 P HES1
203395 s at 3280 1 P 1.282 P 1.810 P HES1
203403 s at 6049 1 P 1.450 P 1.592 P RNF6
203410 at 10947 1 P 1.715 P 1.592 P AP3M2
203411 s at 4000 1 P 0.584 P 0.631 P LMNA
203413 at 4753 1 P 1.221 P 1.667 P NELL2
203415 at 10016 1 P 0.762 P 0.605 P PDCD6
203417 at 4237 1 P 0.573 P.A 0.607 P MFAP2;
203422 at 5424 1 P 0.869 P 0.584 P P0LD1
203439 s at 8614 1 P 0.531 M,A 0.541 P.A STC2
203442 X at 256364 1 P 0.829 P 0.569 P FLJ35827
203446 s at 4952 1 P 1.498 P 1.553 P OCRL
203452 at 26229 1 P 0.695 P 0.526 P B3GAT3
203456 at 11230 1 P 0.810 P 0.584 P JM4
203466 at 4358 1 P 1.533 P 1.685 P MPVI7
203467 at 5372 1 P 0.791 P 0.625 P PMM1
203468 at 8558 1 A 0.995 P.A 0.653 P.A CDKIO
203485 at 6252 1 P 1.231 P 1.843 P RTNI; NSP
203490 at 2000 1 A 1.674 P.M 1.520 P.A ELF4; MEF
203501 at 10404 1 P.A 1.500 P 1.426 P.M PGCP
203502 at 669 1 P 1.617 P 1.991 P BPGM
203510 at 4233 1 P 1.154 P 1.745 P MET
203526 s at 324 1 P 1.402 P 1.570 P APC; GS;
203555 at 26469 1 P 0.814 A 0.620 A PTPN18; BDPI
203562 at 9638 1 P 1.110 P 1.581 P FEZ1
203573 s at 5875 1 P 0.789 P 0.486 P RABGC.TA
203574 at 4783 1 P 1.122 P 1.561 P NFIL3; E4BP4
203576 at 587 1 P 0.791 P 0.532 P BCAT2; BCAM
203578 s at 9057 1 P.M 1.525 P 1.464 P SLC7A6
203588 s at 7029 1 P 1.604 P 1.961 P TFDP2
203589 s at 7029 1 P.A 1.544 P 2.083 P TFDP2; Dp-2
203599 s at 11193 1 P 1.365 P 1.593 P WBP4; FBP21
203603 s at 9839 1 P.A 1.732 P,A 3.432 P ZFHXIB; SIPI
203607 at 22876 1 P 1.469 P 1.519 P INPP5F; SAC2;
203622 s at 56902 1 P 1.662 P 1.434 P LOC56902
203646 at 2230 1 P 1.424 P 1.591 P FDX1 ; ADX
203648 at 9797 1 P 1.565 P 1.615 P KIAA0218
203657 s at 8722 1 P 0.558 P 0.639 P C rSF; CATSF
203665 at 3162 1 P 2.534 P 2.982 P HMOXI; HO-1
203669 s  at 8694 1 P 0.684 P 0.555 P DGATI
203671 at 7172 1 P.A 1.564 P 1.833 P TPMT
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203674 at 9931 1 P 1.568 P 1.585 P HELZ
203675 at 4925 1 P 1.450 P 1.884 P NUCB2; NEFA
203679 at 11018 1 P 0.781 P 0.494 P IL1RL1LG
203680 at 5577 1 P 1.352 P 1.671 P PRKAR2B
203682 s at 3712 1 P.M 0.868 P 0.651 A IVD; ACAD2
203686 at 4350 1 P 0.849 P 0.634 P MPG; AAG
203693 s at 1871 1 P 1.539 P 1.455 P E2F3; E2F-3
203696 s at 5982 1 P 1.613 P 1.251 P RFC2; Al
203710 at 3708 1 P 1.939 P 1.964 P 1TPRI
203711 s at 26275 1 P 0.922 P 0.520 P HIBCH
203712 at 9933 1 P 1.748 P 1.821 P KIAA0020
203713 s at 3993 1 P 0.758 P 0.524 P.A LLGL2; HGL
203714 s at 6905 1 P 1.475 P 1.510 P TBCE; HRD
203720 s at 2067 1 P 0.799 P 0.640 P ERCC1; UV20
203722 at 8659 1 P 0.720 P 0.554 P ALDH4AI
203737 s at 23082 1 P 1.556 P 1.486 P PPRCI
203738 at 55322 1 P 1.752 P 1.804 P F IJI 1193
203740 at 10200 1 P 1.684 P 1.464 P MPH0SPH6
203743 s at 69% 1 P 1.857 P 1.563 P TDG
203746 s at 3052 1 P 1.575 P 1.235 P HCCS; CCHL
203767 s at 412 1 P 1.514 P 1.148 P STS
203771 s at 644 1 P 1.548 P 1.198 P Bl.VRA; BVRA
203778 at 4126 1 P 1.037 P.M 1.519 P MAN BA
203787 at 23635 I P 1.678 P 1.752 P SSBP2
203810 at 11080 1 P 2.306 P 2.987 P DNAJB4
203811 s at 11080 1 P.M, A 1.751 P 2.377 P DNAJB4
203814 s at 4835 1 P 0.836 P 0.584 P NQ02;
203815 at 2952 1 P 0.606 P.M 0.527 P.A GSTT1
203816 at 1716 1 P 2.034 P 2.302 P DGUOK
203821 at 1839 1 A 2.686 P 2.629 P DTR; DTS
203840 at 8548 1 P.A 1.508 P 1.463 P BLZFI; JEM1
203851 at 3489 1 P.A 1.556 P 1.833 P IGFBP6; IBP6
203853_s_at 9846 1 A 1.394 P A 1.639 P.A GAB2;
203856 at 7443 1 P 1.542 P 1.361 P VRKI
203857 s at 10954 1 P 0.768 P 0.644 P PDIR
203860 at 5095 1 P 0.781 P 0.585 P.A PCCA
203870_at 64854 1 P 1.623 P 1.712 P USP46;
203876 s at 4320 1 P.A 0.466 P.A 0.3% A MMPII
203878 s at 4320 1 P 0.575 P 0.432 P MMPII
203880 at 10063 1 P 1.866 P 1.835 P COX 17
203882 at 10379 1 P 0.616 P 0.661 P ISGF3G
203893_at 6880 1 P 1.654 P 1.778 P TAF9
203910 at 9411 1 P 1.239 P 1.897 P PARG1
203916 at 8509 1 P 0.6% P.A 0.548 A NDST2
203917 at 1525 1 P 1.2% P 1.788 P CXADR;
203919 at 6919 1 P 0.719 P 0.614 P TCEA2; TFIIS
20392 l_at 9435 1 P 0.652 P 0.523 P CHST2; C6ST
203926 x_at 513 I P 0.720 P 0.450 P ATP5D
203935_at 90 1 P 1.480 P 1.545 P ACVR1
203944 x at I I 120 1 P 1.500 P 1.641 P BTN2AI
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203946_s_at 384 1 P,A 1 760 P 1 353 P,A ARG2
203960_s_at 51668 1 P 1 619 P 1 528 P Clorf41
203967_at 990 1 P 1 778 P 1 624 P CDC6,
203968_s_at 990 1 P 1 709 P 1 453 P CDC6
203970_s_at 8504 1 P 1409 P 1 593 P PEX3
203976_s_at 10036 1 P 1 528 P 1 324 P CHAF1A
203980_at 2167 1 P 1999 P 2 462 P FABP4
20398 l_s_at 5826 1 P 0 657 P 0 694 P ABCD4
203986_at 8987 1 P 2 200 P 2 284 P GENX-3414
203989_x_at 2149 1 A 1 755 P,A 3 086 P F2R, TR
204019_s_at 26751 1 P 0 723 P 0 566 P SH3YL1
204020_at 5813 1 P 1323 P 1 515 P PURA
204022_at 11060 1 P 0 822 P 0619 P WWP2
204023_at 5984 1 P 1617 P 1 373 P RFC4, A l,
204024_at 734 1 P 1634 P 1 681 P C8orfl, hT41
20403 0_s_at 29970 1 P 1 563 P 1 944 P SCHIP1
20403 3_at 9319 1 P 1 658 P 1 526 P TRIP 13
20403 5_at 7857 1 P 1 612 P 1 267 P SCG2
20405 l_s_at 6424 1 P 1 347 P 1 798 P SFRP4
204054_at 5728 1 P>A 1 394 P 1 659 P,M PTEN, BZS
204064_at 9984 1 P 1600 P 1 545 P THOC1, P84
204073_s_at 745 1 P 0 625 P 0 564 P Cl lor©,
204076_at 9583 1 P 0 834 P 0 553 P LYSAL1
204077_x_at 9583 1 P 0 929 P 0 660 P,A LYSAL1
204078_at 10609 1 P 0 816 P 0 579 P SC65, NOL55
20408 l_at 4900 1 P 1 528 P 2 036 P NRGN, RC3,
204083_s_at 7169 1 P 1698 P 1 599 P TPM2, DAI
204088_at 5025 1 P 0 605 P 0 463 P P2RX4
20409 l_at 5147 1 P 0 675 P 0 520 P PDE6D, PDED
204099_at 6604 1 P 0 788 P 0 625 P SMARCD3
204106_at 7016 1 P 1 522 P 1 093 P TESK1
204108_at 4800 1 P 1673 P 1 428 P NFYA,
204125_at 51103 1 P 1 611 P 1 447 P NDUFAF1
204127_at 5983 I P 1 511 P 1 661 P RFC3
204128_s_at 5983 1 P 1 671 P 1 481 P RFC3
204133_at 9136 1 P 1 536 P 1 169 P RNU3IP2
204135_at 11259 1 P 1 238 P 1 740 P DOC1, GIP90
204139_x_at 7593 1 P 0 661 A 0 466 P,A ZNF42, MZF1
204141_at 7280 1 P 1 868 P 1 973 P TUBB
204142_at 55556 1 P 0 877 P 0 647 P HSRTSBETA
204144_s_at 9091 1 P 0 807 P,A 0 605 P,A PIGQ, GPU
204146_at 10635 1 P 1 601 P 1 809 P PIR51
204149_s_at 2948 1 P 0 740 P 0 375 P GSTM4
204182_s_at 23099 1 P,A 1 500 P 1691 P ZNF297B
204185_x_at 5481 1 P 1 525 P 1 543 P PPID, CYPD
204186_s_at 5481 1 P 1 624 P 1 613 P PPID
204208_at 8732 1 P 1 480 P 1 572 P RNGTT, HCE
204217_s_at 6253 1 P 0 341 P 0 403 P RTN2, NSP2
204218_at 25906 1 P 1 512 P 1 038 P DKFZP564M082
204227_s_at 7084 1 P 0 861 P 0 652 P,M TK2
x l l l l
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204235 s at 51454 1 P 1.189 P 1.518 P GULPI
204238 s at 10591 1 P 0.712 P 0.451 P C6orfl08
204243 at 6018 1 P 1.390 P 1.579 P RLF
204260 at 1114 1 P 0.419 P 0.311 P CHGB; SCGI
204264 at 1376 1 P 0.840 P 0.571 P CPT2; CPT1
204279 at 5698 1 P 1.323 P 1.765 P PSMB9; LMP2
204285 s at 5366 1 P.A 1.563 P.A 2.275 P PMAIPI
204286 s at 5366 1 A 2.536 P.A 3.391 P.A PMAIPI; APR
204290 s at 4329 1 P 0.704 P 0.551 P ALDH6A1
204295 at 6834 1 P 0.810 P 0.551 P SURFI
204313 s at 1385 1 P 1.382 P 1.649 P crf; b i
204314 s at 1385 1 P 1.489 P 1.642 P CREB1
204317 at 1 P 1.429 P 1.889 P GTSEI; B99
204320 at 1301 I P 0.837 P 0.639 P COLIIAI
204330 s at 6183 1 P 1.730 P 1.629 P MRPSI2
204331 s at 6183 1 P 1.601 P 1.166 P MRPS12
204333 s at 175 1 P 0.613 P 0.6% P AGA; AGU
204340 at 8269 1 P 0.631 P 0.611 P CXorfl2; 1TBA1
204343 at 21 1 P 0.610 P 0.520 P ABCA3; ABC3
204346 s at 11186 1 P.M 1.376 P 1.849 P RASSF1
204347 at 205 1 P 1.302 P 1.566 P AK3
204352 at 7188 1 P 1.408 P 1.864 P TRAF5: RNF84
204358 s at 23768 1 P 0.694 P 0.524 P.A FLRT2
204359 at 23768 1 P 0.632 P 0.458 P FLRT2
204360 s at 4669 1 P 0.508 P 0.399 P NAGLU
204361 s at 8935 1 P 1.433 P 1.661 P SCAP2;
204362 at 8935 1 P 1.357 P 1.700 P SCAP2
204371 s at 8570 1 P 0.740 P 0.611 P KHSRP
204394 at 8501 1 P 0.603 P 0.644 P.A SLC43AI
204398 s at 24139 1 P 0.689 P 0.547 P EML2
204407 at 8458 1 P 1.791 P 1.785 P TTF2; HuF2
204418 X at 2946 1 P 0.923 P 0.556 P GSTM2;
204420 at 8061 1 P 1.606 P 1.457 P DIPA
204421 s at 2247 1 P 1.809 P 1.850 P FGF2
204422 s at 2247 1 P 1.451 P 1.551 P FGF2
204423 at 4289 1 P 1.855 P 1.961 P MKLN1
204425 at 393 1 P 0.602 P.M 0.462 P.A ARHGAP4
204435 at 9818 1 P 1.611 P 1.567 P NUPL1
204441 s at 23649 1 P 1.617 P 1.341 P P0LA2
204442 X at 8425 1 P 0.723 P 0.654 P 1/1131*4
204459 at 1478 1 P 1.614 P 1.194 P CSTF2
204460 s at 5810 1 P 1.566 P 1.402 P RADI; HRADI
204465 s at 9118 1 P 1.743 P 1.507 P INA
204472 at 2669 1 P 1.182 P 1.735 P GEM; KIR
204473 s at 9640 1 P 1.564 P 1.757 P KIAA0211
204475 at 4312 1 P 1.787 P 2.786 P MMP1;
204477 at 5877 1 P 1.767 P 2.088 P KAB1F
204478 s at 5877 1 P 1.726 P 1.590 P RABIF
204481 at 7862 1 P.A 1.516 P 1.467 P.A BRPFI; BRI40
204490 s at 960 1 P,A 1.341 M,A 2.521 P.A CD44; IN
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204492 at 9824 1 P 1233 P 1 540 P ARHGAP11A
204512 at 3096 1 P 1 563 P 1 528 P HIVEP1, MBP-1
204514_at 1802 1 P 1 717 P 1 518 P DPH2L2
20452 l_at 29902 1 P 0 845 P 0 642 P HSU79274
204523 at 7699 1 P 1 479 P 1 602 P ZNF140, pHZ-39
204530_s_at 9760 1 P,A 1 538 P,M,A 1 204 M,A TOX
20453 l_s_at 672 I P 1 640 P 1 746 P BRCA1
204547_at 10966 1 P 0 652 P 0 557 P RAB40B
204550_x_at 2944 1 P 0 880 P 0 520 P GSTM1
204558 at 8438 1 P 1 986 P 1 587 P RAD54L
204569_at 22858 1 P 0 765 P 0 622 P,A ICK, MRK
204580 at 4321 1 P 2 706 P 3 028 P MMP12, HME,
204589 at 9891 1 P I 203 P 1 522 P ARK5
204593 s at 29787 1 P 1 542 P 1381 P FLJ20232
204603 at 9156 1 P 2 735 P 2211 P EXOl,
204605 at 10668 1 P 1 549 P 1 891 P CGRRF1
204608 at 435 1 P 0 863 P 0 509 P,A ASL
204616_at 7347 1 P 1 614 P 1 409 P UCHL3
204622 x at 4929 1 P 1 826 P 1 407 P NR4A2,
20463 2_at 8986 1 P 1 720 P 1 535 P RPS6KA4,
20463 3_s_at 9252 I P,M 0 732 A 0 628 A RPS6KA5
20463 9_at 100 1 P 0 925 P 0 654 P ADA
204642_at 1901 1 P 1 690 P 1 541 P EDG1
204646_at 1806 1 P 0 825 P 0 599 P
DPYD, DHP, 
DPD
204667_at 3169 1 P 1 348 P 1 552 P FOXA1
204668_at 1 P 1 541 P 1 696 P
204690_at 9482 1 P 1 463 P 1 647 P STX8, CARB
204692_at 4034 1 P 0 832 P 0 538 P,A LRCH4
204695_at 993 1 A 2 647 P 1 946 P CDC25A
204696_s_at 993 1 A 1623 P,M 1 196 M A CDC25A
204700_x_at 27042 1 P 1 423 P 1 517 P MGC29875
204702_s_at 9603 1 P 1485 P 1 611 P NFE2L3, NRF3
204703_at 8100 1 P 0 853 P 0 650 P TTC10,
204712_at 11197 1 P 1220 P 2 049 P WIFI, WIF-1
204717_s_at 3177 1 P 0 697 P 0 533 P SLC29A2
204727_at 11169 1 P,A 1 886 P 2 089 P WDHD1
204728_s_at 11169 1 P 1 747 P 1 743 P WDHD1, AND-1
204740_at 10256 1 A 1 449 M,A 1 605 P,M,A CNKSR1, CNKl
204748_at 5743 1 M,A 1 950 P,A 2 226 P COX2,
204749 at 4675 1 P 1 812 P 2 359 P NAP1L3
204759 at 1102 1 P 2 688 P 3 253 P CHC1L
204766_s_at 4521 1 P 1821 P 1 512 P NUDT1, MTH1
204772_s_at 7270 1 P 1 615 P 1 361 P TTFl
204783_at 4291 1 P 1 841 P 1 900 P MLF1
204784_s_at 4291 1 P 1 553 P 1 579 P MLF1
204788_s_at 5498 1 P 0 597 P 0 522 P PPOX
204790_at 4092 1 P 1 773 P 1 845 P SMAD7
20479 l_at 7181 1 P 0 762 P 0 656 P NR2C1
204793_at 9737 1 P 1 222 P 1 529 P GASP
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204805 s at 8971 1 P 0.567 P 0.495 P HIFX.H1X;
204807 al 10329 1 P 1.408 P 1.554 P TMEM5
204808 s ai 10329 1 P 1.703 P 1.594 P TMEM5;
204831 al 1 P 1.414 P 1.549 P
204837 al 66036 1 P 1.407 P 1.533 P MTMR9
204840 s al 8411 1 P.A 1.536 P.A 1.919 P EEA1
204849 al 10732 1 P 0.676 P 0.512 P TCFL5;
204854 at 10536 1 P 0.730 P.A 0.517 A LEPREL2
204857 at 8379 1 P 0.619 P 0.426 P MAD1L1;
204858 s al 1890 1 P 0.625 P 0.537 P ECGF1; TP
204862 s at 4832 1 P 0.859 P 0.552 P NME3
204867 at 2644 1 P 0.735 P 0.589 P GCHFR;
204868 at 3396 1 P 1.501 P 1.090 P 1CT1; DS-1
204880 at 4255 1 P 0.794 P 0.420 P MGMT
204883 s at 3364 1 P 1.992 P 1.587 P HUSI
204886 at 10733 1 P 0.685 P 0.631 P PLK4
204897 at 5734 1 P 1.775 P 2.393 P PTGER4
204905 s at 9521 1 P 1.584 P 1.469 P EEFIEI; PI8
204928 s at 8273 1 P 1.667 P 1.339 P SLCI0A3
204936 al 5871 1 P.A 1.035 P 0.637 P.A MAP4K2
204947 at 1869 1 P.M.A 1.612 P 1.430 P E2F1; RBP3
204948 s at 10468 1 A 1.166 P.A 2.265 P FST
204955 at 8406 1 P 1.309 P 1.812 P SRPX;ETX1
204957 at 5001 1 P 1.674 P 1.702 P 0RC5L; ORC5P
204967 at 357 \ P.A 1.177 P 1.620 P APXL; HSAPXL
204977 at 1662 1 P 1.654 P 1.818 P DDX10; HRH-J8
204979 s at 6450 1 A 2.152 P 2.223 P SH3BGR
204981 at 5002 1 P 0.598 P.A 0.503 A SLC22AI8
204983 s at 2239 1 P 1.372 P 1.630 P GPC4
204984 at 2239 1 P 1.350 P 1.743 P GPC4
204985 s at 79090 1 P 0.590 P 0.597 P MGC2650
204990 s at 3691 1 P 0.827 P.A 0.641 A 1TGB4
204991 s at 4771 1 A 3.015 P 2.297 P NF2; CAN
204998 s al 22809 1 P 0.835 P 0.610 P ATF5; ATFX
204999 s at 22809 1 P 0.686 P 0.422 P ATF5; ATFX
205003 at 9732 1 P.A 1.307 P 1.522 P DOCK4
205006 s at 9397 1 P 1.612 P 1.575 P NMT2
205007 s at 10518 I P 0.806 P 0.609 P CIB2
205034 at 9134 1 P 2.516 P 1.527 P CCNE2; CYCE2
205047 s at 440 1 P 0.377 P 0.278 P ASNS; TSII
205052 at 549 1 P 0.638 P.M 0.428 P.M AUH
205060 at 8505 1 P 1.275 P 1.549 P PARG
205061 s at 5393 1 P 1.541 P 1.328 P EX0SC9; p5
205070 at 54556 1 P 1.400 P 1.667 P ING3;
205076 s at 10903 1 P 1.319 P 1.830 P CRA
205081 at 1396 1 P 2.199 P 2.220 P CRIPI
205085 at 4998 1 P 1.912 P 1.805 P ORCIL;
205088_at 10046 1 M 1.179 P.A 1.702 P
CXorf6; CGI; 
FI8
205090 s at 51172 1 P 0.980 P 0.647 P NAGPA
x lv i
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205092_x_at 22890 1 P,A 0 686 A 0 647 P,A ZBTB1
205107_s_at 1945 1 P 0 680 P 0 594 P EFNA4, EFL4
205115_s_at 9904 1 A 2 047 P 2 141 P RBM19, NPO
205122_at 8577 1 P 1 599 P 1672 P TMEFF1
205123_s_at 8577 1 P 1 555 P 1 555 P TMEFF1, H7365
205126_at 7444 1 P 1 795 P 1 769 P VRK2
205134_s_at 26747 1 P 1 813 P 1938 P NUFIP1
205135_s_at 26747 1 P 1 782 P 1 759 P NUFIP1
205136_s_at 26747 1 P,A 2 241 P 3 564 P NUFIP1
20514 l_at 283 1 P 0 606 P,A 0 873 P ANG, RNASE5
205153_s_at 958 1 P,M,A 0 926 P,M 0 643 P,M,A TNFRSF5, p50
205158_at 6038 1 P 0 569 P 0 706 P RNASE4
205174_s_at 25797 1 P 1 291 P 2 557 P QPCT, QC, GCT
205192_at 9020 1 P,M 1366 P 1631 P MAP3K14
205193_at 23764 1 P,M 1 544 P 1242 P MAFF, U-MAF
205205_at 5971 1 P 1603 P 1 581 P RELB, I-REL
205217 at 1678 1 P 1 828 P 1 924 P TIMM8A, DDP
205218 at 10621 1 P 1 540 P 1 396 P POLR3F
205219 s at 2585 1 P 0 733 P 0 603 P GALK2
205224 at 6835 1 A 1955 P,A 1 740 P,M,A SURF2
205249 at 1959 1 P 1 708 P 2 299 P EGR2,
205264_at 10849 1 P 1 520 P 1 559 P ASE-1
205268_s_at 119 1 P 1 643 P 2 027 P ADD2, AD DB
20527 l_s_at 23552 1 A 1684 P,A 1 732 P,A CCRK
205279_s_at 2743 1 P 0 552 P 0 422 P GLRB
205280_at 2743 1 P 0 502 P 0 393 P GLRB
205282_at 7804 1 P 0 808 P 0 441 P LRP8
205284_at 9816 1 A 1630 P,M 1 845 P,M KIAA0133
205286_at 7022 1 A 1 281 P,A 1 867 P,M,A TFAP2C
205320_at 10297 1 P 0 600 P 0 669 P APC2, APCL
205345_at 580 1 P 1 658 P 1892 P BARDI
205350_at 1381 1 P 1 279 P 1 882 P CRABP1
205354_at 2593 1 P 0 635 P 0 454 P GAMT
205358_at 2891 1 P 1 050 P 1 505 P GRIA2, GLUR2
20536 l__s_at 5203 1 P 1 637 P 1 646 P PFDN4
205405_at 9037 1 P 0 810 P 0 476 P,A SEMA5A, semF
205406_s_at 53340 1 P 1 548 P 2 062 P SPA17, SP17
205407__at 8434 1 P 0 458 P 0 398 P RECK
205420__at 5191 1 P 1 017 P 0 592 P PEX7, PTS2R
205427__at 6940 1 P 2 098 P 2 272 P ZNF354A, EZNF
205429_s_at 51678 1 P 1 795 P 1690 P MPP6, VAM1
20544 l_at 79629 1 P 0 736 P 0 624 P FLJ22709
205443_at 6617 1 P 1 486 P 1 592 P
SNAPC1,
SNAP43
205447_s_at 7786 1 P 0 685 P,A 0 588 P,A MAP3K12
20546 l_at 11021 1 P,M,A 0 772 M,A 0 530 A RAB35, RAY
205479_s_at 5328 1 A 1 261 A 1 555 P PLAU UPA
205493_s_at 10570 1 P 1 949 P 1 956 P
DPYSL4,
CRMP3
205498_at 2690 1 P,M,A 1 253 P 1 560 P GHR
205510_s_at 55056 1 P 0 547 P,M 0 535 P>A GABPB2
x l v n
Affymetrix
Id
LocusLink
Day 0 Day 3 Day 7
Common Name
Normalized Flags Normalized Flags Normalized Flags
205519_at 79968 1 P 1 503 P 1 461 P FLJ12973
205521 at 9941 1 P,M 1 565 P 1 276 P ENDOGL1
205526 s at 11104 1 P 1 378 P 1 621 P KATNA1
205527_s_at 50628 1 P 1 657 P 1 464 P GEMIN4
205534_at 5099 1 A 1 583 A 2 336 P PCDH7
205547_s_at 6876 1 P 3 365 P 2 114 P TAGLN
205561_at 79734 1 P 1 724 P 1 338 P,M,A FLJ 12242
205575 at 10882 1 P 0 578 P 0 520 P CIQL1
205578_at 4920 1 A 1 139 M,A 1 606 P,A ROR2
205581 s at 4846 1 P,A 0 784 P,A 0 562 A NOS3
205588 s at 11116 1 P I 610 P \ 653 P FGFRIOP
20562 l_at 8846 1 P 1 543 P 1490 P ALKBH, ABH
205628 at 5558 1 P 2 090 P 2 006 P PRIM2A, p58
205633_s_at 211 1 P 1 691 P 1 406 P ALAS1
205634 x at 79143 1 P 0 756 P 0 569 P LENG4, BB1
205652_s_at 25809 1 P 0 630 P 0 527 P TTLLl
205677_s_at 10301 1 P 1 712 P 2 001 P DLEU1
205691 at 9143 1 P 0 546 P 0 360 P SYNGR3
205742_at 7137 1 P 0 664 P,A 0 649 P,A TNNI3, TNNC1
205748_s_at 55658 1 P 0 894 P 0 564 P RNF126
205760j>_at 4968 1 P 1 634 P 1 298 P OGGI
205763_s_at 8886 1 P 1 620 P 1 427 P DDX18, MrDb
205770_at 2936 1 P 0 983 P 0 600 P GSR
20577 l_s_at 9465 1 P 0 785 P 0 545 P AKAP7
205774_at 2161 1 P 0 653 P 0 487 PjA F12, HAF
205776_at 2330 1 P,M 0 595 P,A 0 653 A FM05
20578 l_at 9605 1 P 0 727 P 0610 P,M ATP-BL
205802_at 7220 1 P 1 339 P 1 709 P TRPC1
205803_s_at 7220 1 P 1 409 P 1 790 P TRPC1
205807_s_at 7286 1 P 1 500 P 1 541 P TUFT1
205822_s_at 3157 1 P 0 768 P 0611 P HMGCS1
205828_at 4314 1 P 3 382 P 3 934 P MMP3
20584 l_at 3717 1 M,A 1 789 P 2 204 P,A JAK2
205842_s__at 3717 1 P,A 1 757 P 1 858 P JAK2
205858_at 4804 1 A 3 290 M,A 6 523 P NGFR
205876_at 3977 1 P,M 2 022 P 3 180 P LIFR
205880_at 5587 1 P 1 364 P 1 582 P PRKCM
205895_s_at 9221 1 P 1 579 P 1 399 P NOLC1
205924_at 5865 1 A 2 226 P 1 677 P RAB3B
205925_s_at 5865 1 P 1 583 P 1 413 P RAB3B
205928_at 10224 1 P 1 614 P 1 876 P ZNF443, ZK1
205932_s_at 4487 1 P,A 1 413 P 1 804 P MSX1
20595 5_at 55310 1 P 0 800 P 0 596 P,A TAF6L
205964_at 79088 1 P 1 561 P 1 670 P ZNF426
205967_at 8364 1 P 0 567 P 0 654 P HIST1H4C
205973_at 9638 1 P,A 1 656 P 1 389 P FEZ1
205995_x_at 9657 1 A 1 563 M,A 1 728 P M A IQCB1
206003_at 9662 1 P 1 701 P 1 860 P KIAA0635
206016_at 28952 1 P 0 912 P 0 616 P JM1
206036_s_at 5966 1 P 1 537 P 1 775 P REL, C-Rel
x l v m
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206039 at 9363 1 P 0.557 P.M.A 0.639 P.A RAB33A
206055 s at 6627 1 P 1.776 P 1.444 P SNRPAI
206067 s at 7490 1 A 2.087 P.A 2.391 P W TI; GUD;
206103 at 5881 I P 0.423 P 0.217 A RAC3
206104 at 3670 1 P,A 1.663 P 2.113 P ISLI; lsl-1
206106 at 6300 1 P 0.856 P 0.586 P MAPKI2
206108 s at 6431 1 P 0.631 P 0.545 P SFRS6; B52
206110 at 8357 1 P 1.250 P 1.671 P HISTIH3H
206116 s at 7168 1 P 1.992 P 2.370 P TPM I; CMH3
206128 at 152 1 P 0.759 P 0.602 P.M. A ADRA2C
206140 at 9355 1 P 1.859 P 1.873 P LHX2; LH2
206142 at 7694 1 P.M 0.654 A 0.638 P.A ZNFI35; ZNF6I
206157 at 5806 I P 2.827 P 2.316 P PTX3; TSG-14
206172 at 3598 1 P 1.066 P 2.208 P 1LI3RA2: IL-13R
206182 at 7693 1 P 1.395 P 1.507 P ZNFI34; pHZ-15
206204 at 2888 1 A 1.524 P.A 1.353 P GRB14
206235 at 3981 1 P 1.573 P 1.669 P LIG4
206261 at 8187 1 P 1.888 P 2.078 P ZNF239; M0K2
206290 s at 6000 1 P 1.427 P 1.586 P RGS7
206299 at 27112 1 P.A 1.771 P 2.069 P TMEM28; TED
206336 at 6372 1 P.A 1.060 P.A 1.565 M.A CXCL6; GCP2
206343 s at 3084 I P 4.211 P 4.886 P NRG1.GGF
206352 s at 5192 1 A 1.639 P 1.401 P.M PEXIO; NALD
206377 at 2295 1 P 1.411 P 1.671 P F0XF2; FKHL6
206397 x at 2657 1 P 0.772 P 0.583 P.A GDF1
206401 s at 4137 1 P 0.646 P.A 0.408 P.A MAPI'; TAU
206424 at 1592 1 P 1.631 P 1.340 P CYP26AI
206440 at 8825 1 A 1.832 P 1.330 P.A UN7A; VELI1
206448 at 22891 1 P 1.376 P 1.980 P ZNF365
206452 x at 5524 1 P 1.526 P 1.334 P PPP2R4
206489 s at 9229 1 P 1.073 P 0.644 P DLGAP1
206507 at 9753 1 P 2.250 P 3.405 P ZNF305
206508 at 970 1 P.A 1.099 P 1.545 P TNFSF7;
206550 s at 9631 1 P 1.515 P 1.516 P NUP155
206552 s at 6863 1 M.A 1.164 P.A 1.521 P.A TACI
206578 at 1482 1 P 1.692 P 1.600 P NKX2-5
206613 s at 9015 1 P 2.270 P 2.403 P TAFIA
206615 s at 53616 1 P.A 0.858 P.A 0.625 A ADAM22
206632 s at 9582 1 P 1.306 P 1.749 P AP0BEC3B
206653 at 1 P 1.609 P 1.160 P POLR3G
206662 at 2745 1 P 1.696 P 2.747 P GI.RX; GRX
206667 s at 9522 1 P 0.622 P 0.722 P SCAMPI
206675 s at 6498 1 P.A 2.301 P 2.118 P.M SKIL; SNO
206688 s at 10898 1 P 0.811 P 0.609 P CPSF4
206689 x at 10524 1 P 0.788 P 0.574 P 11TATIP
206693 at 3574 1 P.M 1.603 P 3.207 P 11.7; IL-7
206699 x at 4861 1 P.A 1.581 P 1.253 P.A NPASl;
206721 at 57821 1 P 1.503 P,M 1.703 P LOC 57821
206770 s at 23443 1 P 1.354 P 1.521 P SLC35A3
206772 at 5746 1 P.A 1.246 P 1.653 P PTHR2
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206773 at 4062 1 P,A 1 322 P,M 1 661 P LY6H, NMLY6
206782_s_at 3338 1 P 0 639 P,M 0 537 P,A DNAJC4
206809_s_at 1 P 1 596 P 1 860 P HNRPA3
206826_at 5375 1 P 1 330 P 1 517 P PMP2, FABP8
206833_s_at 98 1 P 0 839 P 0 650 P ACYP2
206846_s_at 10013 1 P 0 677 P 0 499 P HDAC6, HD6,
206848 at 3204 1 P 1 379 P 1 589 P HOXA7, ANTP
20689 l_at 89 1 P 0 677 P,A 0 565 P,A ACTN3
206906_at 7087 1 P 0 652 P 0 652 P ICAM5
207006_s_at 29903 1 P 0 661 P,A 0 473 P,A HSU79303
20703 0_s_at 1466 1 P 2 372 P 2 355 P CSRP2
207039_at 1029 1 P 1 272 P 1 541 P CDKN2A
207088„s_at 8402 1 P 0 815 P 0 644 P SLC25A11
207145 at 2660 1 P,A 2 027 P 1 671 P GDF8, MSTN
207147_at 1746 1 P 2217 P 2 191 P DLX2, TES1
207153_s_at 11146 1 P 1 859 P 1 471 P GLMN, GVM
207164 s at 10472 1 P 1 750 P 1605 P ZNF238, RP58
207199_at 7015 1 P,A 1 539 P 1 396 P TERT, TP2, TRT
207302_at 6445 1 P 0 681 P 0 572 P
SGCG, A4, 
MAM
207332_s_at 7037 1 P 1 556 P 1 342 P TFRC, CD71
20739 l_s_at 8394 1 P 1 352 P 1 503 P P1P5K1A
207415_at 22925 1 P,A 1 455 P,A 1 509 P,A PLA2R1
20743 7_at 4857 1 P 1 281 P 1 760 P NOVA1,
207469_s_at 8544 1 P 0 558 P 0 236 P PIR
207574_s_at 4616 1 P 2 624 P 2 869 P GADD45B
207633_s_at 4593 1 P,M,A 1 527 P 1 126 P,M MUSK
207688_s_at 3626 1 P 1 517 P , 1 390 P INHBC, IHBC
207713_s_at 10616 1 P 0 769 P 0 626 P C20orfl8, XAP4
207714_s_at 871 1 P 1 797 P 1 770 P SERPINH1
207722_s_at 55643 1 P 0 720 P 0 519 P»A BTBD2
207753_at 57343 1 P 1459 P 1 751 P ZNF304
207768_at 1961 1 A 1 995 P 2 562 P,A EGR4
20778 l_s_at 7552 1 P 1 425 P 2 020 P ZNF6, ZNF4
207813_s_at 2232 1 P 0 457 P 0 220 P FDXR, ADXR
207826_s_at 3399 1 P 7 454 P 6419 P ID3, HEIR-1
20783 l_x_at 1725 1 P 0 856 P 0 595 P DHPS
207855_s_at 23155 I P 1 613 P 1 347 P MCLC
207876_s_at 2318 1 P 1 512 P 1 685 P FLNC, ABPA
207891_s_at 11219 1 P 1 559 P 1 001 P TREX2
207978_s_at 8013 1 P 2 087 P 1 290 P NR4A3, CHN
208003_s_at 10725 1 P 1 505 P 1 738 P NFAT5
208018_s_at 3055 1 A 1 611 P,A 1 861 P,A HCK
20802 l_s_at 5981 1 P 1 856 P 2 057 P RFC1
208025_s_at 8091 1 P 1 003 P 0 640 P HMGA2
208055_s_at 26091 1 P 1 618 P 1 558 P HERC4
208078_s_at 6935 1 P 1 776 P 1290 P,M TCF8, BZP
208114_s_at 81875 1 P 2 005 P 1 741 P FLJ12671
208117_s_at 81887 1 P 1605 P 1 411 P FLJ12525
208119_s_at 81931 1 P 1399 P 1 520 P ZNF505
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208180 s at 8365 1 P 1.717 P 2.090 P HIST1H4H
208264 s al 8669 1 P 1.670 P 1.558 P clF3-alpha
208270 s at 6051 1 P 0.887 P 0.653 P RNPEP
208273 at 57116 1 P.A 1.401 A 1.958 P.M LOC571I6
208290 s at 1983 1 P 2.199 P 2.124 P F.IF5; EIF-5A
208309 s at 10892 1 P 1.807 P 1.742 P MALTI
208336 s at 9524 1 P 0.631 P 0.558 P GPSN2
208361 s at 661 1 P.M 1.682 P 1.656 P P0LR3D
208368 s at 675 1 P.A 1.803 P 1.779 P BRCA2; FAD
208370 s at 1827 1 P 1.388 P 1.633 P DSCRI; CSP1
208433 s at 7804 1 P 0.593 P 0.308 P I.RP8; APOER2
208447 s at 5631 1 P 1.536 P 1.299 P PRPS1
208478 s at 581 1 P 0.536 P 0.361 P BAX
208611 s at 6709 1 P 1.415 P 1.506 P SPTAN1
208634 s al 23499 I P 1.468 P 1.590 P MACF1
208649 s at 7415 1 P 0.932 P 0.610 P VCP; p97
208650 s at 934 1 P.M,A 2.429 P 5.150 P CD24
208651 x at 934 1 P.A 1.757 P 3.434 P CD24; CD24A
208676 s at 1 P 1.7% P 1.422 P PA2G4
208677 s at 682 1 P 0.668 P 0.630 P BSG
208693 s at 2617 1 P 0.692 P 0.650 P GARS; CMT2D
208699 x at 7086 1 P 0.900 P 0.642 P TXT
208705 s at 1983 1 P 1.678 P 1.593 P EIF5; EIF-5A
208706 s at 1983 1 P 1.899 P 1.949 P EIF5; EIF-5A
208708 x at 1983 1 P 2.023 P 1.994 P EIF5; EIF-5A
208711 s at 595 1 M,A 1.707 P 1.648 P.A CCND1
208712 at 595 1 P.A 2.242 P 2.582 P CCND1
208735 s at 10106 1 P 0.717 P 0.567 P CTDSP2
208740 at 10284 1 P 2.951 P 3.168 P SAP 18
208741 at 10284 1 P 2.042 P 2.295 P SAP18
208742 s at 10284 1 P 1.994 P 1.968 P SAP 18
208745 at 10632 1 P 1.410 P 1.608 P ATP5L
208759 at 23385 1 P 0.902 P 0.648 P NCSTN
208782 at 11167 1 P 1.079 P 1.681 P FSTLI
208789 at 22939 1 P 1.593 P 1.765 P PTRF
208791 at 1191 1 P 1.180 P 1.510 P CLU
208792 s al 1191 1 P 1.160 P 1.534 P CLU
208798 x at 23015 1 P 1.550 P 1.814 P GOLGIN-67
208802 at 6731 1 P 1.536 P 1.432 P SRP72
208803 s at 6731 1 P 1.649 P 1.513 P SRP72
208813 at 2805 1 P 0.610 P 0.571 P GOTI
208828 at 54107 1 P 1.513 P 1.274 P POLE3;
208832 al 25814 1 P 1.755 P 1.839 P E46L
208843 s at 26003 1 P 1.529 P 1.551 P G0RASP2; p59
208848 at 128 1 P 1.403 P 1.551 P ADII5
208851 s at 7070 1 P 1.525 P 1.936 P THYI; CD90
208865 at 1452 1 P 1.489 P 1.827 P CSNKIA1
208866 al 1452 1 P 1.716 P 2.209 P CSNK1AI
208867 s at 1452 1 P 1.383 P 1.573 P CSNK1AI
208871 at 1822 1 A 1.722 P 1.654 P.M.A DRPLA
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208874 x at 5524 1 P 1 511 P 1 357 P PPP2R4
208879_x_at 24148 1 P 0 761 P 0 521 P C20orfl4
208883 at 51366 1 P 1 089 P 1 523 P DD5
208884j>_at 51366 1 P 1 273 P 1 520 P DD5, EDD
208886 at 3005 1 P 0 367 P 0 371 P H1F0, H10
20889 l_at 1848 1 P 0 653 P 0 596 P DUSP6
208892_s_at 1848 1 P 0 662 P 0 624 P DUSP6
208893_s_at 1848 1 P 0512 P 0 437 P DUSP6
208896_at 8886 1 P 1 711 P 1 600 P DDX18, MrDb
208898_at 51382 1 P 2 456 P 2 748 P ATP6V1D
208899_x_at 51382 1 P 2 242 P 2 568 P ATP6V1D
20891 l_s_at 5162 1 P 0 929 P 0 629 P PDHB, PHE1B
208916 at 6510 1 P 0 730 P 0 632 P SLC1A5, R16
208917_x_at 65220 1 P 0 872 P 0 546 P FLJ13052
208918_s_at 65220 1 P 0 993 P 0 590 P FLJ13052
208919_s_at 65220 1 P 0 805 P 0 583 P FLJ13052
208920 at 6717 1 P 1 682 P 1 908 P SRI
208922_s_at 10482 1 P 1407 P 1 628 P NXF1, TAP
20893 0_s_at 3609 1 P 0 638 P 0 442 P ILF3
20893 l_s_at 3609 1 P 0 922 P 0 471 P ILF3, MMP4
208932_at 5531 1 P 0 932 P 0 657 P PPP4C,PPX
20893 7_s_at 3397 1 P 4 295 P 3 094 P ID1
208939_at 22929 1 P 1 184 P 1 526 P SEPHS1
208940_at 22929 1 P 1 024 P 1 526 P SEPHS1
208944_at 7048 1 P 1 236 P 1 516 P TGFBR2
208955_at 1854 1 P 1 625 P 1 955 P DUT, dUTPase
208968_s_at 57019 1 P 1 514 P 1 178 P LOC57019
208969_at 4704 1 P 1 618 P 1 597 P NDUFA9
208975_s_at 3837 1 P 1 541 P 1443 P KPNB1
208985_s_at 8669 1 P 1 579 P 1499 P eIF3-alpha
209003_at 8402 1 P 0 841 P 0 632 P SLC25A11
209010_s_at 7204 1 A 4 240 A 12 140 P,M TRIO
209014_at 9500 1 P 0 717 P 0 569 P MAGED1
209015_s_at 10049 1 P 1 754 P 2 181 P DNAJB6, MRJ
209017_s_at 9361 1 P 0 608 P 0 403 P PRSS15, LON
2090l9_s_at 65018 1 P 1 306 P 1 740 P PINK1, BRPK,
209025_s_at 10492 1 P 1 512 P 1 265 P SYNCRIP
209040_s_at 5696 1 M,A 1 168 M,A 1 668 P PSMB8
209052_s_at 7468 1 P 0 903 P 0 655 P,A WHSC1
209068_at 9987 1 P 1 293 P 1 642 P HNRPDL
209076_s_at 56270 1 P 1 556 P 1 549 P LOC56270
209085_x_at 5981 1 P 1 637 P 1 654 P RFC1
209087_x_at 4162 1 P,A 1438 P 1 657 P MCAM
209090_s_at 1 P 1 447 P 1 778 P
209102_s_at 26959 1 P 0 490 P 0 683 P HBP1
209106_at 8648 1 P 1 228 P 1 561 P NCOA1
209113_s_at 10362 1 P 0 632 P 0 533 P HMG20B
209117_at 23558 1 P 0 703 P 0613 P WBP2
209139_s_at 8575 1 P 1 530 P 1 284 P PRKRA
209l52_s_at 6929 1 P 1 745 P 1 668 P TCF3
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209156 s at 1292 1 P 0 590 P 0 557 P COL6A2
209161 at 9128 1 P 2 141 P 1 732 P PRPF4
209162 s at 9128 1 P 1 836 P 1 528 P PRPF4, PRP4
209165_at 26574 1 P 1 540 P 1 472 P AATF, DED
209172 s at 1063 1 P 1 195 P 1 780 P CENPF, CENF
209173 at 10551 1 P 2 030 P 1 954 P AGR2, AG2
209175 at 11196 1 P 1 557 P 1 543 P SEC23IP
209180 at 5876 1 P I 707 P 1 786 P RABGGTB
209181 s at 5876 1 P 1 544 P 1 503 P RABGGTB
209187 at 1810 1 P 1 661 P 1 910 P DR1
209188 x at 1810 1 P 1 471 P 1 615 P DR1, NC2
209192 x at 10524 1 P 0711 P 0 543 P HTATIP
209196_at 9277 1 P 1 794 P 1 554 P C6orfl 1, BING4
209205 s at 8543 1 P 1 581 P 2 534 P LM04
20921 l_at 688 1 P 1 455 P 1 708 P KLF5
209213_at 873 1 P 0 733 P 0 619 P CBR1
20922 l_s_at 9885 1 P 1 457 P 1 682 P OSBPL2
209233 at 10436 1 P 1666 P 1 304 P C2F
209234_at 23095 1 P 0817 P 0 595 P KIF1B
20923 8_at 6809 1 P 1 706 P 2 020 P STX3A
209242 at 5178 I P 1 510 P 1 405 P PEG3
209243_s_at 23619 1 P 1 721 P 1 459 P PEG3
209244_s_at 10749 1 A 2 048 P 1 504 A KIF1C
209263_x_at 7106 1 P 0 747 P 0 580 P TM4SF7
209264_s_at 7106 1 P 0 625 P 0 514 P TM4SF7
209267_s_at 64116 1 P,M 1 907 P 2 684 P SLC39A8
209268_at 11311 1 P 1 660 P 1 336 P VPS45A
209273_s_at 81689 1 P 1 737 P 1 349 P HBLD2
209276_s_at 2745 1 P,M 1 321 P 2 187 P GLRX
209277_at 7980 1 P 1 915 P 3 052 P TFPI2
209278_s_at 7980 1 P 1 532 P 2 279 P TFPI2
209286_at t A 1 954 P,A 2 430 P,M CDC42EP3
209288_s_at 10602 1 P 1 401 P 2 037 P CDC42EP3
209291_at 3400 1 P 4 160 P 5 427 P ID4
209292_at 3400 1 P 3 185 P 3 789 P ID4
209293_x_at 3400 1 P 2 886 P 2 748 P ID4
209294_x_at 8795 1 P 0 700 P,A 0 604 P,A TNFRSF10B
209304_x_at 4616 1 A 2 200 P 2 556 P,M,A GADD45B
209305_s_at 4616 1 P,A 1 778 P 1 867 P GADD45B
209306_s_at 23075 1 P 1 453 P 1 527 P SWAP70
209307_at 23075 1 P 1 481 P 1 687 P SWAP70
209330_s_at 3184 1 P 0 753 P 0 639 P HNRPD, P37
209340_at 6675 1 P 2 249 P 2 366 P UAP1, AgX
209344_at 7171 1 P 1 515 P 1 317 P TPM4
209348_s_at 4094 1 P,A 1 701 P,A 2 435 P,A MAF
209349_at 10111 1 P 1 598 P 1 667 P RAD50
209366_x_at 1528 1 P 1 580 P 1 386 P CYB5
209367_at 6813 1 P 0 702 P 0 551 A STXBP2
209379_s_at 54462 1 P 1 427 P 1 538 P KIAA1128
209383_at 1649 1 P 0 951 P 1 605 P DDIT3, CHOP
l i l i
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209384_at 11212 1 P 1 531 P 1 505 P PROSC
209407_s_at 10522 1 P 0 600 P 0 340 A DEAF1
209417_s_at 3430 1 P 0 482 P 0 493 P IFI35, IFP35
209428_s_at 7542 1 P 0 695 P 0 358 P,A ZFPL1
209432 s at 10488 1 P 1 518 P 1 560 P CREB3
209440 at 5631 1 P 1 575 P 1 533 P PRPS1, PRSI
209457_at 1847 1 P 1 427 P 1 695 P DUSP5, HVH3
209459_s_at 57416 1 A 2 323 M,A 1 992 P,A ABAT, GABAT
20946l_x_at 57418 1 P,A 1 101 P 0 624 A WDR18
209468 at 4041 1 P 0 686 P 0 638 P,A LRP5, HBM
209478_at 201254 1 P 2 051 P 1 580 P STRAI3
209490 s at 9374 1 P 0 933 P 0 619 P PPT2
209504_s_at 58473 1 P 0610 P,M,A 0 559 A PLEKHB1
209516_at 10322 1 P,M 1 584 P 1 381 P SMYD5
209519 at 4686 1 P,A 1 506 P 1 654 P NCBP1
209522_s_at 1384 1 P 0 813 P 0 566 P CRAT, CAT1
209523_at 6873 1 P I 527 P 1 480 P TAF2, TAF2B
209527_at 23404 1 P 1 581 P 1 421 P EXOSC2
209529_at 8612 1 P 0 647 P 0 597 P PPAP2C
209531_at 2954 1 P 0 632 P 0 425 M,A GSTZ1
20953 2_at 9373 1 P,A 1 690 P,M 1 539 P PLAA
209533_s_at 9373 1 P 1 772 P 1 581 P PLAA
209544_at 8767 1 P,A 1 257 P 1 653 P RIPK2
209549_s_at 1716 1 P 1484 P 1 553 P DGUOK
209556_at 23154 1 P 1 543 P 1 459 P NCDN
20956 l_at 7059 1 P 0 977 P 1 661 P THBS3, TSP3
209567_at 23212 1 P 1690 P 1 675 P RRS1
209568_s_at 23179 1 P 1 528 P 1 803 P RGL1
209587_at 5307 1 P,A 1 877 P 1 549 P PITX1
209592_s_at 10238 1 P 0 650 P 0 474 P HAN11
209593_s_at 27348 1 P 1 516 P 1405 P TOR IB
209598_at 10687 1 P 2 262 P 4 527 P PNMA2
209607_x_at 6818 1 P 1 454 P 1 529 P SULTI A3
20961 l_s_at 6509 1 P,A 0 725 P,A 0 660 A SLC1A4
209620_s_at 22 1 P 0 806 P 0 621 P hABC7
20963 l_s_at 1 A 1 145 A 2 884 P
20965 l_at 7041 1 P 1 443 P I 746 P TGFB1I1
209653_at 3840 1 P 1 989 P 1 706 P KPN A4
209656_s_at 83604 1 P 1 573 P 2 707 P TM4SF10
209658_at 8881 1 P 1 625 P 1 494 P CDC16, APC6
209666_s_at 1147 1 P 2 045 P 1 912 P CHUK, IKK1
209674_at 1407 1 P 1 379 P 1 626 P CRY1, PHLL1
209694_at 5805 1 P 1 528 P 0 971 P PTS, PTPS
209707_at 10026 1 P 1 562 P 1 851 P PIGK, GPI8
209708_at 26002 1 P 1 371 P 1 766 P MOXD1
209710_at 84724 1 P 2 409 P 2 266 P GATA2
209725_at 27340 1 P 1 526 P 1 377 P DRIM
209750_at 9975 I P,A 1 426 P 1 506 P NR1D2
209759_s_at 1632 1 P 0 607 P 0 464 P DCI
20977 l_x_at 934 I P 2 313 P 4 957 p CD24
l iv
AfTymetrix
Id
Day 0 Day 3 Dav 7
Common NameLocusLink
Normalized Flags Normalized Flags Normalized Flags
209772 s at 934 1 A 1.698 P.A 2.682 P.M CD24; CD24A
209773 s  at 6241 1 P 1.5% P 1.266 P RRM2; R2
209777 s at 6573 1 A 1.629 P.A 1.407 P.M.A SLC19A1
209781 s at 10656 1 P.M.A 1.808 P 2.380 P KHDRBS3
209782 s at 1628 1 P 0.557 P 0.633 P DBP; DABP
209803 s at 7262 1 P.M 1.975 P 2.322 P PHLDA2
209805 at 5395 1 M.A 1.573 P 1.480 P.M PMS2
209818 s at 22927 1 P 1.722 P 2.078 P HABP4
209822 s at 7436 1 P 0.631 P 0.771 P VLDLR
209831 x at 1777 1 P 0.643 P 0.577 P DNASE2
209834_at 9469 1 P.A 2.077 P 2.175 P CHST3
209835 x at 960 1 A 1.292 P 1.919 P CD44; IN
209836 x at 79008 1 P 2.284 1» 2.104 P MGC5I78
209838 at 1 P 1.820 P 1.925 P TRIP15
209840 s at 54674 1 P 1.563 P 1.584 P LRRN3
209841 s at 54674 1 P 1.613 P 1.610 P LRRN3
209845 at 23608 1 P 1.649 P 1.731 P MKRN1; RNF61
209852 x at 10197 1 P 1.772 P 1.512 P PSME3
209865 at 23443 1 P 1.371 P 1.661 P SLC35A3
209875 s at 66% 1 A 1.126 P.M.A 2.060 P SPPI
209892 at 2526 1 P 1.479 P 1.623 P FUT4
209917 s at 11257 1 P 0.782 P 0.565 P.M.A TP53AP1
209921 at 23657 1 P 0.594 P 0.555 P SLC7AII
209927 s  at 26097 \ P 1.547 P 1.346 P DK1ZP547E1010
209934 s at 27032 1 P 1.468 P 1.618 P ATP2CI
209935 at 27032 1 P 1.320 P 1.668 P ATP2CI
209943 at 26235 1 P 1.516 P 1.522 P I BXL4; FBL4
209944 at 57862 1 P 1.431 P 1.512 P ZNF4I0; APA1
209945 s at 2932 1 P 1.524 P 1.358 P GSK3B
209959 at 8013 1 P.M 3.086 P 2.098 P NR4A3
209% 1 s at 3082 1 P 1.011 P 0.630 P HGF; SF; HPTA
209%3 s at 2057 1 P 0.814 P 0.643 P EPOR
209%9 s at 6772 1 P 0.692 P 0.445 A STATI;
209998 at 84720 1 P 0.745 P 0.511 P PIGO
210006 at 25864 1 P 0.761 P 0.638 P DKFZP5640243
210007 s at 2820 1 P 1.624 P 1.722 P GPD2; GDH2
210008 s at 6183 1 P 2.028 P 1.545 P MRPSI2
210009 s at 9570 1 P 1.679 P 1.354 P GOSR2
210010 s at 6576 1 P 0.813 P 0.645 P SLC25A1
210017 at 10892 1 P 1.486 P 1.529 P MALTI
210018 x at 10892 1 P 1.654 P 1.635 P MALTI
210028 s at 23595 1 P 1.590 P 1.225 P ORC3L
210033 s at 9576 1 P.A 1.390 P.M 2.134 P SPAG6
210070 s at 1375 1 P 1.203 P 1.672 P CPTIB
210073 at 6489 1 P A 1.910 P.M 1.135 P.A SIAT8A
210093_s_at 4116 1 P 1.584 P 1.259 P MAGOH
210095 s at 3486 1 P 1.781 P 1.937 P IGFBP3
210105 s at 2534 1 P 1064 P 1.518 P FYN; SLK
21011 2 a t 3257 1 P 1.754 P 2.189 P HPS1; MGC5277
210115 at 116832 1 P 1.592 P 1.522 P RPL39L
lv
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210117 at 6674 1 P 1.977 P 2.118 P SPAG1
210130 s at 7108 1 P 0.348 P 0.229 P TM7SF2; ANG1
210138 at 8601 1 P 1.544 P 0.982 P RGS20
210150 s at 3911 1 P 0.626 P 0.539 P 1.AMA5;
210151 s at 8444 1 A 1.814 P 1.872 P DYRK3
210171 s at 1390 1 P 0.735 P 0.513 P.A CREM
210175 at 6936 1 P 1.626 P 1.294 P C2orf3;
210180 s at 6434 1 P 0.771 P.M 0.649 P SFRSIO
210205 at 8705 1 P 0.589 P.A 0.557 P B3GALT4;
210215 at 7036 1 P 0.919 P 0.637 P TFR2
210216 X  at 5810 \ P 1.537 P 1.419 P RADI; IIRADI
210220 at 2535 1 P 0.606 P 0.621 P FZD2
210221 at 1136 1 P.A 1.546 P.M 1.882 P CHRNA3
210233 at 3556 1 P.A 2.028 P.A 3.241 P ILI RAP
210236 at 8500 1 P 1.685 P 1.947 P PPFIAI; L1PI
210241 s at 11257 1 P 0.700 P.A 0.623 P TP53AP1
210243 s at 8703 1 P 0.737 P 0.503 P B4GALT3
210253 at 10553 1 P 0.522 P.M 0.401 P HTATIP2
210255 at 5890 1 P.A 1.502 P 1.665 P RAD51LI
210284 s at 23118 1 P 1.143 P 1.553 P MAP3K7IP2
210285 X at 9589 1 P 0.784 P 0.609 P WTAP
210298 X at 2273 1 P 1.139 P 1.714 P FHLI
210299 s at 2273 1 P 1.600 P 2.131 P FHLI; KYO-T
210306 at 26013 1 P,A 0.632 P.A 0.858 P.A L3MBTL
210312 s at 1 P 0.579 P 0.611 P LOC904I0
210320 s at 11056 1 P 1.495 P 1.671 P DDX52; ROKI
210336 X at 7593 1 P 0.662 P.A 0.502 P.A ZNF42; MZFI
210337 s at 47 1 P 0.7% P 0.578 P ACLY
210346 s at 1 P 1.401 P 1.908 P CLK1
210358 X at 84724 1 A 2.211 P 1.935 P.M GATA2
210394 X at 6759 1 P 0.712 P 0.644 P SSX4
210396 s at 1 P 1.734 P 1.485 P
210405 X at 8795 1 P 0.632 P.A 0.536 P.A TNFRSFIOB
210415 s at 4957 1 P.M 2.124 P 1.788 P 0DF2
210416 s at 11200 1 P 1.443 P 1.502 P CHEK2
210425 X at 23015 1 P 1.407 P 1.627 P GOLGIN-67
210465 s at 6619 1 P 1.591 P 1.692 P SNAPC3
210480 s at 1 P.A 1.650 P 1.856 P MY06
210513 s at 7422 1 P 0.732 P 0.613 P VEGF
210534 s at 27077 1 P 0.883 P 0.653 P EPPB9
210538 s at 330 1 P.A 5.671 P 6.522 P BIRC3; AIP1
210560_at 2637 1 P.M 3.801 P 3.943 P GBX2
210567 s at 6502 1 P 1.038 P 0.620 P SKP2: FBLI
210580 X at 6818 I P 1.460 P 1.563 P SULTIA3
210605 s at 4240 1 P 1.592 P 2.192 P MFGE8; BA46
210612 s at 8871 1 P.A 1.301 P 1.788 P.A SYNJ2; INPP5II
210622 X at 8558 1 P 0.831 P 0.576 P»A CDKIO
210643 at 8600 1 A 1.536 A 2.189 P TNFSFII
210653 s at 594 1 P 0.735 P 0.446 P BCKDHB; E1B
210667 s at 8209 1 P 0.704 P 0.521 P C2lort33; ESI
Ivi
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210697 at 113835 1 A 1.536 P 1.733 P ZNF257
210715 s at 10653 1 P 0.609 P 0.577 P SPINT2
210720_s_at 63941 1 P 0.754 P 0.629 P APBA2BP
210732 s at 3964 1 P 0.879 P 0.488 P LGALS8
210750 s at 9229 1 P 0.773 P.A 0.586 A DLGAPI
210755 at 3082 1 P 1.676 P 2.079 P HGF; SF;HPTA
210776 X at 1 P 1.554 P 1.571 P TCF3
210802 s at 27292 1 P 0.910 P 0.477 P HSA976I
210809 s at 10631 1 P 1.581 P 1.667 P POSTN;
210815 s at 10203 1 P 0.766 P 0.659 P CALCRL
210869 s at 4162 1 P.A 1.420 P.M 1.589 P MCAM
210871 X at 22892 1 P 1.411 P 1.705 P SSX2IP
210876 at 303 1 P.A 1.519 P.A 1.649 P ANXA2PI
210892 s at 2969 1 P 0.504 P 0.383 P GTF21
210912 X at 2948 1 P 0.895 P 0.583 P GSTM4
210975 X at 10922 1 P 0.769 P.M 0.594 P.A FASTK
210986 s at 7168 1 P 2.091 P 2.377 P TPMI
210987 X at 7168 1 P 1.917 P 2.251 P TPM1
211009 s at 10778 \ P 1.374 P 1.639 P ZNF271
211015 s at 3308 1 P 1.529 P 1.425 P HSPA4
211017 s at 4771 1 P.M 1.893 P 1.562 P NF2
211019 s at 4047 I P 0.548 P 0.416 P.A LSS; OSC
211023 at 5162 1 P 0.814 P 0.591 P PDHB; PHE1B
211027 s at 3551 1 P 0.671 M.A 0.471 A IKBKB
211049 at 51407 1 P 0.763 P.A 0.532 P.A TLX 2
211052 s at 6904 I P 0.651 P 0.492 P TBCD
211088 s at 1 P 0.600 P 0.474 P PLK4
211091 s at 4771 1 P.A 2.657 P 2.214 P NF2
211092 s at 4771 1 A 2.125 P.M.A 1.779 P.M NF2
211126 s at 1466 1 P 1.874 P 1.829 P CSRP2
211200 s at 84288 1 A 3.178 P 4.783 P FGR
211212 s at 5001 1 P 1.528 P 1.502 P 0RC5L
211219 s at 9355 1 A 1.586 P 1.532 P.M L1IX2
211256 X at 11120 1 P 1.556 P 1.710 P BTN2A1
211273 s at 6899 1 P 0.673 P 0.476 P TBXI
211284 s at 28% 1 P 0.607 P 0.738 P GRN; PEPI
211299 s at 2319 1 P 0.701 P 0.521 P FL0T2; ESA
211340 s at 4162 1 P.M.A 1.500 P 2.044 P MCAM
211425 X at 6757 1 P 0.699 P 0.623 P SSXT/SSX4
211458 s at 23766 1 P 1.227 P 1.530 P GABARAPL3
211467 s at 4781 1 P 0.785 P 0.599 P NFIB
211471 s at 9609 1 P 1.552 P 1.370 P RAB36
211474 s at 5269 1 P 0.723 P 0.651 P SERPINB6
211475 s at 573 1 P 0.508 P 0.357 P BAGI
211527 X at 7422 1 P 0.649 P.M 0.501 P.M.A VEGF; VEGFA
211540 s at 5925 1 A 1.537 P.A 2.079 P RBI; OSRC
211552 s at 8659 1 P.A 0.691 P.M. A 0.578 M.A ALDH4AI
211558 s at 1725 1 P 0.820 P 0.558 P DHPS
211559 s at 901 1 P 0.640 P 0.625 P CCNG2
211575 s at 10109 1 P 1.542 P 1.490 P ARPC2
Aflymetrix
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211576 s at 6573 1 P 1.633 P 1.292 P SLCI9A1
211595 s at 64963 1 P 1.832 P 1.626 P MRPS11
211615 s at 10128 1 P 1.825 P 2.026 P LRPPRC
211622 s at 377 I P 0.763 P 0.573 P ARF3
211658 at 7001 1 P 0.894 P 0.573 P PRDX2
211666  X at 6122 1 P 0.705 P 0.607 P RPL3
211671 s at 2908 1 P 1.535 P 1.628 P NR3CI
211672 s at 10093 1 P 0.674 P 0.526 P ARPC4
211675 s at 29969 \ P 1.183 P 1.527 P H1C
211676 s at 3459 1 P 1.724 P 1.740 P IFNGR1; CD119
211700_s_at 7216 1 P 1.254 P 1.931 P TRO
211701 s at 7216 1 P 1.239 P 1.822 P TRO
211707 s at 9657 1 P 1.795 P 1.888 P IQCBI
211721 s at 90233 1 P 1.526 P 1.407 P ZNF551
211724 X at 54468 1 P 1.533 P 1.339 P FU20323
211725 s at 1 P 1.703 P 1.677 P
211752 s at 4727 I P 0.697 P 0.485 P NDUFS7
211800 s at 7375 I P 0.821 P 0.621 P USP4; UNP
211810 $ at 2581 1 P 0.653 P 0.560 P GALC
211814_s_al 9134 I P 2.067 P 1.190 P CCNE2; CYCE2
211833 s at 581 I P 0.585 P 0.415 P BAX
211852 s at 8455 1 P 0.686 P 0.656 P.A ATRN
211855_s_at 9016 1 P 1.527 P 1.671 P SLC25A14
211864 s at 26509 I A 1.785 P.A 2.653 P.M.A FER1L3
211928 at 1778 I P 1.465 P 1.510 P DNCHI; p22
211929 at 1 P 1.393 P 1.548 P hnRNPA3
211932 at 1 P 1.676 P 1.807 P hnRNPA3
211933 s at 1 P 1.563 P 1.745 P hnRNPA3
211937 at 1975 I P 0.624 P 0.547 P EIF4B; EIF-4B
211947 s at 23215 I P.A 1.536 P 1.304 P XTP2
211948 X at 23215 1 P 1.688 P 1.553 P XTP2
211951 _at 9221 1 P 1.710 P 1.755 P N0LC1
211952_at 3843 1 P 1.382 P 1.559 P KPNB3
211953 s at 3843 1 P 1.484 P 1.561 P KPNB3
211973_at 1 P 0.749 P 0.658 P
211976 at 1 P 0.780 P 0.633 P
211982 X at 23214 1 P 1.548 P 1.551 P XP06
211986 at 195 1 P 1.600 P 2.087 P MGC5395
211988 at 6605 1 P 1.504 P 1.573 P SMARCEI
211990 at 3113 1 P.M 1.035 P 2.069 P IILA-DPA1
212010 s at 55573 1 P 1.697 P 1.801 P 1141
212012 at 1 A 0.978 M.A 1.638 P.A D2S448
212014 X at 960 1 P.M 1.150 P.A 1.635 P CD44; IN
212016_s_at 5725 1 P 0.958 P 0.629 P PTBP1
212032_s_at 53635 1 P 0.556 P 0.385 P PTOVI
212037 at 5411 1 P 1.695 P 1.712 P PNN
212038 a at 7416 1 P 1.566 P 1.387 P VDACI
212046 X at 5595 1 P 0.817 P 0.566 P,A MAPK3; ERKI
212052 s at 23061 1 P 0.786 P 0.659 P KIAA0676
212058 at 23350 \ P 0.732 P 0.624 P SRI 40
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212061 at 23350 1 P 0.611 P 0.728 P SRI 40
212063 at 960 1 A 1.154 A 2.336 P CD44
212064 X at 4150 1 P 1.525 P 1.268 P MAZ
212068 s at 23121 1 A 1.304 P 1.523 P KIAA0515
212069 s at 23121 1 P.M.A 1.739 P 1.525 P KIAA05I5
212085_at 293 1 P 0.602 P 0.411 P SLC25A6
2 1 2 0 8 6  X a t 4000 1 P 0.616 P 0.680 P LMNA; FPL
212092 at 23089 1 P 1.623 P 2.188 P PEG 10
212094 at 23089 1 P 1.510 P 2.244 P PEG 10
212097 at 857 1 P 1.505 P 1.269 P CAVI
212099 at 1 P 1.794 P 1.471 P RHOB
212105 s at 1660 1 P 0.683 P 0.470 P DIIX9
212129 at 81614 I P 1.617 P 1.561 P NIPA2
212143 s at 3486 1 P 1.870 P 1.935 P IGFBP3; IBP3
212147 at 23381 1 A 2.328 P 2.305 P.M EST1B
212154 at 6383 1 P,M 1.446 P 1.731 P SDC2
212157 at 6383 1 P 1.581 P 1.986 P SDC2
212158 at 6383 1 P,M 1.448 P 1.961 P SDC2
212163 at 57498 1 P 1.331 P 1.522 P KIDINS220
212165 at 92703 1 P 0.981 P 0.640 P Clort37
212171 X at 7422 I P 0.752 P 0.653 P VEGF
212184 s at 23118 1 P 1.548 P 1.974 P MAP3K7IP2
212190 at 5270 1 P 1.767 P 1.903 P SERPINE2
212194 $ at 9777 1 P 0.827 P 0.601 P KIAA0255
212211 at 26057 1 P 1.542 P 1.582 P ANKRDI7
212214 at 4976 1 A 1.802 P 2.280 P 0PA1
212215 at 9581 1 P 1.337 P 1.890 P KIAA0436
212217 at 1 P 1.186 P 1.630 P KIAA0436
212218 s at 2194 1 P 0.816 P 0.607 P FBX09; FBX9
212222 at 23198 1 P 1.310 P 1.658 P PSME4
212225 at 10209 1 P 0.620 P.M.A 0.468 A su n
212234 at 23393 1 P 1.245 P 1.597 P ASXLI
212249 at 5295 1 P.M.A 1.597 P 1.400 P.A P1K.3R1
212254 s at 667 1 P 1.433 P 1.606 P BP AGI
212259 s at 57326 1 P 0.402 P.A 0.518 P PBXIP1
212274 at 23175 1 A 1.711 P.A 1.836 P.A LPINI
212276 at 23175 1 P 1.703 P 2.027 P LPINI
212294 at 55970 1 P 1.441 P 1.880 P GNG12
212299 at 91754 1 P 1.256 P 1.588 P NEK9
212307 s at 8473 1 P 0.652 P 0.761 P OGT
212310 at 23124 1 P 1.373 P 1.831 P FIJ39207
212312 at 598 1 P 1.720 P 1.476 P BCL2L1
212336 at 2036 1 P 1.964 P 2.035 P EPB4IL1
212339 at 2036 1 A 1.471 P.A 1.942 P EPB4ILI
212350 at 23216 1 P 1.511 P 1.461 P TBC1DI
212361 s at 1 P 0.803 P 0.554 P ATP2A2
212364 at 4430 1 P.A 1.546 P 2.223 P MYOIB; mvrl
212365 at 4430 1 P 1.284 P 1.504 P MY01B; myrl
212366 at 23036 1 P 1.499 P 1.863 P ZNF292
212395 s at 23065 1 P 1.417 P 1.502 P KIAA0090
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212403 al 89910 1 P 0.818 P 0.611 P UBE3B
212418 ai 1997 1 P 1.423 P 1.678 P ELFI
212421 al 23313 1 P 1.390 P 1.579 P C22orf9
212422 al 22984 1 P 1.512 P 1.387 P PDCDll
212434 al 80273 1 P 1.603 P 1.308 P GRPEL1
212436 al 1 P 1.517 P 1.363 P TRIM33
212459 x al 8801 1 P 0.927 P 0.582 P SUCLG2
212461 al 51582 1 P 1.683 P 1.681 P OAZIN
212465 al 84193 1 P 1.574 P 1.7% P FLJ23027
212473 s al 1 P 1.549 P 1.571 P
212483 al 25836 1 P 1.399 P 1.711 P 1DN3; CDLS
212492 s al 23030 1 P 0.539 P 0.626 P JMJD2B
212499 s al 1 P 1.399 P 1.522 P C14orf32
212501 al 1051 1 P 0.545 P 0.492 P CEBPB
212511 ai 1 P 1.386 P 1.544 P PICALM
212514 x al 1654 1 P 0.757 P 0.568 P DDX3X
212525 s al 3014 1 P 0.806 P 0.584 P H2AFX
212542 s ai 55023 1 P 1.454 P 1.621 P PHIP
212559 al 5575 1 P.A 0.655 P.A 0.590 P.A PRKARIB
212565 al 23012 1 P.A 1.596 P 1.861 P STK38L; NDR2
212574 x al 91304 1 P 0.419 P 0.303 P R32I84 3
212593 s al 27250 1 P 0.582 P 0.647 P PDCD4
212594 al 27250 1 P 0.593 P 0.742 P PDCD4
212599 al 26053 1 P 1.728 P 2.244 P AUTS2
212603 al 10240 1 P 1.610 P 1.245 P MRPS3I
212611 ai 23220 1 P 1.154 P 1.530 P MPEGl
212619 al 23306 1 P 1.520 P 1.799 P KIAA0286
212621 ai 23306 1 P 1.204 P 1.514 P KIAA0286
212622 ai 23027 1 P 1.506 P 1.517 P KIAA0033
212623 al 23027 1 P 1.586 P 1.485 P KIAA0033
212624 s al 1123 1 P 2.008 P 2.265 P CI INI
212632 ai 1 P 1.568 P 1.842 P STX7
212635 ai 1 P 1.546 P 1.701 P TNPOl
212636 ai 1 P 1.518 P 1.895 P QKI; QK3
212638 s al 11059 l P 1.509 P 1.340 P WWP1
212641 al 3097 1 P 1.935 P 2.381 P HIVEP2
212642 s al 3097 1 P 1.778 P 1.980 P HIVEP2
212654 al 7169 1 P.A 1.857 P 1.458 P TPM2
212656 al 10102 1 P 0.7% P 0.635 P TSFM
212662 ai 5817 1 P 1.632 P 1.1% P PVR
212665 al 25976 1 P 1.861 P 2.235 P TIPARP
212687 al 1 P 1.554 P 1.710 P LIMSI
212689 s al 55818 1 P 1.557 P 1.603 P JMJDIA
212708 at l P 0.567 P 0.444 P CASC3
212709 at 23279 1 P 1.644 P 1.405 P NUPI60
212710 ai 157922 1 P 1.630 P 1.966 P CAMSAP1
212714 at 113251 1 P 1.577 P 1.678 P LOCI 13251
212721 at 140890 1 P 1.472 P 1.575 P SFRS12
212724 at 390 1 P 1.665 P 2.057 P ARHE
212739 s_at 4833 1 P 0.861 P 0.619 P NME4
Ix
Affvmetrix
Id
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212751 at 7334 1 P 1.321 P 1.519 P UBE2N
212765 at 23271 1 P 1.853 P 1.972 P KIAAI078
212766 s at 81875 1 P 2.169 P 1.782 P F IJI 2671
212767 at 92170 1 P 0.843 P 0.532 P Spm
212774 at 10472 1 P 1.705 P 1.834 P ZNF238
212780 at 6654 1 P 1.534 P 1.433 P SOSI
212803 at 4665 1 P 1.545 P 1.349 P STAT6
212815 at 10973 1 P 1.847 P 1.838 P HELICI
212816 s at 875 1 P 0.521 P 0.390 P CBS
212822 at 57493 1 A 1.501 P.A 1.542 M.A HEG
212826 s at 293 1 P 0.630 P 0.450 P SLC25A6
212828 at 1 P 1.444 P 1.763 P SYNJ2: INPP5H
212829 at 1 P 1.661 P 1.814 P
212830 at 1955 1 P 0.744 P 0.599 P EGFL5
212833 at 91137 1 P 1.508 P 1.587 P LOC91137
212835 at 23172 1 P 1.524 P 1.400 P KIAA0157
212837 at 23172 1 P 1.859 P 1.805 P KIAA0I57
212838 at 23268 1 P 1.626 P 1.937 P DNMBP
212839 s at 1 P 2.098 P 1.924 P SSA2
212845 at 23034 I P 1.822 P 1.638 P SAMD4
212847 at 1 P 1.093 P 1.511 P NEXN
212866 at 1 P.M 0.915 P 0.595 A LOC203069
212877 at 3831 1 P 2.041 P 2.167 P KNS2
212884 X at 348 1 P 0.929 P 1.560 P APOE
212886 at 26112 1 M.A 1.435 P.A 1.536 P DKFZP434C171
212893 at 26009 1 P 1.641 P 1.704 P ZZZ3
212928 at 23270 I P 1.521 P 1.262 P RPS5PI
212934 at 1 P 1.328 P 1.520 P LOCI 37886
212955 s at 5438 I P 0.954 P 0.628 P P0LR2I
212957 s at 1 P 1.331 P 1.813 P LOC92249
212961 X  at 3423 1 P 1.642 P 1.500 P LOC91966
212962 at 85360 1 P.A 1.627 P 1.474 P.A 7h3; FU13511
212969 X at 256364 1 P 0.756 P 0.561 P FIJ35827
212971 at 833 1 P 0.590 P 0.562 P CARS
212977 at 57007 1 M.A 1.989 P 2.528 P CMKORI
212980 at 23021 1 P 1.344 P 1.781 P AHSA2
212990 at 8867 1 P 1.808 P 1.700 P SYNJ1; INPP5G
213012 at 4734 1 P 1.837 P 2.103 P NEDD4
213015 at 1 P 1.046 P.M.A 1.700 P BBX
213016 at 1 P 1.262 P 2.513 P BBX
213021 at 1 P 1.637 P 1.636 P GOSR1
213025 at 55623 1 P 1.567 P 1.448 P FU20274
213032 at 1 P 0.774 P 0.623 P NFIB
213033 s at 1 P.M 0.840 P 0.566 P.A NFIB
213035 at 23243 1 P 1.283 P 1.913 P ANKRD28
213038 at 127544 1 P 1.607 P 1.411 P FU90005
213041 s at 513 I P 0.642 P 0.338 P ATP5D
213044 at 6093 1 P 1.666 P 2.125 P ROCK 1
213064 at 79882 1 P 1.448 P 1.601 P FLJI1806
213069_at 1 M.A 1.948 P 2.214 P HEG
Ixi
Affy metri* 
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DayO Dav 3 Dav 7
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213072 at 157542 1 P 1.892 P 2.322 P MGC130I0
213081 at 9278 1 P 0.768 P 0.622 P ZNF297
213088 s at 23234 1 P 1.547 P 1.408 P KIAA0974
213092 X at 23234 1 P 2.274 P 2.153 P K1AA0974
213093 at 1 P 0.680 P 0.566 P PRKCA
2130% at 9911 1 A 1.340 P.A 1.506 P.M.A HUCEPI1
213097 s at 27000 1 P 1.663 P 1.536 P ZRF1
213115 at 115201 1 P 1.607 P 1.563 P COL4A6
213118 at 23074 1 P 1.500 P 1.683 P KIAA0701
213124 at 25888 1 P 1.537 P 1.385 P ZNF473
213126 at 112950 1 P 0.742 P 0.645 P MED8
213128 s at 7337 1 P 1.507 P 1.451 P UBE3A
213130 at 25888 1 P 1.367 P 1.553 P ZNF473
213135 at 1 P 1.511 P 1.399 P T1AM1
213169 at 1 P 0.725 P 0.426 P.A SEMA5A
213170 at 27234 1 P 0.897 P 0.629 P GPX7
213176 s at 8425 1 P 0.449 A 0.372 A LTBP4
213190 at 91949 1 P 0.937 P 0.633 P C0G7
213191 at 148022 1 P.M.A 1.368 P 1.503 P TRIF
213199 at 26005 1 P.M 1.527 P 1.554 P DKFZP586POI23
213206 at 9570 ! P 1.620 P 1.704 P G0SR2
213207 s at 9570 1 P.A 1.775 P 1.669 P GOSR2
213211 s at 10629 1 P 0.680 P.A 0.548 P.A TAF6L
213216 at 23252 1 P 1.905 P 1.733 P KIAA0459
213223 at 6158 1 P 0.576 P.M 0.519 P.M.A RPL28
213224 s at 27250 1 P.A 1.346 P 1.638 P LOC92482
213225 at 5495 1 P 1.540 P 2.187 P PPM IB
213238 at 57205 1 P 1.342 P 1.752 P ATP 1 OD
213246 at 26175 1 P 1.635 P 1.614 P C14orfl09
213248 at 1 M.A 1.227 P.A 1.503 P.A
213251 at 1 P 1.419 P 1.525 P
213256 at 1 A 1.636 P.M 1.449 P MGC48332
213259 s at 23098 1 P.M.A 1.416 P 1.517 P SARM1
213263 s at 7786 1 P 0.593 P 0.695 P MAP3KI2
213269 at 57209 1 P 1.228 P.A 1.618 P LOC57209
213279 at 1 P 0.5% P 0.533 P DHRSI
213281 at 3725 1 P 2.935 P 3.450 P JIJN
213288 at 1 P 1.4% P 1.743 P LOC129642
213298 at 4782 1 P 0.765 P.A 0.602 P.A NFIC
213306 at 8777 1 P 0.654 P 0.528 P MPDZ
213310 at 1 P 1.573 P 1.664 P EIF2C2
213315 X at 3423 1 P 1.744 P 1.541 P LOC91966
213316 at 1 P 1.745 P 2.185 P
213322 at 221443 1 P 0.686 P 0.577 P MGC19570
213325 at 25945 1 P.A 1.183 P.A 1.525 P PVRL3
213334 X at 11219 1 P 1.500 P 1.024 P TREX2
213338 at 25907 1 A 1.759 P 1.264 PA RISI
213342 at 10413 1 P 1.454 P 1.500 P YAP1
213350 at 6205 1 P 1.644 P 1.540 P RPS1I
213365 at 57638 1 P 1.537 P 1.756 P KIAA1504
Ixii
Affymetrix
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213389 at 1 P,A 1.506 P 1.703 P PNKP
213391 at 1 P 1.345 P 1.635 P LOC286I48
213397 x at 6038 1 P 0.617 P 0.860 P RNASK4
213402 at 1 P 1.689 P 1.276 P LOCI 26208
213410 at 26098 1 1» 1.645 P 1.523 P EDRF1
213411 at 1 P 0.536 A 0.602 A ADAM22
213413 at 11037 1 P.A 1.362 P 1.581 P SBLF
213419 at 323 1 P 0.927 P 0.653 P.A HFE65L
213427 at 10799 \ P 2.554 P 2.132 P RPP40
2I34S2 at 7738 \ P 1.644 P 2.052 P ZNFI84
213469 at \ P 1.545 P 1.921 P F IJI 2377
213471 at 261734 1 P 1.560 P 1.620 P NPIIP4
213474 at 154881 1 P 2.093 P 2.131 P KCTD7
213479 at 4885 1 P 1.568 P 1.722 P NPTX2; NP2
2134%  at 9890 1 P 1.706 P 2.126 P PRG!
213504 at 10980 1 P 1.517 P 1.264 P C0PS6
213505 s at 10147 1 P 1.585 P 1.605 P SFRSI4
213523 at 898 1 P 2.189 P 1.416 P CCNEI
213540 at 7923 1 P 0.525 P.M.A 0.380 A HSDI7B8
213549 at 1 P 1.687 P 1.591 P SLCI8A2
213558 at 27445 1 P 1.275 P 1.509 P PCLO
213581 at 5134 1 P 1.557 P 1.152 P PDCD2
213595 s at 9876 1 P.A 1.452 P 1.786 P CDC42BPA
213599 at 11339 1 P 1.530 P 1.561 P 0IP5
213604 at 1 P 1.401 P 1.554 P TCEB3
213606 s at 3% 1 P 0.988 P 0.529 P ARHGDIA
213607 x at 65220 1 P 0.932 P 0.553 P.A F U 13052
213618 at 116984 1 P 1.800 P 2.212 P CENTDI
213634 s at 55687 1 P 1.620 P 1.176 P FLJ10140
213644 at 201134 1 P 1.679 P 1.888 P MGC33887
213647 at 1763 1 P 1.661 P 1.624 P DNA2L
213653 at 1 P.A 1.365 P 1.574 P METTL3
213671 s at 4141 1 P 0.581 P 0.505 P MARS
213689 x at 6125 1 P 0.749 P 0.641 P RPL5
2136% s at 112950 1 P 0.895 P 0.638 P MED8
213704 at 5876 1 P 1.760 P 1.893 P RABGGTB
213716 s at 6398 1 M.A 1.629 P 2.457 P SECTM1
213722_at 6657 1 P.M 0.650 A 0.564 P.A SOX2
213737 x at 1 P 1.423 P 1.689 P
213742 at 9295 1 P 1.636 P 0.931 P SFRS1I
213757 at 1984 1 P 1.551 P 1.372 P EIF5A
213761 at 56890 1 P 1.700 P 1.566 P MDMI
213780 at 1 A 2.122 P.M.A 2.556 P.A THH
213786_at 8887 1 P 1.543 P 1.904 P TAXIBP 1
213787 s at 10682 1 P 0.694 P 0.555 P EBP
213793 s at 9456 1 P 1.898 P 1.983 P HOMER 1
213795_5_at 5786 1 P 0.811 P 0.584 P PTPRA
213804 at 1 P 0.721 P.A 0.601 P.A INPP5B
213811 x at 6929 1 P 1.592 P 1.605 P TCF3
213812 s at 10645 1 P 0.726 P 0.645 P.M CAMKK2
Ixiii
Affymetrix
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213822_s_at 89910 1 P 1 757 P 1669 P UBE3B
213838_at 51406 1 P 1 559 P 1 641 P NOL7
213846_at 1350 1 P 1 508 P 1 376 P COX7C
213861_s_at 25895 1 P 1 663 P 1 685 P DKFZP586D0919
213869_x_at 7070 1 P 1 348 P 1 801 P THY1
213878_at 79912 1 P 0 730 P 0 568 P RECQL
213882_at 83941 1 P,A 1 648 P,A 1 744 P,A BBP
213887_s_at 5434 1 P 0914 P 0 643 P POLR2E
213889_at 9487 1 P,M,A 1 259 P 1 608 P,M PIGL
213892 s at 353 1 P 0 961 P 0 637 P APRT
213896_x_at 23234 1 P 0 760 P,A 0 564 A KIAA0974
213899_at 10988 1 P 1 778 P 1 785 P METAP2
213906_at 4603 1 P 1 971 P 2 328 P MYBL1
21393 l_at 3398 1 M,A 7 620 P 4 792 P ID2
213939_s_at 1 P,A 1 538 P 1 552 P RIPX
21395 l_s_at 29893 1 P 1 757 P 1 241 P HUMGT198A
213986_s_at 91304 1 P 0415 P 0 291 P,A C19orf6
213989_x_at 54093 1 A 2 067 P 2216 P C21orfl8
213996_at 29799 1 P 0 449 P 0 369 P YPEL1, FKSG3
214005_at 2677 1 P 0 895 P 0 568 P GGCX
214006_s_at 2677 1 P 0 756 P 0 520 P GGCX
214012_at 51752 1 P 0 600 P 0 586 P ARTS-1
214023_x_at 7280 1 P 1 522 P 2 003 P MGC8685
214030_at 131544 1 P 1 458 P 1 609 P MINA
214052_x_at 23215 1 P 1 745 P 1 528 P XTP2
214055_x_at 23215 1 P 1 803 P 1 539 P XTP2
214083_at 5527 1 A 1 769 P,A 2 598 P PPP2R5C
214096_s_at 6472 1 P 0 755 P 0 526 P LOC56901
214097_at 6227 1 P 2 074 P 2 319 P RPS21
214107_x_at 9520 1 P 0 738 P 0 595 P NPEPPS
214112_s_at 3423 1 P 1 563 P 1 394 P LOC91966
214113_s_at 9939 1 P t 565 P 1 529 P RBM8A
214114_x_at 10922 1 P 0 821 P 0 660 P FASTK
214126_at 1 A 1 409 P 1 505 P,A MCART1
214151_s_at 9488 1 P 1 326 P 1 641 P CPR8
214152 at 9488 1 P 1 186 P 1 601 P CPR8
214155_s_at 113251 1 P 1 532 P 1 404 P LOCI 13251
21415 7_at 2778 1 P 2 270 P 2 470 P GNAS
214177_s_at 57326 1 P 0515 P 0 748 P PBX1P1
214182_at 382 1 P 1 517 P 1 510 P ARF6
214193_s_at 27042 1 P 1 562 P 1 729 P MGC29875
214196_s_at 1200 1 P 0 613 P 0 572 P CLN2
214205_x__at 10539 1 P 1 565 P 1661 P TXNL2, PICOT
214210_at 10478 1 P 1 506 P 1 382 P SLC25A17
214240_at 2586 1 P 1 747 P 1 651 P GAL
214247_s_at 10530 1 M,A 1 262 P,A 2 240 P DKK3
214251_s_at 4926 1 P 0 526 A 0 379 A NUMA1
214252_s_at 1203 1 P 0 745 P 0 646 P CLN5
214258_x_at 10524 1 P 0 720 P 0 549 P HTATIP
214260_at 10920 1 P A 1 712 P 1 757 P COPS8
lx i v
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214266 s at 9260 1 P 0.995 P 0.592 P.A PDLIM7
214290 s at 8337 1 P 0.651 P 0.739 P HIST2H2AA
214293 at 55752 1 P 2.149 P 2.454 P F U  10849
214306 at 4976 1 P 1.422 P 1.581 P OPAI
214310 s at 7542 1 P 0.803 P 0.516 P.M ZFPLI
214313 s at 9669 1 P.M 1.993 P 1.565 P IF2
214336 s at 1314 1 P 0.581 P 0.523 P PEXI9
214383 X at 116138 1 P 0.738 P 0.562 P K.LHDC3
214409 at 10737 1 P.A 1.564 P 1.481 P RFPL3S
214427 at 4839 1 P 1.670 P 1.497 P NOLI; pl20
214434 at 9893 1 P 1.454 P 1.763 P HSPAI2A
214437 s at 6472 1 P 0.654 P 0.441 P SHMT2; GLYA
214442 s at 9063 1 P 1.504 P 1.634 P PIAS2; miz
214500 at 9555 1 P 1.610 P 1.673 P H2AFY; H2A.y
214505 s at 2273 1 P 1.179 P 1.627 P FHLI
214507 s at 23404 1 P 1.731 P 1.451 P EX0SC2; p7
214578 s at 6093 1 P 1.962 P 2.297 P ROCKI
214581 X at 27242 1 A 2.256 P 2.572 P TNFRSF2I
214594 X at 5205 1 P 1.361 P 1.582 P ATP8B1
214639 s at 3198 1 P 1.975 P 2.030 P H0XA1
214649 s at 8898 1 P 1.768 P 1.610 P MTMR2
214657 s at 1 P 0.624 P 0.658 P.A
214662 at 23160 1 P 1.615 P 1.666 P KIAA0007
214683 s at 1195 1 P 1.269 P 1.748 P CLKI
214690 at 9014 1 P 1.501 P 1.549 P TAF IB
214691 X at 54629 1 P 0.649 P 0.682 P.A KlAAl 164
2146% at 84981 1 P.A 1.757 P 1.684 P MGC14376
214716 at 55589 1 P.A 1.361 P.A 1.693 P.A BMP2K
214722 at 1 P 1.285 P 1.820 P LOC376745
214727 at 1 P 1.690 P 1.702 P BRCA2; FAD
214742 at 22994 1 P.M 0.790 P.A 0.567 A AZI 1 ; A Z1
214778 at 1954 1 P 0.413 P.A 0.378 P.A EGFL4; MEGF8
214784 X at 23214 1 P 1.555 P 1.487 P XP06
214794 at 1 P 1.629 P 1.492 P PA2G4
214816 X at 91442 1 P 1.723 P 1.505 P MGC32020
214828 s at 91695 1 P 1.778 P 1.323 P dJ222E 13.2
214835 s at 8801 1 P 0.765 P 0.594 P SUCLG2
214878 at 7587 1 P,A 1.563 P.A 1.470 P ZNF37A
214909 s at 23564 1 P 1.487 P 1.548 P DDAH2
214924 s at 22906 1 P 1.576 P 1.699 P OIPI06
214934 at 11071 1 P 0.618 P 0.604 P.M ATP9B
214960 at 8539 1 M.A 1.508 P 1.309 P.A API5;
214983 at 64595 1 P 1.735 P 1.751 P TTTYI5
214992 s at 1777 1 P 0.3% P 0.393 P DNASE2
215001 s at 2752 1 P 1.544 P 1.835 P GLUL; GLNS
215009 s at 1 P 1.715 P 1.862 P SEC3IL1
215014 at 1 A 2.582 P.A 2.067 P.A
215016 X at 667 1 P 1.359 P 1.543 P BPAG1 ; BP240
215047 at 25893 1 P 1.532 P 1.524 P DKFZp434C091
215073 s at 1 P 1.171 P 1.517 P NR2F2
Ixv
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215079_at 1 P 1351 P 1 574 P
215090_x_at 9520 1 P 0 773 P 0 596 P FLJ11822
215099_s_at 6257 1 P 0 509 P,A 0 386 M,A RXRB
21511 l_s„at 8848 1 P 1 344 P 1 642 P TGFB1I4
215116_s_at 1759 1 P 0 644 P 0 529 P DNM1
215143_at 1 P 1 271 P 1 504 P FLJ36166
215146 s at 23331 1 P 0 672 P 0 658 P KIAA1043
215158_s_at 9191 1 P 1 502 P 1265 P DEDD, DEFT
215159_s_at 65220 1 P 0 870 P 0 561 P,A FLJ13052
215165 x at 7372 1 P 1 571 P 1 279 P UMPS, OPRT
215167_at 9282 1 A 1 504 P,A 1 396 P CRSP2
215170 s at 22995 1 P,A 1 249 P,M,A 1510 P KIAA0912
215171 _s_at 10440 1 P 1 560 P 1 339 P TIMM17A
215204_at I A 1 324 P,M,A 1 575 P,A
215220_s_at 1 P 0713 P 0 588 P TPR
215242_at 1 A 1 579 P 1 712 P,A PIGC
215324_at 223117 1 P 0 962 P 0 649 P SEMA3D
215359_x_at 7595 1 P 1424 P 1 714 P ZNF44
215380 s at 79017 1 P 1 549 P 1479 P MGC3077
215424_s_at 22938 1 P 1645 P 1485 P SK11P
215425_at 10950 1 P I 612 P 1 852 P BTG3, ANA
215440_s_at 56271 1 P 0 601 P 0 747 P BEXL1
215446_s_at 114990 1 P,M,A 1 166 P,A 1 554 P LOX
215493_x_at 11120 1 P 1625 P 1 776 P BTN2A1
215495_s_at 23034 1 P,A 2 971 P 2 223 P SAMD4
215532_x_at 57615 1 P 1641 P 1 867 P ZNF492
215548_s_at 23256 1 P 1 624 P 1 393 P SCFD1
215629_s_at 79469 1 P 0 950 P 0 564 P BCMSUNL
215643_at 1 P 0 676 P 0 503 P SEMA3D
215684_s_at 84164 1 P 1 802 P 1 708 P ASClplOO
215695_s_at 8908 1 P 1 692 P 2 522 P GYG2
215706_x_at 7791 1 P 1978 P 1729 P ZYX
215719_x_at 355 1 P 1 317 P,A 1 961 P,A TNFRSF6
215722_s_at 6627 1 P 1 995 P 1 759 P SNRPA1
215723_s_at 5337 1 P 0 723 P 0 568 P PLD1
215728_s_at 11332 1 P 0 804 P 0 540 P BACH
215735_s_at 7249 1 P 0 881 P 0612 P TSC2
215743_at 10557 1 P 1 402 P 1 748 P RPP38
215747_s_at 1104 1 P 0 898 P 0 660 P CHC1, RCC1
215760_s_at 22904 1 P,M 0 784 P,A 0 544 P,A KIAA0963
215765_at 10489 1 P 1 704 P 1 931 P MUF1
215772_x_at 8801 1 P 0 968 P 0 567 P SUCLG2
215780_s_at 1 P 0 797 P 0 658 P
215812_s_at 1 P 1 576 P 1 364 P SLC6A10
215842_s_at 23250 1 P 0 793 P 0 520 P ATP11A
215891_s_at 2760 1 P 0 649 P M A 0 625 M,A GM2A, SAP-3
215945_s_at 23321 1 P 1 304 P 1 634 P TRIM2 RNr86
216041_x_at 2896 1 P 0 633 P 0 778 P GRN, PEPI
216044_x_at 6125 1 P 0 692 P 0 608 P RPL5
216064_s_at 175 1 P 0 635 P 0 568 P AGA
lx v i
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216080 s at 3995 1 P 0.716 P 0.570 M.A FADS3
216228 s at 11169 1 P 1.783 P 1.705 P WDHD1
216246 at 6224 1 P 1.512 P 1.300 P RPS20
216248 s at 4929 1 P 1.955 P 1.338 P NR4A2; NOT
216250 s at 9404 1 P 1.477 P 1.986 P LPXN
216253 s at 29780 1 P 0.893 P 0.645 P PARVB
216282 x at 5432 1 P 1.579 P 1.305 P POLR2C
216299 s at 7517 I P.A 2.575 P 2.219 P XRCC3
216305 s at 6936 1 P 1.979 P 2.205 P MRPLI9
216338 s at 25844 1 P 0.617 P 0.537 P KLIPI
216379 x at 934 1 P 2.247 P 4.929 P NaGLTl
216411 s at 196951 1 P 0.673 P.A 0.539 P.A FLJ32800
216537 s at 27036 1 P.A 1.631 P.A 1.743 P SIGLEC7; p75
216556 x at 1 P 0.622 P 0.673 P
216559 x at 1 P 0.710 P 0.570 P
216685 s at 1 P.A 1.085 P 0.619 P.A MTAP
216705 s at 1 P.M.A 0.778 P.M 0.509 A ada
216733 s at 2628 \ P 0.602 P 0.727 P GATM;AGAT
216746 at 1 A 1.363 M.A 1.515 P.A
216855 s at 3192 1 P 0.676 P 0.610 P.A HNRPU
216860 s at 10220 1 P 0.661 P.A 0.481 A GDF11
216899 s at 8935 1 P 1.360 P 1.617 P SCAP2
216941 s at 9014 1 P 1.544 P 1.411 P TAF1B
216969 s at 3835 1 P 0.694 P 0.529 P KNSL4
216971 s at 5339 1 P.A 0.571 A 0.486 M.A PLEC1
216975 x at 4861 1 A 1.927 P 1.4% M.A NPASI
216977 x at 6627 1 P 1.935 P 1.670 P SNRPA1
217007 s at 8751 1 P 0.599 P 0.595 P ADAM 15
217010 s at 995 1 P 0.590 P 0.619 P.A CDC25C
217028 at 7852 1 A 1.586 P.A 3.898 P CXCR4
217127 at 1491 1 P 0.608 P 0.590 P CTH
217150 s at 4771 1 P.A 1.900 P 1.784 P NF2
217168 s at 9709 1 P 0.562 P 0.467 P HERPUDI;
217173 s at 3949 1 P 0.730 P.A 0.595 A l-DLR; FH; FHC
217185 s at 1 P 2.112 P 1.671 P ZNF259P
217188 s at 11161 1 P 0.704 P 0.507 P C l4orfl
217250 s at 26038 1 P.A 1.525 P 1.394 P CHD5
217284 x at 253190 1 P 0.745 P.M.A 0.515 A dJ222E 13.1
217289 s at 2542 1 P 0.584 P 0.428 M.A G6PC
217299 s at 4683 1 P 1.578 P 1.280 P NBSI
217309 s at 10311 1 P.M 0.695 P.A 0.643 P.A DSCR3
217317 s at 60438 1 P 1.539 P 1.877 P MN7
217364 x at 1 P 1.527 P 1.392 P
217370 x at 1 P 0.724 P 0.548 P
217416 x at 1 P.A 1.350 P 1.502 P VAPA
217437 s at 6867 I P.A 1.638 P 1.501 P TACCI
217492 s at 11191 1 P 1.555 P 1.407 P PTENP1
217494 s at 11191 1 A 1.647 P 1.291 P.M.A PTENPI
217543 s at 8720 1 P 0.801 P 0.637 P MBTPSI
2l7554_at 1 P 1.659 P 1.629 P .
Ixvii
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217585 at 1 P 1.893 P 2.274 P NEBL
217591 at 1 P 1.648 P 1.462 P SKIL
217604 at 1 P,A 1.533 P 1.314 P
217618 x at 1 P 1.555 P 1.525 P HUSI
217631 at 23560 1 P.A 1.498 P 1.714 P GTPBP4
217678 at I P 0.599 P 0.602 P SLC7A11
217682 at 1 P 1.474 P 1.773 P PR00149
217722 s at 51335 1 P 1.491 P 1.554 P NEUGRIN
217738 at 10135 1 P 1.524 P 1.838 P PBEFl
217752 s at 55748 1 P 1.723 P 1.313 P CNDP2
217766 s at 23585 1 P 1.244 P 1.579 P SMP!
217784 at 10652 1 P 1.607 P 1.343 P YKT6
217786 at 10419 1 P 1.570 P 1.320 P SKB1
217787 s at 2590 1 P 0.866 P 0.632 P GALNT2
217789 at 58533 1 P.A 1.380 P 1.619 P SNX6
217790 s  at 6747 I P.A 1.345 ? A 1.524 P SSR3; TRAPG
217806 s at 26073 1 P 1.743 P 1.434 P P0LDIP2
217807 s at 29997 1 P 0.726 P 0.556 P GLTSCR2
217808 s at 79109 1 P 1.567 P 1.269 P MAPKAP1
217809 at 28969 1 P 1.843 P 1.913 P BZW2
217820 s at 55740 I P 1.708 P 1.932 P ENA11: mcna
217829 s at 10713 I P 1.555 P 1.549 P USP39
217835 x at 55969 1 P 1.628 P 1.503 P C20orf24
217842 at 51631 1 P 1.654 P 1.806 P LUC7L2
217844 at 58190 1 P 0.733 P 0.574 P CTDSPI
217846 at 5859 1 P 0.771 P 0.552 P QARS
217858 s at 51566 1 P 1.399 P 1.866 P ARMCX3
217859 s at 55334 1 P 1.455 P 1.605 P SLC39A9
217872 at 55011 1 P 0.690 P 0.514 P FU20643
217890 s at 55742 1 A 1.689 P.A 1.605 P.A PARVA
217892 s at 51474 1 P 1.506 P 1.577 P EPLIN; SREBP3
217895 at 55037 1 P 0.743 P 0.544 P F1J20758
217896 s at 80011 1 A 1.551 P 1.621 P NIP30
217897 at 53826 1 P.A 1.533 P.M 2.4% P FXYD6
217901 at 1 P.A 1.161 P 1.823 P DSG2
217905 at 79892 1 P 1.460 P 1.565 P F U 13081
217907 at 29074 1 P 1.624 P 1.402 P MRPL18
217919 s at 28977 1 P 1.948 P 1.713 P MRPL42
217923 at 23578 1 P 1.514 P 1.197 P PEF; PE FUN
217930 s at 54472 1 P 0.774 P 0.573 M.A 70LLIP
217932 at 51081 1 P 1.523 P 1.209 P MRPS7
217936 at 1 P 1.319 P 1.794 P ARHGAP5
217941 s at 55914 1 P 1.427 P 1.633 P ERBB2IP
217942 at 60488 1 P 1.634 P 1.605 P MRPS35
217966 s at 1164% 1 P 0.727 P 0.606 P Clorf24; NIBAN
217967 s at 1164% 1 P 0.652 P 0.619 P Clorf24; NIBAN
217980 s at 54948 1 P 0.849 P 0.610 P MRPLI6
217985 s at 11177 1 P 1.614 P 1.279 P BAZIA
217986 s at 11177 1 P 1.563 P 1.344 P BAZ1A
217987 at 54529 1 P 1.895 P 1.720 P NS3TPI
Ixviii
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217988 at 57820 1 P 1.421 P 1.786 P CCNB11PI
217992 s at 79180 1 P 1.505 P 1.453 P EFHD2
217994 x at 54973 1 P 0.710 P 0.527 P FU20542
217996 at 22822 1 P 1.680 P 1.598 P PHLDAI
217997 at 22822 1 P 2.140 P 2.698 P PHLDA1
218012 at 64061 1 P 1.892 P 2.115 P SE20-4
218021 at 10901 1 P 0.866 P 0.592 P.M DHRS4
218022 at 51231 1 P 0.724 P.M.A 0.647 P.M. A VRK3
218024 at 51660 1 P 1.651 P 1.078 P BRP44I.
218029 at 79567 1 A 1.656 P 1.665 P FLJ13725
218050 at 51569 1 P 1.366 P 1.552 P Ufml; BM-002
218060 s at 79650 1 P.A 1.814 P 1.548 P FLJ13154
218061 at 4201 1 P 1.573 P 1.342 P MEA: HYS
218066 at 10723 1 P 1.391 P 1.645 P SLC12A7
218070 s at 29926 1 P 1.025 P 0.622 P GMPPA
218071 s at 23609 1 P 1.554 P 1.523 P MKRN2
218091 at 3267 1 P 1.469 P 1.843 P HRB
218092 s at 3267 1 P 1.708 P 1.800 P HRB
218099 at 55852 1 P 1.416 P 1.579 P UT008
218100 s at 55081 1 P 1.767 P 1.785 P ESRRBL1
218104 at 54881 1 P 1.255 P 1.559 P TEX 10
218105 s at 51073 1 P 0.842 P 0.580 P MRPL4
218106 s at 55173 I P 1.551 P 1.634 P MRPSIO
218107 at 80232 1 P 1.569 P 1.714 P WDR26
218108 at 55148 1 P 1.565 P 1.423 P CI4orfl30
218117 at 9978 1 P 1.560 P 1.482 P RBX1; ROCI
218124 at 54884 1 P 0.639 P 0.512 P FLJ202%
218138 at 8195 1 P 1.382 P 1.550 P MKKS
218139 s at 55745 1 P 1.482 P 1.757 P FLJ10813
218145 at 57761 1 P 0.262 P 0.251 P TRIB3; NIPK
218146 at 55830 1 P 0.682 P 0.448 P AD-017
218147 s at 55830 1 P 0.554 P 0.326 P AD-017
218156 s at 55720 1 P 1.643 P 1.307 P F IJ 10534
218163 at 28985 1 P 1.731 P 1.638 P MCTS1; MCT-1
218181 s at 54912 1 P 1.420 P 1.770 P MAP4K4
218187 s at 65265 1 P 1.746 P 1.817 P FU20989
218199 s at 65083 1 P.A 1.915 P 1.766 P N0L6: NRAP
218205 s at 2872 1 P 0.870 P 0.615 P MNK2
218214 at 60673 1 P 1.514 P 1.478 P FLJ11773
218244 at 55035 1 P 1.867 P 1.760 P N0L8; Nop 132
218248 at 63901 1 P 1.510 P 1.685 P FIJ22794
218261 at 10053 1 A 1.737 P 1.907 P APIM2
218262 at 64777 1 P 0.800 P 0.551 P FU22318
218269 at 29102 1 P 1.773 P 1.844 P RNASE3L
218272 at 55020 1 P.A 0.860 P.A 0.590 A FIJ20699
218275 at 1468 1 P 0.852 P 0.514 P.M.A SLC25AIO; DIC
218282 at 55741 1 P 0.776 P 0.561 P C20orl31
218290 at 55111 1 P 0.775 P 0.574 P PLEKHJ1
218291 at 28956 1 P 0.751 P 0.520 P MAPBP1P
218299 at 53838 1 A 1.803 P 1.628 P C llorf24
Ixix
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218303 x at 51315 1 P 1.326 P 1.548 P LOC513I5
218304 s at 114885 1 P 1.587 P 1.589 P 0SBPL1I
218307 at 55316 1 P 0.767 P 0.451 P F U I 1164
218309 at 55450 1 P 1.236 P 1.859 P CaMKIINalpha
218310 at 27342 1 P 1.327 P 1.566 P RABGEFI
218332 at 55859 1 P 1.447 P 2.236 P BEXI
218333 at 51009 1 P 1.519 P 1.240 P F-LANa
218335 x at 79155 1 P.M.A 1.512 P 1.510 P TNIP2
218336 at 5202 1 P 1.746 P 1.605 P PFDN2: PFD2
218341 at 79717 1 P 1.535 P 1.466 P F U I 1838
218348 s at 29066 1 P 1.407 P 1.561 P ZC3HDC7
218355 at 24137 1 P 1.290 P 1.517 P KIF4A;
218356 at 29960 1 P 1.912 P 1.603 P FTSJ2; FJHI
218358 at 79174 1 P 0.788 P 0.463 P MGC11256
218364 at 9209 1 P 1.583 P 1.956 P LRRFIP2
218367 x at 27005 1 P 0.798 P 0.535 P USP2I
218374 s at 57102 1 P 1.685 P 1.754 P CI2orf4
218380 at 60368 1 P 1.776 P 2.641 P NALPI
218383 at 54930 1 P 0.704 P 0.527 P C14orf94
218385 at 55168 1 P 1.556 P 1.319 P MRPS18A
218388 at 257% 1 P 0.770 P 0.639 P PGLS; 6PGL
218394 at 79641 1 P 0.635 P 0.464 P FU22386
218408 at 26519 1 P 1.671 P 1.489 P TIMM 10;
218414 s at 54820 1 P 0.598 P 0.698 P.A NDE1;
218417 s at 55652 1 P.M.A 2.012 P 1.914 P FIJ20489
218424 s at 55240 1 P 1.722 P 1.318 P TSAP6
218426 s at 54476 1 P 0.737 P 0.541 M.A TRIAD3
218434 s at 65985 1 P 0.605 P 0.577 P AACS
218438 s at 80306 1 P 0.852 P 0.591 P EG1
218442 at 7268 1 P 1.800 P 1.705 P TTC4
218456 at 65981 1 P 1.487 P 1.682 P C1QDCI
218465 at 55161 1 P 1.599 P 1.797 P FLJ10525
218466 at 79735 1 P 0.713 P 0.542 P TBC1D17
218488 at 8891 1 P 1.510 P 1.331 P EIF2Bgamma
218490 s at 55900 1 P 1.117 P 1.570 P ZNF302
218493 at 7%22 1 P 1.545 P 1.137 P C16orf33
218496 at 246243 1 P 1.563 P 1.461 P RNASEH1
218497 s at 246243 1 P 1.579 P 1.223 P RNASEH1
218499 at 51765 1 P 1.290 P 1.564 P MST4; MASK
218500 at 51337 1 P 0.718 P 0.529 P.M LOC5I337
218507 at 29923 1 P 1.447 P 1.521 P 11102
218508 at 55802 1 P.A 1.520 P 1.281 P HSA275986
218513 at 55319 1 P 1.584 P 1.579 P F U I 1184
218517 at 79960 1 P 1.442 P 1.593 P PHFI7;
218518 at 51306 1 P 1.117 P 1.579 P C5orf5: N61
218523 at 64077 1 P 0.606 A 0.417 A LHPP
218535 s at 55781 1 P 1.637 P 1.683 P R10K2
218536 at 1 P 0.895 P 0.654 P MRS2L
218545 at 55297 1 P 1.480 P 1.781 P F U  11088: p56
218547 at 79947 1 P 1.580 P 1.366 P DHDDS
Ixx
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218561 s at 57128 1 P 1.821 P 1.477 P C6orfl49
218564 at 55159 1 P 1.714 P 1.825 P F IJI 0520
218566 s al 26973 1 P 1.794 P 1.825 P CHORDCI
218574 s at 29995 1 P 1.989 P 1.766 P LMCD1
218575 at 64682 1 P 1.672 P 1.502 P ANAPC1
218576 s at 11266 1 P 1.662 P 1.763 P DUSP12; YVHI
218579 s at 60625 1 P.M.A 1.738 P 1.392 P DHX35
218585 s at 51514 1 P 1.974 P 2.025 P RAMP; L2DTL
218588 s at 10827 1 P 1.236 P 1.591 P C5orf3; I33K02
218590 at 56652 1 P 1.757 P 1.689 P PE01; TWINl.
218591 s at 79954 1 P.A 1.556 P.A 1.538 P.A F U 14075
218608 at 23400 1 P 0.768 P,A 0.488 PA HSA9947
218625 at 51299 1 P 1.937 P 2.374 P NRN1
218640 s at 79666 1 P 1.514 P 1.939 P PLEKHF2
218642 s at 79145 1 P.M 2.367 P 2.145 P CHCHD7
218647 s at 79693 1 P 1.771 P 1.577 P FLJ23476
218664 at 51102 1 P 0.843 P 0.619 P CGI-63; NRBFI
218670 at 80324 1 P 1.812 P 1.590 P PUS1; MLASA
218672 at 79005 1 P.A 1.655 P 1.623 P SCNM1
218675 at 57100 1 P.A 1.305 P 1.712 P SLC22A17
218679 s at 51160 1 P 0.772 P 0.526 P VPS28
218681 s at 23753 1 P 0.949 P 0.617 P SDF2L1
218688 at 26007 1 P 0.712 P 0.438 PA DKFZP586B1621
218689 at 2188 1 A 1.654 PA 1.803 P FANCF; FAF
218692 at 55638 1 P 1.338 P 1.573 P FU20366
218701 at 51110 1 P 1.298 P 1.548 P LACTB2; CGI-83
218708 al 29107 I P 1.755 P 1.500 P NXT1; P15
218710 at 55622 1 P 1.656 P 1.628 P FU20272
218712 at 54955 1 P 1.597 P 1.447 P FU20508
218714 al 78994 1 P 0.848 P 0.559 P MGC312I
218715 at 55813 1 P 1.621 P 1.443 P HCA66
218719 s at 64785 1 A 1.640 P 1.328 P F U 139 2
218721 s at 54953 1 P 1.661 P 1.865 P FLJ20505
218731 s at 64856 1 P 0.615 P.A 0.378 A WARP
218733 at 55167 1 P 1.573 P 1.672 P F U  10546
218736 s at 54873 1 P 1.563 P 1.437 P PALMD
218740 s at 80279 1 P 0.839 P 0.635 P CDK5RAP3
218750 at 79101 1 P 1.754 P 1.834 P MGC5306
218751 s at 55294 1 P 1.541 P 1.416 P FBXW7; AGO
218754 at 79707 1 P 1.565 P 1.487 P FU23323
218757 s at 65109 1 P 1.456 P 1.539 P UPF3B
218760_at 51004 1 P 1.701 P 1.388 P COQ6
218767 at 57109 1 P.M.A 1.537 P 1.392 P XPMC2II
218768 at 57122 1 P 1.680 P 1.703 P NUPI07
218772 x at 55151 1 P 1.523 P 1.808 P C9orf87
218773 s at 22921 1 P 0.746 P 0.514 P MSRB
218774 at 28960 1 P 1.524 P 1.088 P DCPS
218777 at 80346 1 P 0.681 P 0.636 P PP432
218783 at 25896 1 P 1.709 P 2.043 P DKFZP434BI68
218813 s at 56904 1 P 0.747 P 0.546 P SH3GLB2
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218820 at 56967 1 P 1258 P,M 1 785 P C14orfl32
218825 at 51162 1 P 0 578 A 0 448 A EGFL7, ZNEU1
218834_s_at 54972 1 P 0 635 P 0 577 P HSPA5BP1
218836_at 79897 1 P 1633 P 1 323 P RPP21
218838_s_at 64427 1 P 0 949 P 0 653 P FLJ12788
218847_at 10644 1 P 1 759 P 1 615 P IMP-2
21885 l_s_at 55339 1 P,A 2 367 P 3 437 P WDR33
218853_s_at 56180 1 P 1435 P 1 655 P MOSPD1
218871_x_at 55454 1 P 1 504 P 1 581 P GALN ACT-2
218880_at 2355 1 P 2 146 P 1 984 P FOSL2
21888 l_s_at 79579 1 A 1 561 P 1 534 M,A FOSL2
218882_s_at 10885 1 P 1697 P 1 651 P WDR3
218884_s_at 60558 1 P 1 701 P 1 852 P FLJ 13220
218885 s at 79695 1 P 0 501 P 0 335 P GALNT12
218886_at 55003 1 P 2 000 P 1 604 P PAKIIPI
218889_at 64318 1 P 1 513 P 1 356 P ClOorfl 17
218901_at 57088 1 P,A 1 478 P,A 1 596 P,M,A PLSCR4
218904_s_at 55071 1 P 1605 P 1 531 P FLJ10110
218915_at 51219 1 P 2219 P 2 288 P NF2, CAN
218918_at 57134 1 P 0 568 P,A 0 674 P,A M ANICI, HMIC
218921_at 59307 1 P 0 682 P 0 539 P SIGIRR
218923_at 1486 1 P 1 300 P 1 766 P SPAT Al
218924_s_at 1486 1 P 1 225 P 1 665 P CTBS
218929_at 55602 1 P 1 411 P 1 703 P CARF
218932_at 54680 1 P 2 273 P 2 580 P FLJ20729
218938_at 79176 1 P,M 0 742 A 0 639 M,A MGC11279
218941_at 26190 1 P 1 564 P 1 423 P FBXW2, FBW2
218948_at 55278 1 P,A 1 646 P 1 628 P,M QRSL1, GatA
218949_s_at 55278 1 P 1658 P 1 474 P QRSL1
21895 l_s_at 55344 1 P 0 641 P 0 707 P FLJ11323
218953_s_at 78991 1 P 0 759 P 0 388 P MGC3265
218959_at 3226 1 P 1 272 P 1 609 P HOXCIO
218961_s_at 11284 1 P 0 613 P 0 397 P PNKP
218972_at 55761 1 P 1 527 P 1 823 P TTC17
218977_s_at 54952 1 P 0 900 P 0 624 P SECP43
218981_at 57001 1 P 1 635 P 1620 P ACN9, DC 11
218983_at 51279 1 P 0 303 A 0 252 P,A C1RL, C1RL1
218995 _s_at 1906 1 A 2 095 P,M 1 952 P,M EDN1, ET1
218997_at 64425 1 P 1 915 P 1 583 P PAF53
219000_s_at 79075 1 P 2 121 P 2 086 P MGC5528
219004_s_at 54069 1 P 1 643 P 1 610 P C21orf45
219007_at 79700 1 P 1 549 P 1 579 P NUP43
219008_at 60526 1 P 1 701 P 1 366 P FLJ21820
219010_at 55765 1 P I 398 P 1 623 P FLJ10901
219014_at 51316 1 P 1 861 P 2 168 P PLAC8, C15
219022_at 64897 1 P 1576 P 1 373 P FLJ 12448
219026_s_at 9462 1 P 1 696 P 1 785 P RASAL2
21903 l_s_at 51388 1 P 1 711 P 1 518 P CGI-37
219032_x_at 23596 1 P 0 952 P 0 490 P OPN3
219037_at 51018 ..... 1 p 1 598 P 1 501 p 1 CGI-115
lx x i l
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219038 at 79710 1 P 1 248 P 1 550 P ZCWCC2
219049 at 55790 1 P M 1 639 P 1 430 P ChGn
219066 at 60490 1 P,M 1 553 P 1 464 P MDS018
219069 at 54851 1 P 1 548 P 1 652 P FGIF, FLJ20189
219070 s at 64598 1 P 0 782 P 0 572 P M0SPD3
219073 s at 114884 1 P,A 1 149 P 1 608 P OSBPLIO
219081 at 54882 1 P 1 326 P 1 508 P
ANKHD1,
MASK
219083 at 55164 1 A 1 777 P 1 791 P,M FLJ10539
219088 s at 79177 1 A 1 545 P,M 1 168 P,M ZNF576
219094 at 29067 1 P,A 1 820 P 1 903 P HSPC056
219102 at 57333 1 P 0 634 P 0 637 P RCN3, RLP49
219105 x at 23594 1 P 1 631 P 1 546 P ORC6L
219109 at 79582 1 P 1 345 P 1 524 P PF20, WDR29
219125_s_at 55974 1 P 0813 P 0 645 P LOC55974
219126 at 55274 1 P 0 604 P 0 521 P PHF10
219130 at 54482 1 P 1 297 P 1 603 P FLJ 10287
219138 at 9045 1 A 1 544 P>A 1 169 P,A RPL14
219142_at 65997 1 P 1 280 P 1 628 P RASL11B
219147 s at 54981 1 P 0 654 P 0 567 P NRK1
219149 x at 51163 1 P,M 1 658 P 1 387 P DBR1
219152_at 50512 1 P,M 0 706 P,A 0413 A PODLX2
219158_s_at 80155 1 P 1 909 P 1 727 P TBDN100
219163_at 54811 1 P 1 509 P 1421 P ZNF562
21917 5_s_at 54946 1 P 0 726 P 0 622 P SLC41A3
219177_at 55299 1 P 1 639 P 1 464 P BRIX, FLJ11100
219178_at 79691 1 P 1 737 P 1 665 P QTRTD1
2l9l88_s_at 28992 1 P 0 425 P 0 265 P,A LRP16
219202_at 79651 1 P 0 771 P 0 589 P RHBDL6
21921 l_at 11274 1 P 1 391 P 1 748 P USP18
219214_s_at 30833 1 P,A 0 764 P,A 0 503 A RBAK
219240_s_at 80007 1 P 1 597 P 1 681 P FLJ13490
219244_s_at 26589 1 P 1 635 P 1433 P MRPL46
219248_at 80745 1 P 1 514 P 1 607 P THUMPD2
219250_s_at 23767 1 A 1 361 P,A 1 502 P,A FLRT3
219253_at 79134 1 P 0813 P 0 657 P FAMI IB
219254_at 79701 1 P 1 022 P A 0 623 P,A FLJ22222
219258_at 54962 1 P 2314 P 2 346 P FLJ20516
219263_at 79589 1 P,A 1 851 P 2 232 P RNF128
219266_at 59348 1 P,A 1 563 P,M 2 048 P ZNF350
219270_at 79094 1 P 0 274 M,A 0 242 A MGC4504
219274_at 23554 1 P,A 1 391 P,M,A 1 809 P TM4SF12
219275_at 9141 1 P 1 799 P 1 663 P PDCD5
219283_at 29071 1 P 0 573 P 0 510 P CIGALT2
219288_at 57415 1 P 2 172 P 1 595 P HT021
219292_at 55145 1 P 1 496 P 1 758 P THAP1
219293_s_at 29789 1 P 1 509 P 1 539 P PTD004
219299_at 55039 1 P 1 553 P 1 587 P FLJ20772
219303_at 79596 1 P 1 746 P 1 810 P C13orf7
219312_s__at 65986 1 P 1 102 P 1 534 P ZBTB10
lxxill
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219313 ai 54762 1 M.A 1.180 P.A 1.545 P.A DKFZp434C0328
219321 at 64398 1 P 1.555 P 1 481 P MPP5
219324 at 79159 1 P 1.720 P 1.198 P MGC3731
219343 at 55664 1 P 1.488 P 1.577 P CDC37LI
219345 at 51027 1 P 0.816 P 0.616 P CGI-143
219346 at 79414 1 P 0.974 P 0.659 P LRFN3
219347 at 55270 1 P 1.769 P 1.545 P NUDTI5
219361 s at 64782 1 A 2.215 P 2.006 P F U 12484
219362 at 79688 1 P.A 1.521 P 1.328 P MAKIO
219363 s at 51001 1 P 1.750 P 1.585 P CGI-12
219366 at 57099 1 P.A 1.679 P 1.319 P AVEN; PDCDI2
219371 s at 10365 1 P 1.910 P 1.3% P KLF2; LKLF
219373 at 54344 1 P 0.739 P 0.617 P DPM3
219376 at 79692 1 P 1.568 P 1.654 P ZNF322A
219377 at 64762 1 P 1.532 P 1.656 P C18orfl 1
219384 s at 23536 1 P 1.826 P 1.699 P HADATI
219387 at 55580 1 P.M 1.673 P 1.611 P LOC55580
219401 at 64132 1 P 0.610 P 0.610 A XYLT2; XT2
219410 at 55076 1 P 1.261 P 1.731 P FLJ 10134
219416 at 51435 1 P 1.336 P 1.501 P SCARA3
219427 at 79633 1 P 1.611 P 1.4% P FATJ; FIJ23056
219447 s at 51006 1 P 0.892 P 0.641 P SLC35C2
219459 at 55703 1 P.M 1.578 P 1.451 P POLR3B
219460 s at 55654 1 P.A 1.523 P 1.434 P FIJ20507
219469_at 79659 1 P 1.509 P 1.579 P F IJI 1756
219470 x at 54619 1 P 1.524 P 1.226 P CCNJ
219472 at 79172 1 P 1.550 P 1.376 P MGC11266
219473 at 54834 1 P 1.505 P 1.574 P GDAP2
219477 s at 55901 1 M.A 1.852 P 2.185 P THSDI
219479 at 79070 1 P 0.925 P 0.582 P KDELCI
219484 at 29915 1 P 1.599 P 1.739 P HCFC2
219490 s at 64858 1 P 1.691 P 1.406 P DCLREIB
219493 at 79801 1 P 1.554 P 1.334 P SHCBPI
219495 s at 7733 1 P 1.516 P 1.471 P ZNFI80
219499 at 55176 1 P 1 882 P 2.024 P SEC6IA2
219523 s at 55714 1 P 0.837 P 0.547 P F U  10474
2l9540_at 1 P 1.416 P 1.688 P ZNF267
219555 s at 55839 1 P 1.550 P 1.234 P BM039
219557 s at 56675 1 P 1.475 P 1.662 P NRIP3
219560__at 79680 1 P 1.529 P 1.124 P F U 2II25
219562_at 25837 1 P 0.325 A 0.249 A RAB26; V46133
219567_s_at 64789 1 P 1.427 P 1.785 P FLJ2I144
219575_s_at 64146 1 P 0.836 P 0.617 P PDF
219577 s_at 10347 1 P 0.666 P 0.652 P.M.A ABCA7
219582 at 79627 1 P 1.940 P 1.812 P OGFRLl
219595 at 7574 1 A 1.976 P 2.431 P ZNF26
219612_*_ot 2266 1 A 2 124 P 2.150 P Fflfl
219626 at 79649 1 P 1.310 P 1.505 P F IJI 2649
219628 at 64393 1 P 1.870 P 1.949 P W1G1
219631_at 29967 1 P 1.876 P 2.302 P ST7
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219646 at 54849 1 P 1.738 P 1.465 P FU20I86
219648 at 55686 1 P 1.520 P 1.436 P FLJI0116
219650 at 54821 1 P 1.483 P 1.642 P FIJ20I05
219664 s at 26063 I P 0.826 P 0.649 P DECR2; PDCR
219690 at 79713 1 P 1.608 P 1.349 P FU22573
219703 at 55329 1 P 1.687 P 1.701 P MNS1
219709 x at 65990 1 P 0.827 P 0.643 P MGC2494
219717 at 54876 1 P 1.289 P 1.514 P FU20280
219736 at 55521 1 P.A 1.380 P 1.943 P TRIM36
219742 at 80758 1 P 0.830 P 0.545 P MGC10772
219760 at 64130 1 P 1.763 P 1.140 P LIN7B
219774 at 54520 1 P 1.589 P 1.421 P F IJI 09%
219800 s at 798% t P 1.335 P.A 1.566 P THNSL1
219802 at 79912 1 P 0.818 P 0.620 P FIJ22028
219805 at 63932 1 P 1.380 P 1.535 P FU22965
219825 at 56603 1 P.A 2.387 P 2.119 P CYP26B1
219834 at 79800 1 P 0.551 A 0.792 P.A ALS2CR8
219861 _at 55192 1 P 0.956 P 0.613 P.A F U 10634
219884 at 26468 1 P 1.658 P 1.510 P LHX6; LHX6.I
2l9895_at 55026 1 A 1.092 A 2.294 P.M FU207I6
219917 at 80001 1 P.A 1.553 P 1.117 P.A FU23024
219933 at 51022 1 P 1.549 P 1.524 P GLRX2; GRX2
2l9938_s_at 9050 1 P.A 1.408 P.A 1.613 P PSTPIP2
219944 at 79745 1 P.A 1.905 P.A 2.992 P FU 2I069
219945_at 29118 1 P 0.386 P.A 0.423 P DDX25; GRTH
219966 x at 54971 I P 1.494 P 1.606 P BANP
219984 s at 57110 1 P 1.126 P.A 1.531 P.M.A HRASLS
219987_at 79584 1 P.A 1.556 P 1.622 P F IJI 2684
219990 at 79733 1 P 1.652 P 1.538 P FU23311
219997 s at 64708 1 P 1.557 P 1.404 P COPS7B
2l9998_at 29094 1 P 1.673 P 1.228 P IISPCI59
22001 l_at 79000 1 P 1.607 P 1.413 P MGC2603
2200l4_at 51334 1 P 1.625 P 1.662 P LOC5I334
220044_x_at 51747 1 P 1.653 P 1.469 P LUC7A; CROP
220051 _at 10942 1 P 0.724 P 0.627 P.M PRSS21
220092 s at 84168 1 PA 1.462 P.M.A 1.653 P ANTXRI
220140 s at 29916 1 P 1.501 P 1.378 P SNXII
220143 x at 55692 1 P 1.939 P 2.100 P LUC7L2
220l72_at 80067 1 P 1.716 P 1.613 P F U  13096
220179_at 64180 1 P 0.518 P 0.739 P DPEP3
220183_s_at 11162 1 P 0.749 P.A 0.655 P.M NUDT6
220199_s_at 64853 1 P 1.826 P 1.849 P F IJI 2806
220205_at 7179 I P 0.615 P 0.725 P TPTE; PTEN2
220253_s_at 29967 I P 1.508 P 1.902 P S T 7;F U  12929
220254_at 29%7 1 P 1.500 P 1.736 P ST7; F IJ I2929
220262_s at 65989 1 P 0.713 P.M 0.626 P.M EGFL9
220358_at 55509 1 P.A 1.819 P 1.783 P.M SNFT; JUNDMI
220368_s_at 55671 1 P 1.559 P 1.479 P KIAA2010
220397 at 56890 1 A 2.070 P 2.824 P MDMI
220432 s at 51302 1 P 1.161 P 1.641 P CYP39AI
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220452 x at I M,A 1479 P 1 771 P,M
220466 at 80071 1 P 1 746 P 1 796 P FLJ13215
220484 at 55283 1 P,A 1 156 P 1 562 P MC0LN3
220488 s at 54828 1 P 0 619 P,M 0 488 A BCAS3
220500 s at 11159 1 P 0 825 P 0 657 P RABL2A
220520 s at 54830 1 M,A 1483 P 1 974 P FLJ20130
220545 s at 60385 1 P 0 606 P 0 583 P,A TSKS, TSKS1
220565_at 2826 1 P,M 0 644 P,M,A 0 675 P GPR2, CCR10
220610_s_at 9209 1 P 1 745 P 1892 P LRRFIP2
220633 s at 50809 1 P 0 770 P 0 649 P,A HP1-BP74
220643 s at 55179 1 P 0 823 P 0 643 P FAIM, FAIM1
220647 s at 51287 1 P 1 569 P 1 348 P E2IG2
220651 s at 55388 1 P 2 028 P 1 748 P MCM10
220688 s at 51154 1 P 1 707 P 1 373 P Clorf33
220707 s at 80020 1 P,A 0 832 P,M,A 0 598 A FLJ23322
220748 s at 51157 1 P 0 722 P 0 517 P ZNF580
220771 at 51152 1 P 1 227 P 1 815 P LOC51152
220839_at 29081 1 P,A 1960 P,A 1 583 P,A HSPC133
220840 s at 55732 1 P 1 832 P 1 842 P FLJ10706
220841 s at 54806 1 P 1 574 P 1 304 P AHI1
220892 s at 29968 1 P 0 354 P 0 300 P PS ATI
220934_s__at 79064 1 P 0 638 P,M,A 0 537 A MGC3196
220936_s__at 55766 1 P,A 1 212 P,A 1 529 P H2AFJ
220937_s_at 27090 1 P 0 987 P 0 563 P SIAT7D
220987_s__at 81788 1 P 1 556 P 1 560 P SNARK
220992_s__at 81627 1 P 1691 P 2013 P Clorf25
22101 l_s__at 81606 1 P 1 150 P 2 247 P LBH
221014_s_at 83452 1 P 1 566 P 1 511 P RAB33B
221021_s_at 56259 1 P 1 528 P 1 589 P CTNNBL1
221031_s_at 81575 1 P,M 1 265 P 1 677 P DKFZP434F0318
221045_s_at 8863 1 P M 1889 P 1 933 P PER3
221059_s_at 4166 1 P 1 682 P 1 503 P CHST6, MCDC1
221104_s_at 55335 1 P 1 249 P I 551 P NIPSNAP3B
221156_x_at 9236 1 P 1485 P 1 609 P CPR8
221190_s_at 29919 1 P I 562 P 1 437 P C18orfô,
221193_s_at 54819 1 P 1 635 P 1 812 P ZCCHC10
221196_x__at 79184 1 P,A 1 524 P 1 270 P C6 1A
221206_at 1 P 1 436 P 1 596 P
221213 s at 54816 1 P,A 0 703 P,A 0 638 P,A FLJ20086
221219_s_at 54758 1 P 1 711 P 1 381 P DKFZp434G0522
221255_s_at 83460 1 P 1 513 P 1 303 P MGC2963
221260_s_at 81566 1 P 1 519 P 1 652 P C12orf22
221267_s_at 81926 1 P 0 774 P 0 574 P C19orf27
221270_s_at 81890 1 P,A 0 894 P,A 0 552 A QTRT1, TGT
221434_s_at 81892 1 P 1 867 P 1 867 P C14orfl56
221435_x_at 81888 1 P 0 819 P 0 585 P HT036
221437_s_at 64960 1 P 1 857 P 1 754 P MRPS15
221448_s_at 56154 1 P,M 1247 P 1 711 P TEX 15
221489_s_at 81848 1 P 1 551 P 1 553 P SPRY4
221503_s_at 3839 I P 1 556 P 1 493 P KPNA3
l x x v i
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221510 s at 2744 1 P 1.833 P 2.008 P GLS; GLSI
22151 l_x_al 57499 1 P 1.214 P 1.638 P
CPR8;
KIAAI254
221515 s at 51451 1 P 1.549 P 1.368 P LCMT1; CGI-68
221523 s at 58528 1 P 0.978 P 1.602 P RAGD
221524 s at 58528 1 P 0.922 P 1.580 P RRAGD
221528 s at 63916 1 P 1.669 P 1.380 P ELM02
221535 at 55341 1 P 1.848 P 1.862 P F U I 1301
221536 s at 55341 1 P 1.943 P 1.910 P F U I 1301
221537 at 84202 1 P 1.634 P 1.402 P DKFZp564AI76
221550 at 1355 1 P 1.526 P 1.124 P COX 15
221551 X at 27090 1 P.A 0.801 P 0.609 P.A SIAT7D
221559 s at 79003 1 P 1.507 P 1.509 P MISI2
221562 s at 23410 1 P 0.706 P 0.488 P.M.A SIRT3; SIR2L3
221577 X at 9518 1 P.M 0.441 A 0.273 A GDF15
221582 at 92815 1 P 0.581 P.M 0.469 P.A HIST3H2A
221589 s at 4329 1 P 0.749 P 0.629 P CI4orf45
221598 s at 9442 1 A 1.789 P 1.696 P.M CRSP8
221628 s at 84656 1 P 0.582 P.M, A 0.572 P.A N-PAC
221633 at 29781 1 P.A 1.538 P 1.300 P 384D8-2
221648 s at 1 P 1.527 P 1.493 P PNAS-4
221652 s at 55726 \ P 1.843 P 1.922 P F U  10637
221664 s at 50848 1 P 0.529 A 0.489 A FIIR ;
221676 s at 23603 1 P 1.642 P 1.619 P CORO 1C
221677 s at 29980 1 P 1.563 P 1.598 P DONSON
221693 s at 55168 1 P 1.529 P 1.274 P MRPS18A
221695 s at 10746 1 P 1.487 P 1.798 P MAP3K2
221704 s at 79720 1 P 1.591 P 1.544 P F U  12750
221713 s at 79929 1 P.A 1.756 P 1.680 P F U  12748
221718 s at 11214 1 P 1.591 P 1.552 P AKAPI3
221727 at 10923 I P 1.517 P 1.795 P PC4
221741 s at 54915 1 P 1.575 P 1.651 P dJ 9631:22.1
221754 s at 57175 1 P 0.790 P 0.553 P CORO IB
221755 at 254102 1 P 0.647 P.M 0.469 P.A DKFZp762CI86
221759 at 92579 1 P 0.734 P 0.487 P.A G6PC3
221760 at 1 A 1.742 P 2.686 P MANIAI
221768 at 1 P 1.601 P 1.638 P SFPQ
221780 s at 55661 1 P 1.501 P 1.237 P DDX27
221788 at 5238 1 P 1.134 P 1.547 P PGM3
221800 s at 80233 1 P 0.863 P 0.605 P FIJ22175
221810 at 1 P A 1.513 P 1.488 P
221820 s at 84148 1 P 0.814 P 0.638 P MYST1
221823 at 90355 1 P 1.703 P 2.045 P LOC90355
221832 s at 1 P 1.392 P 1.535 P LUZPI
221837 at 84861 1 P 0.739 P.A 0.454 M.A F U  14360
221841 s at 1 A 1.647 A 1.684 P KLF4
221864 at 93129 1 P 0.567 P 0.605 P MGC13024
221873 at 7702 1 P 1.410 P 1.507 P ZNI 143
221892 at 1 P 0.599 P 0.532 P H6PD
221919 at 3178 1 P 1.530 P 1.499 P IINRPAI
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221934 s  at 55152 1 P 0.738 P 0.533 P FLJ104%
221951 at 1 P 0.566 P.A 0.534 P.A LOC283232
221953 s ai 10893 1 M.A 0.824 P.A 0.529 A MMP24
221970 s al 25926 1 P 1.656 P 1.514 P PKFZP586L0724
221973 at 1 P 0.816 P.A 1.506 P LOCI 50759
221987 s at 55720 1 P 1.784 P 1.202 P FUI0534
221998 s at 51231 1 P 0.620 P 0.553 P LOC5I23I
222006 at 1 P 1.623 P 1.382 P FGFR3
222010 al 39 1 P 1.890 P 2.057 P ACAT2
222011 s at 6950 1 P 1.702 P 1.775 P ACAT2
222040 at 3178 1 P 1.590 P 1.306 P HNRPAI
222043 at 1191 1 P 1.116 P 1.552 P CLU
222045 s al 63935 1 P 0.951 P 0.657 P.M C20orft>7
222074 at 7389 1 P.A 2.217 P 2.461 P UROD
222088 s at 144195 1 P 1.554 P 1.342 P SLC2A14
222103 at 466 1 P 1.429 P 1.640 P ATF1
222108 at 1 P 1.393 P 1.626 P
222111 at 1 P 0.643 P 0.677 P K.1AA1164
222125 s at 54681 1 P 0.579 P 0.580 P PH-4; FU20262
222130 s at 29960 1 P 1.878 P 1.537 P FTSJ2; FJHI
222149 X at 1 A 1.346 P.A 1.519 P.M DKFZp434P162
222154 s at 26010 1 P 1.348 P 1.658 P DNAPTP6
222156 X at 57499 1 P 1.251 P 1.601 P CPR8
222162 s at 9510 1 A 1.512 P.M 1.463 P ADAMTS1
222204 s at 54700 1 P 1.857 P 1.703 P RRN3
222231 s at 55379 1 P 1.611 P 1.356 P PRO 1855
222233 s at 64421 1 P 1.526 P 1.558 P DCLRE1C
222234 s at 79007 1 P.A 0.707 P.M 0.631 P.A MGC310I
222235 s at 1 P 1.906 P 1.879 P dJ19NLl
222240 s al 51477 1 P 0.664 P 0.518 P ISYNA1
222249 at 1 P.A 1.632 P.A 1.595 P KIAAI65I
222250 s at 258% 1 P 2.134 P 2.027 P PKFZP434BI68
222258 s at 23677 1 P 1.589 P 2.227 P SH3BP4
222263 at 79939 1 P.M 0.957 P 0.658 P.A SLC35EI
222266 at 1 P 1.618 P 1.621 P C l% rf2
222269 at 1 A 1.916 P.A 1.682 P.A UNQ8193
222274_at 150244 1 A 1.544 P.A 1.537 P FU31568
222305 at 1 P.A 3.630 P 3.539 P HK2
222312 s at 5350 1 P.A 1.429 P 1.518 P PLN
222360_at 51611 1 P 1.587 P 1.785 P CGI-30
222382 X at 23165 1 P.A 1.699 P.A 1.537 P NUP205
266 s at 934 1 P.A 2.416 P 5.457 P CD24; CD24A
31845 at 2000 1 P 1.572 P 1.333 P ELF4
32088 at 8548 1 P.M.A 1.340 P 1.632 P BLZFI
32094 at 9469 1 P 1.807 P 1.822 P CHST3
33132 at 29894 1 P 0.801 P 0.627 P CPSFI
33307_at 27341 1 P 1.551 P 1.124 P CGI-96
33778 at 25771 1 P 0.726 P 0.564 P C22orf4
34408 at 6253 1 P 0.403 P 0.463 P RTN2
34868 at 23381 1 P 1.907 P 1.878 P EST1B
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35156 at 1 P 0 830 P 0 578 P LOC203069
35179 at 26229 1 P 0 855 P 0 625 P B3GAT3
35436 at 2801 1 P 0 875 P 0 648 P G0LGA2
35626 at 6448 1 P 0 707 P 0 459 P SGSH, HSS
36545 s at 9814 1 P 0 838 P 0 604 P KIAA0542
36552_at 26005 1 P 1 574 P 1 743 P DKFZP586P0123
36553 at 8623 1 P 0 931 P 0 580 P ASMTL
36554 at 8623 1 P 0 861 P 0 533 P ASMTL
36564 at 127544 1 P 1692 P 1 466 P IBRDC3
36711 at 23764 1 P 1 550 P 1 338 P MAFF
37028 at 23645 1 P 1 894 P 2 523 P PPP1R15A
37170 at 55589 1 P 1 487 P 1 745 P BMP2K
37408_at 9902 1 P 0 680 P 0 639 P MRC2
37796 at 4034 1 P 0 793 P 0 505 P LRRN1
37802 r at 54629 1 P,M,A 0 741 P 0 532 P,A KIAA1164
37892_at 1301 1 P 0 842 P 0 614 P COL11A1
37950 at 5550 1 P 0 884 P 0 650 P PREP
37966 at 29780 1 P 0 881 P 0 641 P PARVB
38037 at 1839 1 P,A 1804 P 2 034 P DTR
39729 at 7001 1 P 0 904 P 0 582 P PRDX2
39817_s_at 10591 1 P 0 803 P 0 582 P C6orfl08
40489_at 1822 1 P 1 821 P 1 574 P DRPLA, B37
40665_at 2328 1 P,M,A 0 629 A 0 858 P,A FM03
41660_at 9620 1 P 0 605 P 0510 P CELSR1
44654_at 92579 1 P 0 874 P 0 586 P G6PC3
45633_at 64785 1 P 1961 P 1 606 P FLJ13912
46142_at 64788 1 P,A 0 654 P,M}A 0 443 A FLJ12681
46167_at 7268 1 P 1 768 P 1 589 P TTC4
48106_at 55652 1 P 1 755 p 1 523 P FLJ20489
48808_at 1719 1 P 1 685 p 1 707 P DHFR
50965_at 25837 1 P 0 441 p 0 383 P I RAB26
51176_at 9442 1 P 1 558 p 1483 P CRSP8
52164_at 53838 1 P 1 659 p 1484 P Cllorf24
52940_at 59307 1 P 0 703 p 0 553 P S1GIRR
56256_at 51092 1 P 0 708 p 0 482 P TAGLN
57539_at 84619 1 P 0 887 p 0 650 P FLJ20406
58308_at 55223 1 P 1 445 p 1 655 P FLJ 10759
59625_at 8996 1 P 0 824 p 0 659 M,A LOC283849
60794_f_at 1 P 1 512 p 1 575 P
60815„at 5439 1 P,A 1 427 p 1 837 P POLR2J
61732_r_at 80173 1 P 0 692 P,A 0 659 P,A CCDC2
61734_at 57333 1 P 0 560 P 0615 P RCN3
63825_at 1 P 1 736 P 1654 P ABHD2
64371_at 10147 1 P,A 1 369 P 1 576 P SFRS14
64486_at 57175 1 P 0 771 P 0 571 P CORO IB
65517_at 10053 1 P 1 728 P 1 970 P AP1M2
65588_at 1 P 1 609 P 1 540 P
65630_at 1 P 0 633 P 0 452 P LOC283232
91703_at 254102 1 P 0 737 p 0 550 P DKFZp762C186
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A FFX -D apX -3_at 1 P 0 687 P 0 566 P
A FFX -D apX -5_at 1 P 0 559 P 0 490 P
AFFX-DapX-M__at 1 P 0 662 P 0 542 P
A FFX -H U M ISG F3A /M 97935_3_at 1 P 1 348 P 1 949 P STA TI
A FFX -
H U M ISG F3A /M 97935 M B at
1 P 1 285 P 1 760 P STA TI
A FFX -L ysX -3_at 1 P 0 737 P 0 550 P
A FFX -L ysX -5_at 1 P 0 707 P 0 576 P
A FFX -L ysX -M _at 1 P 0 696 P 0 550 P
A FFX -M 27830_5_at 1 P,A 0 955 P,A 1 841 P,M ,A
A FFX -PheX -3_at 1 P 0 756 P 0 598 P
A FFX -PheX -5_at 1 P 0 629 P 0 510 P
A FFX -PheX -M _at 1 P 0 675 P 0 568 P
A FFX -r2-B s-dap-3_at 1 P 0 746 P 0 632 P
A FFX -r2-B s-dap-5_at 1 P 0 6 1 1 P 0 488 P
A FFX -r2-B s-dap-M _at 1 P 0 658 P 0 529 P
A FFX -r2-B s-lys-3_at 1 P 0 696 P 0 589 P
A FFX -r2-B s-lys-5_at 1 P 0 693 P 0 493 P
A FFX -r2-B s-lys-M _at 1 P 0 691 P 0 557 P
A FFX -r2-B s-phe-3_at 1 P 0 674 P 0 540 P
A F FX -r2 -B s-phe '5_at 1 P 0 536 P 0 457 P
A F FX -r2-B s-phe-M _at 1 P 0  687 P 0 518 P
A FFX -r2-B s-thr-3_s_at 1 P 0 682 P 0 598 P
A FFX -r2-B s-thr-5_s_at 1 P 0 599 P 0 522 P
A FFX -r2-B s-thr-M _s_at 1 P 0 621 P 0 472 P
A FFX -T hrX -3_at 1 P 0 677 P 0 543 P
A FFX -T hrX -5_at 1 P 0 549 P 0 424 P
A FFX -T hrX -M _at 1 P 0 631 P 0 474 P
lxxx
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List o f differentially expressed genes identified from microarray analysis o f IdU 
microarray experiment Genes listed are sorted by Affymetrix ID number
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207331 at 1063 1 P 0.645 P CENPF
1405 i at 6352 1 P,A 2.996 P CCL5
200696 s at 2934 1 P 1.552 P GSN
200697 at 3098 1 P 1.622 P HK1
200762 at 1808 1 P 1.536 P DPYSL2
200768 s at 4144 1 P 0.544 P MAT2A
200838 at 1508 1 P 1.543 P CTSB
200872 at 6281 1 P 1.588 P S100AI0
200878 at 29952 1 P.A 1.539 P EPASI
200887 s at 6772 1 P 1.857 P STATI
200983 x at 966 1 P 1.602 P CD59
200985 s at 966 1 P 1.505 P CD59
201015 s at 3728 1 P,M,A 1.715 P JUP
201042 at 7052 1 P.A 1.989 P TGM2
201058 s at 10398 1 P 1.528 P MYL9
201060 x at 2040 1 P 1.541 P STOM
201110 s at 7057 1 P,A 3.583 P THBS1
201122 x at 1984 1 P 1.584 P E1F5A
201123 s at 1984 I P 1.689 P EIF5A
201141 at 10457 1 P 1.920 P GPNMB
201149 s at 7078 1 P.A 2.564 P TIMP3
201150 s at 7078 I P.A 1.750 P.A TIMP3
201162 at 3490 1 P.A 2.617 P IGFBP7
201163 s at 3490 I P 2.360 P IGFBP7
201169 s at 8553 1 P.A 1.888 P BHLHB2
201185 at 5654 1 P.A 2.074 P PRSS11
201205 at 6238 1 P.A 1.504 P RRBPI
201266 at 7296 1 P 1.610 P TXNRD1
201295 s at 26118 1 P 0.647 P WSB1
201330 at 5917 1 P 0.499 P RARS
201341 at 8507 1 P.A 1.746 P ENC1
201348 at 2878 1 P 1.669 P GPX3
201427 s at 6414 1 P.A 1.795 P.A SEPPI
201464 x at 3725 1 P.A 1.863 P JUN
201466 s at 3725 1 P.A 2.065 P JUN; API
201473 at 3726 1 P 1.871 P JUNB
201502 s at 4792 1 P 1.555 P NFKBIA
201505 at 3912 1 P 1.933 P LAMBÌ
201506 at 7045 1 A 2.585 P.M TGFB1
201578 at 5420 1 P.M.A 1.529 P.M.A PODXL
201596 x at 3875 1 P.A 2.271 P KRTI8
201631 s at 8870 1 P 1.775 P IER3
201666 at 7076 1 P 1.638 P T1MP1
201693 s at 1958 1 P 1.813 P EGRI
201719 s at 2037 1 P 1.558 P EPB41L2
201733 at 1 P 0.657 P CLCN3
201739 at 6446 1 P 2.196 P SGK; SGK1
201793 x at 9887 1 M.A 1.732 P.A Clorfl6
201798 s at 26509 1 P.A 2.298 P FERIL3
201843 s at 2202 1 P.A 1.682 P.A EFEMP1
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201927 s at 8502 1 P 1.541 P PKP4
201945 at 5045 1 A 1.679 P.M FUR1N
202008 s at 4811 1 P 1.533 P N1D
202017 at 2052 1 P 1.622 P EPHX1
202086 at 4599 1 P,A 1.925 P M X I
202132 at 25937 1 P 1.550 P TAZ
202159 at 2193 1 P 1.565 P FARSLA
202284 s at 1026 1 P 2.209 P P21
202307 s at 5696 1 P 1.669 P TAPI
202328 s_at 5310 1 P 0.619 P.M PKD1; PBP
202424 at 5605 1 P 1.619 P MAP2K2
202436 s at 1545 1 P.A 1.542 P CYP1B1
202446 s at 5359 1 P 1.827 P PLSCR1
202458 at 11098 1 P.A 2.022 P SPUVE
202472 at 4351 1 P 0.620 P MPI
202524 s at 9806 1 P 0.402 P SPOCK2
202575 at 1382 1 M.A 1.965 P CRABP2
202598 at 6284 1 P 1.560 P S100AI3
202662 s at 3709 1 A 1.654 P ITPR2
202665 s at 7456 1 P.A 1.649 P WASPIP
202672 s at 467 1 P.A 2.023 P ATF3
202686 s at 558 1 P.A 2.035 P AXL; UFO
202687 s at 8743 I P.A 2.233 P TNFSF10
202688 at 8743 1 P.A 1.673 P.A TNFSF10
202700 s at 9725 1 P.A 0.587 P.A KIAA0792
202719 s at 26136 1 P.A 1.846 P TES
202720 at 26136 1 P 1.696 P TES
202747 s at 9452 1 P.A 3.918 P.A ITM2A
202760 s at 11217 1 P.M.A 1.590 P.A AKAP2
202765 s at 2200 1 P.A 1.780 P FBNl
202766 s at 2200 1 P 1.545 P FBN1
202920 at 1 P 0.525 P.A ANK2
202949 s at 2274 1 P 1.899 P FHL2
202996 at 57804 1 P 1.613 P POLD4
203058 s at 9060 1 P 1.641 P PAPSS2
203065 s at 857 1 P 1.943 P CAVI
203066 at 51363 1 P 1.604 P GALN AC4S-6ST
203072 at 4643 1 P.A 1.876 P.A M Y01E
203091 at 8880 1 P 1.514 P FUBP1; FBP
203109 at 9040 1 P 1.524 P UBE2M
203117 s at 9924 1 P 0.586 P USP52
203140 at 604 1 P.A 2.202 P BCL6
203153 at 3434 1 P.A 2.185 P IFIT1
203172 at 9513 1 P 1.508 P FXR2
203184 at 2201 1 P 2.158 P FBN2
203227 s at 6302 1 P 0.622 P SAS
203229 s at 1196 1 P 0.612 P.M,A CLK2
203243 s at 10611 1 P 1.514 P LIM; ENH
203304 at 25805 1 P.A 1.722 P BAMBI
203368 at 78987 1 P 1.554 P CRELDI
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203394 s at 3280 1 P 1 619 P HES1
203423 at 5947 1 P 1 703 P RBP1
203446 s at 4952 1 P 0 604 P OCRL
203452 at 26229 1 P 1 524 P B3GAT3
203455 s at 6303 1 P 1 832 P SAT
203469 s at 8558 1 P,A 1 610 P,A CDK10
203501 at 10404 1 P 0 520 P PGCP
203504 s at 19 1 P 1 556 P ABC Al
203646 at 2230 1 P 1 686 P FDX1
203665 at 3162 1 P 1 622 P HM0X1
203722 at 8659 1 P 1 528 P ALDH4A1
203725 at 1647 1 P 1 921 P GADD45A
203821 at 1839 1 P,M 1 612 P DTR
203837 at 4217 1 P 1 566 P MAP3K5
203882 at 10379 1 P 1 612 P ISGF3G
203910 at 9411 1 P,A 3 529 P PARG1
203926 x at 513 1 P 1 522 P ATP5D
203929 s at 4137 1 P»A 0 602 PjA MAPT
203952 at 22926 1 P,A 0 569 P,M,A ATF6
203980 at 2167 1 P 1 515 P FABP4
203989 x at 2149 1 P,A 1 843 P,A F2R
203999 at 1 P,A 1 923 P SYT1
204030 s at 29970 1 P 1 636 P SCHIP 1
204035_at 7857 1 P 0 338 P SCG2
204036_at 1902 1 P 0 432 P EDG2
204037 at 1902 1 P 0 618 P EDG2
204038 s at 1902 1 P 0 580 P EDG2
204135_at 11259 1 P 1 624 P D0C1, GIP90
204260 at 1114 1 P 0 537 P CHGB, SCG1
204268_at 6273 1 P,A 2 684 P S100A2,
204279 at 5698 1 P 1 597 P PSMB9
204326 x at 4500 1 P l 771 P MT1L
204346 s at 11186 1 P,A 1 671 P RASSF1
204359_at 23768 1 P 1 593 P FLRT2
204421 s at 2247 1 P 1 610 P FGF2
204422 s at 2247 1 P 1 556 P FGF2
204439_at 10964 1 P 0 481 P Clorf29
204452_s_at 8321 1 P 0 654 P,M,A FZD1
204455 at 667 1 P,A 2 264 P BPAG1
204475_at 4312 1 P 2 186 P MMP1
204490 s at 960 1 P,A 1 850 P,A CD44
204529 s at 9760 1 P,A 1 583 P,M TOX
204564 at 10336 1 P,A 1 513 P RNF3
204577_s_at 23059 1 P 0 602 P,A KIAA0643
204589_at 9891 1 P 1 729 P ARK5
204604 at 5218 1 P,A 1 904 P PFTK1
204612_at 5569 1 P 0 542 P,A PKIA
204627_s_at 3690 1 P,A 2 471 P»A ITGB3
204653_at 1 P»A 1 730 P TFAP2A
204655_at 6352 1 P,A 2 353 P CCL5
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204665 at 80143 1 P,A 1 527 P,A FLJ21168
204682 at 4053 1 P,A 1 573 P LTBP2
204697 s at 1113 1 P,A 1 540 P CHGA, CGA
204718 at 2051 1 P,A 0 613 P,A EPHB6, HEP
204748 at 5743 1 P,A 2 701 P C0X2
204762 s at 2775 1 P,M,A 0512 M,A GNA01
204779 s at 3217 1 P 1 647 P H0XB7
204840 s at 8411 1 P,M 1 614 P EE Al
204841 s at 8411 1 P,A 1 529 P EEA1
204859 s at 317 1 P 1 558 P APAF1
204864 s at 3572 1 P 1 687 P IL6ST
204865 at 761 1 P,A 2 305 P CA3, CAIII
204897 at 5734 1 P 1 895 P PTGER4
204947 at 1869 1 P 0613 P E2F1
204955 at 8406 1 P,A 1 670 P SRPX
204967 at 357 1 P,A 1 552 P,A APXL
204983 s at 2239 1 P 1 763 P GPC4
205013_s_at 135 1 P 1 586 P AD0RA2A
205016 at 7039 1 P»A 2 817 P TGFA
205034 at 9134 \ P 1 521 P CCNE2
205047 s at 440 1 P 0 628 P ASNS
205050 s at 23542 1 P 0 509 P MAPK8IP2
205068 s at 23092 1 P,A 1 517 P ARHGAP26
205082 s at 316 1 P,M 0 604 P,A A0X1, A0H1
205222 at 1962 1 P 0 599 P,A EHHADH
205224 at 6835 1 P,A 1 556 P SURF2
205286 at 7022 1 P,A 1 772 P TFAP2C
205296_at 1 P 0 638 P
205301 s at 4968 1 P 0 609 P OGGI
205303 at 3764 1 P 0 551 P,M KCNJ8
205304 s at 3764 1 P 0 543 P KCNJ8
205357_s_at 185 1 P,M 2 281 P AGTR1
205366 s at 3216 1 P,A 2 016 P HOXB6
205374_at 6588 1 P,A 1 880 P,A SLN,
205386_s_at 4193 1 P,A 1 985 P MDM2
205405 at 9037 1 P,A 1 619 P SEMA5A
205479 s at 5328 1 P,A 2 166 P PLAU
205500 at 727 I P 0 633 P,A C5
205523 at 1404 1 P 0 371 P HAPLN1
205524_s_at 1404 1 P,M 0 164 A HAPLN1
205534 at 5099 1 P,A 1 748 P PCDH7
205547 s at 6876 1 P 2 453 P TAGLN
205594 at 22834 1 P 0 561 P KIAA0924
205625 s at 793 1 P,A 2 737 P CALB1
205626 s at 793 1 P,A 1 920 P CALB1
205657 at 23498 1 P,A 0 621 P,M,A HAAO
205660 at 8638 1 P,A 1 771 P OASL
205698 s at 5608 1 P 0 652 P,M,A MAP2K6
205780 at 638 1 P»A 2 508 P,M,A BIK
205828 at 4314 1 P 1 721 P MMP3
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205829 at 3292 1 P 1.742 P HSDI7B1
205832 at 51200 1 P.A 1.678 P CPA4
205841 at 3717 1 P 1.711 P JAK2
205862 at 9687 1 P,M,A 1.692 P.A GREBI
205887 X at 4437 1 P 0.552 P.M MSH3
205896 at 6583 1 P,A 1.656 P SLC22A4
205924 at 5865 1 P.A 2.074 P RAB3B
205925 s at 5865 1 P.M 2.018 P RAB3B
205964 at 79088 1 P 0.623 P ZNF426
205975 s at 3231 1 P 1.747 P HOXDI
206056 X at 1 P.A 0.403 P.A SPN
206116 s at 7168 1 P 1.924 P TPM1
206117 at 7168 1 P.A 1.968 P TPMI
206172 at 3598 1 P 1.525 P IL13RA2
206201 s at 4223 1 M.A 2.059 P.A M E0X2
206209 s at 762 1 P.A 1.771 P CA4; CA1V
206259 at 5624 1 P.A 2.062 P PROC
206290 s at 6000 1 P 0.656 P RGS7
206299 at 27112 1 P.A 0.618 P.A TMEM28; TED
206300 s at 5744 1 P.A 1.834 P PTHLH
206314 at 55888 1 P 0.575 P ZNF167
206343 s at 3084 1 P.A 1.581 P NRGI
206377 at 2295 1 P.A 1.573 P.A FOXF2
206429 at 2150 1 P.A 3.982 P.A F2RLI
206452 X at 5524 1 P.A 1.543 P PPP2R4
206461 X at 4496 1 P,A 1.762 P MT1H
206508 at 970 1 P.A 1.845 P TNFSF7
206529 X at 5172 1 P.A 1.681 P.M SLC26A4
206543 at 6595 1 P 0.601 P SMARCA2
206555 s at 55623 1 P 0.568 P THUMPD1
206615 s at 53616 1 P 0.491 P.M ADAM22
206695 X at 7594 1 P 0.595 P ZNF43
206757 at 8654 1 P 0.501 P PDE5A
206769 at 9087 1 P.A 1.616 P TMSB4Y
206773 at 4062 1 P.A 1.685 P LY6H;
206825 at 5021 1 P.A 2.873 P OXTR; OT-R
206868 at 9754 1 P.M 1.500 P STARD8
207030 s at 1466 1 P 1.505 P CSRP2
207059 at 5083 1 P.M 0.654 P.A PAX9
207068 at 7539 1 P 0.625 P ZFP37
207145 at 2660 1 P 0.450 P.A GDF8
207160 at 3592 1 P.A 2.213 P IL12A
207187 at 3718 1 M.A 1.501 P JAK3
207324 s at 1823 1 P 0.324 P.A DSCI
207387 s at 2710 1 P.M 1.519 P GK
207437 at 4857 1 P 0.436 P NOVAI
207536 s at 3604 1 P.A 1.767 P.A TNFRSF9
207684 at 6911 1 P 0.660 P.A TBX6
207765 s at 80256 1 M.A 1.514 P.A K1AA1539
207826 s at 3399 1 P 1.632 P ID3
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207876 s at 2318 1 P 1.533 P FLNC
207922 s at 10296 1 P 0.625 P MAEA; EMP
207960 at 1 P.A 1.653 P.A
207963 at 26236 1 P 0.649 P C6orf54
207969 x at 56 1 P.M.A 1.945 P ACRVI
208016 s at 185 1 P.A 1.587 P AGTRI
208035 at 2916 1 P.A 2.790 P.A GRM6
208086 s at 1756 1 P 1.855 P DMD
208116 s at 4121 1 P.A 1.589 P MAN1A1
208185 x at 1 P 1.541 P
208190 s at 51599 1 P 1.504 P LISCH7
208241 at 3084 1 P.A 1.659 P NRG1
208250 s at 1755 1 P,A 1.521 P DMBT1
208511 at 26255 1 P 0.626 P PTTG3
208514 at 3753 1 P.A 2.581 P.M.A KCNE1
208546 x at 8345 1 P 0.623 P HIST1H2BH
208581 x at 4501 1 P 2.075 P MT1X
208588 at 59347 1 P 0.572 P.A FKSG2
208610 s at 23524 1 P 0.626 P SRRM2
208637 x at 87 1 P 1.518 P ACTNI
208650 s at 934 1 P 1.550 P CD24
208690 s at 9124 1 P 1.531 P PDLIM1
208704 x at 334 1 P 1.561 P APLP2
208719 s at 10521 1 P 0.656 P DDXI7;
208738 x at 6613 1 P 0.583 P SUM02
208747 s at 716 1 P.A 1.850 P CIS
208782 at 11167 1 P 2.006 P FSTLI
208789 at 22939 1 P 1.558 P PTRF
208798 x at 23015 1 P 0.577 P GOLG1N-67
208902 s at 1 P.A 0.607 P.A F1J4606I
208937 s at 3397 1 P 1.588 P IDI
208944 at 7048 1 P 1.576 P TGFBR2
208991 at 1 P 1.579 P STAT3
208992 s at 6774 1 P.A 1.698 P STAT3
209040 s at 5696 1 P 1.713 P PSMB8
209087 x at 4162 1 P 1.603 P MCAM
209129 at 7205 1 P 0.616 M.A TR1P6
209184 s at 8660 1 P.A 1.561 P.M.A IRS2
209189 at 2353 1 P.A 3.182 P FOS
209193 at 5292 1 P.A 2.245 P PIMI
209202 s at 2137 1 P.A 1.775 P.A EXTL3
209212 s at 688 1 P 1.716 P KLF5
209260 at 2810 1 P.A 1.884 P SFN
209261 s at 2063 1 P.A 1.565 P.M.A NR2F6
209267 s at 64116 1 P 1.707 P SLC39A8
209278 s at 7980 1 P 1.869 P TFPI2
209283 ut 1410 1 M.A 2.427 P.M.A CRYAB
209287 s at 10602 1 P 1.536 P CDC42EP3
209291 at 3400 1 P 1.779 P ID4
209293 x at 3400 1 P 2.098 P ID4
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209304 x at 4616 1 P.A 1.898 P GADD45B
209340 at 6675 1 P 1.540 P UAP1
209356 x at 30008 1 P 1.500 P EFEMP2
209438 at 1 P 0.651 P.A
209457 at 1847 1 P 1.589 P DUSP5
209459 s at 57416 1 P.A 2.042 P ABAT
209469 at 2823 1 P 0.596 P.M GPM6A
209470 s at 2823 1 P 0.398 P.A GPM6A
209487 at 11030 1 P.A 2.015 P RBPMS
209494 s at 23598 1 P 0.602 P ZNF278
209504 s at 58473 \ P.M 0.654 P.A PLEKHB1
209560 s at 8788 1 P.A 2.255 P DLK1
209574 s at 753 1 P.A 1.750 P.A C18orfl
209584 x at 27350 1 P.A 1.576 P.A AP0BEC3C
209598 at 10687 1 P 1.566 P PNMA2
209604 s at 2625 1 P 1.734 P GATA3
209631 s at 1 P.A 1.821 P
209656 s at 83604 1 P 1.526 P TM4SF10
209703 x at 25840 1 P.A 1.854 P.A DKFZP586A0522
209708 at 26002 1 P.A 1.579 P M0XD1
209758 s at 8076 1 P 1.909 P MFAP5
20977 l_x_at 934 1 P 2.001 P CD24
209803 s at 7262 1 P 2.472 P PHLDA2
209806 at 85236 1 P 0.652 P HISTIH2BK
209835 x at 960 1 A 3.576 P CD44
209846 s at 11118 1 P 0.620 P BTN3A2
209875 s at 6696 1 P 1.666 P SPPI
209885 at 29984 1 P 1.700 P RHOD
209904 at 7134 1 P.A 2.212 P.A TNNC1
209908 s at 7042 1 P.A 1.661 P,M,A TGFB2
209936 at 10181 1 P.A 0.599 P.A RBM5
209946 at 7424 1 P 0.340 P VEGFC
209960 at 3082 1 P 0.531 P HGF;
209969 s at 6772 1 P 1.870 P STAT1
210012 s at 2130 1 P 0.528 P.A EWSR1
210102 at 4013 1 P 1.573 P LOH1ICR2A
210144 at 25771 1 P.A 1.958 P.A C22orf4
210145 at 5321 1 P.A 2.828 P.M PLA2G4A
210162 s at 4772 1 P.A 0.611 P.A NFATC1
210172 at 1 P 0.537 P SFI;
210200 at 11060 1 P.A 0.636 P.A WWP2
210205 at 8705 1 P 0.619 P B3GALT4
210230 at 6066 1 P.A 0.544 P.A RNU2
210233 at 3556 1 A 1.817 P.M ILIRAP
210234 at 2914 1 P.A 1.547 P.A GRM4
210241 s at 11257 1 P 0.628 P TP53AP1
210315 at 6854 1 P.A 1.596 P.A SYN2
210322 x at 7404 1 P.A 1.549 P.M.A UTY; U TY 1
210355 at 5744 1 M.A 1.953 P.A PTHLH
210385 s at 51752 1 P 1.675 P ARTS-I
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210424 s at 23015 1 P,A 0 627 P,A GOLGIN-67
210495 x at 2335 1 P,A 3 236 M,A FN1
210538 s at 330 1 P 2 377 P BIRC3
210552 s at 9649 1 P,M 0 631 P,A RALGPS1
210560 at 2637 1 P,M,A 1 788 P GBX2
210564 x at 8837 1 P 1 754 P CFLAR
210592 s at I P 1 885 P SAT, SSAT
210605 s at 4240 1 P,A 1643 P,A MFGE8,
210612 s at 8871 1 P,M 1 511 P SYNJ2
210674 s at 56137 1 P 0 635 P,M,A PCDHA12
210715 s at 10653 1 P 2 191 P SPINT2
210752 s at 6945 1 P 1 553 P TCFL4
210809 s at 10631 1 P 1 503 P POSTN
210867 at 4850 1 P 0 532 A CNOT4
210926 at 1 P 1 545 P FKSG30
210986 s at 7168 1 P 2 028 P TPM1
210987 x at 7168 1 P 2 069 P TPM1
211017 s at 4771 1 P 1 569 P NF2
211043 s at 1212 1 P 1 596 P CLTB
211097 s at 5089 1 P 0 579 P PBX2
211098 x at 54499 1 P 1 502 P LOC54499
211160 x at 87 1 P,A 1 619 P ACTN1
211177 s at 10587 1 P 1 554 P TXNRD2
211364_at 4507 1 P 1 618 P MTAP
211374_x_at 1 P,M,A 0 573 P,A
211387 x at 8732 1 P,M 0 636 P,A RNGTT
211456 x at 1 P,M 2 242 P
211466_at 4781 1 P 0618 P NFIB
211538 s at 3303 1 P 1 660 P HSPA1A
211540 s at 5925 1 P 1 506 P RBI
211571 s at 1462 1 P 0 460 P,A CSPG2
211573 x at 7052 1 P,A 2 186 P TGM2
211593 s at 23139 1 P 1 509 P MAST2
211600 at 1 P 0 613 P PTPRO
211602 s at 7220 1 P 1 544 P TRPC1
211668 s at 5328 1 P,A 1 896 P PLAU
211700 s at 7216 1 P 0 607 P,A TRO
211756 at 5744 1 P,A 3 128 P PTHLH
211819 s at 10580 1 P,A 0 558 M,A SORBS 1
211864 s at 26509 1 P,A 2 344 P,A FER1L3
211911 x at 3106 1 P 1 589 P HLA-B
211930 at 1 P 0 639 P hnRNPA3
211990 at 3113 1 P 0513 P,A HLA-DPA1
212014 x at 960 1 P,A 1 519 P,A CD44
212061 at 23350 1 P 0 657 P SRI 40
212063 at 960 1 P»A 3 062 P CD44
212067 s at 715 1 P 0 654 PA C1R
212097 at 857 1 P 1 566 P CAV1
212127 at 5905 1 P 1 742 P RANG API
212143 s at 3486 1 P 1 642 P IGFBP3
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212157 at 6383 1 P 0 605 P SDC2
212172 at 1 P,M,A 0617 P,A AK2, ADK2
212185 x at 4502 1 P 1 876 P MT2A
212207 at 23389 1 P,A 1 674 P THRAP2
212225 at 10209 1 P,A 1 556 P,A SUI1
212230 at 1 P,A 2 188 P,A PPAP2B
212290 at 1 P 0 656 P SLC7A1
212294 at 55970 1 P 1 671 P GNG12
212311 at 23231 1 P 1 602 P KIAA0746
212314 at 23231 1 P 1 655 P KIAA0746
212325 at 22998 1 P,A 1 815 P,M KIAA1102
212327 at 22998 1 P,A 1 548 P,A KIAA1102
212384 at 7919 1 P 0 463 P BAT1
212418 at 1997 1 P 1 628 P ELFI
212501 at 1051 1 P 0 657 P CEBPB
212543 at 202 1 A 2 144 P AIM1, ST4
212553 at 23248 1 P 0 597 P KIAA0460
212587 s at 5788 1 P 0 632 P PTPRC
212646_at 23180 1 P,A 2 378 P,M RAFTLIN
212651 at 9886 1 P 0 645 P RH0BTB1
212654 at 7169 1 P 1 631 P TPM2
212717_at 9842 1 P,A 1 815 P PLEKHM1
212727_at 1741 1 P 0 450 P,A DLG3
212814 at 23382 1 P 0613 P KIAA0828
212859_x_at 1 P,A 1 945 P MT2A
212865_s_at 7373 1 P 0618 P COLMAI
212923_s_at 1 P 1 535 P C6orfl45
213014_at 9479 1 P,A 1 548 P MAPK81P1
21313 5_at 1 P 1 562 P TI AMI
213143_at 1 P 0 493 M,A LOC257407
213164_at 1 P 1 590 P MRPS6
213204_at 23113 1 P 0 580 P,A PARC
213271_s_at 23033 1 P 1 530 P KIAA1117
213274 s at 1508 1 P 1 679 P CTSB
213281_at 3725 1 A 1 988 P JUN
213290_at 1292 1 P,A 0 646 P,M,A COL6A2
213362_at 1 P 0 651 P,M
213403_at 1 P,A 1 807 P,A MGC11332
213430_at 22902 1 P 0 520 P,A RIPX
213449_at 10940 1 P 1 635 P POPI
213456 at 25928 1 P,A 2 059 P SOSTDC1
213496_at 9890 1 P 0 466 P PRG1
213506_at 2150 1 P,A 3 084 P F2RL1
213528_at 92342 1 P 0 574 P MGC9084
213558 at 27445 1 P 1 939 P PCLO
213618_at 116984 1 P 1 715 P CENTD1
213624_at 10924 1 P 0 584 P SMPDL3A
213650_at 23015 1 P 0 634 P GOLGIN-67
213668_s_at 6659 1 P,A 1 619 P SOX4
213764_s_at 1 P 1 971 P MFAP5
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213765 at 1 P 1.834 P MFAP5
213802 at 8492 1 M,A 1.554 P,M,A PRSS12
213803 at 3837 1 P 0.656 P KPNB1
213810 s at 55122 1 P,M,A 1.539 P.A C6orfl66
213835 x at 84705 1 P 0.654 P GTPBP3
213849 s at 5521 1 P 0.428 M,A PPP2R2B
213854 at 9145 1 P 1.581 P SYNGR1
213882 at 83941 1 P.A 0.561 P.A BBP
213929 at 1 P.A 1.557 P
213930 at 1 P 1.601 P APG12L
213931 at 3398 1 P 1.538 P ID2
213932 x at 3105 1 P 1.808 P HLA-A
213964 x at 1 P 0.603 P.A
214043 at 1 P 0.637 P PTPRD
214071 at 65258 1 P 0.644 P GNAL
214077 x at 4213 1 P 0.659 P MEIS4
214079 at 1 P.A 1.527 P.A DHRS2
214091 s at 2878 1 P 1.630 P GPX3
214163 at 51668 1 P 0.590 P,M,A LOC51668
214175 x at 8572 1 P.A 1.501 P PDLIM4
214196 s at 1200 1 P 0.638 P CLN2
214209 s at 23457 1 P.A 0.601 P.A ABCB9
214216 s at 23185 1 P 1.709 P KIAA0217
214247 s at 10530 1 P 1.807 P DKK3
214251 s at 4926 1 P 0.643 P.A NUMA1
214321 at 4856 1 P.A 1.663 P NOV
214329 x at 8743 1 P.A 1.929 P.M.A TNFSF10
214543 x at 9444 1 P 1.521 P QUAKING
214666 x at 3658 1 P 0.622 P IREB2
214668 at 57213 1 P 1.528 P CI3orfl
214700 x at 26109 1 P 0.602 P Rifl
214722 at 1 P 1.725 P LOC376745
214734 at 23086 1 P.A 1.577 P SLAC2-B
214761 at 23090 1 P 1.553 P ZNF423
214776 x at 9942 1 P 0.394 A XYLB
214823 at 7754 1 P 0.629 P.A ZNF204
214850 at 1 P 1.546 P.M SMA5
214917 at 1 P.A 0.419 P.A PRKAA1
214934 at 11071 1 P 0.529 P.A ATP9B
214954 at 26032 1 P 1.700 P K1AA0527
215012 at 26036 1 P 0.633 P ZNF451
215019 x at 84436 I P 0.585 P ZNF528
215034 s at 1 A 3.141 P TM4SFI
215073 s at 1 P 0.585 P NR2F2
215079 at 1 P 0.557 P.A
215095 at 1 P 0.569 A ESD
215114 at 26168 1 P,M 0.589 M.A SENP3
215132 at 1 P 0.494 M.A
215169 at 9906 1 P 0.494 P.A SLC35E2
215189 at 3892 1 P 0.390 P.A KRTIIB6
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215252 at 1 P.A 0.615 P.A
215263 at 7789 1 P 1.523 P ZXDA
215331 at 22989 1 P.A 0.610 P.A K1AAI000
215359 X at 7595 1 P 0.654 P ZNF44
215410 at 5380 1 P,M,A 0.639 P.A PMS2L2
215469 at 1 P.A 1.599 P.A
215489 X at 9454 1 P 1.720 P H0MER3
215498 s at 5606 1 P 1.597 P MAP2K3
215506 s at 9077 1 P.A 2.351 P ARMI
215507 X at 1 P 0.465 P.A RAB22A
215551 at 2099 1 P.A 0.412 P.M.A ESR1
215591 at 23314 1 P 0.590 P.A SATB2
215604 X at 1 P 0.632 P.A
215607 X at 1 P.A 1.648 P.A
215643 at 1 P 0.357 P SEMA3D
215646 s at 1462 1 P 0.462 P CSPG2
215660 s at 1 P,M 0.521 P.A MAST2
215694 at 79029 1 P 0.556 P.A SPATA5LI
215706 X at 7791 1 P 1.709 P ZYX
215719 X at 355 1 P.A 2.013 P TNFRSF6
215760 s at 22904 1 P 0.500 P.A KIAA0963
215779 s at 8339 1 P 0.592 P.A HIST1H2BG
215834 X at 1 P.A 1.827 P.A SC ARBI
215883 at 1 P.A 1.761 P.A CTNNAI
215919 s at 64963 1 P.A 0.524 P.A MRPS11
215930 s at 4253 1 P 0.626 P MGEA6
215945 s at 23321 1 P.A 1.830 P.A TRIM2
215977 X at 2710 1 P.A 1.942 P GK; GKD
216049 at 22836 1 P.A 1.599 P.A RHOBTB3
216101 at 1 P.A 0.625 P.A
216178 X at 3688 1 P.A 1.524 P.A ITGBI
216217 at 23228 1 A 1.919 P.M PLCL2
216229 X at 80867 1 P 0.600 P.A HCG2P7
216248 s at 4929 1 P 1.610 P NR4A2
216279 at 10794 1 P 1.651 P ZNF272
216336 X at 1 P 1.812 P
216379 X at 934 1 P 1.867 P NaGLTI
216442 X at 2335 1 P.A 2.498 P FN1
216598 s at 6347 1 M.A 2.128 P.M CCL2
216604 s at 23428 1 M.A 1.520 P.A SLC7A8
216739 at 1 P 0.580 P.A
216770 at 1 P.A 1.705 P.A
216804 s at 1 P 1.781 P LIM
216865 at 7373 1 P 0.446 P C0L14A1; UND
216885 s at 50717 1 P 0.658 P H326
217019 at I P 0.536 P
217028 at 7852 1 P*A 1.541 P.A CXCR4
217052 X at 1 P 0.634 P TIAI
217107 at 1 P.M 0.530 P.M
217120 s at 9282 1 P.A 1.596 P CRSP2
Affymetrix 
’ Id LocusLink
Day 0 Day 7
Common Name
Normalized Flags Normalized Flags
217193 X at 3535 1 P.A 1.517 P.A IGL@
217212 s at 1 P 0.545 P.A
217218 at 23063 I P.A I.57I P KIAA0261; FOE
217340 at 1 P.A 0.503 P.M.A
217363 X at 1 P.A 0.536 P.A
217365 at 1 P 0.539 P.M.A LOC65I22
217550 at 1 P 0.651 P ATF6
217554 at 1 P 0.624 P
217602 at 5478 1 P 0.656 P.A PPIA
217608 at 57515 1 P 0.596 P FU  36754
217625 X at 1 P.A 1.751 P,M A
217630 at 90806 1 P.M.A 0.424 P.A LOC90806
217653 X at 1 P.M 0.610 P.A
217728 at 6277 1 P.A 3.321 P SIOOA6
217749 at 28831 1 P 1.668 P COPG
217809 at 28969 1 P 1.516 P BZW2
217813 s at 10927 1 P 0.631 P SPIN
217817 at 10093 1 P 1.668 P ARPC4
217818 s at 10093 1 P 1.763 P ARPC4
217853 at 64759 1 P.A 2.894 P TENS1
217866 at 79869 1 P 0.645 P F U  12529
217880 at 996 \ P 0.539 P CDC27
217890 s at 55742 1 P 1.594 P PARVA
217896 s at 80011 1 P 0.657 P NIP30
217974 at 51768 1 P 0.574 P TM7SF3
218087 s at 10580 1 P.A 0.618 P.A SORBS 1
218278 at 54663 1 P.A 1.710 P F U  10439
218292 s at 51422 1 P 1.764 P PRKAG2
218309 at 55450 I P 1.563 P CaMKIINalpha
218400 at 4940 1 P 1.658 P OAS3
218413 s at 51193 1 P.M 0.570 A ANC 2H0I
218486 at 1 P 0.619 P TIEG2
218532 s at 54463 1 P.A 1.506 P.A FLJ20152
218625 at 51299 1 P.M.A 2.530 P NRNI
218674 at 80006 1 P 0.641 P F U  13611
218715 at 55813 1 P 1.512 P HCA66
218736 s  at 54873 I P 0.405 P PALMD
218798 at 65095 1 M.A 0.566 P.M.A F U  12949
218849 s at 10848 1 P 1.531 P RAI
218880 at 2355 1 P.A 1.567 P.M FOSL2
218885 s at 79695 1 P 0.614 P GALNT12
218902 at 54781 1 P.A 1.566 P.A NOTCH 1
218915 at 51219 1 P 1.618 P NF2
218940 at 79609 1 P 0.588 P C14orfl38
218943 s  at 23586 1 P.A 1.648 P.A DDX58
218980 at 80206 1 P.M 0.549 A KIAAI695
219014 M 51316 1 P 2 403 P PLAC8: C l 5
219040 at 79585 1 M.A 1.522 P.M.A FU22021
219049 at 55790 1 P.A 1.503 P ChGn
219134 at 64123 1 P 0.558 P ETL
xciii
Afíymetrix
Id
Day 0 Day 7 Common ÑameLocusLink
Normalized Flags Normalized Flags
219197 s at 1 P,M 1.643 P SCUBE2
219209 at 64135 1 P 1.847 P MDA5
219222 at 64080 1 P,A 1.601 P.A RBKS
219250 s at 23767 1 P.M.A 1.582 P FLRT3
219325 s at 55520 1 P 0.417 P.A ELACI; D29
219353 at 54835 1 P 0.637 P NHLRC2
219370 at 56475 1 A 2.475 P.M REPRIMO
219410 at 55076 1 P 1.621 P FU10134
219427 at 79633 1 P 1.522 P FATJ
219437 s at 29123 1 P.M 0.547 A ANKRDI1
219550 at 64221 1 P 0.532 P.A R0B03;
219561 at 51226 1 P.A 2.218 P.M.A COPZ2
219603 s at 7769 1 P 0.465 P ZNF226
219612 s at 2266 1 M.A 1.891 P.A FGG
219628 at 64393 1 P 1.617 P WIG1
219638 at 26263 I P.A 1.590 P.M,A FBX022
219641 at 55070 1 P 0.634 P DET1
219657 s at 51274 1 P.M.A 1.686 P.A KLF3
219683 at 7976 1 P 1.667 P FZD3
219692 at 79412 1 P.A 1.829 P.A KREMEN2
219694 at 54491 1 P 1.923 P FU  11127
219697 at 9956 1 P 2.369 P.M HS3ST2;
219789 at 4883 l P.A 1.835 P.A NPR3
219800 s at 79896 1 P 0.424 P.A THNSL1
219813 at 9113 1 P.A 1.548 P.A LATS1
219825 at 56603 1 P.A 1.749 P.A CYP26BI
219869 s at 64116 1 P.A 1.523 P SLC39A8
219892 at 53346 1 P 1.530 P TM6SF1
219901 at 55785 1 P 1.510 P F U I 1183
219992 at 6866 1 P,A 2.027 P.A TAC3
220029 at 54898 1 M.A 1.580 P.A ELOVL2
220104 at 56829 1 P 1.752 P ZC3HAV1
220122 at 79772 1 P 0.551 P FU22344
220148 at 64577 1 P.M,A 1.633 P.M.A ALDH8AI
220212 s at 63892 1 P 1.512 P THADA
220217 x at 64663 1 P.A 2.163 P SPANXC
220230 s at 51700 1 P.M.A 1.643 P CYB5R2
220321 s at 79635 1 P 0.593 P FU  13646
220327 at 51159 1 P 0.589 P FLJ38507
220358 at 55509 1 P 1.507 P SNFT
220372 at 54943 1 P 0.611 P.A C2Iorf55
220407 s at 7042 1 P 1.668 P TGFB2
220520 s at 54830 1 P,A 1.699 P FU20I30
220544 at 60385 1 P 0.637 P.A TSKS; TSKSI
220591 s at 80258 1 P.A 1.992 P FU22843
220643 s at 55179 1 P 0.651 P FAIM
220675 s at 80339 1 P 0.657 P.A C22or£20
220696 at 29048 1 P.A 0.586 P.A PR00478
220712 at l P.M.A 0.576 P.A
220719 at 80079 1 | P.A 1.940 P.A F U  13769
xciv
Affymetrix
Id
Day 0 Dav 7 Common NameIjOCusLink
Normalized Flags Normalized Flags
220769 s at 79819 1 P 0.656 P.A FU23129
220771 at 5 1152 1 P 0.602 P LOC51152
220838 at 54932 1 P.M.A 0.635 P.A FU20433
220860 at 29942 1 P 1.531 P PURG
220922 s at 30014 1 P.A 3.515 P SPANXAI
220954 s at 29990 1 P 0.642 P P1LRB
220986 s at 8 1789 1 P 0.296 A TIGD6
220991 s at I40545 1 P 0.476 P.A RNF32
221011 s at 81606 1 P.A 2.132 P LBH
221024 s at 81031 1 P 0.415 P SLC2AI0
221059 s at 4 166 1 P 1.723 P CHST6
221120 at 54889 1 P.A 1.576 P.A FU20306
221156 X at 9236 1 P 0.573 P CPR8
221168 at 59336 1 P.A 1.847 P PRDMI3
221251 X at 83444 1 P.A 1.635 P.A HMGAIL4
221261 X at 8 1557 1 P 0.494 P MAGED4
221391 at 50840 1 P.A 1.608 P.A TAS2R14
221419 s at 1 P 0.282 P
221489 s at 8 1848 1 P 1.535 P SPRY4
221594 at 84060 1 P.A 1.565 P DKFZP564 00523
221616 s at 516 16 1 P.M.A 1.723 P.A TAF9L
221626 at 1 P.A 1.524 P.M.A ZNF506
221633 at 29781 1 P.A 2.103 P 384D8-2
221664 s at 50848 1 P.A 2.047 P F11R;
221841 s at 1 A 2.224 P.M KLF4
221865 at 203197 1 P 0.629 P C9orf91
221875 X at 3134 1 P 1.567 P HLA-F
221898 at 10630 1 P 0.615 P T1A-2
221958 s at 79971 1 P.A 2.133 P FU2309I
221967 at 11247 1 P.A 1.529 P NXPH4
221997 s at 116539 1 P.A 0.639 P.A MRPL52
222018 at 4666 1 P 0.596 P.A NACA
222067 X at 3017 1 P 0.481 P H2BFB
222082 at 51341 1 M.A 1.825 P.M.A ZBTB7
222116 s at 54493 1 P 1.654 P TBC1DI6
222131 X at 89941 1 P 1.527 P RHOT2
222162_s_at 9510 1 P.A 2.423 P ADAMTS 1
222208 s at 5439 1 P 0621 P,M P0LR2J
222224 at 1 P.A 0 596 P.M.A MGC71999
222229 X at 1 P 0604 P
222237_s_at 7771 1 P 0.570 P ZNF228
222313 at 1 P 0.588 P.A
222326 at 1 P 0.522 P
222329 X at 1 P 0.616 P
222361_at 1 P 0598 P
222366 at 1 P 0 498 P
222370 X at 1 P, A 1.578 P, A
266 s at 934 1 P 1.670 P CD24; CD24A
32088 at 8548 1 P 0 646 P BLZF1
32723 at 1477 1 P 0.639 P CSTF1
xcv
Affymetrix
Id LocusLink
Day 0 Day 7 Common Name
Normalized Flags Normalized Flags
33322 i at 2810 1 P 1 552 P SFN
33323 r at 2810 1 P 1 504 P SFN
34697 at 4040 1 P 0 625 P LRP6
37462 I at 8175 1 P 1 508 P SF3A2
37892 at 1301 1 P 1 546 P COL11A1
38037 at 1839 I 1 P.A 1 504 P DTR
39548 at 4862 1 P,M,A 0 357 P.A NPAS2
39549 at 4862 1 P.A 0 599 P.A NPAS2
40524 at 11099 i * P.A 1 694 P PTPN21
47105_at 54920 1 P 0 655 P FLJ20399
48031 r at 10826 1 P 0 578 P.A C5orf4
53202 at 79020 1 P 0 591 P C7orf25
60794 f at 1 P 0 646 P
61297 at 57513 1 P 0 592 P.A CASKIN2
64418 at I I P 0 658 P AP1GBP1
Affymetrix Id Day 0 Day 7 Common Name
Normalized Flags Normalized Flags
AFFX-HUMISGF3A/M97935 3 at t | P 1 851 P STATI
AFFX-HUMISGF3A/M97935_5_at 1 P 1 790 P STATI
AFFX-
HUMISGF3A/M97935 MA at P 1 781 P STATI
AFFX-
HUMISGF3A/M97935 MB at
i
1 P 1 747 P STATI
AFFX-HUMRGE/M10098 3 at 1 P 1 922 P
AFFX-HUMRGE/M10098_5_at 1 P 3 107 P
AFFX-HUMRGE/M10098_M_at 1 P 1 921 P
I.
I
I
I
X C V 1
7 5 Appendix D -  List of 93 up-regulated genes common to the BrdU 5,2' 
FdU and IdU DNA Microarray Experiment
X C V l l
Affymetrix Id LocusLink Common Name
200697 at 3098 HKI
200762 at 1808 DPYSL2
200872 at 6281 SIOOAIO
200887 s at 6772 STATI
201042 at 7052 TGM2
201060 x at 2040 STOM
201149 s at 7078 TIMP3
201464 x at 3725 JUN
201466 s at 3725 JUN; API
201502 s at 4792 NFKBIA
201719 s at 2037 EPB4IL2
201739 at 6446 SGK
201798 s at 26509 FER1L3
202017 at 2052 EPHXI
202284 s at 1026 CDKN1A
202436 s at 1545 CYP1BI
202760 s at 11217 AKAP2
202949 s at 2274 FHL2
203058 s at 9060 PAPSS2
203140 at 604 BCL6
203304 at 25805 BAMBI
203665 at 3162 HMOXI
203821 at 1839 DTR
203910 at 9411 PARG1
203989 x at 2149 F2R
204030 s at 29970 SCHIP 1
204135 at 11259 DOCI
204279 at 5698 PSMB9
204346 s at I I 186 RASSF1
204422 s at 2247 FGF2
204475 at 4312 MMP1
204490 s at 960 CD44
204748 at 5743 C0X2
204897 at 5734 EP4
204955 at 8406 SRPX
204983 s at 2239 GPC4
205479 s at 5328 PLAU
205534 at 5099 PCDH7
205547 s at 6876 TAGLN
205925 s at 5865 RAB3B
206116 s at 7168 TPM1
206508 at 970 TNFSF7
206773 at 4062 LY6H
207030 s at 1466 CSRP2
207826 s at 3399 ID3
207876 s at 2318 FLNC
208650 s at 914 CD24
208782 at 11167 FSTL1
208789 at 22939 PTRF
208937 s at 3397 IDI
xcviii
Affymetrix Id LocusLink Common Name
208944 at 7048 TGFBR2
209040 s at 5696 PSMB8
209087 x at 4162 MCAM
209267 s at 64116 SLC39A8
209278 s at 7980 TFPI2
209291 at 3400 ID4
209293 x at 3400 ID4
209340 at 6675 UAP1
209457 at 1847 DUSP5
209771 x at 934 CD24
209803 s at 7262 PHLDA2
209835 x at 960 CD44
210538 s at 330 BIRC3
210560 at 2637 GBX2
210605 s at 4240 MFGE8
210612 s at 8871 SYNJ2
210986 s at 7168 TPM1
210987 x at 7168 TPM1
212063 at 960 CD44
212143 s at 3486 IGFBP3
212294 at 55970 GNG12
213281 at 3725 JUN
213618 at 116984 CENTD1
214247 s at 10530 DKK3
214722 at LOC376745
215706 x at 7791 ZYX
215719 x at 355 TNFRSF6
216379 x at 934 NaGLTl
217809 at 28969 BZW2
218625 at 51299 NRN1
218880 at 2355 F0SL2
218915 at 51219 NF2
219014 at 51316 PLAC8
219410 at 55076 FLJ10134
219612 s at 2266 FGG
220520 s at 54830 FLJ20130
221011 s at 81606 LBH
221841 s at KLF4
266 s at 934 CD24
38037 at 1839 DTR
AFFX HUMISGF3A/M97935 3 at STATI
AFFX HUMISGF3A/M97935 MA at STATI
AFFX HUMISGF3A/M97935 MB at STATI
X C 1 X
7 6 A ppendix  E  -  EA SE Analysis
This appendix contains part o f the results generated following subjecting the 93 up- 
regulated genes identified as common to the BrdU, 5,2 -FdU and IdU DNA 
microarray experiments Due to size constraints only part o f the EASE report is listed 
in this Appendix
c
System Gene Category List
Hits
List
Total
Population
Hits
Population
Total
EASE
score
Bonferroni
Bootstrap
within
system
Gene
identifiers
AfTymetrix probesets
G O
B iolog ical
Proccss
cell d o t h 1! 71 404 10937 2 .31E -04 I.2 0 E -0 I 4.00E-03
330 ; 355; 
970 ; 1026; 
2149; 2355; 
4792; 6446; 
6772; 7052; 
7262
200887 S A T; 201042  A T; 
201502 S  A T; 20 1 7 3 9  A T; 
202284  S  A T; 203 9 8 9  X AT;
206508 A T ; 209803 S AT; 
210538  S A T ; 215719  X  AT;
218880  A T; A FFX - 
H U M ISG F3A /M 97935 3 AT; 
A FFX -
H U M 1SG F3A /M 97935 M A  AT; 
A FFX -
H U M ISG F3A /M 97935_M B _A T
QQ
BjfflOgittl
Process
death 11 71 408 10937 2 .50E -04 I.30E -01 5.00E-03
330; 355; 
970; 1026; 
2149; 2355; 
4792; 6446; 
6772; 7052; 
7262
200887 S  A T; 201042 AT; 
201502 S A T; 201739  AT; 
202284 S  AT; 203989_X  AT;
206508 A T; 209803 S AT; 
210538  S  A T; 21 5 7 1 9  X  AT;
218880 A T ; A FFX - 
H U M ISG F3A /M 97935 3 AT; 
A F FX -
H U M ISG F3A /M 97935  M A  AT; 
A FFX -
H U M ISG F3A /M 97935_M B _A T
QQ
Pifiliigisal
Proccss
apoptosis 10 71 379 10937 6 .57E -04 3 .40E -0I 1.30E-02
330; 355; 
970 ; 1026; 
2149; 4792; 
6446; 6772; 
7052; 7262
200887 S AT; 201042 AT; 
201502 S AT; 201739  A T; 
202284 S  A T ; 203989  X  AT;
206508  A T ; 209803 S  AT; 
210538 S  A T ; 215 7 1 9  X  AT; 
A FFX -
H U M ISG F3A /M 97935 3 AT; 
A FFX -
H U M ISG F3A /M 97935 M A  AT; 
A FFX -
H U M ISG F3A /M 97935 M B  AT
System Gene Category ListHits
List
Total
Population
Hits
Population
Total
EASE
score Bonferroni
Bootstrap
within
system
Gene
identifiers Affymetrix probesets
GO
B io loe ica l
Process
program m ed cell 
death
10 71 380 10937 6 70E-04 3 47E-01 1 40E -02
3 3 0 ,3 5 5  
970, 1026, 
2149, 4792, 
6446, 6772, 
7052 7262
200887  S AT, 201042 AT, 
201502  S AT, 201739 AT, 
202284  S AT, 203989  X AT, 
206508  AT, 209803 S AT, 
210538  S A T, 215719 X AT, 
A FFX -
H U M ISG F3A /M 9793 5 3 AT, 
A FFX -
H U M ISG F3A /M 97935 M A  AT, 
A FFX -
H U M ISG F3A /M 97935 M B  AT
G O
B iolog ical
P rocess
response to 
external stim ulus
19 71 1263 10937 7 67E -04 3 97E-01 1 40E -02
355 , 604, 
934 , 970, 
1 5 4 5 ,2 0 5 2 , 
2149 , 2247, 
2637, 4062 , 
4 7 7 1 ,4 7 9 2 , 
5328, 5696, 
5698, 5734, 
5743, 6772 , 
7078
200887  S AT, 201149  S AT, 
201502 S AT, 202017 AT, 
202436  S AT, 203140 AT, 
203989  X AT, 204279  AT, 
204422 S AT, 204748 AT, 
204897  AT, 205479 S AT, 
206508  AT, 206773 AT, 
208650  S A T, 209040 S AT, 
209771 X AT, 210560  AT, 
215719  X AT, 218915 AT, 
266 S AT, A FFX - 
H U M ISG F3A /M 97935 3 AT, 
A FFX -
H U M ISG F3A /M 97935 M A  AT, 
A FFX -
H U M ISG F3A /M 97935 M B A T
Cil
System Gene Category
List
Hits
List
Total
Population
Hits
Population
Total
EASE
score
Bonferroni
Bootstrap
within
system
Gene
identifiers
Affymetris prohesets
QQ
B ioloaical
Proccss
regulation  o f 9 71 323 10937 I.02E -03 5.27E-OI 1.90E-02
604 ; 1026; 
1839; 2247; 
2266; 3486; 
4771; 7048; 
9314
202284 S A T; 203 1 4 0  AT; 
203821 A T; 204422 S  AT; 
208944 A T; 212143 S  AT; 
218915 AT; 219612 S  A T; 
2 2 l8 4 f_ S _ A T ; 38037_A T
C &
B iological
P rocess
regulation  o f  ccll 
proliferation
8 71 249 10937 1.03E-03 5.33E-01 1.90E-02
604; 1026; 
1839; 2247; 
2266; 4771; 
7 0 4 8 ;9 3 1 4
202284 S A T; 203140  A T; 
20382 f  A T; 204422 S  A T; 
208944 A T; 218915 AT; 
219612 S A T; 221841 S AT; 
38037  A T
CiQ
B io losica l
P ro f i ts b iological
9 71 328 10937 1 .I2E -03 5.82E-01 2.00E-02
604; 1026; 
1839; 2247; 
2266; 3486; 
4771; 7048; 
9314
202284 S A T; 203140  A T; 
20382 1 A T; 204422 S  AT; 
208944 A T; 212143 S  A T; 
218915 A T; 219612 S  AT; 
221841 S  A T; 38037  AT
o n
B ioloeical 16 71 1010 10937 L 54E -03 7.98E-OI 2.30E-02
1466; 1545; 
1808; 1839; 
2037; 2149; 
2239; 2247; 
2637; 4062; 
4162; 6876; 
7168; 9060; 
9 3 1 4 ;2 7 1 2 2
200762 A T ; 201719  S_A T; 
202436  S A T; 203058 S AT; 
203821 A T; 203989  X  AT; 
204422 S A T; 204983 S_A T; 
205547  S A T; 206116  S A T; 
206773 AT; 207030 S AT; 
209087 X  A T; 210 5 6 0  AT; 
210986  S A T; 210987 X AT; 
214247 S A T; 221841 S AT; 
38037  AT
P rocess
System Gene Category ListHits
List
Total
Population
Hits
Population
Total
EASE
score
Bonferroni
Bootstrap
within
system
Gene
identifiers Affymetrix probesets
GO
B iological
Process
DeDtidvl-amino 
acid modification 3 71 17 10937 5 16E-03 1 OOE+OO 8 40E-02
2149, 6772 
7052
200887  S A T, 201042 AT, 
203989  X  A T , A FFX - 
H U M ISG F3A /M 97935 3 AT, 
A FFX -
H U M ISG F3A /M 97935 M A  AT, 
A FFX -
H U M ISG F3A /M 97935 M B AT
GO
B iological
Process
cell
communication 29 71 2791
10937 5 40E-03 1 OOE+OO 8 90E-02
330 , 355, 
960 , 970, 
1 8 0 8 ,1 8 3 9 , 
2149 , 2247, 
3 4 8 6 ,4 1 6 2 , 
4 2 4 0 ,4 7 9 2 , 
5099, 5328, 
5734, 5865, 
6 2 8 1 ,6 7 7 2 , 
7048, 7052, 
7 7 9 1 ,8 4 0 6 , 
9411, 11186, 
11217, 
25805, 
27122, 
55970, 
116984
200762  AT, 200872 AT, 
200887  S A T, 201042 AT, 
201502  S AT, 202760  S AT, 
203304  A T, 203821 AT, 
203910  AT, 203989  X AT, 
204346  S A T, 204422  S AT, 
2 04490  S A T , 204897  AT, 
204955 A T, 205479  S AT, 
205534  A T, 205925 S AT, 
206508  A T, 208944 AT, 
209087  X A T, 209835 X AT, 
210538  S A T, 210605 S AT, 
212063 AT, 212143 S AT, 
212294  AT, 213618 AT, 
2 14247  S AT, 215706 X AT,
215719  X  A T, 38037  A T, A FFX - 
H U M ISG F3A /M 97935 3 AT, 
A F FX -
H U M ISG F3A /M 9793 5 M A  AT, 
A F FX -
H U M ISG F3A /M 97935 M B AT
GO
B iological
Process
positive regulation 
o f  cell 
proliferation
5 71 111 10937 5 51E-03 1 00E+00 9 10E-02
604 , 1839, 
2247, 2266, 
7048
203140  AT, 203821 AT, 
204422  S A T, 208944 AT, 
219612  S A T , 38037 AT
CIV
System Gene Category ListHits
List
Total
Population
Hits
Population
Total
EASE
score Bonferroni
Bootstrap
within
system
Gene
identifiers AfTymetrix pro besets
GO
B iological
Process
developm ent 20 71 1683 10937 7 97E-03 1 00E +00 1 47E-01
1466, 1545, 
1808, 1839, 
2 0 3 7 ,2 1 4 9 , 
2239, 2247, 
2 6 3 7 ,3 1 6 2 , 
3397, 3399, 
4 0 6 2 ,4 1 6 2 , 
6876, 7168, 
7262, 9060, 
9314, 27122
200762 A T, 201719  S AT 
202436  S A T , 203058  S AT, 
203665 A T , 203821 AT, 
203989  X  A T, 204422  S AT, 
204983 S A T , 205547  S AT, 
206116  S A T, 206773 AT, 
207030  S A T, 207826  S AT, 
208937  S A T , 209087  X AT, 
209803 S A T, 210560  AT, 
210986  S A T, 210987  X  AT, 
214247  S A T, 221841 S AT, 
38037 A T
GO
B iological
Process
sienal transduction 24 71 2196 10937 8 06E-03 1 OOE+OO 1 48E-01
330, 355, 
970 1808, 
183 9 ,2 1 4 9  
2247, 3486, 
4792, 5328, 
5734, 5865, 
6 2 8 1 ,6 7 7 2 , 
7048, 7052, 
7 7 9 1 ,9 4 1 1 , 
11186, 
11217, 
25805, 
27122, 
55970, 
116984
200762  A T, 200872  AT, 
200887  S AT, 201042  AT, 
201502  S A T, 202760  S AT, 
203304  A T, 203821 AT, 
203910  A T , 203989  X  AT, 
204346  S A T, 204422  S AT, 
204897  A T , 205479  S AT, 
205925  S A T, 206508  AT, 
208944  A T, 210538  S AT, 
212143 S A T, 212294  AT, 
213618  A T, 214247  S AT, 
215706  X  A T, 215719  X AT, 
38037 AT, A FFX - 
H U M ISG F3A /M 9793 5 3 AT 
A FFX -
H U M ISG F3A /M 9793 5 M A  AT, 
A FFX -
H U M ISG F3A /M 97935 M B AT
cv
System Gene Category ListHits
List
Total
Population
Hits
Population
Total
EASE
score Bonferroni
Bootstrap
within
system
Gene
identifiers Affymetnx pro besets
GO
Biologica!
Process
cellu lar process 48 71 5719 10937 8 24E-03 1 OOB+OO 1 49E-01
330, 355, 
604 , 960 
970, 1026, 
1466, 1808, 
1839, 2037 , 
2149, 2239 , 
2247, 2266, 
2355, 3486 , 
3725, 4062 , 
4162 4240 , 
4 7 7 1 ,4 7 9 2 , 
5099, 5328, 
5734, 5743, 
5865, 6281, 
6446, 6772, 
7048, 7052, 
7168, 7262, 
7791, 8406, 
9314, 9411 , 
11167, 
11186, 
11217, 
25805, 
26509 , 
27122 , 
54830, 
55970, 
64116, 
116984
200762  A T, 200872  AT, 
200887  S A T, 201042 AT, 
201464  X  A T, 201466  S AT, 
201502  S A T, 201719  S AT, 
201739  A T , 201798  S A T, 
202284  S A T, 202760  S AT, 
203140  A T, 203304  AT, 
203821 A T 203910  AT, 
203989  X A T, 204346  S AT, 
204422  S AT, 204490  S AT, 
204748  AT 204897  AT, 
204955 A T, 204983 S AT, 
205479  S A T, 205534 AT, 
205925  S A T, 206116  S AT, 
206508  AT, 206773 AT, 
2070 3 0  S A T, 208782 AT, 
208944  AT, 209087  X  AT, 
209267  S A T, 209803 S AT, 
209835 X  A T, 210538 S AT 
210605  S AT, 210986  S AT, 
210987  X A T, 212063 AT, 
212143 S A T, 212294 AT, 
213281 A T, 213618  AT, 
214247  S A T, 215706  X  AT, 
215719  X  A T, 218880  AT, 
218915 A T, 219612  S AT, 
220520  S A T, 221841 S AT, 
38037  A T, A FFX - 
H U M ISG F3A /M 97935  3 AT, 
A FFX -
H U M ISG F3A /M 97935  M A  AT, 
A FFX -
H U M ISG F3A /M 97935 M B A T
evi
System Gene Category
List
Hits
List
Total
Population
Hits
Population
Total
EASE
score
Bonferroni
Bootstrap
within
system
Gene
identifiers
AfTymetru probesets
Q Q
B iological
P ro c o s
muM.lc
developm ent 5
71 133 10937 L 03E -02 I.OOE+OO 1.84E-01
1466: 1839; 
2247; 6876; 
7168
203821 A T ; 204422 S AT; 
205547 S A T ; 206 1 1 6  S  AT; 
207030 S A T; 210986  S AT; 
2 I0 9 8 7 _ X _ A T ; 38 0 3 7_AT
G Q
B iological
Process
cell proliferation 14 71 1036 10937 I.33E -02 1.00E+00 2.45E-01
604; 970: 
1026; 1466; 
1839 :2149 ; 
2239; 2247; 
2266; 3725; 
4 7 7 l;6 7 7 2 ; 
7048; 9314
200887 S A T; 201464 X AT; 
201466 S A T; 202284 S AT;
203140  A T ; 203821 AT; 
203989  X A T; 204422 S AT; 
204983 S  A T: 206508 AT; 
207030  S A T: 208944 AT; 
213281 A T; 218915 AT; 
219612 S A T: 221841 S AT;
38037  A T; A FFX - 
H U M ISG F3A /M 97935 3 AT; 
A FFX -
H U M ISG F3A /M 97935 M A  AT: 
A FFX -
H U M ISG F3A /M 97935 M B  AT
M olecular
Function
çlvcosam inoelvca
n_hi.ncl.ing
4 70 82 11065 I.45E -02 I.OOE+OO 2.44E -0I
960 ; 1839; 
2 2 4 7 ;1 1 1 6 7
203821 A T; 204422 S AT; 
204490~S A T; 208782 AT; 
209835 X  A T; 212063 AT: 
38037  A T
GO
Biological
Process stim ulus
12 71 821 10937 I.46E -02 LOOE+OO 2.72E-OI
355; 604; 
934 ; 970; 
2637; 4062; 
4792; 5696: 
5698; 5734; 
5 7 4 3 ;6 7 7 2
200887 S A T; 201502 S AT; 
203140  A T; 204279  AT; 
204748 A T ; 204897  AT; 
206508 A T; 206773 AT; 
208650 S  A T: 209040 S AT; 
209771 X A T; 210560  AT; 
215719  X A T; 266  S A T; AFFX- 
H U M ISG F3A /M 97935 3 AT; 
A FFX -
H U M ISG F3A /M 97935 M A  AT; 
A FFX -
H U M ISG F3A /M 97935 M B  AT
System Gene Category List
Hits
List
Total
Population
Hits
Population
Total
EASE
score Bonferroni
Bootstrap
within
system
Gene
identifiers
Affymetrix pro besets
GO
C ellu lar
Com Donent
extracellular s Dace 8 74 391 10787 1 63E -02 1 00E +00 1 41E-01
1839, 2247, 
2266, 3486, 
4312 , 5328, 
11167, 
27122
203821 A T, 204422  S AT, 
204475 A T , 205479  S AT, 
208782  AT, 212143 S A T, 
214247  S A T, 219612  S AT, 
38037 A T
G O
B iological
Process
ST A T  orotem  
nuclear 
translocation
2 71 3 10937 1 91E -02 1 00E +00 3 40E-01 2 1 4 9 ,6 7 7 2
200887  S A T, 203989  X  AT, 
A FFX -
H U M ISG F3A /M 97935 3 AT, 
A FFX -
H U M ISG F3A /M 97935  M A  AT, 
A FFX -
H U M ISG F3A /M 97935 M B  A T
GO
B ioloeical
P rocess
blood coaeulation 4 71 92 10937 2 10E-02 1 00E +00 3 85E-01
2149, 2266, 
5 3 2 8 ,7 9 8 0
203989  X A T, 205479  S AT, 
209278_S_A T , 219612_S_A T
GO
B ioloeical
Process
hem ostasis 4 71 97 10937 2 41E -02 1 00E +00 4 37E-01
2149 , 2266, 
5328, 7980
203989  X A T, 205479  S AT, 
209278_S_A T  219612_S_A T
GO
B ioloe ica l
Process
immune resDonse 10 71 682 10937 2 91E -02 1 OOE+OO 5 18E-01
3 55 , 604, 
9 34 , 970, 
2637 , 4062, 
5696, 5698, 
5734, 5743
203140  A T, 204279  AT, 
204748 AT, 204897  AT, 
206508  AT, 206773 AT, 
208650  S A T, 209040  S AT, 
209771 X  A T, 210560  AT, 
215719  X A T, 266  S AT
G O
M olecu lar
F unction
recep tor binding 8 70 494 11065 3 37E -02 1 OOE+OO 5 24E-01
9 7 0 ,1 8 3 9 , 
2149, 2247, 
2266, 4062, 
6 2 8 1 ,2 7 1 2 2
200872  A T, 203821 AT, 
203989  X  AT, 204422  S AT, 
206508  A T, 206773 AT, 
214247  S A T, 219612  S AT, 
38037 A T
CV111
System Gene Category
List
Hits
List
Total
Population
Hits
Population
Total
EASE
score
Bonferroni
Bootstrap
within
system
Gene
identifiers
Affym etri* probesets
QQ
B K >lpgi«l
Pr99«5
transm cm brane
pathw ay
3 71 48 10937 3.77E-02 1 00E +00 6 .I3 E -0 I
7048: 11217; 
25805
202760  S A T ; 203304 AT; 
208944_A T
QQ
Rjo!Q£i«il
Prows
tYfPSilK 
ohosohorvlation of
ST AT protein
2 71 6 10937 3.78E-02 1.00E+00 6.13E -0I 2149; 6772
200887 S  A T; 203989  X AT; 
A FFX -
H U M ISG F3A /M 97935 3 AT; 
A FFX -
H U M ISG F3A /M 97935_M A _A T;
A FFX -
H U M ISG F3A /M 97935 M B AT
G O
B iological
Process
phosphorv lation 2 71 8 10937 5.01 E-02 1 OOF.- 0 0 7.23E-01 2149; 6772
200887 S A T; 203989 X  AT; 
A FFX -
H U M ISG F3A /M 97935 3 AT; 
A FFX -
H U M ISG F3A /M 97935 M A AT; 
A FFX -
H U M ISG F3A /M 97935 M B A T
QQ
Bifflogical
Proifiijs
defense  resooflsc 10 71 756 10937 5.09E-02 1.00E+00 7.29E-01
355 ; 604; 
934 ; 970; 
2637; 4062; 
5696; 5698; 
5 7 3 4 ;5 7 4 3
203140 A T; 204279_A T; 
204748 A T; 204897 AT; 
206508 A T; 206773 AT; 
208650  S A T; 209040’ S AT; 
209771 X A T; 210560  AT; 
215719 X AT; 266 S AT
QQ
M olecular
Function
molecule activity 6 70 330 11065 5.46E-02 I.00E + 00 7.15E-OI
960; 4162; 
4240; 5099; 
7791; 8406
204490  S  A T; 204955 AT; 
205534 AT; 209087 X  AT; 
209835 X A T; 210605 S AT; 
212063 A T; 215706  X  AT
c ix
System Gene Category ListHits
List
Total
Population
Hits
Population
Total
EASE
score Bonferroni
Bootstrap
within
system
Gene
identifiers Affymetrix probesets
GO
M olecular
F unction
oxidoreductase 
activitvV acting  on 
paired donorsV 
w ith incorporation  
o r reduction  o f  
m olecu lar 
oxveenV 
m iscellaneous
2 70 9 11065 5 48E -02 1 OOE+OO 7 15E-01 3 1 6 2 ,5 7 4 3 203665_A T , 204748_A T
GO
M olecular
Function
heoarin b inding 3 70 61 11065 5 54E-02 1 00E +00 7 22E-01
1839, 2247, 
11167
203821 AT, 204422 S AT, 
208782_A T , 38037_A T
GO
Biological
Process
organogenesis 11 71 901 10937 5 98E-02 1 00E +00 7 88E-01
1466 1545, 
1808, 1839, 
2247, 2637, 
4 0 6 2 ,6 8 7 6 , 
7 1 6 8 ,9 0 6 0 , 
9314
200762  AT, 202436  S AT, 
203058 S AT, 203821 AT, 
204422  S A T, 205547 S AT, 
206116  S A T, 206773 AT, 
207030  S A T, 210560 AT, 
210986  S A T, 210987 X  A T 
221841 S AT 38037 AT
GO
Biological
Process
Deptidvl-tvrosme
m odification
2 71 10 10937 6 22E-02 1 00E +00 7 99E-01 2149 6772
200887 S AT, 203989  X  AT, 
A FFX -
H U M ISG F3A /M 97935 3 AT, 
A FFX -
H U M ISG F3A /M 97935 M A  AT, 
A FFX -
H U M ISG F3A /M 97935 M B AT
GO
B iological
Process
response to 
nest/patho  een/oara  
site
7 71 444 10937 6 42E -02 1 00E +00 8 12E-01
604, 934, 
2637, 4062 , 
4792, 5743, 
6772
200887 S AT 201502 S AT 
203140 AT 204748 AT 206773 AT 
208650 S AT 209771 X AT 
210560 AT 266 S AT AFFX 
HUMISGF3 A/M97935 3 AT AFFX- 
HUM1SGF3A/M97935 MA AT, 
AFFX-HUMISGF3A/M97935 MB AT
ex
System Gene Category ListHits
List
Total
Population
Hits
Population
Total
EASE
score Bonferroni
Bootstrap
within
system
Gene
identifiers Affymetrix pro besets
GO
B iological
Process
pro tein  km ase 
cascade
4 71 155 10937 7 69E-02 1 OOE+OO 8 69E-01
2149, 2247 , 
4792, 6772
200887 S A T, 201502 S AT, 
203989  X  AT, 204422 S AT, 
A FFX -
H U M ISG F3A /M 9793 5 3 AT, 
A FFX -
H U M ISG F3A /M 97935  M A  AT, 
A FFX -
H U M ISG F3A /M 97935 M B A T
GO
B iological
P rocess
D osttranslational
m em brane
targeting
2 71 14 10937 8 60E-02 1 00E +00 8 98E-01 2 2 3 9 ,4 0 6 2 204983_S_A T , 206773_A T
GO
C ellu lar
C om ponent
ex tracellu lar 13 74 1175 10787 9  52E-02 1 00E + 00 6 87E-01
1839, 2239 , 
2247, 2266  
3486, 4312 , 
4 7 7 1 ,5 3 2 8 , 
7052, 7078, 
7980, 11167, 
27122
201042  AT, 201149  S AT, 
203821 A T 204422  S AT, 
204475 AT, 204983 S AT, 
205479  S AT, 208782 AT, 
209278  S AT, 212143 S AT, 
214247  S A T, 218915 AT, 
219612  S A T, 38037 AT
GO 
M olecular 
T unction
oxidoreductase 
activitvV acting on 
paired  donorsY. 
w ith incorporation  
o r reduction  o f  
m olecu lar oxveen
3 70 84 11065 9 65E-02 1 00E +00 9 08E-01
1 5 4 5 ,3 1 6 2 ,
5743
202436  S A T, 203665 AT, 
204748_A T
GO
B iological
Process
cell surface 
recen to r linked 
signal transduction
11 71 991 10937 9 86E-02 1 OOE+OO 9 34E-01
330 , 2149, 
5734, 7048, 
7052, 11186, 
11217, 
25805 , 
27122 , 
55970 
116984
201042  AT, 202760  S AT, 
203304  AT, 203989  X AT, 
204346  S AT, 204897 AT, 
208944  AT, 210538 S AT, 
212294  AT, 213618 AT, 
214247  S AT
CXI
System Gene Category ListHits
List
Total
Population
Hits
Population
Total
EASE
score Bonferrom
Bootstrap
within
system
Gene
identifiers Affymetrix pro besets
GO
B iological
Process
regulation  o f  cell 
cycle
6 71 384 10937 9 90E-02 1 00E +00 9 35E-01
1 0 26 ,2149 , 
2247, 3725, 
4 7 7 1 ,6 7 7 2
200887  S A T, 201464  X AT, 
201466  S A T, 202284 S AT, 
203989  X  AT, 204422 S AT, 
213281 A T, 218915 AT, A FFX - 
H U M ISG F3A /M 97935 3 AT, 
A FFX -
H U M 1SG F3A /M 9793 5 M A AT, 
A FFX -
H U M ISG F3A /M 97935 M B AT
GO
B iological
Process
anti-aDODtosis 3 71 88 10937 1 09E-01 1 00E +00 9 49E-01
330, 355, 
7052
201042  A T, 210538 S AT, 
215719_X _A T
GO
B iological
Process
negative 
regulation  o f  
apoDtosis
3 71 88 10937 1 09E-01 1 OOE+OO 9 49E-01
330, 355, 
7052
201042  A T, 210538 S AT, 
215719_X _A T
GO
M olecu lar
Function
signal transducer 
activity
18 70 2009 11065 1 09E-01 1 OOE+OO 9 30E-01
355, 960, 
970, 1839, 
2149, 2239, 
2 2 4 7 ,2 2 6 6  
4062, 5734, 
6 2 8 1 ,6 7 7 2 , 
7048, 7791, 
11217, 
25805, 
27122, 
55970
200872  A T, 200887 S AT, 
202760  S AT, 203304 AT, 
203821 A T, 203989  X  AT, 
204422  S AT, 204490 S AT 
204897  A T, 204983 S AT, 
206508  AT, 206773 AT, 
208944  A T, 209835 X AT, 
212063 AT, 212294 AT, 
214247  S A T, 215706 X  AT, 
215719  X  A T, 219612 S AT, 
38037 A T, A FFX - 
H U M ISG F3 A /M 9793 5 3 AT, 
A FFX -
H U M 1SG F3A /M 97935 M A  AT, 
A FFX -
H U M ISG F3A /M 97935 M B AT
C X11
System Gene Category ListHits
List
Total
Population
Hits
Population
Total
EASE
score Bonferroni
Bootstrap
within
system
Gene
identifiers
Affymetrix probesets
GO
B ioloeical
Process
in tracellu lar 
signaling  cascade 9
71 761 10937 1 12E-01 1 00E+00 9 50E-01
2149, 2247, 
4792, 5734, 
5865, 6772, 
7052, 9411, 
11186
200887  S AT, 201042  AT, 
201502  S A T , 203910  A T, 
203989  X  A T, 204346  S A T, 
204422  S AT, 204897  AT, 
205925 S AT, A FFX - 
H U M ISG F3A /M 97935  3 AT, 
A FFX -
H U M 1SG F3A /M 97935 M A  AT, 
A FFX -
H U M ISG F3A /M 97935 M B A T
CX111
